<?xml version="1.0" encoding="UTF-8"?>
<VIOLIN>
	<pathogen pathogen_id="pathogen8">
		<pathogen_name>Brucella spp.</pathogen_name>
		<taxon_id>234</taxon_id>
		<pathogenesis refs="reference410 reference412 reference411">The mechanism of Brucella pathogenesis and infection of natural animal hosts is not completely understood (Corbel, 1997). It is well accepted that its pathogenesis relies on its ability to live and replicate inside the vacuolar phagocytic compartment of macrophages (Kohler et al., 2002). The host macrophage-Brucella interaction is critical for establishment of chronic Brucella infections. The Type IV secretion system encoded by the virB operon and the two-component regulatory system encoded by the bvrRS operon are required for successful replication of Brucella in macrophages. Smooth Brucella strains with intact lipopolysaccharide (LPS) O-side chains are virulent and invade macrophages through lipid rafts. On entry into the macrophage, Brucella reside in an acidified compartment that fuses with components of the early endosomal pathway. The majority of Brucella die at the early infection stage. A subpopulation of virulent Brucella strains is trafficked to an intracellular compartment known as the replicative phagosome (brucellosome) through continual interactions between the Brucella-containing vacuoles and the endoplasmic reticulum of the host macrophages. Once inside the replicative phagosome, Brucella are resistant to further attack and rapidly propagate. Virulent Brucella also inhibit macrophage apoptosis that in turn favors pathogen survival and replication. Brucella also infects placental trophoblast cells where acute infection leads to abortion and disease transmission (Roop et al., 2004).</pathogenesis>
		<disease_name>Brucellosis</disease_name>
		<protective_immunity refs="reference11">Both humoral and cell-mediated immune responses can influence the course of a Brucella infection, cell-mediated immune responses are essential for clearance of intracellular Brucella (Schurig et al., 2002).  </protective_immunity>
		<host_range refs="reference410 reference413 reference415 reference414">Brucella has a broad host range infecting vertebrate animal species and humans. Brucella infections are most often identified in humans, cattle, swine, goats, sheep, deer, caribou, elk, dogs and coyotes. There are six Brucella species based on the preferential host specificity: B. melitensis (goats), B. abortus (cattle), B. suis (swine), B. canis (dogs), B. ovis (sheep) and B. neotomae (desert mice). The first four species are pathogenic and exhibit a decreasing order of severity in humans.  Therefore, brucellosis is a zoonotic disease (Corbel, 1997). Mouse models are often used in Brucella vaccine research. BALB/c and C57BL/10 mice differ in their abilities to induce immune responses and protection against virulent Brucella infections (Fernandes et al., 1996) (Li, 1991) (Montaraz et al., 1986).</host_range>
		<introduction refs="reference410 reference12">Brucella species are gram-negative, facultative intracellular bacteria that cause brucellosis (or called Malta fever, undulant fever, Bang's disease, Mediterranean fever ) in humans and a variety of animals (Corbel, 1997). B. melitensis, B. abortus, B. suis, and B. canis are pathogenic to humans. The first three species have been identified as priority agents amenable for use in biological warfare and bio-terrorism, and are listed as NIAID and CDC category B priority pathogens. To date, there is no safe, effective Brucella vaccine available for human use. The vaccine strains used in animals are considered to be too virulent and unsafe for humans (Schurig et al., 1991). Novel vaccines that are non-infectious to humans but effective in stimulating a broad protective immune response are needed.</introduction>
	</pathogen>

	<host host_id="host55">
		<common_name>Baboon</common_name>
		<scientific_name>Papio cynocephalus</scientific_name>
		<taxon_id>9556</taxon_id>
    </host>
	<host host_id="host43">
		<common_name>Bank vole</common_name>
		<scientific_name>Clethrionomys glareolus</scientific_name>
		<taxon_id>447135</taxon_id>
    </host>
	<host host_id="host31">
		<common_name>Bear</common_name>
		<scientific_name>Ursus americanus</scientific_name>
		<taxon_id>9643</taxon_id>
    </host>
	<host host_id="host51">
		<common_name>Birds</common_name>
		<scientific_name>Passeroidea</scientific_name>
		<taxon_id>175121</taxon_id>
    </host>
	<host host_id="host35">
		<common_name>Brown Trout</common_name>
		<scientific_name>Salmo trutta</scientific_name>
		<taxon_id>8032</taxon_id>
    </host>
	<host host_id="host30">
		<common_name>Buffalo</common_name>
		<scientific_name>Bison bison</scientific_name>
		<taxon_id>9901</taxon_id>
    </host>
	<host host_id="host53">
		<common_name>Carnivores</common_name>
		<scientific_name>Vulpes</scientific_name>
		<taxon_id>9625</taxon_id>
    </host>
	<host host_id="host37">
		<common_name>Cat</common_name>
		<scientific_name>Felis catus</scientific_name>
		<taxon_id>9685</taxon_id>
    </host>
	<host host_id="host52">
		<common_name>Catfishes</common_name>
		<scientific_name>Siluriformes</scientific_name>
		<taxon_id>7995</taxon_id>
    </host>
	<host host_id="host12">
		<common_name>Cattle</common_name>
		<scientific_name>Bos taurus</scientific_name>
		<taxon_id>9913</taxon_id>
    </host>
	<host host_id="host8">
		<common_name>Chicken</common_name>
		<scientific_name>Gallus gallus</scientific_name>
		<taxon_id>9031</taxon_id>
    </host>
	<host host_id="host42">
		<common_name>Chimpanzee</common_name>
		<scientific_name>Pan troglodytes</scientific_name>
		<taxon_id>9598</taxon_id>
    </host>
	<host host_id="host26">
		<common_name>chinchillas</common_name>
		<scientific_name>Chinchillidae</scientific_name>
		<taxon_id>10150</taxon_id>
    </host>
	<host host_id="host24">
		<common_name>Copper Pheasant</common_name>
		<scientific_name>Syrmaticus soemmerringii</scientific_name>
		<taxon_id>9067</taxon_id>
    </host>
	<host host_id="host29">
		<common_name>Deer</common_name>
		<scientific_name>Cervus elaphus</scientific_name>
		<taxon_id>9860</taxon_id>
    </host>
	<host host_id="host32">
		<common_name>Deer mouse</common_name>
		<scientific_name>Peromyscus maniculatus</scientific_name>
		<taxon_id>10042</taxon_id>
    </host>
	<host host_id="host36">
		<common_name>Dog</common_name>
		<scientific_name>Canis familiaris</scientific_name>
		<taxon_id>9615</taxon_id>
    </host>
	<host host_id="host9">
		<common_name>Ducks</common_name>
		<scientific_name>Anas</scientific_name>
		<taxon_id>8835</taxon_id>
    </host>
	<host host_id="host19">
		<common_name>Ferret</common_name>
		<scientific_name>Mustela putorius furo</scientific_name>
		<taxon_id>9669</taxon_id>
    </host>
	<host host_id="host48">
		<common_name>Fish</common_name>
		<scientific_name>Hyperotreti</scientific_name>
		<taxon_id>117565</taxon_id>
    </host>
	<host host_id="host41">
		<common_name>Gerbil</common_name>
		<scientific_name>Gerbillina</scientific_name>
		<taxon_id>10045</taxon_id>
    </host>
	<host host_id="host13">
		<common_name>Goat</common_name>
		<scientific_name>Capra hircus</scientific_name>
		<taxon_id>9925</taxon_id>
    </host>
	<host host_id="host47">
		<common_name>Gray wolf</common_name>
		<scientific_name>Canis lupus</scientific_name>
		<taxon_id>9612</taxon_id>
    </host>
	<host host_id="host7">
		<common_name>Guinea pig</common_name>
		<scientific_name>Cavia porcellus</scientific_name>
		<taxon_id>10141</taxon_id>
    </host>
	<host host_id="host16">
		<common_name>Hamster</common_name>
		<scientific_name>Mesocricetus auratus</scientific_name>
		<taxon_id>10036</taxon_id>
    </host>
	<host host_id="host18">
		<common_name>Horse</common_name>
		<scientific_name>Equus caballus</scientific_name>
		<taxon_id>9796</taxon_id>
    </host>
	<host host_id="host2">
		<common_name>Human</common_name>
		<scientific_name>Homo sapiens</scientific_name>
		<taxon_id>9606</taxon_id>
    </host>
	<host host_id="host39">
		<common_name>Macaque</common_name>
		<scientific_name>Macaca fascicularis</scientific_name>
		<taxon_id>9541</taxon_id>
    </host>
	<host host_id="host40">
		<common_name>Mongolian Gerbil</common_name>
		<scientific_name>Meriones unguiculatus</scientific_name>
		<taxon_id>10047</taxon_id>
    </host>
	<host host_id="host5">
		<common_name>Monkey</common_name>
		<scientific_name>Platyrrhini</scientific_name>
		<taxon_id>9479</taxon_id>
    </host>
	<host host_id="host3">
		<common_name>Mouse</common_name>
		<scientific_name>Mus musculus</scientific_name>
		<taxon_id>10090</taxon_id>
    </host>
	<host host_id="host59">
		<common_name>None</common_name>
		<scientific_name>None</scientific_name>
		<taxon_id></taxon_id>
    </host>
	<host host_id="host50">
		<common_name>Parrot</common_name>
		<scientific_name>Psittacidae</scientific_name>
		<taxon_id>9224</taxon_id>
    </host>
	<host host_id="host15">
		<common_name>Pig</common_name>
		<scientific_name>Sus scrofa</scientific_name>
		<taxon_id>9823</taxon_id>
    </host>
	<host host_id="host6">
		<common_name>Rabbit</common_name>
		<scientific_name>Oryctolagus cuniculus</scientific_name>
		<taxon_id>9986</taxon_id>
    </host>
	<host host_id="host45">
		<common_name>Rainbow trout</common_name>
		<scientific_name>Oncorhynchus mykiss</scientific_name>
		<taxon_id>8022</taxon_id>
    </host>
	<host host_id="host4">
		<common_name>Rat</common_name>
		<scientific_name>Rattus</scientific_name>
		<taxon_id>10114</taxon_id>
    </host>
	<host host_id="host34">
		<common_name>Raven</common_name>
		<scientific_name>Corvus corax</scientific_name>
		<taxon_id>56781</taxon_id>
    </host>
	<host host_id="host54">
		<common_name>sei whale</common_name>
		<scientific_name>Balaenoptera borealis</scientific_name>
		<taxon_id>9768</taxon_id>
    </host>
	<host host_id="host17">
		<common_name>Sheep</common_name>
		<scientific_name>Ovis aries</scientific_name>
		<taxon_id>9940</taxon_id>
    </host>
	<host host_id="host28">
		<common_name>Squirrel</common_name>
		<scientific_name>Spermophilus richardsonii</scientific_name>
		<taxon_id>37591</taxon_id>
    </host>
	<host host_id="host44">
		<common_name>Tree shrew</common_name>
		<scientific_name>Tupaiidae</scientific_name>
		<taxon_id>9393</taxon_id>
    </host>
	<host host_id="host49">
		<common_name>Trouts, salmons &amp; chars</common_name>
		<scientific_name>Salmoninae</scientific_name>
		<taxon_id>504568</taxon_id>
    </host>
	<host host_id="host38">
		<common_name>Turkey</common_name>
		<scientific_name>Meleagris gallopavo</scientific_name>
		<taxon_id>9103</taxon_id>
    </host>
	<host host_id="host33">
		<common_name>Vole</common_name>
		<scientific_name>Microtus ochrogaster</scientific_name>
		<taxon_id>79684</taxon_id>
    </host>
	<host host_id="host27">
		<common_name>Water buffalo</common_name>
		<scientific_name>Bubalus bubalis</scientific_name>
		<taxon_id>391902</taxon_id>
    </host>
	<vaccine vaccine_id="vaccine299">
		<vaccine_name>B. abortus and B. melitensis mutants with unmarked deletion of asp24, virB2, or manBA</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Aerosal Vaccine</type>
		<status></status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference694">Each vaccine consisted of 5 × 10^7 CFU/ml in a chamber nebulizer, which is thousands of organisms per dose.  The bacteria were introduced in Farrell's medium: TSA supplemented with 5 mg/liter nalidixic acid, 25,000 IU/liter bacitracin, 100 mg/liter cycloheximide, 5000 IU/liter polymyxin B sulfate, 20 mg/liter vancomycin, 100,000 IU/liter nystatin 10% (vol/vol) horse serum, and 2% (wt./vol.) dextrose (Kahl-McDonagh et al., 2007).</preparation>
		<route refs=""></route>
		<antigen refs="reference694">The vaccines tested in this study include B. abortus unmarked mutants BAΔasp24, BAΔvirB2, and BAΔmanBA, and B. melitensis unmarked mutants BMΔasp24, BMΔvirB2, and BMΔmanBA (Kahl-McDonagh et al., 2007).</antigen>

		<gene_engineering gene_engineering_id="gene_engineering803" gene_id="gene997">
			<type>Gene mutation</type>
			<description refs="reference694">This asp24 mutant is from Brucella abortus (Kahl-McDonagh et al., 2007).</description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering804" gene_id="gene998">
			<type>Gene mutation</type>
			<description refs="reference694">This virB2 mutant is from Brucella melitensis (Kahl-McDonagh et al., 2007).</description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering805" gene_id="gene1000">
			<type>Gene mutation</type>
			<description refs="reference694">This manBA mutant is from Brucella melitensis (Kahl-McDonagh et al., 2007).</description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering806" gene_id="gene999">
			<type>Gene mutation</type>
			<description refs="reference694">This manBA mutant is from Brucella melitensis (Kahl-McDonagh et al., 2007).</description>
		</gene_engineering>
		<host_response host_response_id="host_response385" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference694">Groups of four or five female 6- to 8-week-old BALB/c mice were vaccinated via i.p. injection of 1 × 10^6 CFU/ml of unmarked deletion mutant or PBS for naïve controls (Kahl-McDonagh et al., 2007).</vaccination_protocol>
			<persistence refs="reference694">Mice receiving a dose of 5 × 10^7 CFU/ml  had lung colonization with B. abortus strain 2308 that gradually increased over the first 4 weeks postchallenge, then gradually decreased over the following 4 weeks to 90% of the maximum value. Despite this slight decrease, colonization by the organism in the other tissues was consistent with a chronic infection. Colonization of the liver, although barely detectable at 1 week postchallenge, steadily increased over the first 4 weeks postchallenge and then declined negligibly between weeks 4 and 8. The spleens of infected mice displayed a colonization pattern similar to that of the livers, although the total number of CFU recovered was consistently higher. Spleen colonization increased between weeks 4 and 8, consistent with a persistent infection (Kahl-McDonagh et al., 2007).</persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference694">The bacterial burden in the spleen following aerosol challenge was reduced 2.02 U by vaccination with BAΔasp24 and by 0.86 U by vaccination with BAΔvirB2 relative to the burden in naïve mice. The rough BAΔmanBA mutant was unable to elicit significant protective immunity relative to the immunity of naïve mice. At 24 weeks postvaccination, less protection was observed in the lungs of mice vaccinated with BAΔasp24 and BAΔvirB2, although the protection was significantly greater than that observed for naïve controls. The rough mutant, BAΔmanBA, protected mouse lungs to a lesser degree, which was not significant(Kahl-McDonagh et al., 2007) .</protection_efficacy>
			<side_effects refs="reference694">Mice receiving a dose of 5 × 10^7 CFU/ml  had lung colonization with 2308 that gradually increased over the first 4 weeks postchallenge, then gradually decreased over the following 4 weeks to 90% of the maximum value. Despite this slight decrease, colonization by the organism in the other tissues was consistent with a chronic infection. Colonization of the liver, although barely detectable at 1 week postchallenge, steadily increased over the first 4 weeks postchallenge and then declined negligibly between weeks 4 and 8. The spleens of infected mice displayed a colonization pattern similar to that of the livers, although the total number of CFU recovered was consistently higher. Spleen colonization increased between weeks 4 and 8, consistent with a persistent infection (Kahl-McDonagh et al., 2007).</side_effects>
			<challenge_protocol refs="reference694">BALB/c mice were challenged with an aerosol chamber dose of 5 × 10^9 CFU/ml of the homologous wild-type strain at 20 weeks postvaccination. Four weeks after the virulent challenge (corresponding to 24 weeks postvaccination), the mice were euthanized and the recovery of the challenge orgainsm was measured (Kahl-McDonagh et al., 2007).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine831">
		<vaccine_name>B. abortus DNA vaccine encoding RplL and Omp16</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0011380</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>Expression vector pcDNA3.1</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs="">B. abortus ribosomal protein rplL and outer membrane lipoprotein 16</antigen>

		<gene_engineering gene_engineering_id="gene_engineering298" gene_id="gene682">
			<type>DNA vaccine construction</type>
			<description refs="reference697">Full-length open reading frames of the L7/L12 gene and Omp16 gene were amplified with PCR from the genome of attenuated B. abortus strain RB51. The gene amplified with L7/L12 primers (FL and RL-1) and the gene amplified with Omp16 primers (FO and RO) were inserted into pcDNA3.1(+) vector (Invitrogen) at the EcoRV/XhoI and BamHI/XhoI sites to construct recombinant plasmids L7/L12-pcDNA3.1 and Omp16-pcDNA3.1, respectively. To construct the recombinant fusion plasmid L7/L12-Omp16-pcDNA3.1, the L7/L16 gene fragment was amplified with the L7/L16 PCR primers (FL and RL-2) first, which removed only the TAA stop codon from the L7/L16 gene. This PCR product and the amplified Omp16 gene above were digested with EcoRV/BamHI and BamHI/XhoI, respectively, and ligated with T4 ligase; the ligated product was then inserted into the pcDNA3.1(+) vector between the EcoRV and XhoI sites (Luo et al., 2006b).</description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering299" gene_id="gene260">
			<type>DNA vaccine construction</type>
			<description refs="reference697">Full-length open reading frames of the L7/L12 gene and Omp16 gene were amplified with PCR from the genome of attenuated B. abortus strain RB51. The PCR primers were designed as shown in Table 1. The gene amplified with L7/L12 primers (FL and RL-1) and the gene amplified with Omp16 primers (FO and RO) were inserted into pcDNA3.1(+) vector (Invitrogen) at the EcoRV/XhoI and BamHI/XhoI sites to construct recombinant plasmids L7/L12-pcDNA3.1 and Omp16-pcDNA3.1, respectively. To construct the recombinant fusion plasmid L7/L12-Omp16-pcDNA3.1, the L7/L16 gene fragment was amplified with the L7/L16 PCR primers (FL and RL-2) first, which removed only the TAA stop codon from the L7/L16 gene. This PCR product and the amplified Omp16 gene above were digested with EcoRV/BamHI and BamHI/XhoI, respectively, and ligated with T4 ligase; the ligated product was then inserted into the pcDNA3.1(+) vector between the EcoRV and XhoI sites (Luo et al., 2006b).</description>
		</gene_engineering>
		<host_response host_response_id="host_response590" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference697">The mice were anesthetized with methoxyflurane (Metofan; Mallinckrodt) and inoculated intramuscularly with 100 μg of pcDNA3.1-L7/L12-Omp16, pcDNA3.1-L7/L12, or pcDNA3.1-Omp16 in 100 μl of PBS (50 μl of the solution was injected into each tibialis anterior muscle). The control mice were infected with PBS or the expression vector alone (pcDNA3.1). Each mouse in another group was injected with 10 μg of rL7/L12-Omp16 in 100 μl PBS according to the same schedule. Each mouse was injected on weeks 0, 2, and 4. The mice used as positive controls were inoculated intraperitoneally on day 0 with 2× 10^8 CFU of B. abortus strain RB51 in 0.2 ml of PBS (Luo et al., 2006b).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference697">This divalent DNA vaccine induced a significant level of protection against challenge with the virulent B. abortus in BALB/c mice (Luo et al., 2006b).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference697">Two weeks after the final vaccination, five mice from each group were challenged intraperitoneally with relatively higher dose of strain 544 (5 × 10^5 CFU).  Four weeks postchallenge, the mice were killed by cervical dislocation, and their spleens were removed aseptically and weighed (Luo et al., 2006b).</challenge_protocol>
			<description refs=""></description>
              <host_gene_response host_gene_response_id="host_gene_response305" gene_id="gene1107">
			    <description refs="reference697">Sera collected 2 weeks after the last immunization were assayed for the presence of L7/L12- and/or Omp16-specific antibodies by ELISA.  The pcDNA 3.1-L7/L12-OMP16 vaccine elicited significantly higher levels of IgG1 antibodies than did the negative control vaccine, pcDNA 3.1 (Luo et al., 2006b).</description>
			  </host_gene_response>
              <host_gene_response host_gene_response_id="host_gene_response306" gene_id="gene1106">
			    <description refs="reference697">Sera collected 2 weeks after the last immunization were assayed for the presence of L7/L12- and/or Omp16-specific antibodies by ELISA.  The pcDNA 3.1-L7/L12-OMP16 vaccine elicited significantly higher levels of IgG2a antibodies than did the negative control vaccine, pcDNA 3.1 (Luo et al., 2006b).</description>
			  </host_gene_response>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine211">
		<vaccine_name>B. abortus DNA vaccine expressing  BCSP31, SOD and L7/L12</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000321</vo_id>
		<type>DNA vaccine</type>
		<status></status>
		<vector>pJW4303 [Ref480:Yu et al., 2007]</vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="">Vaccine combines three known antigens, BCSP31, SOD, and L7/L12, in a single DNA vaccine.</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs="">None</virulence>
		<preparation refs="reference480">The coding regions for the antigens BCSP31, SOD, and L7/L12 were amplified from B. abortus strain 2308 chromosomal DNA. GenBank accession numbers for the sequences reported in this study are M20404 for BCSP31, L19101 for L7/L12, and AE017334 for SOD.  All antigen-coding regions were fused individually to the tissue plasminogen activator signal sequences, and the DNA constructs were purified using the Qiagen Mega plasmid DNA kit (Qiagen, Valencia, CA) and verified by commercial DNA sequencing. The DNA vaccine was diluted in saline solution to a final concentration of 1–2 mg/mL before use  (Yu et al., 2007).</preparation>
		<route refs=""></route>
		<antigen refs="reference480">B. abortus BCSP31, SOD, and L7/L12 (Yu et al., 2007).</antigen>

		<gene_engineering gene_engineering_id="gene_engineering216" gene_id="gene3">
			<type>DNA vaccine construction</type>
			<description refs="reference480">The DNA vaccine comprising genes encoding the antigens BCSP31, superoxide dismutase (SOD), and L7/L12 was constructed and evaluated for its immunogenicity and protective efficacy (Yu et al., 2007).</description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1494" gene_id="gene114">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1495" gene_id="gene1676">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response250" host_id="host3">
			<immune_response refs="reference480">Mice vaccinated with the combined DNA produced a rapid and specific IgG response 3 weeks after the initial vaccination, and peak titers were detected 3 weeks after the last immunization. The S19-vaccinated mice also induced antibody production, but the rise was not as pronounced.  Combined DNA–vaccinated mice had significantly higher BCSP31-, SOD-, L7/L12-, and Brucella-specific total IgG production than S19-vaccinated mice.  Combined DNA–vaccinated mice produced significantly higher levels of IFN-g and TNF-a ( p &lt; 0.01) compared with the two negative control groups.  A significant T cell response was observed after incubating spleen cells from combined DNA–vaccinated mice with the specific antigens rBCSP31, rSOD, rL7/L12, and heat-killed B. abortus  (Yu et al., 2007).</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="">Plasmids carrying BCSP31, SOD, and L7/L12 genes were administered by intramuscular injection of 150 ug DNA (50 ug of each plasmid) in 150 uL saline solution into each of the quadriceps.  For the vector control group, 150 mg pJW4303 empty vector DNA in 150 mL saline was used for injection. As an additional negative control, mice were injected with 150 mL saline. Immunization of mice was repeated thrice at 3-week intervals.  The positive control group of mice was vaccinated intraperitoneally with 5x10^6 colony-forming units (CFU) of B. abortus </vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference480">The levels of infection were evaluated by measuring CFU in the spleen. The combined DNA–vaccinated mice displayed a significantly higher level of protection than mice vaccinated with vector DNA or saline (3.58 log units higher; p &lt; 0.001; n=10). In addition, our vaccine provided significantly higher protection than S19 (log units=2.87 for S19; p=0.034); that is, after infection, the number of CFU in the spleen of the combined DNA vaccine group was reduced to less than 20% of that in the S19 group. Indicating that the combined DNA vaccine affords a significant degree of protection against Brucella infection  (Yu et al., 2007).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference480">Mice were challenged intravenously with 5x10^6 CFU (Yu et al., 2007).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine138">
		<vaccine_name>B. abortus DNA vaccine pcDNA-SOD</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000018</vo_id>
		<type>DNA vaccine</type>
		<status></status>
		<vector>pcDNA3 [Ref220:Munoz-Montesino et al., 2004]</vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference220">Cu-Zn superoxide dismutase (SOD) is one of the protective immunogens of Brucella abortus. Intramuscular injection with a plasmid DNA carrying the SOD gene (pcDNA-SOD) was able to induce a protective immune response in mice  (Munoz-Montesino et al., 2004).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference220">Recombinant plasmid pBAII-3, containing the gene for B. abortus Cu-Zn SOD (sodC), and its own promoter, was initially obtained from a pUC9 genomic library of B. abortus strain 2308. A 1.1-kb fragment containing the sodC gene and its promoter sequences was excised and ligated into the expression vector pcDNA3 downstream of the cytomegalovirus promoter. The resulting plasmid was designated pcDNA-SOD. A colony of E. coli containing pcDNASOD was cultured and used for large-scale plasmid DNA isolation. The DNA was resuspended in PBS at a final concentration of 1 mg/ml. The pcDNA-SOD plasmid construct was verified by restriction digestion and by sequencing of the complete insert (Munoz-Montesino et al., 2004).</preparation>
		<route refs=""></route>
		<antigen refs="reference220">B. abortus Cu/Zn Superoxide dismutase (Munoz-Montesino et al., 2004).</antigen>

		<gene_engineering gene_engineering_id="gene_engineering124" gene_id="gene3">
			<type>DNA vaccine preparation</type>
			<description refs="reference220">B. abortus sodC was subcloned into the expression vector pcDNA3 (Munoz-Montesino et al., 2004).</description>
		</gene_engineering>
		<host_response host_response_id="host_response163" host_id="host3">
			<immune_response refs="reference220">Animals vaccinated with pcDNA-SOD did not develop SOD-specific antibodies, at least until week 4 after immunization (the end of the experiment), and in vitro stimulation of their splenocytes with either recombinant Cu-Zn SOD or crude Brucella protein induced the secretion of gamma interferon (IFN-γ), but not interleukin-4, and elicited the induction of cytotoxic-T-lymphocyte activity. Upon analyzing the SOD-specific T-cell responses, the pcDNA-SOD vaccination was found to be stimulating both CD4+- and CD8+-T-cell populations. However, only the CD4+ population was able to produce IFN-γ and only the CD8+ population was able to induce cytotoxic activity (Munoz-Montesino et al., 2004).</immune_response>
			<host_strain refs="">BALB/c mice</host_strain>
			<vaccination_protocol refs="reference220">Mice premedicated with atropine (16 µg/mouse) were anesthetized with ketamine (2 µg/mouse), their abdominal regions shaved. One 3-mm-long incision was made through the skin.  The mice were injected in the spleen with 10 µg of plasmid DNA in 30 µl of PBS.  Mice were injected i.m. in the right tibialis anterior muscle with 10 µg of plasmid DNA per mouse. The mice were vaccinated once with pcDNA-SOD construct or with pcDNA3 as a negative control. For protection assays, an additional group was inoculated with PBS as a negative control  (Munoz-Montesino et al., 2004).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference220">Immunization (i.s.) with pcDNA-SOD induced a significant degree of protection (1.52-log-unit increase in protection) compared to the control group (P &lt; 0.008). The mice that were immunized (i.m.) with pcDNA-SOD showed minimal protection, (P &lt; 0.2). No significant difference was seen between the CFU numbers in control groups injected with pcDNA3 and PBS. Vaccination with pcDNA-SOD vaccination (i.s.) therefore provided a significant degree of protection against Brucella infection  (Munoz-Montesino et al., 2004).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference220">Four weeks after vaccination, six mice from each group were challenged by intraperitoneal injection of 10^4 CFU of B. abortus 2308. Two weeks later, the infected mice were sacrificed, their spleens homogenized, and dilutions of the extract were plated to determine the number of Brucella CFU per spleen  (Munoz-Montesino et al., 2004).</challenge_protocol>
			<description refs=""></description>
              <host_gene_response host_gene_response_id="host_gene_response9" gene_id="gene1">
			    <description refs="reference220">pcDNA-SOD induced Cu-Zn SOD specific IFN-γ production from CD4+ but not CD8+ T cells from in pcDNA-SOD immunized mice (Munoz-Montesino et al., 2004). </description>
			  </host_gene_response>
              <host_gene_response host_gene_response_id="host_gene_response10" gene_id="gene125">
			    <description refs="reference220">pcDNA-SOD did not induce interleukin-4 production in immunized mice (Munoz-Montesino et al., 2004).</description>
			  </host_gene_response>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3607">
		<vaccine_name>B. abortus DNA vaccine pcDNA3-SOD encoding Cu-Zn SOD</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004393</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pcDNA3 [Ref564:Onate et al., 2003]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1152" gene_id="gene3">
			<type>DNA vaccine construction</type>
			<description refs="reference564">Vector pcDNA3 expressed Cu-Zn SOD (Onate et al., 2003).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1427" host_id="host3">
			<immune_response refs="reference564">Vaccination was able to induce a broad range of immune responses including antibody production, CD8+ cytotoxic T cells (CTLs), and CD4+ T helper cell activation (Onate et al., 2003).</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference564">Immunization with pcDNA-SOD resulted in a significantly higher degree of protection (2.16 log increase in protection) compared to the unimmunized control groups (P &lt; 0.0005). The level of protection was similar to the one induced by B. abortus vaccine strain RB51.  Thus, pcDNA-SOD vaccine afforded a significant degree of protection against Brucella infection (Onate et al., 2003).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3605">
		<vaccine_name>B. abortus DNA vaccine pcDNA3.1-p39-L7/L12 encoding p39-L7/L12 fusion protein</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004392</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pcDNA3.1 [Ref491:Luo et al., 2006a]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs="reference491">p39-L7/L12 fusion protein from RB51 (Luo et al., 2006a)</antigen>

		<gene_engineering gene_engineering_id="gene_engineering1496" gene_id="gene114">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1497" gene_id="gene1358">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response1426" host_id="host3">
			<immune_response refs="reference491">Inoculation of plasmid DNA containing the L7/L12-P39 gene leads to both TH1 type antibody and CMI responses (Luo et al., 2006a).</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference491">Among the three DNA vaccines (including pcDNA3.1(+)-L7/L12 and pcDNA3.1(+)-P39), the pcDNA3.1 (+)-L7/L12-P39 DNA vaccine could provide the highest protective level against Brucella infection, as it confers protection against A544 challenge (Luo et al., 2006a).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3900">
		<vaccine_name>B. abortus DNA vaccine pVF278</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004546</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pVF [Ref2664:Sislema-Egas et al., 2012]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1449" gene_id="gene1644">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response1542" host_id="host3">
			<immune_response refs="reference2664">Mice injected with pVF278 had a dominant immunoglobulin G2a (IgG2a) response and elicited a T-cell-proliferative response (Sislema-Egas et al., 2012).</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2664">Data from two independent protection experiments demonstrated that immunization with pVF278 DNA vaccine resulted in a significantly degree of protection (1.28 log increase in protection) with P &lt; 0.05 after determination of CFU in the spleen (Sislema-Egas et al., 2012).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine449">
		<vaccine_name>B. abortus P39 deletion vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000826</vo_id>
		<type>Live, attenuated vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference877">A B. abortus vaccine that is recombinant B. abortus strain 19vaccine with the p39 gene deletion (Tibor et al., 1998).</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine199">
		<vaccine_name>B. abortus pcDNA-BLS</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000421</vo_id>
		<type>DNA vaccine</type>
		<status></status>
		<vector>pcDNA3 [Ref416:Velikovsky et al., 2002]</vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference416">This is about pcDNA-BLS, a B. abortus DNA vaccine encoding lumazine synthase (Velikovsky et al., 2002).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs="">No.</virulence>
		<preparation refs="reference416">The Brucella abortus lumazine synthase (BLS) gene was cloned into the pcDNA3 plasmid. It is driven by the cytomegalovirus promoter (Velikovsky et al., 2002).</preparation>
		<route refs=""></route>
		<antigen refs="reference416 reference417">Brucella abortus lumazine synthase (BLS) (Velikovsky et al., 2002). It was was cloned and identified in 1995 (Hemmen et al., 1995).</antigen>

		<gene_engineering gene_engineering_id="gene_engineering118" gene_id="gene113">
			<type>DNA vaccine preparation</type>
			<description refs="reference416">The Brucella abortus lumazine synthase (BLS) gene was cloned into the pcDNA3 plasmid. This gene is driven by the cytomegalovirus promoter. The plasmid was amplified in E. coli JM109 (Promega, Madison, Wis.) and isolated with Mega Prep plasmid isolation columns (Qiagen, Dorking, United Kingdom) (Velikovsky et al., 2002). </description>
		</gene_engineering>
		<host_response host_response_id="host_response1488" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference416">Two independent protection experiments demonstrated that mice given pcDNA-BLS had a significantly higher degree of protection (1.65 log increase in protection) than did controls receiving PBS (P &lt; 0.01) (Velikovsky et al., 2002).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine109">
		<vaccine_name>B. abortus strain 19</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000022</vo_id>
		<type>Attenuated live vaccine</type>
		<status>Licensed</status>
		<vector></vector>
		<route></route>
		<location_licensed>USA; European countries</location_licensed>
		<description refs="reference11">Strain 19  induces reasonable protection against B. abortus, but at the expense of persistent serological responses (Schurig et al., 2002).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs="reference188">Although  effective, strain 19 vaccine has a tropism   for   the   placenta   and   causes   abortion   when   given   to   pregnant   cows   ,   is   infectious   for   humans   ,   and   causes   serologic   responses   in   calves   that   are the same as those in cattle  infected with   natural  field strains (Cheville, 2000).</virulence>
		<preparation refs="reference11">Strain 19, first described in 1930, is a laboratory-derived strain attenuated by an unknown process.  It was originally   isolated   from bovine milk as  a virulent  strain in  1923,  but became attenuated after  storage at  room   temperature for  over a  year.   Strain 19 is able   to   induce   protective   immunity   in  cattle (Schurig et al., 2002). </preparation>
		<route refs=""></route>
		<antigen refs="">Whole Brucella organism</antigen>
		<host_response host_response_id="host_response138" host_id="host12">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference190">Mature   female   cattle   were   immunized   with   strain      19    (   2x10^8 and 6x10^8  CFU respectively)   and   6-12   month old calves  with   strain 19    (   4x10^10   and 12x10^10 CFU  )   .    Mature   females   and   calves   were   inoculated   with   sterile   vaccine   diluent   and   formed   a   non-vaccinated,   in-contact   control   group   (Geong et al., 2000).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference190">Of the 599 animals bled initially, 83.5, 72.6, 73.8 and 64.1%, respectively, were represented at 3, 6, 9 and 24 months post infection, respectively. No significant differences between the two villages in the percentage of animals presented at each sampling were found. During the trials, no difference was observed in the presenting of animals identified as seropositive and those identified as seronegative  (Geong et al., 2000).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference190">Cattle were allowed to graze for 24 months under conditions where infection was possible  (Geong et al., 2000).</challenge_protocol>
			<description refs=""></description>
		</host_response>
		<host_response host_response_id="host_response139" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference191">Mice (10/treatment group) were injected i.p. with 0.2 ml of a 0.15 M NaCl saline solution (controls) or with 0.2 ml of saline containing approximately 1x10^5 cfu of strain 2308 or 1x10^7 cfu of strain 19 or RB51. Blood samples and spleens were taken from age-matched noninfected control mice and from infected mice at 2, 4, 6, 10, or 20 weeks respectively after infection  (Stevens et al., 1994b). </vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="">No challenge performed.</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine123">
		<vaccine_name>B. abortus strain 45/20</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000723</vo_id>
		<type>attenuated live vaccine</type>
		<status></status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference209">B. abortus strain 45/20 is a rough form of the bacterium that can confer immunity  (Moriyon et al., 2004).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs="reference209">The original strain of 45/20 was known to revert to smooth pathogenic forms when injected into cattle.  Due to this instability, the vaccine is not currently marketed  (Moriyon et al., 2004).
 </virulence>
		<preparation refs="reference209">The 45/20 strain was isolated from guinea pigs in 1938  (Moriyon et al., 2004). </preparation>
		<route refs=""></route>
		<antigen refs="">Whole Brucella organism</antigen>
		<host_response host_response_id="host_response155" host_id="host17">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference210">15 lambs were vaccinated with 45/20 bacterin, and a control group remained unvaccinated. Revaccinations were performed 18 weeks later.  At regular intervals after vaccination and revaccination, blood samples were taken and animals were examined for genital lesions  (Blasco et al., 1993). 
</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference210">Two weeks after challenge, ten of the 15 control rams excreted B. ovis. All animals were slaughtered 15 weeks after the challenge inoculation and subjected to bacteriological and histological examinations. A ram was classified as protected if no B. ovis was isolated from any of the 13 organs sampled at necropsy. Significant levels of protection in comparison with the control group were obtained by vaccination with 45/20 bacterin (PC 0.05)  (Blasco et al., 1993).
</protection_efficacy>
			<side_effects refs="reference210">One ram died from enterotoxemia during the course of the experiment  (Blasco et al., 1993). 
</side_effects>
			<challenge_protocol refs="reference210">Challenge inoculations were performed 31 weeks after the second vaccination with a virulent strain of B. ovis obtained from a naturally infected ram. Each ram received a total volume of 60 uL ( 1 x 10^9 CFU), as shown by viable cell counts made on the day of inoculation), both conjunctivally (30 uL) and preputially (30 uL)  (Blasco et al., 1993).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine111">
		<vaccine_name>B. abortus subunit vaccine using L7/L12</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000323</vo_id>
		<type>Subunit vaccine</type>
		<status></status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs="reference419">Maltose binding protein (MBP) (Oliveira et al., 1996).</adjuvant>
		<storage refs=""></storage>
		<virulence refs="">None</virulence>
		<preparation refs="reference419">The recombinant Brucella abortus L7/L12 ribosomal protein was fused to maltose binding protein (MBP). The  animals  vaccinated with  MBP-L7/L12  received  25  mg  of  the  specific  B. abortus  L7/L12  ribosomal  protein.  Different  protein  concentrations  per  dose containing  the  same  MBP  amounts  were used to  vaccinate  each group to ensure that both mouse groups received the same amount of MBP (Oliveira et al., 1996).</preparation>
		<route refs=""></route>
		<antigen refs="reference419">B. abortus ribosomal protein L7/L12 (Oliveira et al., 1996).</antigen>

		<gene_engineering gene_engineering_id="gene_engineering119" gene_id="gene114">
			<type>Recombinant protein preparation</type>
			<description refs="reference419">Recombinant  Brucella  abortus  L7/Ll2  ribosomal protein was  fused  to maltose  binding protein  (MBP). The detail is described (Oliveira et al., 1996).</description>
		</gene_engineering>
		<host_response host_response_id="host_response383" host_id="host3">
			<immune_response refs="reference419">There was a specific  antibody  response  from animals  immunized  with  recombinant  MBP-L7/L12 fusion  protein.  Serum  samples  from mice immunized with MBP-L7/L12  contained  anti-MBP  and  anti-L7/L12 antibodies.  No anti-MBP-L7/L12 antibodies were detected in the sera of naive mice used as a negative control (Oliveira et al., 1996).</immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference419">Five  groups  of  15 BALB/c mice  were  immunized  intraperitoeally with  0.2 ml  of  the  following  treatments: either phosphate-buffered  saline  (PBS); Immuneplus  adjuvant  system; adjuvant  containing  75 micrograms  of maltose  binding  protein (MBP); 4  adjuvant  containing  100 micrograms  of  MBP-L7/L12  fusion protein;  or B.  abortus strain  19 (Oliveira et al., 1996).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference419">Three  immunizations  with  100 micrograms  of  the  recombinant L7/L12  ribosomal  protein  fused  to  MBP  protected  mice against  B.  abortus infection,  while  vaccination  with  75  micrograms  of  MBP alone  resulted  in  no  protection. The recombinant L7/L12  protein  engendered  substantial  protective  immunity  to  BALB/c mice  against  challenge  when  compared  to  the  protection levels  conferred  to  mice vaccinated  with  B.  abortus  S19.  The  greatest  levels  of  protection  observed  in immunized mice were  at  2  and  4  weeks  post-challenge (Oliveira et al., 1996). The irrelevant  Escherichia coli protein  (MBP)  does  not  protect  mice  against  brucellosis (Oliveira et al., 1996).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference419">Mice  were  challenged one week after their final immunization (day 28) with  an  i.v.  injection  of  1 x  10^6 c.f.u.  B.  abortus in  100 microliters  of  sterile  phosphate  buffer saline (Oliveira et al., 1996).</challenge_protocol>
			<description refs=""></description>
		</host_response>
		<host_response host_response_id="host_response1121" host_id="host3">
			<immune_response refs="reference2102">Activation of Th1 cell response. (Abtahi et al., 2008)</immune_response>
			<host_strain refs="">BALB/C</host_strain>
			<vaccination_protocol refs="reference2102">Three intra-muscular vaccinations of DNA vaccine encoding L7/L12 protein at 3 week intervals.(Abtahi et al., 2008)</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2102">Lower bacterial cfu from vaccinated mice in comparison with control groups show the efficiency of L7/L12 DNA vaccination in mice model. (Abtahi et al., 2008)</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
              <host_gene_response host_gene_response_id="host_gene_response18" gene_id="gene1">
			    <description refs="reference2102">Splenic lymphocytes from L7/L12pCDNA3-vaccinated mice produced high levels of IFNy (3100 pg mL(-1)) 3 weeks post-vaccination. (Abtahi et al., 2008)</description>
			  </host_gene_response>
              <host_gene_response host_gene_response_id="host_gene_response19" gene_id="gene1105">
			    <description refs="reference2102">Splenic lymphocytes from L7/L12pCDNA3-vaccinated mice produced low levels of IL-5 (300 pg mL(-1)) 3 weeks post-vaccination. (Abtahi et al., 2008)</description>
			  </host_gene_response>
              <host_gene_response host_gene_response_id="host_gene_response20" gene_id="gene1106">
			    <description refs="reference2102">L7/L12pCDNA3 immunizations elicited high IgG2a isotype response in mice immunized (Abtahi et al., 2008)</description>
			  </host_gene_response>
              <host_gene_response host_gene_response_id="host_gene_response21" gene_id="gene1107">
			    <description refs="reference2102">IgG1 titers induced post-immunization with L7/L12pCDNA3 vaccine. (Abtahi et al., 2008)</description>
			  </host_gene_response>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine10">
		<vaccine_name>B. abortus vaccine strain RB51</vaccine_name>
		<proper_name></proper_name>
		<brand_name>RB51</brand_name>
		<manufacturer>Colorado Serum Company CZ Veterinaria</manufacturer>
		<vo_id>VO_0000021</vo_id>
		<type>Live attenuated B. abortus strain</type>
		<status>Licensed</status>
		<vector></vector>
		<route></route>
		<location_licensed>USA, Mexico, South American, India, Spain, Middle East, Iran</location_licensed>
		<description refs="reference11 reference12">RB51 has been the official cattle Brucella vaccine in the USA since 1996 and now in many other countries (Schurig et al., 2002). RB51 is a rifampin-resistant rough attenuated mutant of Brucella abortus derived by repeated passage of strain 2308 on Trypticase soy supplemented with 1.5% agar and varying concentrations rifampin or penicillin.  Rabbits, goats and cattle hyperimmunized with sonicates of RB51 develop antibodies to B. abortus cellular antigens but do not develop specific antibodies for the Brucella O-chain (Schurig et al., 1991).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs="reference12">RB51 is a rough attenuated strain (Schurig et al., 1991).                       </virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs="reference12">The antigen for this live attenuated vaccine is the whole cells of strain RB51.  This strain has rough characteristics and is devoid of O-chain. The RB51 was derived from the virulent smooth B. abortus 2308 by several passages in media supplemented with sub-inhibitory concentrations of rifampicin (Schurig et al., 1991).</antigen>
		<host_response host_response_id="host_response10" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">BALB/c mice</host_strain>
			<vaccination_protocol refs="">~4 x 10^8 CFU</vaccination_protocol>
			<persistence refs="reference12">Inoculation (ip) of RB51 into mice results in a splenic colonization which is cleared within four weeks post infection. RB51 does not revert to smooth colony morphology upon passage in vivo (mice) or in vitro (Schurig et al., 1991).</persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="">The CFU in spleen decreases 1-2 logs.</protection_efficacy>
			<side_effects refs="">No obvious symptoms were observed in immunized mice.</side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs="reference13">Vaccination of mice with RB51 induces specific cytotoxic T lymphocytes (CTLs) against strain RB51 and strain 2308-infected J774.A1 macrophages but not against Listeria monocytogenes-infected J774.A1 cells. Antigen-specific cytotoxic activity is exerted by T lymphocytes but not by NK cells. CD3+ CD4+ T cells secrete the highest level of IFN-γ and induce low but significant level of lysis of Brucella-infected macrophages. In contrast, CD3+ CD8+ T cells secrete low levels of IFN-γ but high levels of specific lysis of Brucella-infected macrophages. No nonspecific lysis was observed. Hence CD3+ CD4+ and CD3+ CD8+ T cells play synergistic roles in anti-Brucella activity (He et al., 2001).</description>
              <host_gene_response host_gene_response_id="host_gene_response1" gene_id="gene1">
			    <description refs="reference13">IFN-gamma is up-regulated in RB51-immunized mice (He et al., 2001).</description>
			  </host_gene_response>
		</host_response>
		<host_response host_response_id="host_response486" host_id="host12">
			<immune_response refs="reference689">Sera from all animals of RB51 vaccinated and control groups did not show anti-Brucella antibodies on Days −30, 0, 15, and monthly thereafter until the day of challenge (Poester et al., 2006).</immune_response>
			<host_strain refs="">Crossbreed</host_strain>
			<vaccination_protocol refs="reference689">At Day 0 of the experiment, heifers in the vaccinated group were divided in two sub-groups: 12 heifers were vaccinated at Day 0 of the experiment and the remaining 8 heifers were vaccinated at the 60th day of gestation, with a 2 mL dose. The heifers of the control group received 2 mL of sterile saline solution (Poester et al., 2006).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference689">Vaccination with RB51 vaccine did not result in the production of any antibodies against the O-side chain of lipopolysaccharide. The results indicate that vaccination with RB51 prevented 59.4% of abortions, 58.6% of cow infections, and 61.0% of fetal infections. The relative risk revealed that non-vaccinated animals have 2.462 times higher risk of aborting than RB51-vaccinated animals (Poester et al., 2006).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference689">All animals were challenged with the virulent B. abortus strain 2308. Each heifer received a 3.0 × 10^7 CFU challenge per heifer (Poester et al., 2006).</challenge_protocol>
			<description refs=""></description>
		</host_response>
		<host_response host_response_id="host_response500" host_id="host12">
			<immune_response refs="reference879">During the study period, supramammary (N = 303) and retro-pharyngeal (N = 342) lymph nodes and spleen (N = 298) samples from 343 sero-positive animals slaughtered due to brucellosis suspicion were submitted for culture. Brucella was isolated from 176 animals (51%). Similar isolation rates (39%) were observed for supramammary and retro-pharyngeal lymph nodes, but a lower rate was seen for spleen (7%) (Martins et al., 2009).</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference879">Mass vaccination of the cattle population of 3 Azore islands (Terceira, S. Miguel and S. Jorge) targeted breeding herds with the RB51 vaccine supplied by CZ Veterinaria S.A (Pontevedra, Spain).  It was administered to heifers or adult female cattle s.c. at 10–34 × 10^9/dose (2 ml).  In herds still infected with an intra-herd incidence of more than 10% after 6 months, all adults were re-vaccinated, as were adjacent herds (Martins et al., 2009).</vaccination_protocol>
			<persistence refs="reference879">During the study period, supramammary (N = 303) and retro-pharyngeal (N = 342) lymph nodes and spleen (N = 298) samples from 343 sero-positive animals slaughtered due to brucellosis suspicion were submitted for culture. Brucella was isolated from 176 animals (51%). Similar isolation rates (39%) were observed for supramammary and retro-pharyngeal lymph nodes, but a lower rate was seen for spleen (7%) (Martins et al., 2009).</persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference879">The overall trend is a regular decrease of the three parameters from the beginning of the vaccination programme up to the end of the study period.  Average herd incidence, herd prevalence and animal prevalence decreased 69.26%, 39.26% and 75.41% respectively, from 2002 to 2007 for the whole area.  Mean within-herd prevalence followed the same pattern, declining on a gradual pace until 2007 (Martins et al., 2009).</protection_efficacy>
			<side_effects refs="reference879">No side-effects, such as abortion were reported (passive reporting).  The only outstanding observation that could be related to vaccination was a weak newborn calf from which RB51 was isolated.  The annual number of human cases was also low (≤4) and none of them was due to RB51, but to field strain B. abortus biovar 1.  It was impossible to relate the disease occurrence in humans with the prevalence in animals (Martins et al., 2009).</side_effects>
			<challenge_protocol refs="reference879">n/a (Martins et al., 2009)</challenge_protocol>
			<description refs="reference879">RB51 vaccine supplied by CZ Veterinaria S.A (Pontevedra, Spain) (Martins et al., 2009).</description>
		</host_response>
		<host_response host_response_id="host_response137" host_id="host12">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference188">To establish the efficacy of RB51 in cattle, female calves were inoculated SC at 3, 5, 7, and 10 months, respectively with RB51 (n = 26), S19 (n = 22), or saline (n = 15) (Cheville, 2000). </vaccination_protocol>
			<persistence refs="reference188">B. abortus strain RB51 was cultured from biopsies of superficial cervical lymph nodes in heifers vaccinated with RB51 and S19 at 10 weeks, but not at 12 weeks  (Cheville, 2000).</persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference188">After vaccination, heifers administered  RB51 developed no serum antibodies that reacted in the agglutinate test , but yielded a positive dot -blot assay using  RB51  antigen . B. abortus strain  RB51  was cultured from biopsies of superficial cervical lymph nodes from cows challenged with RB51and S19 vaccines at 10 weeks , but not at 12 weeks. Three month old vaccinated heifers  were protected from infection and abortion; strain 19-vaccinated heifers were not infected nor aborted.  Control heifers were infected.  Vaccination at five and seven months of age gave equivalent, but less than complete protection. Heifers given strain 19 (n = 16) were protected 95%; those given RB51 were 87% protected; controls (administered saline) (n = 15) exhibited a high incidence of infection and abortion. No significant differences in the efficacy of either vaccine was found in animals at any given age. However, when compared to controls marked differences in the efficacy of each vaccine were noted. No gross or microscopic evidence of brucellosis was found in the tissues and organs of cows not infected at birth (Cheville, 2000).

All heifers vaccinated with RB51 at three months were protected against infection and abortion. Vaccination at five and seven months of age yielded equivalent protection. Heifers given strain 19 were 95% protected. In calves, the results obtained suggest that RB51 protects at dosage levels comparable to those of strain 19.(Cheville, 2000).</protection_efficacy>
			<side_effects refs="">In cattle, RB51 is less virulent than B. abortus cattle vaccine Strain 19.</side_effects>
			<challenge_protocol refs="reference188">Calves were bred at 16 to 17 months of age and challenged during the first pregnancy with virulent B. abortus (Cheville, 2000).
</challenge_protocol>
			<description refs="reference188">Strain RB51 is protective in cattle at doses comparable to those of strain 19 (Cheville, 2000).  Brucella abortus strain  RB51 is the  vaccine  of choice against brucellosis of  cattle  in the United States .</description>
		</host_response>
		<host_response host_response_id="host_response501" host_id="host27">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference880">Thirty Brucella-free female buffaloes were divided in three groups.  Group A consisted of 10 non-pregnant water buffaloes 4–5 years old that were vaccinated once with RB51 (10.2 × 10^10 CFU/ml) during lactation.  Group B consisted of 10 adult water buffaloes 28–36 months old at the first lactation that were previously vaccinated twice (4 weeks apart) as calves (6–9 months old) with 10.2 × 10^10 CFU/ml RB51, but were not revaccinated with RB51 as adults.  Group C consisted of 5 adults 4–5 years old during the fourth month of lactation and 5 adult water buffaloes 28–36 months old at the first lactation that were not vaccinated (controls) (Longo et al., 2009).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference880">RB51 was identified from milk samples collected during the first week post-vaccination (days 1 and 4) in 3/10 of the vaccinated animals of group A but was never isolated in groups B and C.  Moreover, RB51 DNA was detected during the first week until the fourth week post-vaccination in the milk samples from group A but was not detected in milk samples of the animals of B and C (Longo et al., 2009).</protection_efficacy>
			<side_effects refs="reference880">No side effects attributable to vaccine administration were noted in any treatment group. All the experimental water buffaloes appeared clinically normal throughout the study (Longo et al., 2009).</side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
		<host_response host_response_id="host_response502" host_id="host28">
			<immune_response refs="reference881">On examination, all livers displayed hepatocellular vacuolization with a pronounced centrilobular pattern consistent with lipidosis and occasional multifocal areas of pleocellular infiltrates consisting of small and large mononuclear cells, suggesting mild hepatitis.  One animal in the RB51 group also had focal necrotizing hepatitis.  Other lesions observed in these animals included multifocal interstitial pyogranulomatous nephritis and nephrosis, focal necrotizing pancreatitis, and sparse mononuclear cellular infiltrates in the oviduct and uterus (Nol et al., 2009).</immune_response>
			<host_strain refs="">Richardson's ground squirrel</host_strain>
			<vaccination_protocol refs="reference881">Each Richardson’s ground squirrel received 250 µl of inoculum directly into the mouth via tuberculin syringe.  All squirrels were observed twice daily for clinical signs for 21 days and once daily thereafter.  RB51, strain 19 (S19), and virulent B. abortus strain 9941 (S9941) were administered orally to squirrels to further characterize B. abortus infection in this species.  Six groups of nongravid ground squirrels were orally inoculated with 6 x 10^8 CFU RB51, 2.5 x 10^4 CFU S19, 2.5 x 10^7 CFU S19, 1.3 x 10^6 CFU S9941, 2.1 x 10^8 CFU S9941, or vaccine diluent (control) (Nol et al., 2009).</vaccination_protocol>
			<persistence refs="reference881">One of 5 animals in the lower-dose S19 group and 2 of 3 animals in the higher-dose S19 group showed persistence of bacteria in various tissues at 14 weeks post-inoculation (WPI).  At 18 WPI, 1/5 animals in the RB51 group and 1/5 animals in the high-dose S9941 group were
culture positive.  There was a general lack of persistence of the three strains of B. abortus in Richardson’s ground squirrels at 18 wk PI (Nol et al., 2009).</persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference881">It is unknown if and when the three animals that were culture positive at 14 wk and the two positive animals at 18 wk may have cleared the infection if given more time.  No evidence of shedding of RB51 or S19 beyond 2 days PI, and only 2/25 animals cultured at 18 wk showed evidence of persistent infection.  Even if infected, squirrels are unlikely to be severely affected by B. abortus or serve as sources of Brucella in the field (Nol et al., 2009).</protection_efficacy>
			<side_effects refs="reference881">There was no evidence of pathology caused by B. abortus strains in nonpregnant squirrels based on clinical signs, gross lesions, and microscopic lesions (Nol et al., 2009).</side_effects>
			<challenge_protocol refs="reference881">Richardson’s ground squirrels experience minimal clinical signs and pathology at challenge levels ranging from 2.5 x 10^4 CFU to 6 x 10^8 CFU (Nol et al., 2009).</challenge_protocol>
			<description refs="reference881">In summary, RB51, S19, and S9941 do not produce disease in nonpregnant Richardson’s ground squirrels when given orally at challenge doses ranging from 2.5 x 104 cfu to 6 x 108 cfu.  This species is unlikely to act as a reservoir or source of infection for either vaccine or wild type strains of B. abortus.  The Richardson’s ground squirrel would be a poor model for oral Brucella infection as well.  These data provide useful information for researchers and those charged with the management of brucellosis in wildlife in the GYA (Nol et al., 2009).</description>
		</host_response>
		<host_response host_response_id="host_response504" host_id="host30">
			<immune_response refs=""></immune_response>
			<host_strain refs="">Bison (Bison bison)</host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
		<host_response host_response_id="host_response505" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">CD1</host_strain>
			<vaccination_protocol refs="reference883">Four groups of 10 female CD1 mice per group (5-6 weeks old) were vaccinated intraperitoneally (IP) with 3-5 x 10^8 CFU in 100 µl of RB51, RB51leuB, RB51leuB/pNS4, or RB51leuB/pNS4/GFP.  Another group of 10 mice were vaccinated with saline to serve as a negative control.  Three mice from each group were bled at 5 weeks post-vaccination to harvest serum.  The sera were screened for GFP-specific antibodies by immunoblot (Rajasekaran et al., 2008).</vaccination_protocol>
			<persistence refs="reference883">Mice vaccinated with the leuB mutant and the complemented RB51leuB strains were able to clear the virulent challenge strain B. abortus 2308 (S2308) at significant rates compared with clearance in the mice vaccinated with saline.  No significant difference was observed in the rates of clearance of the challenge strain in the mice vaccinated with auxotrophic vaccine strains and the standard strain RB51 and also between the RB51leuB strains.  In a separate experiment, the leuB auxotroph and the complemented leuB auxotroph were found to be cleared from CD1 mouse spleens by 4 to 5 weeks, at the same rate as the parent vaccine strain RB51 (Rajasekaran et al., 2008).</persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference883">The leuB/GFP construction was shown to complement a leucine auxotroph of RB51, which protected CD1 mice from virulent B. abortus 2308 (S2308) and elicited GFP antibodies.  The leuB auxotroph and the complemented auxotroph of strain RB51 were able to protect the CD1 mice against an S2308 challenge.  There was no significant difference in the protection levels (as measured by splenic clearance) afforded by the leuB auxotroph when the protection levels in the mice vaccinated with the complemented leuB auxotroph and with the complemented leuB auxotroph expressing GFP were compared to the protection level in the mice vaccinated with strain RB51.  There was, however, a significant difference in protection afforded between the mice vaccinated with any of the RB51 strains and the saline control.  Only sera from the group inoculated with RB51leuB/pNS4/GFP possessed GFP-specific antibodies (Rajasekaran et al., 2008).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference883">At 6 weeks post-vaccination, all groups of mice were challenged IP with 4 x 10^4 CFU of B. abortus strain 2308 (S2308).  At 2 weeks post-challenge, mice were euthanized by CO2 asphyxiation, and their spleens were recovered, homogenized, serially diluted, and plated on trypticase soy agar (TSA) plates to estimate CFU (Rajasekaran et al., 2008).</challenge_protocol>
			<description refs=""></description>
		</host_response>
		<host_response host_response_id="host_response506" host_id="host3">
			<immune_response refs="reference891">(Olsen et al., 2007)</immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference891">To characterize the optimal aerosol dosage of Brucella abortus strain 2308 (S2308) and B. melitensis (S16M), 10^3–10^10 CFU were nebulized to BALB/c mice.  A range of dosages was evaluated to determine optimal dosages for aerosolization.  Protection in vaccinated and non-vaccinated mice were compared after experimental B. abortus challenge via IP and aerosol routes.  For aerosol delivery, the nebulization apparatus consists of a compressed air tank and a jet nebulizer connected via a rubber hose to a port in a metal cage cover.  A flow rate of 2 l/min produces a 5 ml particle size.  Compressed air was used to jet nebulize 2 ml of challenge inoculum directly into a plexiglass cage containing 5 mice.  Nebulization continued until all inoculum, plus 2 ml saline was delivered over ~15 min.  
Experiment 1:  S2308 or S16M were spectrophotometrically adjusted to concentrations between 10^3 and 10^10 CFU and delivered by aerosol to female 10-week-old BALB/c mice.  At 2 weeks after nebulization, mice were euthanized with CO2.  Spleen, liver, and lung from each mouse were removed and weighed.  Tissues were macerated and serially diluted, with standard plate counts used to determine bacterial concentrations.
Experiment 2:  Mice were injected IP with 0.2 ml of saline +/- ~1 x 10^7 CFU of SRB51.  At 12 weeks after vaccination, mice were challenged with S2308 IP (0.2 ml saline + 5 x 10^4 CFU) or via nebulization (~10^9 CFU).  Two weeks after challenge, mice were euthanized with CO2.  Spleens, livers and lungs were weighed and processed for isolation and quantification of Brucella as described in Experiment 1.
(Olsen et al., 2007)</vaccination_protocol>
			<persistence refs="reference891">Total CFU per tissue increased beginning at 10^6–10^7 CFU dosages, with 10^9 CFU appearing to be an optimal dosage for S16M or S2308 aerosol delivery. 
(Olsen et al., 2007)</persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference891">Mice vaccinated with SRB51 had reduced splenic, liver and lung colonization after IP challenge with S2308 as compared with control mice after IP S2308 challenge.  Control and SRB51-vaccinated mice did not differ in splenic, liver, or lung colonization after aerosol S2308 challenge.  
(Olsen et al., 2007)</protection_efficacy>
			<side_effects refs="reference891">(Olsen et al., 2007)</side_effects>
			<challenge_protocol refs="reference891">At 12 weeks after vaccination with 10^7 CFU of SRB51 or saline (control), mice were challenged IP with 6.4 x 10^4 CFU or via aerosol (1.76 x 10^9 CFU) with S2308.
(Olsen et al., 2007)</challenge_protocol>
			<description refs="reference891">(Olsen et al., 2007)</description>
		</host_response>
		<host_response host_response_id="host_response507" host_id="host3">
			<immune_response refs="reference892">(Pasquali et al., 2003)</immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference892">Investigators evaluated the effect of oral inoculation (PO) of Brucella abortus RB51 in BALB/c female mice against a challenge infection with B. abortus (S)2308.  For IP immunization with live bacteria, mice were given 2 x 10^8 CFU of B. abortus RB51 in 0.2 ml of sterile saline or 2 x 10^4 CFU of strain S2308.  For PO immunization, a gastric lavage needle was used.  Ten minutes prior to oral inoculation, mice were administered 0.2 ml of 10% sodium bicarbonate (NaHCO3) to neutralize gastric acidity or 0.2 ml of sterile saline.  Mice were inoculated PO with 2 x 10^10 CFU of RB51 or S2308.  On days 10 and 18 after PO RB51 or S2308, preceded or not by gastric acidity neutralization, mice were killed and their spleens removed.  Spleens were homogenized in 1 ml of sterile saline.  Aliquots of the resulting suspensions were plated to assess spleen colonization.
In separate experiments, mice were inoculated PO with RB51.  Oral inoculation was preceded by gastric acidity neutralization. To evaluate the excretion of bacteria after oral exposure, fecal samples were collected daily for 3 days after inoculation.  At 7, 15, 30, and 42 days after infection, mice were bled and killed and spleens were aseptically removed, weighed, homogenized in PBS, and plated to determine the outcome of infection (Pasquali et al., 2003).</vaccination_protocol>
			<persistence refs="reference892">Gastric acid neutralization prior to the oral inoculation contributed to a more homogeneous and consistent infection with both RB51 and S2308.  Clearance and immune response following oral infection with RB51 was successively assessed.  PO inoculation gave a mild infection, which was cleared 42 days later and induced a delayed humoral and cell-mediated immune (CMI) response (Pasquali et al., 2003).</persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference892">PO RB51 was able to protect mice infected with S2308 PO but not to mice infected IP.  Results indicate that oral inoculation of mice with RB51 is able to give protective immunity against oral infection with virulent strains and that this protection seems to rely on an immune response at the mucosal level (Pasquali et al., 2003).</protection_efficacy>
			<side_effects refs="reference892">(Pasquali et al., 2003)</side_effects>
			<challenge_protocol refs="reference892">Finally, they immunized mice PO with RB51 and challenged them with S2308 PO or intraperitoneally (IP) 42 days after vaccination.  Mice were PO vaccinated with RB51 preceded by gastric acidity neutralization or were IP inoculated with RB51 as mentioned above.  Additional mice served as unvaccinated controls.  PO and IP vaccinated mice and controls were challenged PO (2 x 10^10 CFU) or IP (2 x 10^4 CFU) with S2308 42 days after vaccination.  PO challenge was preceded by gastric acid neutralization.  Mice were bled and killed at 18 days after challenge.  Spleens were weighed and homogenized to determine CFU as a means for assessing the protective response induced by vaccination.  Sera were used to evaluate antibody titer against both S2308 and RB51 (Pasquali et al., 2003).</challenge_protocol>
			<description refs="reference892">(Pasquali et al., 2003)</description>
		</host_response>
		<host_response host_response_id="host_response508" host_id="host3">
			<immune_response refs="reference894">(Ko et al., 2002)</immune_response>
			<host_strain refs="">C57BL/6 (IRF-1-/-)</host_strain>
			<vaccination_protocol refs="reference894">S2308 (the virulent wild-type Brucella abortus strain), S19 and RB51 (live attenuated vaccine strains), cyd and cbp (insertional mutants), and bap (deletion mutant) were used in this experiments.  Interferon regulatory factor 1-deficient (IRF1-/-) mice were originally produced by using C57BL/6 (H-2b) mice.  IRF1-/- mice were injected IP with diverse strains and CFU of B. abortus in 200 ul of PBS (Ko et al., 2002).</vaccination_protocol>
			<persistence refs="reference894">To count residual CFU in the spleens or livers of mice, 5 mice from each group were examined at each sampling period.  Brucella colonies were counted after a 3-day incubation.  Serum glutamic oxalacetic transaminase (GOT) and glutamic pyruvic transaminase (GPT) were also quantitatively measured (Ko et al., 2002).</persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference894">Interferon regulatory factor 1-deficient (IRF1-/-) mice infected with virulent Brucella abortus (S)2308 at 5 x 10^5 CFU developed acute hepatitis similar to many natural hosts but, unlike natural hosts, IRF1-/- mice were unable to resolve infection and died.  In contrast, IRF1-/- mice survived when infected at 5 x 10^5 CFU with several attenuated Brucella strains (S19, RB51, cbp, and cyd).  Brucella-infected mice were also killed 12 days post-infection for histologic analysis (Ko et al., 2002).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference894">After 6 weeks, surviving IRF1-/- mice were challenged with 5 x 10^5 CFU of S2308 in 200 ul of PBS (Ko et al., 2002).</challenge_protocol>
			<description refs="reference894">(Ko et al., 2002)</description>
		</host_response>
		<host_response host_response_id="host_response509" host_id="host3">
			<immune_response refs="reference886">Antibody and cytokine responses were Th1-focused in young mice, but Th-mixed in old mice, including evidence of the Th17 subtype immune response (High et al., 2007).</immune_response>
			<host_strain refs="">BALB/c, DBA/2</host_strain>
			<vaccination_protocol refs="reference886">Young (2–3 month old) or old (16–18 month old) adult female mice (DBA/2 or BALB/c) were infected with either an attenuated Brucella abortus strain that over-expressed superoxide dismutase (RB51-SOD) or with a fully virulent wild-type strain (S2308).  They were inoculated intra-peritoneally (IP) with 3.4 x 10^7 CFU or 6 x 10^8 CFU RB51-SOD, or with 2 x 10^4 or 4 x 10^9 CFU S2308.  Uninfected control mice were injected with saline alone.  Spleens harvested after sacrifice were cultured quantitatively for Brucella.  Splenocytes (80–120 x 10^6) from mice were harvested and cultured in the presence of heat-killed B. abortus, purified SOD, or the mitogen concanavalin A (conA).  Supernatants were assayed for the presence of cytokines by protein array and ELISA, semi-quantitatively measured by densitometry and the intensity of a given dot-blot compared to the mean of the positive control dots.  Blood was obtained via retro-orbital bleeds. Total IgG, IgG1 and IgG2a titers vs. two Brucella proteins, bacterioferritin (BFR) and Cu++/Zn++ SOD, were assessed by ELISA (High et al., 2007).</vaccination_protocol>
			<persistence refs="reference886">All young and old mice survived infection with RB51-SOD (up to 6 x 1^08 CFU) or S2308 (up to 8 x 10^8 CFU).  Old mice had a lower organism burden in the spleen than young mice 5 or more weeks after infection (High et al., 2007).</persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference886">Immunization with the RB51-SOD strain provided protection vs. strain 2308 challenge in young and aged BALB/c, but only young DBA/2 mice (High et al., 2007).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference886">For protection studies, mice were either immunized with 4 x 10^8 CFU RB51-SOD or saline as a control and allowed to recover for 5 weeks.  Mice were then infected with 2 x 10^4 CFU S2308 and sacrificed 2 weeks later for determination of CFU/spleen as above (High et al., 2007).</challenge_protocol>
			<description refs=""></description>
		</host_response>
		<host_response host_response_id="host_response510" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference895">Protection was assessed by a variety of serological tests and recovery of vaccinal and challenge strains by culture.  Mice vaccinated with RB51 gave negative results in the conventional serological tests prior to challenge, standard tube agglutination test (SAT), Rose Bengal plate test (RBPT), buffered acidified plate antigen test (BAPAT), and mercaptoethanol test (MET).  Sero-conversion took place to a whole-cell bacterial buffered RB51 antigen after vaccination and persisted for 7 weeks post-vaccination.  Mice challenged with B. melitensis were assessed for bacterial load and immune response for 12 weeks after challenge.  Protection units were showed that Rev. 1 vaccine was superior to RB51 vaccine in protection of mice against B. melitensis (Hamdy et al., 2002).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference895">Mice were challenged with a B. melitensis field strain.  The humoral immune responses induced in mice after vaccination and challenge were detected by the standard tube agglutination test (SAT), mercaptoethanol test (MET), Rose Bengal plate test (RBPT), and buffered acidified plate antigen test (BAPAT).  The detection of immune responses induced by the RB51 vaccine was measured by RB51 killed antigen.  Mice were bled under anesthesia from the retroorbital sinus or from heart puncture. Sera were stored at -70C unless used on the same day.  Five animals from each of the first and the second groups were sacrificed by CO2 asphyxiation at weekly intervals. Detection of Brucella vaccinal strains in internal organs (spleen, liver and lung) was done at weekly intervals.  Two weeks after elimination of the vaccinal strains from the internal organs and disappearance of any serological reactions, the remaining animals and control were challenged with 5 x 10^5 cfu of B. melitensis i.p. in 0.2 ml PBS. Five of the challenged animals from each group were sacrificed every week until the end of the experiment. Sacrificed animals were subjected to serological and bacteriological investigations.  Bacteriological examinations and viable counts of the Brucella organisms per spleen following challenge were carried out.  Identification of the rough form of the RB51 vaccinal strain was achieved by auto-agglutination reaction with acriflavine solution (1/1000) and the ability to stain with crystal violet (Hamdy et al., 2002).</challenge_protocol>
			<description refs=""></description>
		</host_response>
		<host_response host_response_id="host_response511" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference896">This study determined if murine interleukin-12 (IL-12) would influence immunity in mice vaccinated with live or killed Brucella abortus strain RB51 (SRB51).  Mice received live or irradiated SRB51 bacteria alone, or with IL-12 (0.5 or 1.0 jig, 2x or 3X), whereas other mice received saline or IL-12 alone.  Specifically, female 10-week-old BALB/c AnNHsD mice (n = 12/group) were vaccinated intraperitoneally (IP) with 0.2 mL of saline containing 3 x 10^8 CFU of live SRB51 alone, or combined with 0.5 or 1.0 ug of murine recombinant IL-12, administered thrice (days 0, 5, and 21).  Additional mice were vaccinated IP with 0.2 mL of saline containing 3 x 10^8 CFU of irradiated SRB51 alone, or combined with 0.5 or 1.0 ug of IL-12 administered twice (days 0 and 5) or thrice.  Other mice were injected IP with 0.2 mL of saline alone or with saline containing 0.5 or 1.0 ug of IL-12 administered twice or thrice  (Lee et al., 2001).</vaccination_protocol>
			<persistence refs="reference896">Post-vaccination antibody responses to live or killed SRB51 and clearance of live SRB51 from splenic tissue were not influenced by IL-12 treatments (Lee et al., 2001).</persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference896">The highest IL-12 treatment increased post-challenge antibody responses when co-administered with killed SRB51.  Co-administration of 1.0 ug of IL-12 with live SRB51, but not killed SRB51, reduced S2308 colonization of splenic tissues.  Following euthanasia with C02/02 at 2 wk after S2308 challenge, blood, spleens, and livers were obtained from all mice. Spleens were weighed, approximately onehalf was excised for bacteriologic examination and weighed, and remaining tissue was used to prepare spleen cell suspensions.  Following weighing, the entire liver was designated for bacteriologic examination. Tissue for bacteriologic examination was stored at -69°C until processed (Lee et al., 2001).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference896">Mice were challenged at 12 weeks with 4 x 10^4 CFU of B. abortus strain 2308 (S2308) and were euthanized 2 weeks later.  Remaining mice (n = 8/trt) were challenged IP with 4 X 104 cfu of S2308 at 12 wk after vaccination. The time of challenge was based on data from previous studies which demonstrated that a dosage of 5 X 108 cfu of SRB51 is cleared from BALB/c mice by 12 wk after IP vaccination (Lee et al., 2001).</challenge_protocol>
			<description refs=""></description>
		</host_response>
		<host_response host_response_id="host_response512" host_id="host3">
			<immune_response refs="reference897">After vaccination, both Th1 and Th2 cytokine patterns were observed. Of those, the early production of gamma interferon seems to have the prominent role in inducing an immunologically based protection.  Spleen weight in vaccinated and infected mice did not increase after challenge and were not significantly different from nonchallenged, vaccinated animals killed 42 days after vaccination.  In contrast, spleen weights of unvaccinated and infected mice showed a significant enlargement as early as 6 days after infection.  Vaccinated mice were almost refractory to a subsequent challenge infection with B. abortus 2308 cells, exhibiting significantly lower levels of infection compared to unvaccinated infected animals after infection.  Vaccination alone induced a number of significant effects upon cytokine expression.  Spleen cells from unvaccinated mice stimulated with heat-inactivated RB51 cells did not produce measurable cytokines throughout the course of the experiment.  Similarly, spleen cells from vaccinated mice killed 6 and 18 days after vaccination did not produce measurable bio-active IL-12 (p70) when stimulated in vitro, but a low level of production was detectable in spleen cells from mice killed 42 days after vaccination (Pasquali et al., 2001).</immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference897">The present study was performed to delineate cytokine induction after intraperitoneal (IP) administration of Brucella abortus strain RB51 and subsequent infection with virulent strain B. abortus S2308.  Twelve- to 14-week-old BALB/c female mice were allocated to experimental groups consisting of five animals each.  Mice were vaccinated IP with 0.2 ml of saline containing 2 x 10^8 CFU of RB51.  Unvaccinated control animals remained untreated throughout the experiment (Pasquali et al., 2001).</vaccination_protocol>
			<persistence refs="reference897">Vaccinated mice had higher spleen weights when compared to control animals after vaccination.  Vaccination of mice with live RB51 resulted in a pattern of bacterial growth in which peak numbers were seen 18 days after vaccination, followed by a progressive decline.  Bacteria were absent in the spleen at 42 days postvaccination. Counts on days 6 and 18 were significantly different (Pasquali et al., 2001).</persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference897">RB51 confers a solid immunity that protects mice against a challenge infection with virulent B. abortus 2308. After vaccination, both Th1 and Th2 cytokine patterns were observed. Protection may be more dependent upon the timing of the cytokine response rather than on the absolute level of cytokine expression. Challenge infection of vaccinated and nonvaccinated mice induced even more marked increases in cytokine expression patterns.  IL-12 p40 was detectable in spleen cells from both vaccinated and unvaccinated mice after challenge infection, and there were no significant differences between vaccinated and unvaccinated mice.  Similar results were seen throughout the course of the experiment for IL-12 p70 production, which was low at all times in all groups of mice.  In contrast, IFN- production was detectable as early as 3 days after challenge infection in spleen cells from both vaccinated and unvaccinated mice, although levels were significantly higher in vaccinated mice.  Levels of IFN in spleen cells from vaccinated, challenged mice showed no differences throughout the experiment, in contrast to spleen cells from unvaccinated, challenged mice which showed increased IFN production that reached levels seen in spleen cells from vaccinated, challenged mice 6 days after challenge.  After challenge infection, low levels of IL-4 were detectable, reaching a peak in spleen cells 6 days after challenge. However, levels were not different between vaccinated and unvaccinated mice. IL-10 showed a pattern similar to that of IFN-. IL-10 was detectable in both vaccinated and unvaccinated mice after challenge infection.  However, vaccinated and challenged animals did not show any differences at different times after challenge.  Conversely, IL-10 production in unvaccinated, challenged mice was first detectable 6 days after challenge infection and reached a peak 10 days after challenge infection.  Results of this study indicated that mice vaccinated with RB51 cells were protected as early as 3 days after a challenge infection with virulent B. abortus 2308 cells. In vaccinated mice, challenge infection resulted in high levels of IL-10 production at all times tested. In contrast, in unvaccinated mice, IL-10 production reached levels comparable to that in the vaccinated mice beginning 6 days after infection. Previous studies indicate that both IL-10 and IFN- are produced following a B. abortus infection and that IL-10 induction does not down-regulate IFN- production. This implies that in brucellosis, the effect of IL-10 on the immune response is to limit the consequences of an exaggerated proinflammatory response more than to counterbalance the production of Th1 cytokines. These findings are in agreement with others which measured IL-10 production following Brucella infection (Pasquali et al., 2001).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference897">At 42 days after vaccination, unvaccinated controls and IP vaccinated mice were challenged IP with 0.2 ml of saline containing 2 x 10^4 CFU of B. abortus 2308.  At 6, 18, and 42 days after vaccination and 3, 6, and 10 days after challenge, mice were euthanatized and spleens were aseptically removed.  Approximately one-third of the spleen was weighed and homogenized in PBS, and an aliquot of the resulting cell suspension was plated to determine the number of CFU.  The remaining 2/3 of the spleens were weighed, minced, and used to prepare spleen cell suspensions.  Cytokine expression was assayed in culture supernatants of splenocytes stimulated with 10^8 heat-inactivated B. abortus RB51 or 2308 bacteria per well.  Cytokines were detected by ELISA according to the manufacturer’s instructions (Pasquali et al., 2001).</challenge_protocol>
			<description refs=""></description>
		</host_response>
		<host_response host_response_id="host_response513" host_id="host3">
			<immune_response refs="reference898">Nine of the 20 (45%) orally inoculated (PO) RB51 mice necropsied in the first 4 wk post-inoculation (WPI) had mild multifocal pleocelluar inflammatory infiltrates in the liver; 3/25 (12%) PO RB51 mice necropsied after 4 WPI had similar lesions.  All 10 of the RB51 IP mice necropsied in the first 2 WPI had multifocal pleocellular inflammatory infiltrates in the liver; 2/10 (20%) RB51 IP mice necropsied 3-4 WPI had similar lesions, and only 1 necropsied after 4 WPI from this group had these lesions.  Generally, lesions in the IP group were more severe (more cellular infiltrates) than in the PO RB51 group.  Lesions were milder in mice at longer times PI.  One PO RB51 male mouse necropsied 5 WPI had a mild lymphocytic infiltrate in the interstitium of the seminal vesicle, but no RB51 was recovered from the spleen.  Culture results were usually correlated with histologic lesions.  Mice with the highest number of colonies of RB51 isolated were those with the most severe lesions (Cook et al., 2001).</immune_response>
			<host_strain refs="">Deer mouse (Peromyscus maniculatus)</host_strain>
			<vaccination_protocol refs="reference898">This study was designed to determine effects of strain RB51 on deer mice (Peromyscus maniculatus), a nontarget species that could have access to treated baits in a field situation.  90 mice were orally dosed (PO) or intraperitoneally injected (IP) with 1 x 10^8 colony forming units (CFU) strain RB51, and 77 controls were similarly dosed with sterile saline.  At weekly intervals for 2 months, 4-6 mice from each group were euthanized, gross necropsies performed, spleens and uteruses cultured, and tissues examined histologically (Cook et al., 2001).</vaccination_protocol>
			<persistence refs="reference898">All PO inoculated mice cleared the infection by 6 weeks post-inoculation (wpi).  While most of the injected mice cleared the infection by 7 wpi, a few required 9 w.  With one possible exception (see below), no lesions attributable to brucellosis were noted on gross necropsy.  Mice orally inoculated with RB51 developed low level splenic infections with strain RB51, but all were negative by 6 wk PI.  RB51 was isolated from the uterus of one orally inoculated mouse necropsied 2 wk PI; no other orally inoculated mouse had a uterine infection.  IP inoculated mice had a higher rate of splenic and uterine infections and took longer to clear the infections than orally inoculated mice with some remaining positive at 8 wk PI (Cook et al., 2001).</persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs="reference898">There were minimal adverse effects attributable to strain RB51.  RB51 would not negatively impact P. maniculatus populations if it were used in a field situation.  Incidental findings found in some mice in all groups included: mild myocarditis (19% of controls; 30% of RB51 inoculates), mild metritis (10% of controls; 5% of RB51 inoculates), mild multifocal pyogranulomatous pneumonia (8% of controls; 5% of RB51 inoculates), and nematodes in the small intestines and/or cecum (54% of controls; 33% of RB51 inoculates).  In a field situation, deer mice would only be exposed to the vaccine PO and not IP.  All the orally exposed animals remained clinically healthy with no evidence of illness.  Orally exposed mice had fewer CFU cultured from their spleens and uteruses, cleared the vaccine more quickly, and had milder lesions than mice inoculated IP.  Strain RB51, with the possible exception of one IP inoculated animal, did not cause significant morbidity or mortality (Cook et al., 2001).</side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
		<host_response host_response_id="host_response514" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">Deer mice (Peromyscus maniculatus)</host_strain>
			<vaccination_protocol refs="reference889">Deer mice (Peromyscus maniculatus, n = 14) were orally inoculated (PO) with Brucella abortus strain SRB51 or physiologic saline.  Oral and rectal swabs and blood samples were collected for bacteriologic evaluation.  Rodents were necropsied at 8-10 wk and 12-21 wk post inoculation (WPI).  Spleen, liver and reproductive tissues were collected for bacteriologic and histopathologic evaluation (Januszewski et al., 2001).</vaccination_protocol>
			<persistence refs="reference889">No differences in clinical signs, appetite, weight loss or gain, or activity were observed between saline- and SRB51-inoculated animals.  Oral and rectal swabs were negative throughout the study.  In tissues obtained from SRB51-inoculated animals, the organism was isolated from 1/6 (17%) deer mice necropsied at 8 WPI.  SRB51 was not recovered from deer mice necropsied 12 WPI.  SRB51 was not recovered from saline-inoculated deer mice at any time.  Results indicate oral exposure to SRB51 does not produce morbibity or mortality in deer mice (Januszewski et al., 2001).</persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs="reference889">One SRB51-inoculated mouse died immediately after inoculation, and one control mouse died at 4 days PI.  Deaths were attributed to handling and probable aspiration of the inoculum.  Results indicate oral exposure to SRB51 does not produce morbibity or mortality in deer mice (Januszewski et al., 2001).</side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
		<host_response host_response_id="host_response515" host_id="host3">
			<immune_response refs="reference13">RB51 vaccination of mice induces specific CTLs and suggest that CD3+ CD4+ and CD3+ CD8+ T cells play a synergistic role in the anti-Brucella activity.  Specifically, Brucella abortus strain RB51 vaccination of mice induced specific cytotoxic T lymphocytes (CTLs) against both RB51- and virulent strain 2308-infected J774.A1 macrophages but not against Listeria monocytogenes-infected J774.A1 cells.  The antigen-specific cytotoxic activity was exerted by CTLs but not by NK cells.  CD3+ CD4+ T cells secreted the highest level of gamma interferon (IFN) and were able to exert a low but significant level of specific lysis of Brucella-infected macrophages.  They also exerted a low level of nonspecific lysis of noninfected macrophages.  In contrast, CD3+ CD8+ T cells secreted low levels of IFN-g but demonstrated high levels of specific lysis of Brucella-infected macrophages with no nonspecific lysis (He et al., 2001).</immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference13">Six-week-old BALB/c female mice were inoculated intraperitoneally (IP) with 4 x 10^8 CFU of Brucella abortus strains RB51 or S2308 or the same volume of saline (negative control).  The mice were euthanatized at 6 weeks postimmunization (wpi) by CO2 inhalation.  These mice served as splenocyte sources for CTL assays.  Splenocytes from strain RB51-infected or saline-inoculated mice were resuspended in 2 ml of c-RPMI and passed through nylon wool columns to enrich for cytotoxic T lymphocytes (CTLs).  After 5-day incubation, cells were collected, and live effector cells were obtained by removing dead cells by Histopaque centrifugation.  CTLs were also collected and used for flow cytometric analysis, magnetic cell sorting, and colorimetric CTL assay (He et al., 2001).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference13">RB51 vaccination of mice resulted in the development of a strong cytotoxic T-cell (CTL) response.  The specific anti-Brucella cytolytic activity was mainly exerted by CD3+ CD8+ T cells.  CD3+ CD4+ T cells also developed after immunization, secreted high levels of IFN, and exhibited certain levels of specific and nonspecific lytic activity against Brucella-infected target cells.  NK cells appeared not to contribute significantly to the observed Brucella-specific cytotoxic activity (He et al., 2001).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
		<host_response host_response_id="host_response516" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference899">This study was designed to determine if a single 0.5 ug administration of recombinant murine interleukin-12 (IL-12) would influence immune responses of mice vaccinated with live or killed Brucella abortus strain RB51 (SRB51).  A total of 180 (n = 30/treatment) female 10-week-old BALB/c AnNHsD mice were vaccinated intraperitoneally (IP) with 0.2 mL of saline containing 5 x 10^8 cfu of live or gamma-irradiated SRB51 bacteria alone, or in combination with 0.5 ug of IL-12.  Control mice received saline +/- 0.5 ug of IL-12 (Lee et al., 1999).</vaccination_protocol>
			<persistence refs="reference899">Mice vaccinated with live SRB51 or live SRB51+IL-12 had greater serum antibody titers against SRB51 at 2, 4, 8, and 12 wpv when compared to all other treatments.  When combined with live or killed SRB51, IL-12 as an adjuvant did not influence serologic responses at 2, 4, 8, or 12 wpv.  In the absence of IL-12 as an adjuvant, spleen cells obtained at 12 wk after IP vaccination with live SRB51 had greater stimulation indexes against irradiated S2308 when compared to responses of spleen cells from other treatments.  Administration of IL-12 as an adjuvant with live or killed SRB51 did not enhance lymphocyte proliferative responses to S2308 (Lee et al., 1999).</persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference899">The clearance of SRB51 from spleens of mice vaccinated with live SRB51 alone, or in combination with IL-12, did not differ at 2, 4, 8, or 12 wk after vaccination.  At 12 wk after vaccination, spleens of mice vaccinated with either live SRB51 or live SRB51+IL-12 were culture negative for SRB51.  IL-12 did not influence the clearance of strain RB51 from splenic tissue.  Spleen weights of mice vaccinated with live SRB51 or live SRB51+IL-12 were greater at 2, 4, 8, or 12 wpv when compared to saline controls, IL-12 controls, or mice receiving either vaccination treatment using killed SRB51.  Addition of exogenous IL-12 to culture supernatants of spleen cells obtained at 4 and 8 wk, but not at 2 or 12 wpv, enhanced lymphocyte proliferative responses of all vaccine treatments.  Maximal enhancement of lymphocyte response was associated with 
the addition of IL-12.  Mice vaccinated with live SRB51 (5 X 108 cfu) had lower spleen weights, total spleen cfu, and spleen cfu/g following challenge at 12 wk after vaccination when compared to mice receiving saline control, IL-12 control, or killed SRB51 treatments.  Administration of IL-12 as an adjuvant with live or killed SRB51 did not enhance resistance against experimental challenge with S2308 (Lee et al., 1999).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference899">Mice (n = 10/treatment) were challenged IP with 2 X 10^4 cfu of S2308 at 12 weeks post-vaccination (wpv).  Blood samples and spleens were obtained from mice in all treatments after CO2/O2 euthanasia at 2, 4, 8, and 12 wpv (n = 5/treatment/time).  Following C02/02 euthanasia at 2 weeks after S2308 challenge (wpc), blood and spleens were obtained from mice in all treatments (n = 10/treatment).  Cells from 5 mice from each treatment were evaluated separately at 2, 4, 8, and 12 wpv.  Following S2308 challenge, spleen cell suspensions from 10 mice from each treatment were combined into 5 separate suspensions (2 mice/suspension, 5 suspensions/treatment) for evaluation of lymphocyte proliferative responses.  Cell proliferation results were expressed as stimulation indices (counts/min in presence of antigen divided by counts/min in medium only) (Lee et al., 1999).</challenge_protocol>
			<description refs=""></description>
		</host_response>
		<host_response host_response_id="host_response517" host_id="host3">
			<immune_response refs="reference900">Oral SRB51 vaccination induced lower levels of antibodies to the surface antigens of intact SRB51 bacteria than did IP vaccination (Stevens et al., 1996).</immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference900">Immune responses and resistance to infection with Brucella abortus 2308 (S2308) were measured in mice following oral (PO) or intraperitoneal (IP) vaccination with strain RB51 (SRB51).  Female 10-week-old BALB/c AnNHsD mice were used in the following experiments.  Lyophilized SRB51 reconstituted in a 0.15 M NaCl saline solution was used to vaccinate PO by placing 20 ml of saline containing 5 x 10^8 or 5 x 10^6 CFU onto the pharyngeal mucosa.  Additional groups of mice were vaccinated IP with 0.2 ml of saline containing 5 x 10^8 or 5 x 10^6 CFU of SRB51.  Nonvaccinated control mice were injected IP with 0.2 ml of saline alone (Stevens et al., 1996).</vaccination_protocol>
			<persistence refs="reference900">Bacteria persisted in the parotid lymph node for 4 weeks following PO vaccination of mice with 5 x 10^8 or 5 X 10^6 CFU of SRB51.  Bacteria did not appear in the spleen during 12 weeks after PO vaccination, whereas they did appear in the spleen for 8 weeks following IP vaccination of mice with SRB51.  Increased resistance to S2308 infection occurred at 12-20 weeks in mice vaccinated IP with SRB51 but occurred at 12 weeks only in mice vaccinated PO with 5 x 10^8 CFU SRB51 (Stevens et al., 1996).</persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference900">Neither route of vaccination induced anamnestic antibody responses to the surface antigens of intact S2308 bacteria after challenge infection of the vaccinated mice with S2308.  Mice vaccinated PO with SRB51 and challenged with S2308 at 12-20 weeks had lower and less persistent spleen cell proliferation and production of gamma interferon (IFN) in response to S2308 and certain immunodominant S2308 proteins (&lt;18-32 kDa) than did mice vaccinated IP with SRB51.  However, mice had similar spleen cell tumor necrosis factor alpha (TNF) production.  These results indicate that PO vaccination of mice with SRB51 was effective in inducing protective immunity to S2308 infection, although the immunity was lower and less persistent than that induced by IP vaccination.  The lower protective immunity induced by oral vaccination may have resulted from lower and less persistent cell-mediated immunity and IFN production in response to S2308 and S2308 proteins (Stevens et al., 1996).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference900">Nonvaccinated control mice and vaccinated mice at 12, 16, or 20 weeks after vaccination were challenged with S2308 by an IP injection of 2 x 10^4 CFU in 0.2 ml of 0.15 M NaCl saline solution (Stevens et al., 1996).</challenge_protocol>
			<description refs=""></description>
		</host_response>
		<host_response host_response_id="host_response518" host_id="host3">
			<immune_response refs="reference901">Spleens from RB51-infected mice showed only mild to moderate accumulations of macrophages in marginal zone areas during the peak of RB51 infection (PID 7-10).  Morphometric analysis of RB51-infected spleens showed a decrease in white pulp area, which coincided with peak bacterial numbers.  However, this decrease was not significant.  Spleens from mice infected with htrA showed moderate to marked accumulations of macrophages in marginal zone areas, which persisted through PID 60.  Multifocal necrosis in lymphoid follicles as early as PID 4 was seen in both htrA and 2308 infection (Palmer et al., 1996).</immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference901">BALB/c mice were inoculated intraperitoneally (IP) with suspensions of Brucella abortus strains 2308 or RB51 or an htrA mutant.  Spleens were examined on post-inoculation day (PID) 2, 4, 7, 10, 15, 21, 30, and 60.  132 male BALB/c mice were infected with either one of the 3 B. abortus strains or with saline as a control (Palmer et al., 1996).</vaccination_protocol>
			<persistence refs="reference901">Brucellae were cultured in high numbers from the spleens of mice infected with strains 2308 or htrA through PID 60; however, mice infected with RB51 cleared the infection between PID 30 and 60.  Histopathologic changes in spleens from 2308-infected mice were characterized by marked accumulations of macrophages, which expanded marginal zones beginning as early as PID 7 and persisting through PID 60.  Morphometric analysis showed a decrease in splenic white pulp in 2308-infected mice at PID 10, which correlated with the peak of bacterial infection.  Although this decrease was significant when compared with values at previous and following time periods, it was not significantly different from white pulp values noted at PID 2 or 4 or the values for control spleens (Palmer et al., 1996).</persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference901">Morphometric analysis of htrA-infected spleens revealed no significant decrease in white pulp and no obvious correlation with bacterial numbers in the spleen.  These results suggest that virulent B. abortus does not induce lymphoid depletion significantly below those values seen in noninfected mice; thus, the possible role of lymphoid depletion in the pathogenesis of brucellosis remains questionable (Palmer et al., 1996).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
		<host_response host_response_id="host_response519" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference902">(Stevens et al., 1995a)</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
		<host_response host_response_id="host_response520" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference191">(Stevens et al., 1994b)</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
		<host_response host_response_id="host_response521" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference903">(Stevens et al., 1994a)</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
		<host_response host_response_id="host_response522" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference904">(Jiménez et al., 1994)</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
		<host_response host_response_id="host_response523" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference905">(Stevens et al., 1995b)</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
		<host_response host_response_id="host_response524" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference906">(Tobias et al., 1992)</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
		<host_response host_response_id="host_response525" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference12">(Schurig et al., 1991)</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine293">
		<vaccine_name>B. melitensis 16M DNA vaccine expressing Omp31</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000325</vo_id>
		<type>DNA vaccine</type>
		<status></status>
		<vector>pTargeT [Ref688:Gupta et al., 2007]</vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs="reference688">The strain isolated from the goat was virulent, bu the plasmid created was quite attenuated (Gupta et al., 2007).</virulence>
		<preparation refs="reference688">B. melitensis 16M, the virulent strain, was isolated from the stomach content of the aborted fetus of the goat. B. melitensis DNA fragment encoding omp31 was cloned in pTargeT mammalian expression system vector. The plasmid was then purified and made into a vaccine consisting of 100 μg  of pTargeTomp31 in 50 μl sterile saline  (Gupta et al., 2007).</preparation>
		<route refs=""></route>
		<antigen refs="reference688">The antigen for this vaccine were found in eukaryotic expression vectors called pTargeTomp31, which encoded the outer membrane protein (omp31) of B. melitensis 16M (Gupta et al., 2007).</antigen>

		<gene_engineering gene_engineering_id="gene_engineering214" gene_id="gene231">
			<type>DNA vaccine construction</type>
			<description refs="reference688">The nucleotide sequence of the gene coding for the outer membrane protein omp31 reported for B. melitensis were synthesized by Qiagen. The primers were used to amplify a target sequence of 720 bp within a gene code for the production of a 28–31 kDa outer membrane protein (omp31) specific to the B. melitensis. The omp31 gene of B. melitensis was amplified with primers 5′-TGACAGACTTTTTCGCCGAA-3′ and 5′-TATGGATTGCAGCACCGC-3′. This 720 bp B. melitensis DNA fragment encoding omp31 was cloned in pTargeT mammalian expression system vector. The resultant plasmid (pTargeTomp31) contained the omp31 gene. Competent Escherichia coli JM109   was transformed with pTargeTomp31. Ampicillin-resistant colonies were grown in Luria-Bertani medium containing 100 μg/ml of ampicillin at 37 °C with agitation at 225 rpm. Protein expression was induced by adding 1 mM isopropyl-β-d-thiogalactopyranoside and incubating transformed cells for 4 h. Bacteria were pelleted by centrifugation and frozen at −20 °C. Bacterial cells were suspended in a solution consisting of 50 mM Tris, 5 mM EDTA, and 1% Triton X-100 at a pH of 8.0 and sonicated for three 1-min cycles at 4 °C. Inclusion bodies were pelleted at 20,000 × g for 30 min at 4 °C and washed twice with suspension solution without Triton X-100. Inclusion bodies were solubilized in a solution containing 50 mM Tris, 5 mM EDTA, and 8 M urea at a pH of 8.0 at room temperature overnight with agitation. After centrifugation, soluble protein was purified by chromatography through Ni-agarose. rOmp31 was adsorbed with Sepharose-polymyxin B to eliminate LPS contamination. Plasmid DNA for in vitro transfection or mouse immunization was extracted from a 16-h culture and purified using the Endo-Free Plasmid purification kit. Plasmid DNA was adjusted to a final concentration of 1 mg/ml in PBS and stored at −80 °C (Gupta et al., 2007) .</description>
		</gene_engineering>
		<host_response host_response_id="host_response378" host_id="host3">
			<immune_response refs="reference688">Mice injected with pTargeTomp31 have good IgG2a and IgG1 titers to anti-omp31 antibodies. Antibodies against omp31 could already be detected 1 week after the first pTargeTomp31 DNA injection. Immunization with pTargeT did not induce any production of anti-omp31 antibodies. Humoral response measured 18 weeks postvaccination indicates that pTargeTomp31 DNA vaccine leads to the generation of long-lived IgG1 and IgG2a responses. pTargeTomp31 DNA vaccination resulted in specific T-cell proliferation in response to omp31 or to Brucella extracts. This specific induced proliferative response was also found at 8 weeks postvaccination, although to a lesser extent. In contrast, immunization with pTargeT appeared to have no effect on the level of T-cell proliferative response. The ConA mitogen was able to induce T-cell proliferation in all cases (Gupta et al., 2007).</immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference688">Specific-pathogen-free 4-week-old BALB/c female mice were obtained. 25 mice were randomly divided in to five groups of 5 mice each and received intramuscular injections in the tibialis anterior muscles with 100 μg of pTargeTomp31 in 50 μl sterile saline by using a 1-ml insulin syringe with a 28-gauge needle. Similarly, another set of 6 weeks old 25 female mice (divided in five groups of 5 mice each) were sham immunized with saline only, the control group. From both the DNA immunized and sham immunized mice, one group of 5 mice each was exclusively used in order to obtain sera to test antibody and spleen cells for cytokine production in response to omp31 or B. melitensis extract. Three vaccinations at 3-week intervals were performed (Gupta et al., 2007).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference688">No significant difference in the number of the bacteria isolated from the spleens of the saline vaccinated and pTargeT-vaccinated animals was observed. The mice, which were immunized by pTargeTomp31, showed a significant level of protection at 28 days after challenge. Mice immunized with DNA vaccine made anti-Brucella serum antibody. This vaccine provided the moderate degree of protection to the mice (Gupta et al., 2007).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference688">Mice immunized three times with pTargeTomp31 or pTargeT were infected 9 weeks later the last DNA immunization with B. melietensis 16M. Seven, 14, 21 and 28 days after challenge, mice were killed and the number of bacteria in the spleens was quantitated (Gupta et al., 2007).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine300">
		<vaccine_name>B. melitensis bp26 and TF Nasal Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000411</vo_id>
		<type>Recombinant vector vaccine</type>
		<status></status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs="reference695">Intranasal (i.n.) immunization with bp26 and Tf in conjunction with cholera toxin (CT) adjuvant (Yang et al., 2007).</adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference695">Recombinant bp26 and Tf were produced in Pichia pastoris and purified. Each vaccine consisted of either 50 or 100 micrograms per dose of either bp26, Tf, or both combined with the CT adjuvant (Yang et al., 2007).</preparation>
		<route refs=""></route>
		<antigen refs="reference695">Purified Brucella bp26 and trigger factor (Tf) proteins, also called Tig (Yang et al., 2007).</antigen>

		<gene_engineering gene_engineering_id="gene_engineering1791" gene_id="gene256">
			<type>Recombinant protein preparation</type>
			<description refs="reference695">Recombinant bp26 and Tf were produced in Pichia pastoris and purified, and mixed with cholera toxin (CT) adjuvant(Yang et al., 2007).</description>
		</gene_engineering>
		<host_response host_response_id="host_response386" host_id="host3">
			<immune_response refs="reference695">Mice immunized with Tf alone showed reduced serum and mucosal Ab titers. Between 3 and 5 weeks post-primary immunization, mice given bp26 + Tf showed between 14- and 32-fold greater serum IgG anti-Tf Ab titers when compared to mice given only Tf. Fecal IgA titers were augmented between 24- and 128-fold in mice immunized with bp26 + Tf when compared to mice immunized with Tf alone. These results clearly show that co-immunization with bp26 enhances anti-Tf immunity. To determine whether immune responses evoked by bp26 and Tf are biased towards Th1-type, Th2-type, or a mixture of both, serum samples from bp26 + Tf-immunized BALB/c mice from day 35 were evaluated for IgG subclass responses. IgG1 was the predominant IgG subclass Ab induced by the nasal immunization regimen. IgG2a and IgG2b anti-Tf and anti-bp26 Abs were also observed, but these were significantly less than the induced IgG1 Ab titers (Yang et al., 2007).</immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference695">Specific pathogen-free female BALB/c mice were i.n. immunized with bp26 (50 μg/dose), Tf (100 μg/dose), or both + CT adjuvant on days 0, 7, and 14. Five μg of CT were given on day 0, and with subsequent boosts, 2 μg/dose were given. Mice were sampled for serum and fecal titers at 3–5 weeks post-immunization, before challenge (Yang et al., 2007).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference695">Mice immunized with bp26 and Tf exhibited significantly reduced B. melitensis colonization when compared to PBS-dosed control mice, the control. There was no significant difference between mice immunized with these proteins when compared to RB51-vaccinated mice. No significant differences in splenic weights were observed among any of the immunization groups. These findings show that nasal immunization with bp26 and Tf is able to reduce B. melitensis colonization, and the observed splenic inflammation may be contributed by CT immunization (Yang et al., 2007).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference695">Immunized mice were challenged i.p. with 5 × 10^4 CFU B. melitensis strain 16 M on day 28 post-primary immunization [13]. A positive vaccination control was given i.p. 1 × 10^8 CFU of B. abortus RB51 vaccine 8 weeks prior to challenge. Four weeks post-challenge, splenic CFU and splenic weights were determined (Yang et al., 2007).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine446">
		<vaccine_name>B. melitensis DNA vaccine encoding Omp31 boosted with Omp31</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000436</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pCI-neo prime, recombinant protein boost [Ref489:Cassataro et al., 2005]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs="reference855">A regimen of DNA prime and protein boost is followed, increasing the efficacy of the vaccine compared to DNA or protein alone (Cassataro et al., 2007).</description>
		<adjuvant refs="">Incomplete Freund's Adjuvant</adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference487 reference489">For the propagation of plasmids, Escherichia coli strain JM109 was used. For the expression of the recombinant protein, strain BL21(DE3) was employed. Bacterial strains were routinely grown, and rOmp31 was obtained and treated as described by (Estein et al., 2003). Purity was determined by Coomassie blue staining as described by (Cassataro et al., 2005). The plasmid pCIOmp31 was obtained as described in (Cassataro et al., 2005).</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs="">Omp31 protein</antigen>

		<gene_engineering gene_engineering_id="gene_engineering1498" gene_id="gene1054">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response496" host_id="host3">
			<immune_response refs="reference855">Immunoglobulin G1 (IgG1) and IgG2a titers were higher in sera from pCIOmp31/rOmp31-immunized mice than in sera from mice immunized with pCIOmp31 or rOmp31 alone. Splenocytes from pCIOmp31/rOmp31-immunized mice produced significantly higher levels of gamma interferon than did those from mice given rOmp31 alone. In contrast, interleukin 2 (IL-2) production levels were comparable between the two groups of immunized mice. Cells from all immunized mice produced undetectable levels of IL-4. Notably, rOmp31 stimulated IL-10 production in the pCIOmp31/rOmp31-immunized group but not in the pCIOmp31- or rOmp31-immunized group. Although the prime-boost regimen induced specific cytotoxic responses, these responses could not reach the levels achieved by the pCIOmp31 immunization (Cassataro et al., 2007).</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference855">BALB/c mice was immunized with an Omp31 DNA vaccine (pCIOmp31) followed by boosting with recombinant Omp31 (rOmp31) in incomplete Freund's adjuvant (Cassataro et al., 2007).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference855">pCIOmp31 priming followed by rOmp31 boosting led to moderately improved protection against a challenge with B. ovis or B. melitensis (Cassataro et al., 2007).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference855">Immunized mice were challenged, by intravenous inoculation, with 1x10^5 B. melitensis H38S organisms or 1x10^5 B. ovis organisms. Mice were sacrificed 30 days after the bacterial challenge, and their spleens were removed, homogenized, plated, and incubated. The number of CFU per spleen or liver was counted, and the results were given as the mean log number of CFU (Cassataro et al., 2007).</challenge_protocol>
			<description refs=""></description>
              <host_gene_response host_gene_response_id="host_gene_response307" gene_id="gene1">
			    <description refs="reference855">Cytokine secretion in culture supernatants of spleen cells from immunized mice was evaluated by ELISA 30 days after the last immunization.  IFN-gamma levels were significantly higher in mice immunized with  pCIOmp31 priming and rOmp31 boosting than mice immunized with PBS-, pCI-, or rOmp31 and boosted with rOmp31 (Cassataro et al., 2007).</description>
			  </host_gene_response>
              <host_gene_response host_gene_response_id="host_gene_response308" gene_id="gene1121">
			    <description refs="reference855">Cytokine secretion in culture supernatants of spleen cells from immunized mice was evaluated by ELISA 30 days after the last immunization. IL-2 levels were significantly higher in mice immunized with pCIOmp31 priming and rOmp31 boosting than mice immunized with PBS-, pCI-, or rOmp31 and boosted with rOmp31 (Cassataro et al., 2007).</description>
			  </host_gene_response>
              <host_gene_response host_gene_response_id="host_gene_response309" gene_id="gene126">
			    <description refs="reference855">Cytokine secretion in culture supernatants of spleen cells from immunized mice was evaluated by ELISA 30 days after the last immunization. IL-10 levels were significantly higher in mice immunized with pCIOmp31 priming and rOmp31 boosting than mice immunized with PBS-, pCI-, or rOmp31 and boosted with rOmp31 (Cassataro et al., 2007).</description>
			  </host_gene_response>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3616">
		<vaccine_name>B. melitensis DNA vaccine p-ialB</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004397</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pcDNA3 [Ref863:Commander et al., 2007]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1159" gene_id="gene254">
			<type>DNA vaccine construction</type>
			<description refs="reference863">Vector pCR3.1 expressed IalB (Commander et al., 2007).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1431" host_id="host3">
			<immune_response refs="reference863">Brucella specific IFNγ was still evident at 12 weeks post-vaccination, albeit at low concentration, indicating generation of a lasting Th1 immune response (Commander et al., 2007).</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference863">P-ialB vaccine was very promising in terms of control of Brucella challenge, as they were unable to recover viable Brucella from the spleens of 60% (three out of five) p-ialB treated mice of a study group following challenge with ∼1 × 104 CFU B. melitensis 16M per mouse. The remaining two mice showed significantly reduced Brucella loads compared to the unvaccinated (PBS and vector control) mice.  If the data is considered in terms of the % of animals without detectable Brucella in their spleens (less than 10 CFU per spleen) at 15 days post-challenge, the effect of the p-ialB vaccination is judged to be equivalent to that of the Rev.1 live attenuated vaccine, with each vaccine able to ‘protect’ 60% of the test population. Moreover, a comparison of the total quantitative data available from each sample shows the Brucella load of the p-ialB and Rev.1 vaccinated animals to be significantly lower (p &lt; 0.05, one-way ANOVA, Dunnett's post-test) than that observed for the unprotected controls (PBS or pcDNA3.1 vector control vaccinated mice). This vaccine was shown to have a protective index of greater than 2.5  (Commander et al., 2007).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3615">
		<vaccine_name>B. melitensis DNA vaccine p-Omp25</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004396</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pcDNA3.1 [Ref863:Commander et al., 2007]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1158" gene_id="gene253">
			<type>DNA vaccine construction</type>
			<description refs="reference863">Vector pCR3.1 expressed Omp25 (25 kDa Omp) (Commander et al., 2007).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1430" host_id="host3">
			<immune_response refs="reference863">Brucella specific IFNγ was still evident at 12 weeks post-vaccination, albeit at low concentration, indicating generation of a lasting Th1 immune response (Commander et al., 2007).</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference863">P-omp25 vaccine was very promising in terms of control of Brucella challenge, as researchers were unable to recover viable Brucella from the spleens of 60% (three out of five) p-omp25 treated mice of a study group following challenge with ∼1 × 104 CFU B. melitensis 16M per mouse. The remaining two mice showed significantly reduced Brucella loads compared to the unvaccinated (PBS and vector control) mice.  If the data is considered in terms of the % of animals without detectable Brucella in their spleens (less than 10 CFU per spleen) at 15 days post-challenge, the effect of the p-omp25 vaccination is judged to be equivalent to that of the Rev.1 live attenuated vaccine, with each vaccine able to ‘protect’ 60% of the test population. Moreover, a comparison of the total quantitative data available from each sample shows the Brucella load of the p-omp25 and Rev.1 vaccinated animals to be significantly lower (p &lt; 0.05, one-way ANOVA, Dunnett's post-test) than that observed for the unprotected controls (PBS or pcDNA3.1 vector control vaccinated mice). This vaccine was shown to have a protective index of greater than 2.5 (Commander et al., 2007).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3611">
		<vaccine_name>B. melitensis DNA vaccine pCI-Omp31</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004394</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pCI [Ref489:Cassataro et al., 2005]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1156" gene_id="gene1609">
			<type>DNA vaccine construction</type>
			<description refs="reference489">Vector pCI expressed Omp31 (hemin-binding protein) (Cassataro et al., 2005).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1428" host_id="host3">
			<immune_response refs="reference489">The Omp31 DNA vaccine induces cytotoxic responses that have the potential to contribute to protection against Brucella infection. The protective response could be related to the induction of CD8(+) T cells that eliminate Brucella-infected cells via the perforin pathway (Cassataro et al., 2005).</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference489">Mice given pCIOmp31 exhibited a significant degree of protection against B. melitensis and B. ovis (P &lt; 0.001) compared with controls receiving PBS.  This was determined by comparing the levels of infection in the spleen (CFU) (Cassataro et al., 2005).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3613">
		<vaccine_name>B. melitensis DNA vaccine pCIBLSOmp31 encoding BLSOmp31 (fusion protein)</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004395</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pCI-neo [Ref222:Cassataro et al., 2007]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1499" gene_id="gene113">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1500" gene_id="gene1609">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response1429" host_id="host3">
			<immune_response refs="reference222">The vaccine induced a strong humoral response against the inserted peptide. It also induced peptide- and BLS-specific cytotoxic T responses. The insertion of this peptide on BLS induced stronger T helper 1 responses specific for the carrier (BLS) (Cassataro et al., 2007).</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference222">BLSOmp31 (pCIBLSOmp31) provided the best protection level against Brucella ovis, which was significantly higher than the given by the co-delivery of both plasmids coding for the whole proteins (pcDNABLS+pCIOmp31) and even higher than the control vaccine Rev.1. Moreover, pCIBLSOmp31 induced higher protection against Brucella melitensis than pcDNABLS+pCIOmp31 (Cassataro et al., 2007).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine137">
		<vaccine_name>B. melitensis lipopolysaccharide (LPS) vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000311</vo_id>
		<type>subunit vaccine</type>
		<status></status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="">LPS, an outer membrane endotoxin common to gram negative bacteria, consists of three parts: Lipid A, a core oligosaccharide, and an O-antigen.  The O-antigen is found in smooth strains only.</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs="">None.</virulence>
		<preparation refs="reference219">The LPS was extracted from killed cells and purified by a modification of the method of Bundle et al  (Bhattacharjee et al., 2006).</preparation>
		<route refs=""></route>
		<antigen refs="">B. melitensis strain 16M lipopolysaccharide (LPS)</antigen>
		<host_response host_response_id="host_response159" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference219">Groups of female BALB/c mice (Harlan Sprague-Dawley) were immunized by either i.n. or s.c. with purified B. melitensis LPS or LPS-GBOMP noncovalent complex vaccine. Control mice were immunized subcutaneously with sterile saline. Briefly, 25 µl of vaccine containing either 10 µg LPS or 10 µg LPS and 7.5 µg GBOMP contained in sterile saline was administered dropwise into the nostrils of anesthetized mice. Two doses of vaccine were given four weeks apart. For subcutaneous immunization, mice were given 10 µg vaccine in 200 µl sterile saline under the right hind thigh. A second dose of vaccine was given four weeks after the first dose. Blood was collected from five euthanized mice from each group four weeks after the first dose and four weeks after the second dose of vaccine. Sera were collected and stored at –20°C until analyzed for antibody.  An enzyme-linked immunosorbent assay (ELISA) was used  (Bhattacharjee et al., 2006).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="">Mice immunized subcutaneously with LPS vaccine showed significant protection against infection of the spleen (P &lt; 0.001), liver (P &lt; 0.001), and lungs (P &lt; 0.05).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference219">Groups of immunized mice (15 to 20 mice in each group) were challenged intranasally 4 weeks after the second dose of vaccine with 1x10^4 CFU of B. melitensis 16M suspended in 30 µl phosphate-buffered saline (PBS) (0.01 M sodium phosphate, 0.14 M sodium chloride; pH 7.5) as described previously (21). Blood, spleens, lungs, and livers were aseptically collected from anesthetized mice 8 weeks postchallenge. The numbers of Brucella CFU in organs were determined by dilution and culture on brucella agar as described previously (17). Serum was separated and stored at –20°C until it was used  (Bhattacharjee et al., 2006).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine307">
		<vaccine_name>B. melitensis LPS-GBOMP</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000312</vo_id>
		<type>Subunit vaccine</type>
		<status></status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs="reference703">The outer membrane protein GBOMP (Bhattacharjee et al., 2002).</adjuvant>
		<storage refs="reference703">The vaccines were stored at −20°C until use (Bhattacharjee et al., 2002).</storage>
		<virulence refs=""></virulence>
		<preparation refs="reference703">To create the vaccine, the LPS was extracted from killed B. melitensis cells and purified. N. meningitidis group B strain 8047 bacteria were grown in a synthetic medium, and outer membrane protein (GBOMP) was extracted. The B. melitensis LPS-GBOMP noncovalent complex vaccine was prepared with purified B. melitensis LPS dissolved in 42 ml of TEEN buffer. This mixture was added to the LPS solution and kept at 5°C for 30 min. The detergent was removed, and buffer was exchanged with sterile 0.9% NaCl solution. The final product was filtered and the LPS content was determined (Bhattacharjee et al., 2002).</preparation>
		<route refs=""></route>
		<antigen refs="reference703">The antigens used in this vaccine were purified Brucella melitensis lipopolysaccharide (LPS) as a noncovalent complex with Neisseria meningitidis group B outer membrane protein (GBOMP) (Bhattacharjee et al., 2002).</antigen>
		<host_response host_response_id="host_response393" host_id="host3">
			<immune_response refs="reference703">Anti-B. melitensis LPS IgG titers were significantly increased two weeks after i.n. immunization with B. melitensis LPS-GBOMP vaccine. The pattern of IgG1 response closely resembled that of total IgG, but IgG2a and IgG2b responses were blunted compared to the IgG1 response,and the IgG3 response was also blunted compared to that of IgG1(Bhattacharjee et al., 2002).</immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference703">Each mouse was given an intramuscular injection of 0.3 mg of xylazine hydrochloride  and 1.0 mg of ketamine hydrochloride in 50 μl of sterile saline prior to immunization. The mice were then immunized by administration of 25 μl of vaccine containing 10 μg of LPS slowly into the nostrils with a micropipette, with a second dose of vaccine was given 4 weeks after the initial dose (Bhattacharjee et al., 2002).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference703">I.n. immunization with B. melitensis LPS-GBOMP subunit vaccine significantly protects mice against intranasal challenge with virulent B. melitensis. Vaccination reduces spleen and liver bacterial dissemination but has no effect on the course of lung infection (Bhattacharjee et al., 2002).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference703">Groups of immunized and control mice were challenged intranasally at various times with 10^4 CFU of B. melitensis 16 M suspended in 30 μl of phosphate-buffered saline. In one experiment, mice were challenged with 10^5 CFU of bacteria (Bhattacharjee et al., 2002).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine448">
		<vaccine_name>B. melitensis P39 deletion vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000633</vo_id>
		<type>Live, attenuated vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference877">A B. melitensis vaccine that is recombinant B. melitensis Rev. 1 vaccine with the p39 gene deletion (Tibor et al., 1998).</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine198">
		<vaccine_name>B. melitensis P39 protein vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000412</vo_id>
		<type>Subunit vaccine</type>
		<status></status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference407">P39 has been found to be a Brucella protective antigen (Al-Mariri et al., 2001).</description>
		<adjuvant refs="reference407">A synthetic phosphorothioate oligodeoxynucleotide containing an unmethylated, consensus immunostimulatory CpG motif (5′-purine-purine-CpG-pyrimidine-pyrimidine-3′ oligodeoxynucleotide [CpG ODN]). Specifically, the immunostimulatory CpG 1826 (5′-TCCATGACGTTCCTGACGTT-3′) was used (Al-Mariri et al., 2001).</adjuvant>
		<storage refs=""></storage>
		<virulence refs="">Not reported.</virulence>
		<preparation refs="reference407">The bfr gene of Brucella melitensis 16M was subcloned and expressed in an expression vector. The protein was purified and mixed with the CpG ODN as the vaccine (Al-Mariri et al., 2001). </preparation>
		<route refs=""></route>
		<antigen refs="reference407">Brucella melitensis 16M P39,  a putative periplasmic binding protein (Al-Mariri et al., 2001). </antigen>

		<gene_engineering gene_engineering_id="gene_engineering117" gene_id="gene110">
			<type>recombinant protein</type>
			<description refs="reference407 reference408">The bfr gene of Brucella melitensis 16M was subcloned into a pET-15b expression vector that contains a polyhistidine tag, and the resulting plasmid pET-15b-bfr was introduced in E. coli BL21(DE3). After 2 to 4 of induction with 1 mM IPTG (isopropyl-β-d-thiogalactopyranoside), bacterial cells from a 100-ml culture were washed once and then sonicated. The lysate was centrifuged for 10 min at 9,000 × g at 4°C. The pellet was kept frozen at −70°C. After it had thawed, the pellet was resuspended in a lysis buffer. The resulting lysate was centrifuged at 9,000 × g for 20 min at 4°C (Al-Mariri et al., 2001). P39 was then purified based on metal chelate affinity chromatography as described previously (Letesson et al., 1997).</description>
		</gene_engineering>
		<host_response host_response_id="host_response247" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">Balb/c mice</host_strain>
			<vaccination_protocol refs="reference407">Female BALB/c mice at 4 weeks of age were separated into nine groups of 12 mice. Groups 1, 2, and 3 received PBS, CpG ODN, and non-CpG ODN, respectively, and served as negative controls. Groups 4 and 5 were injected with the purified P39 and bacterioferrin (BFR) alone, respectively. Groups 6 and 7 were injected with the recombinant protein with CpG ODN adjuvant. Finally, groups 8 and 9 received the recombinant antigens with the non-CpG ODN. Vaccines were prepared in PBS and contained combinations of the following: 20 μg of recombinant protein and/or 20 μg of oligonucleotides when needed. Vaccines were given intramuscularly (i.m.) into the left tibial anterior muscles in a total volume of 50 μl three times at 3-week intervals (Al-Mariri et al., 2001). </vaccination_protocol>
			<persistence refs="">Not reported.</persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs="">None reported.</side_effects>
			<challenge_protocol refs="reference407">Three weeks after the last injection, the remaining mice of each group were challenged by the intraperitoneal route (i.p.) with 5 × 10^4 CFU of B. abortus strain 544 in 100 μl of PBS. An additional group of eight mice vaccinated i.p. with B19 (1x10^5 CFU) was challenged 4 weeks later in the same way and served as a vaccinated control. Spleen colonization with the challenge strain was determined at 4 and 8 weeks postinfection (Al-Mariri et al., 2001). </challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine135">
		<vaccine_name>B. melitensis strain VTRM1</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000300</vo_id>
		<type>attenuated live vaccine</type>
		<status></status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference216">Vaccination with the rough strain VTRM1 induces protection against virulent strains of B. abortus (2308), B melitensis (16M), B. suis biovar 1 (750), B. suis biovar 4 (2579), and B. ovis  (Winter et al., 1996).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs="reference216">VTRM1, like RB51, is a stable rough form of B. melitensis that does not revert during passage in mice  (Winter et al., 1996).</virulence>
		<preparation refs="reference216">VTRM1 was obtained from B. melitensis 16M by allelic exchange of the rfbU gene encoding mannosyltransferase with a Tn5-disrupted rfbU gene  (Winter et al., 1996).</preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
		<host_response host_response_id="host_response157" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">VTRM1</host_strain>
			<vaccination_protocol refs="reference216">Five groups of mice, (eight to nine weeks old), were vaccinated with the following live organism vaccines.  These included: VTRM1, VTRS1, and Rev 1 (5 x 10^4 CFU); strain 19 (S19) (5 x 10^3 CFU); and RB51 (3 x 10^8 CFU).  Each vaccine was delivered intravenously except RB51 which was administered intraperitoneally.  All vaccines except RB51 were obtained directly from frozen stock cultures. Large doses of RB51 were required, therefore stock cultures were inoculated onto plates.  After three days of culture and growth after 3 days was diluted to the appropriate concentration  (Winter et al., 1996).  </vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference216">Strains VTRM1 and VTRS1 were effective in inducing protection against virulent strains of heterologous, and homologous, Brucella spp.  Vaccination with either strain conferred substantial protection against exposure to virulent laboratory strains of B melitensis, B abortus, and B suis of biovars 1 and 4.  VTRM1 provided protection against B. ovis  (Winter et al., 1996).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference216">Eight weeks after the initial vaccination, mice were injected IV with 5x10^4 CFU of Brucella.  The time interval between IV injection and euthanasia was two weeks for all Brucella strains with the exception of B abortus 8-954 and 2-1230; for these strains, a one-week time interval was chosen.  Mice were euthanized by CO2 asphyxiation.  Individual spleens were homogenized, the homogenate diluted serially, and plated on Schaedler blood agar.  B abortus, B melitensis, or B suis colonies were counted after three days of incubation; B. ovis colonies were counted after four to five days of incubation at 37 C under 10% CO2  (Winter et al., 1996).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine110">
		<vaccine_name>B. melitensis vaccine strain Rev. 1</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000710</vo_id>
		<type>Attenuated live vaccine</type>
		<status>Licensed</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference192">The   live   attenuated   strain of   B   melitensis     Rev    .     1    is   considered   the   best     vaccine    available   for   the   prophylaxis   of   brucellosis   in   sheep   and   goats    (Cloeckaert et al., 2002).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs="reference685">The vaccine was kept on plates at 5 degrees celsius (ELBERG and FAUNCE, 1957).</storage>
		<virulence refs="reference193">Whether Rev. 1 is virulent is unclear. A Rev. 1-like strain was isolated from the membranes of an aborted fetus at an intensively managed farm that had complied with the vaccination regimen, i.e. ewelambs were vaccinated between two and six months.    When the whole flock (410   ewes) was serologically tested, 34   animals   showed a positive complement   fixation   test.  The ewes were slaughtered and attempts to culture additional isolates from  milk, major   lymph   nodes,   and   mammary   glands   were  unsuccessful.    A   few   months   later   ,   the   flock   owner   contracted   brucellosis   and   Brucella   was   cultured   from   his   blood    (Banai, 2002).</virulence>
		<preparation refs="reference685 reference192">Rev . 1 vaccine,  obtained in the 1950s by a two-step selection involving firstly, a streptomycin resistance and/or dependence, and secondly, a reversion of dependence but  maintaining streptomycin resistance (ELBERG and FAUNCE, 1957). Acquired chromosomal streptomycin resistance is frequently due to mutations in the gene encoding for ribosomal protein S12, rpsL (Cloeckaert et al., 2002).</preparation>
		<route refs=""></route>
		<antigen refs="">Rev.1 is a live attenuated Brucella melitensis strain derived from a virulent B. melitensis isolate.</antigen>

		<gene_engineering gene_engineering_id="gene_engineering217" gene_id="gene236">
			<type>Recombinant protein preparation</type>
			<description refs="">The gene rpsL of B. melitensis reference strain 16 M encodes for ribosomal protein S12. This gene was mutated in the vaccine strain Rev. 1 during its natural selection process. Nucleotide sequencing has revealed that a mutation in the rpsL gene of vaccine strain Rev . 1 compared to that of reference strain 16M leading to an amino acid Pro- to -Leu change at codon position 91 ( Pro91Leu ) (Cloeckaert et al., 2002).</description>
		</gene_engineering>
		<host_response host_response_id="host_response141" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference428">Several groups of 10 (or eight mice in the assay after storage or passage) were vaccinated subcutaneously with Rev. 1 strains. Control unvaccinated mice received BSS alone  (Bosseray, 1991).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference428">Vaccinated and control mice were challenged intraperitoneally 30 or 45 days after vaccination with The virulent B. abortus 544 CO2-dependent reference challenge strain (Bosseray, 1991).</challenge_protocol>
			<description refs=""></description>
		</host_response>
		<host_response host_response_id="host_response142" host_id="host17">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference195">Seven groups, 22 sheep/group were either vaccinated subcutaneously (SC) or conjunctivally (CJ) (right eye) at the age of four months with the following actual doses, Rev.1, 1.1 × 10^9 CFU (SC) and 1.33 × 10^9 CFU (CJ); CGV26, 1.25 × 10^9 CFU (SC) and 1.22 × 10^9 cfu (CJ); CGV2631, 1.11 × 10^9 cfu (SC) and 1.30 × 10^9 cfu (CJ).  The  vaccine doses (&lt;1 mL) were utilized where administered SC and 30 uL where administered CJ  (Jacques et al., 2007).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference195">Regardless of the route of administration of Rev.1 vaccine (SC or CJ), the results obtained agreed with those of previous studies [35], Rev.1 effectively protected ewes challenged at middle of pregnancy with 5 × 10^7 CFU of strain H38.  In the control group (unvaccinated ewes), 100% aborted  (Jacques et al., 2007).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference195">One week before challenge, of 154 ewes, 99 of whiche were pregnant assesd by progesterone levels  were were kept in a high security pen. Each ewe was challenged CJ (left eye) with 5.1 × 10^7 CFU of B. melitensis strain H38 after 76 days of pregnancy.  Each animal was submitted to periodic immunological, clinical, and bacteriological tests and sacrificed 4–6 weeks after delivery. To follow cellular response, six ewes from each group were selected for further investigation  (Jacques et al., 2007).</challenge_protocol>
			<description refs=""></description>
		</host_response>
		<host_response host_response_id="host_response375" host_id="host13">
			<immune_response refs="reference685">The mutant strain stimulated an antibody-producing mechanism within the first ten days of vaccination. The antibody titers were highest at about 20 days postinfection (ELBERG and FAUNCE, 1957).</immune_response>
			<host_strain refs="">Angora</host_strain>
			<vaccination_protocol refs="reference685">Four to five-year-old goats were used. Each goat received 1.5 x 10^9 cells of the bacteria subcutaneously in the left prescapular region. At 2,4,5,7,10,11, and 14 weeks the goats were sacrificed and tested for the presence of brucellae (ELBERG and FAUNCE, 1957).</vaccination_protocol>
			<persistence refs="reference685">At the third week organisms from the spleen, bone marrow, left and right prescapular regions, left and right supramammary nodes, right precrural and the mediastinal nodes were detected. By the fourteenth week, the infection in the single goat sacrificed was isolated to the left prescapular node. It was assumed that at this point the animals were free from infection (ELBERG and FAUNCE, 1957).</persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference685">The vaccine was proven to be an effective immunizing agent for the host species tested (ELBERG and FAUNCE, 1957).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference685">The challenge consisted of 33 ID doses of B. melitensis. It was administered 90 days after vaccination (ELBERG and FAUNCE, 1957).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine295">
		<vaccine_name>B. melitensis with deleted bp26 (CGV26)</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000338</vo_id>
		<type>Live, attenuated vaccine</type>
		<status></status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs="reference690">The virulence of the CGV26 mutant was similar to that of the parental Rev.1 strain (Guilloteau et al., 2006).</virulence>
		<preparation refs="reference690">Mutants were kept freeze-dried. Bacteria were rehydrated in sterile buffered saline solution, seeded on Trypticase Soy Agar, supplemented with yeast extract and incubated at 37 °C. Fresh bacterial suspensions were harvested in BSS from 24 h cultures and spectrophotometrically adjusted. Each suspension used was always checked for purity and dissociation and the exact doses were assembled (Guilloteau et al., 2006).</preparation>
		<route refs=""></route>
		<antigen refs="reference690">The antigen for this vaccine is Brucella melitensis containing a deletion of the bp26 gene, a strain called CGV26 (Guilloteau et al., 2006).</antigen>

		<gene_engineering gene_engineering_id="gene_engineering218" gene_id="gene237">
			<type>Recombinant protein preparation</type>
			<description refs="reference690">The CGV26 and CGV2631 strains were engineered with Brucella melitensis Rev.1 mutant strains containing deletions in the bp26 gene or both bp26 and omp31 genes (Guilloteau et al., 2006).</description>
		</gene_engineering>
		<host_response host_response_id="host_response380" host_id="host17">
			<immune_response refs="reference690">The results together showed that the CGV26 mutant was able to induce both specific antibody response and systemic lymphoproliferation in sheep. Specific systemic antibody response to S-LPS of Brucella was induced after inoculation of the mutant and the Rev.1 strain. The intensity of this response was much higher and earlier after SC vaccination (1 week) than that after CJ vaccination (second week) (Guilloteau et al., 2006).</immune_response>
			<host_strain refs="">Préalpes</host_strain>
			<vaccination_protocol refs="reference690">42 Brucella-free Préalpes females of 3–4 months of age were randomly allotted into seven groups of six animals. Six groups were inoculated either by CJ or SC route with 1 × 10^9 cfu of CGV26 mutant or the Rev.1 vaccine as a vaccinated control group. The vaccine suspension was administered conjunctivally with a calibrated dropper by depositing 33 μl on the surface of the right eye or subcutaneously with a needle by injecting 1 ml just behind the left elbow joint. One group remained as a separate uninfected control group. Swabs were taken from the conjunctiva and nostrils in groups inoculated by CJ route for bacteriological analyses. At regular intervals after inoculation, blood samples were collected for analysis of the immune response induced (Guilloteau et al., 2006).</vaccination_protocol>
			<persistence refs="reference690">The local persistence of the CGV26 mutant was not statistically different from the Rev.1 strain (Guilloteau et al., 2006).</persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference690">This mutant induced significant specific antibody and cell-mediated immunity in sheep (Guilloteau et al., 2006).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine308">
		<vaccine_name>B. melitensis WR201 (16MΔpurEK)</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000345</vo_id>
		<type>Live, attenuated vaccine</type>
		<status></status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs="reference704">The antigens for this vaccine were severely attenuated. The strain WR201 fails to replicate in cultured human monocyte-derived macrophages (Hoover et al., 1999).</virulence>
		<preparation refs="reference704">The WR201 strain was procured and the bacterial cells were killed by treatment for 16 h with 0.5% phenol. These cells were then washed and pelleted several times, eventually leading to a product containing approximately 3.0 mg of protein per ml (Hoover et al., 1999).</preparation>
		<route refs=""></route>
		<antigen refs="reference704">This vaccine is an live, attenuated purine-auxotrophic mutant strain of Brucella meletensis, WR201 (Hoover et al., 1999).</antigen>

		<gene_engineering gene_engineering_id="gene_engineering220" gene_id="gene239">
			<type>Recombinant protein preparation</type>
			<description refs="reference706 reference704">The B. melitensis strain WR201 (or called delta purE201) was created through the deletion of the gene purE and the deletion of the first seven bases of purK (Drazek et al., 1995)(Hoover et al., 1999). Specifically, B. melitensis 16M was electroporated with suicide plasmids containing a kanamycin resistance cassette that replaced 226 bp at the carboxyl end of purE, the intergenic region, and 18 bases of the purK open reading frame. Recombinant B. melitensis delta purE201 required exogenous purines for growth on minimal media. This mutant failed to grow in human monocyte-derived macrophages, while the growth of wild-type 16M and the complemented strain, delta purE201 (pSD5), increased by nearly two logs (Drazek et al., 1995).</description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering813" gene_id="gene939">
			<type>Gene mutation</type>
			<description refs="reference1799">This purE mutant is from Brucella melitensis (Crawford et al., 1996).</description>
		</gene_engineering>
		<host_response host_response_id="host_response394" host_id="host3">
			<immune_response refs="reference704">After mice were innoculated, they were found to have made serum antibody to non-O-polysaccharide and lipopolysaccharideantigens. The splenocytes from the immunized animals were found to have released  interleukin-2, gamma interferon, and IL-10 when cultured with Brucella antigens (Hoover et al., 1999).</immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference704">The mice were immunized by intraperitoneal administration of vaccine. Each vaccine contained approximately 10^5 WR201 cells  Nonimmunized, control mice received 0.9% NaCl intraperitoneally (Hoover et al., 1999).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference704">Immunization of the mice led to protection from disseminated infection. Immunization had only a slight effect on the clearance of the challenge inoculum from the lungs (Hoover et al., 1999).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference704">Nine weeks post immunization, animals were innoculated intranasally with 10^4 CFU of B. melitensis 16M in 30 μl of 0.9% NaCl. The vaccine was administered dropwise into the external nares with a micropipette (Hoover et al., 1999).</challenge_protocol>
			<description refs="reference704">This study suggests that WR201 may be a good vaccine candidate for the prevention of human brucellosis (Hoover et al., 1999).</description>
              <host_gene_response host_gene_response_id="host_gene_response100" gene_id="gene1121">
			    <description refs="reference704">Spleen cells obtained 9 weeks after inoculation of mice with WR201 produced more IL-2 than non-immunized, non-infected control mice.  These results were significant (Hoover et al., 1999).</description>
			  </host_gene_response>
              <host_gene_response host_gene_response_id="host_gene_response101" gene_id="gene126">
			    <description refs="reference704">Spleen cells obtained 9 weeks after inoculation of mice with WR201 produced more IL-10 than non-immunized, non-infected control mice.  These results were significant (Hoover et al., 1999).</description>
			  </host_gene_response>
              <host_gene_response host_gene_response_id="host_gene_response102" gene_id="gene1">
			    <description refs="reference704">Spleen cells obtained 9 weeks after inoculation of mice with WR201 produced more IFN-gamma than non-immunized, non-infected control mice.  These results were significant (Hoover et al., 1999).</description>
			  </host_gene_response>
              <host_gene_response host_gene_response_id="host_gene_response103" gene_id="gene1161">
			    <description refs="reference704">Sera obtained from immunized animals from 1 to 8 weeks after intraperitoneal administration of WR201 showed a rise in anti-protein IgG by week 4 (Hoover et al., 1999).</description>
			  </host_gene_response>
		</host_response>
		<host_response host_response_id="host_response400" host_id="host3">
			<immune_response refs="reference702">When grown in cultures with Brucella antigens, splenocytes from immunized animals released interleukin-2 and gamma interferon. Immunized mice made serum antibody to lipopolysaccharide and non-O-polysaccharide antigens (Izadjoo et al., 2004).</immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference702">Mice were first orally administered 0.2 ml of sterile 2.5% sodium bicarbonate, then they were administered 0.2 ml of the bacterial suspension which had been standardized to 5 × 10^11 cells/ml. In designated experiments, bacteria were further diluted to provide an inoculum of 1010 or 109 CFU, then administered. In another experiment, strain WR201 was killed by treatment overnight at room temperature with 0.8% (vol/vol) formaldehyde prior to administration to mice (Izadjoo et al., 2004).</vaccination_protocol>
			<persistence refs="reference702">No bacteria were recovered from the spleens of 54 mice eight weeks post-vaccination, while no bacteria were recovered from the iguinal lymph nodes of 15 mice at this time either. Strain WR201 was progressively lost from the feces following oral administration (Izadjoo et al., 2004).</persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference702">The mice that were immunized had protection from infection and better clearance of the challenge inoculum from the lungs. The best protection was found with the administration of live bacteria with the inclusion of a booster dose. The results suggest that strain WR201 may be a candidate for a vaccine to prevent human brucellosis (Izadjoo et al., 2004).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference702">For virulent strain 16M i.n. challenge, 30 μl of bacterial suspension adjusted to contain 104 CFU of bacteria. This was administered with a micropipette into the external nares of mice (Izadjoo et al., 2004).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine447">
		<vaccine_name>B. suis strain 2</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000722</vo_id>
		<type>Live, attenuated vaccine</type>
		<status>Licensed</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed>China</location_licensed>
		<description refs="reference876">An orally administrable brucellosis vaccine that was was developed in China. It is effective for oral vaccination of sheep, goats, cattle and pigs (Xin, 1986).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine136">
		<vaccine_name>B. suis strain VTRS1</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000303</vo_id>
		<type>Attenuated live vaccine</type>
		<status></status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference216">Vaccination with the rough strain VTRS1 induces protection against virulent strains of B. abortus (2308), B melitensis (16M), B. suis biovar 1 (750), B. suis biovar 4 (2579)   (Winter et al., 1996).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs="reference216">VTRS1, like RB51, is a stable rough form of the bacterium.  It does not manifest evidence of reversion during passage in mice  (Winter et al., 1996).</virulence>
		<preparation refs="reference216">The rough mutant VTRS1 was obtained from B. suis 2579 by allelic exchange of the rfbU gene encoding mannosyltransferase with a Tn5-disrupted rfbU gene  (Winter et al., 1996).</preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
		<host_response host_response_id="host_response158" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference216">Mice, (eight to nine weeks old), in experimental groups of five, were vaccinated with live vaccines: VTRM1, VTRS1, and Rev 1 with 5 x 10^4 CFU  (IV); strain 19 (S19) 5 x 10^3 CFU given IV; and RB51, 3 x 10^8 CFU given i.p.  All vaccines except RB51 were obtained from frozen stock cultures. The large dose of RB51 administered required that stock cultures be cultured on plates, and after three days diluted to the appropriate concentration  (Winter et al., 1996).  </vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference216">VTRM1 and VTRS1 were effective in inducing protection against virulent strains of heterologous, as well as the homologous, Brucella spp.  Vaccination with either strain conferred protection against challenge exposure with virulent laboratory strains of B. abortus, B. melitensis, and B. suis of biovars 1 and 4.  VTRM1 also provided protection against B. ovis  (Winter et al., 1996). </protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference216">Eight weeks after the initial vaccination, mice were challenged IV with 5x10^4 CFU of Brucella.  From challenge exposure to euthanasia was 2 weeks for all Brucella strains except B abortus 8-954 and 2-1230. For these strains a 1-week interval was used.  Mice were euthanized with CO2.  Individual spleens were homogenized, diluted serially, and plated on Schaedler blood agar.  Colonies were counted after incubation for 3 days (B. abortus, B. melitensis, and B. suis) or 4 to 5 days (B. ovis) at 37 C under 10% CO2  (Winter et al., 1996).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine301">
		<vaccine_name>Brucella abortus bacA mutant</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000347</vo_id>
		<type>Live, attenuated vaccine</type>
		<status></status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference696">The bacA mutant strain designated as bacAmut-KL7 was produced by deleting a portion of the bacA gene from the parent strain, B. abortus 2308. The vaccines were produced, each dose containing  5 × 10^4 bacterial colony forming units per dose (Parent et al., 2007).</preparation>
		<route refs=""></route>
		<antigen refs="reference696">The antigen for this vaccine is a bacA deletion mutant of Brucella abortus, known as KL7 (bacAmut-KL7) (Parent et al., 2007).</antigen>
		<host_response host_response_id="host_response387" host_id="host3">
			<immune_response refs="reference696">The C57BL/6 mice mounted a strong TH1 immune response to infection with B. abortus which was characterized by continuous IFNγ production. At 4 weeks post-infection, a time corresponding to the plateau phase of infection, there was no significant difference in the number of 2308 and bacAmut-KL7 CFU recovered from C57BL/6 mice. BacAmut-KL7 was significantly attenuated in BALB/c mice during this time. During the clearance phase of the infection bacAmut-KL7 did show significant attenuation in C57BL/6 mice relative to 2308 although it was much less than that observed in BALB/c mice (Parent et al., 2007).</immune_response>
			<host_strain refs="">BALB/c, C57BL/6 and C57BL/6 IFNγ−/− mice</host_strain>
			<vaccination_protocol refs="reference696">Eight to 12-week-old mice were infected intra-peritoneally with 5 × 10^4 bacterial colony forming units of B. abortus 2308, bacAmut-KL7 or hfq3 (Parent et al., 2007).</vaccination_protocol>
			<persistence refs="reference696">IFNγ-activated macrophages equivalently controlled strains 2308 and bacAmut-KL7. The bacAmut-KL7 organism and its LPS induced greater amounts of pro-inflammatory cytokines than 2308 (Parent et al., 2007).</persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs="reference696">The bactAmut-KL7 mutant was more pathogenic in C57BL/6 interferon-γ-deficient mice than 2308 causing abscesses and wasting even though the splenic loads of bacAmut-KL7 were significantly lower (Parent et al., 2007).</side_effects>
			<challenge_protocol refs="reference696">No challenge was conducted, but it is known that the mutant created, bacAmut-KL7, has protected against challenge in previous experiments (Parent et al., 2007).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3260">
		<vaccine_name>Brucella abortus exsA mutant vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0002812</vo_id>
		<type>Live, attenuated vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intraperitoneal injection (i.p.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intraperitoneal injection (i.p.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering808" gene_id="gene934">
			<type>Gene mutation</type>
			<description refs="reference1786">This exsA mutant is from Brucella abortus (Rosinha et al., 2002a).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1089" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs="reference1786">Brucella DeltaexsA mutant showed decreased survival in mice compared to the survival of parental strain S2308 (Rosinha et al., 2002a).</persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1786">Challenge experiments revealed that the exsA mutant strain induced superior protective immunity in BALB/c mice compared to the protective immunity induced by strain S19 or RB51 (Rosinha et al., 2002a).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3264">
		<vaccine_name>Brucella abortus pgk mutant vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0002818</vo_id>
		<type>Live, attenuated vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intraperitoneal injection (i.p.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intraperitoneal injection (i.p.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering812" gene_id="gene955">
			<type>Gene mutation</type>
			<description refs="reference1811">This pgk mutant is from Brucella abortus strain 2308 (Trant et al., 2010).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1093" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs="reference1811">A pgk mutant is attenuated in mice (Trant et al., 2010).</persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1811">A pgk mutant induces significant protection from challenge with wild type B. abortus (Trant et al., 2010).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
              <host_gene_response host_gene_response_id="host_gene_response104" gene_id="gene1">
			    <description refs="reference1811">In IRF-1 KO mice, significantly increased levels of IFN-gamma were produced after vaccination with a pgk mutant as compared to medium.  Animals immunized with strain RB51 showed reduced production of IFN-γ compared to mice vaccinated with the Δpgk mutant and S19, but it was not a statistically significant difference (Trant et al., 2010).</description>
			  </host_gene_response>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3263">
		<vaccine_name>Brucella abortus pgm mutant vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0002819</vo_id>
		<type>Live, attenuated vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intraperitoneal injection (i.p.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intraperitoneal injection (i.p.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering811" gene_id="gene978">
			<type>Gene mutation</type>
			<description refs="reference1909">This pgm mutant is from Brucella abortus (Ugalde et al., 2003).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1092" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs="reference1909">A pgm mutant is attenuated in mice (Ugalde et al., 2003).</persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1909">A pgm mutant induces significant protection in mice from challenge with wild type B. abortus (Ugalde et al., 2003).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
              <host_gene_response host_gene_response_id="host_gene_response105" gene_id="gene1">
			    <description refs="reference1909">Spleen cells from Δpgm-vaccinated mice were induced to secrete high levels of IFN-γ 8 weeks after immunization after stimulation with heat-inactivated B. abortus S2308 whole cells.  The levels were compared to a positive control, the nonspecific mitogen ConA, and were significant (Ugalde et al., 2003).</description>
			  </host_gene_response>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3288">
		<vaccine_name>Brucella abortus S19 vjbR mutant vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004283</vo_id>
		<type>Live, attenuated vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intraperitoneal injection (i.p.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intraperitoneal injection (i.p.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering855" gene_id="gene1208">
			<type>Gene mutation</type>
			<description refs="reference2096">The vjbR was mutated in Brucella abortus strain 19 (Arenas-Gamboa et al., 2009).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1115" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs="reference2096">An encapsulated vjbR mutant is attenuated in mice (Arenas-Gamboa et al., 2009).</persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2096">A single dose of an encapsulated vjbR mutant induced protection in mice from challenge with wild type Brucella (Arenas-Gamboa et al., 2009).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
              <host_gene_response host_gene_response_id="host_gene_response106" gene_id="gene1107">
			    <description refs="reference2096">Mouse immunization with encapsulated S19 ΔvjbR::Kan induced higher IgG1 and IgG2a levels compared to the nonencapsulated S19 ΔvjbR::Kan mutant 3 weeks post vaccination and significantly higher levels than naive mice (Arenas-Gamboa et al., 2009).</description>
			  </host_gene_response>
              <host_gene_response host_gene_response_id="host_gene_response107" gene_id="gene1106">
			    <description refs="reference2096">Mouse immunization with encapsulated S19 ΔvjbR::Kan induced higher IgG1 and IgG2a levels compared to the nonencapsulated S19 ΔvjbR::Kan mutant 3 weeks post vaccination and significantly higher levels than naive mice (Arenas-Gamboa et al., 2009).</description>
			  </host_gene_response>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine1383">
		<vaccine_name>Brucella Abortus Strain 19, Live Culture Vaccine (USDA: 1251.01)</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer>Colorado Serum Company</manufacturer>
		<vo_id>VO_0001575</vo_id>
		<type>Live vaccine</type>
		<status>Licensed</status>
		<vector></vector>
		<route></route>
		<location_licensed>USA</location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine1384">
		<vaccine_name>Brucella Abortus Strain 19, Live Culture, Reduced Dose Vaccine (USDA: 1251.02)</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer>Colorado Serum Company</manufacturer>
		<vo_id>VO_0001576</vo_id>
		<type>Live vaccine</type>
		<status>Licensed</status>
		<vector></vector>
		<route></route>
		<location_licensed>USA</location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine1385">
		<vaccine_name>Brucella Abortus Strain RB-51, Live Culture Vaccine (USDA: 1261.00)</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer>Colorado Serum Company</manufacturer>
		<vo_id>VO_0001577</vo_id>
		<type>Live vaccine</type>
		<status>Licensed</status>
		<vector></vector>
		<route></route>
		<location_licensed>USA</location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine139">
		<vaccine_name>Brucella DNA vaccine encoding chimera BLSOmp31</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0001144</vo_id>
		<type>DNA vaccine</type>
		<status></status>
		<vector>pCI-neo [Ref222:Cassataro et al., 2007]</vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference222">Brucella outer membrane protein and lumazine synthase from Brucella spp. (BLS) induce protection against Brucella spp.  A novel mode of delivering these antigens was devised as a DNA vaccine  (Cassataro et al., 2007).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs="">None.</virulence>
		<preparation refs="">To develop the chimerical plasmid, the BLSOmp31 DNA sequence was amplified by PCR using pETBLSOmp31 as template and sub-cloned in the pCI-neo vector (Promega, Madison, WI). The following oligonucleotides were constructed including restriction sites at the 5</preparation>
		<route refs=""></route>
		<antigen refs="reference222">Brucella outer membrane protein and lumazine synthase from Brucella spp. (BLS) (Cassataro et al., 2007).</antigen>
		<host_response host_response_id="host_response164" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="">Mice were anaesthetized and immunized by the intramuscular route with 100 ug of pcDNABLS, pCIOmp31, pCIBLSOmp31, pcDNABLS + pCIOmp31 (100 </vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="">Vaccinationof BALB/c mice with pCIBLSOmp31 provided optimal protection level against B. ovis (3.14 log), a value significantly higher than the protection elicited by the co-delivery of two plasmids (pCIOmp31+pcDNABLS) (2.20log) or by the Rev.1 vaccine  (2.42 log). Mice vaccinated with pCIOmp31 exhibited a significant protection (2.24 log) against B. ovis; pcDNABLS induced 1.94log units of protection.  pCIBLSOmp31 induced significantly higher protection (1.77log) against B. melitensis than pCIOmp31 plus pcDNABLS (1.09log) and similar protection than Rev.1 (2.30 log).  Mice given pCIOmp31 exhibited a significant degree of protection(1.44 log) against B. melitensis as was against B. melitensis (1.44 log), while pcDNABLS induced 1.22 log protection.  Together these results show that the chimera significantly increases protection elicited against B. ovis with respect to either pcDNABLS, pCIOmp31 or Rev.1 and induces a similar degree of protection against B. melitensis infection than Rev.1 vaccination.</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="">Thirty days after the last DNA injection, mice were challenged with 1 ×10^4 CFU of B. melitensis H38S or B. ovis (i.v.).  Thirty days post challenge the animals were sacrificed and their spleens aseptically removed.</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3259">
		<vaccine_name>Brucella melitensis bp26 mutant vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004000</vo_id>
		<type>Live, attenuated vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>subcutaneous injection</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">subcutaneous injection</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering807" gene_id="gene1053">
			<type>Gene mutation</type>
			<description refs="reference1988">This bp26 mutant is from Brucella melitensis (Cloeckaert et al., 2004).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1088" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs="reference1988">A bp26 mutant is attenuated in mice (Cloeckaert et al., 2004).</persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1988">A bp26 mutant induces significant protection in mice from challenge with wild type B. melitensis (Cloeckaert et al., 2004).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3117">
		<vaccine_name>Brucella melitensis mucR mutant vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004277</vo_id>
		<type>Live, attenuated vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering621" gene_id="gene1084">
			<type>Gene mutation</type>
			<description refs="reference2071">This gene is mutated in the B. melitensis 16M mucR mutant (Arenas-Gamboa et al., 2011).</description>
		</gene_engineering>
		<host_response host_response_id="host_response942" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs="reference2071">A mucR mutant has a significantly reduced degree of colonization in mice (Arenas-Gamboa et al., 2011).</persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2071">A mucR mutant of 16M protected against challenge with wild type B. melitensis 16M (Arenas-Gamboa et al., 2011).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3261">
		<vaccine_name>Brucella melitensis omp25 mutant vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004001</vo_id>
		<type>Live, attenuated vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intravenous injection (i.v.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intravenous injection (i.v.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering809" gene_id="gene253">
			<type>Gene mutation</type>
			<description refs="reference1946">This omp25 mutant is from Brucella melitensis (Edmonds et al., 2002).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1090" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs="reference1946">An omp25 mutant is attenuated in mice (Edmonds et al., 2002).</persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1946">An omp25 mutant induces protection from challenge with wild type Brucella melitensis (Edmonds et al., 2002).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3262">
		<vaccine_name>Brucella melitensis omp31 mutant vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004002</vo_id>
		<type>Live, attenuated vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>subcutaneous injection</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">subcutaneous injection</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering810" gene_id="gene1054">
			<type>Gene mutation</type>
			<description refs="reference1988">This omp31 mutant is from Brucella melitensis (Cloeckaert et al., 2004).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1091" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs="reference1988">An omp31 mutant is attenuated in mice (Cloeckaert et al., 2004).</persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1988">An omp31 mutant induces significant protection in mice from challenge with wild type B. melitensis (Cloeckaert et al., 2004).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine296">
		<vaccine_name>Brucella ovis Microparticle Subunit Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004146</vo_id>
		<type>Subunit vaccine</type>
		<status></status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference691">The antigenic extract (HS) was obtained from B. ovis REO 198 cells. The bacterial cells were cultured, suspended in distilled water, and heat-killed in flowing steam. Following centrifugation, the supernatant was dialyzed against deionized water. The dialyzed material was ultracentrifuged, and the pellet (HS) was washed in dH2O and freeze-dried. The batch of antigen used to prepare the vaccine formulation contained 48.7 ± 5.0% protein and 41.7 ± 4.7% rough lipopolysaccharide (R-LPS). The vaccine consisted of F68–CD–MP microparticles suspended in saline.  F68,CD, and MP are different excipients that  were used in order to facilitate the encapsulation and conserve the bioactivity of the encapsulated antigenic complex (HS) (Estevan et al., 2006).</preparation>
		<route refs=""></route>
		<antigen refs="reference691">A high hydrophobic antigenic complex taken from Brucella ovis (HS) (Estevan et al., 2006).</antigen>
		<host_response host_response_id="host_response381" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference691">Five groups of five female BALB/c mice, 9 weeks old, were immunized subcutaneously with one of the following treatments: (i) F68–CD–MP microparticles containing 20 μg of HS per mouse in 0.1 mL saline; (ii) free HS (20 μg/mouse); (iii) empty TROMS microparticles; (iv) 5 × 10^4 CFU/mouse of the living attenuated B. melitensis Rev1 reference vaccine strain; or (v) sterile buffered saline solution, the unvaccinated control group (Estevan et al., 2006).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference691">A single dose administered s.c. 8 weeks before infection produced significant protection with respect to unvaccinated control mice. Moreover, this protection was similar to that conferred by B. melitensis Rev1 reference vaccine. In contrast, no significant protection was obtained when non-encapsulated HS was given to mice (Estevan et al., 2006).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference691">Eight weeks after vaccination, the mice were challenged by the intraperitoneal route with 1 × 10^5 CFU of B. melitensis H38 virulent strain. Two weeks after the challenge, the animals were euthanatised by cervical dislocation. The spleens of the animals were aseptically removed, individually homogenized in BSS, properly diluted, and plated in Blood Agar Base medium for viable counts (Estevan et al., 2006).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine445">
		<vaccine_name>Brucella recombinant SurA protein vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000358</vo_id>
		<type>Subunit vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Nasal spray, Intraperitoneal injection (i.p.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference687">The PCR primers for cloning SurA gene from B. abortus were as follows: sense 5′AGAAAGCATATGTTTGCAAGACCTCTT3′ (NdeI) and antisense 5′TCTTCGGGATCCTCAACGATTGACGATGGT3′ (BamHI). B. abortus genomic DNA was used as template for PCR with Pfu DNA polymerase (Stratagene). The surA gene was cloned to plasmid Pet17b and then transformed to E. coli JM19 and then BL21(DE3) competent cells. Recombinant proteins were adsorbed with Sepharose-polymyxin B (Sigma, St. Louis, MO) to eliminate lipopolysaccharide contamination. The antigen and PBS were administered mixed with Complete Freund's Adjuvant (CFA) (Sigma) on day 0 and with Incomplete Freund's Adjuvant (IFA) on day 15 (Delpino et al., 2007).</preparation>
		<route refs="">Nasal spray, Intraperitoneal injection (i.p.)</route>
		<antigen refs="reference687">The antigen for this vaccine is SurA protein from B. abortus strain 2308, B. abortus strain S19, and Brucella melitensis strain H38 (Delpino et al., 2007).</antigen>

		<gene_engineering gene_engineering_id="gene_engineering1790" gene_id="gene258">
			<type>Recombinant protein preparation</type>
			<description refs="reference687">Mice given rSurA with adjuvant exhibited a significant degree of protection against B. abortus infection (Delpino et al., 2007b).</description>
		</gene_engineering>
		<host_response host_response_id="host_response495" host_id="host3">
			<immune_response refs="reference687">Immunization with rSurA elicited a vigorous IgG response that was detectable after the first immunization, increased further after the second Ag injection. PBS-immunized animals challenged with B. abortus 2308 developed antibodies against rSurA at 1 month after infection. Anti-rSurA IgG2a titers were higher than IgG1 titers during the whole immunization. rSurA stimulated significant production of IFN-γ, IL-2, IL-4 and IL-5 in spleen cells from rSurA-immunized animals but not from the PBS control group. All animals immunized with rDnaK alone elicited a humoral immune response that was detectable 15 days after the first immunization and increased further after the second injection to reach an IgG mean titer of 217,000 at day 30 post-vaccination. Immunization with rDnaK plus adjuvant induced similar anti-rDnaK IgG titers than immunization with rDnaK alone. None of the animals inoculated with PBS showed specific anti-rDnaK Abs at the time of challenge but notably, 30 days after infection all of them produced anti-rDnaK. Stimulation with rDnaK induced a significant production of IFN-γ and IL-2 in spleen cells from all mice immunized with rDnaK plus adjuvant Cells from rDnaK alone- or PBS-immunized mice were unable to stimulate the secretion of IFN-γ, IL-2, IL-4, IL-5 or IL-10 in response to rDnaK (Delpino et al., 2007).</immune_response>
			<host_strain refs="">Balb/c</host_strain>
			<vaccination_protocol refs="reference687">Female BALB/c mice of 6 to 8-weeks old were used for the testing of these vaccines. Mice were anaesthetized with methoxyfuorane and immunized by the intraperitoneal route with (i) 30 μg of rSurA, (ii) 30 μg of rDnaK, (iii) rSurA + rDnaK (30 μg + 30 μg) or iv) PBS, which was the negative control. Antigens and PBS were administered mixed with Complete Freund's Adjuvant (CFA) on day 0 and with Incomplete Freund's Adjuvant (IFA) on day 15. A fifth group of mice was immunized i.p with 30 μg rDnaK in PBS without no adjuvant on days 0 and 15. As reference vaccinated controls other groups were immunized once (i) by the subcutaneous route at day 0 with 8 × 10^8 formalin-killed B. melitensis H38S in IFA or (ii) i.p with 1 × 10^4 live B. abortus S19. Two separate assays of immunization were performed. The first experiment included groups immunized with rDnaK plus adjuvant, rDnaK without adjuvant, rSurA, and the negative (PBS) and reference (H38) control groups. The second experiment included groups immunized with rDnaK, rSurA, and rDnaK + rSurA, all with adjuvant, and the negative (PBS) and reference (B. abortus S19) control groups. Sera for antibody detection were obtained by retro-orbital bleeding under anaesthesia at 15, 30, 45 and 75 days after the first immunization (Delpino et al., 2007).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference687">Mice given rSurA or rDnaK plus adjuvant exhibited a significant degree of protection against B. abortus when compared with controls receiving PBS. Formalin-killed B. melitensis H38S, the control vaccine, induced 2.19 units of protection against B. abortus. Immunization with rDnaK alone induced a low but still significant level of protection. In a second experiment, both evaluated vaccines (rDnaK or rSurA plus adjuvant) induced significant protection against B. abortus infection. There was no additive protection by the simultaneous immunization with both rDnaK and rSurA. All evaluated vaccines induced less protection  than H38 or B. abortus strain 19 control vaccines. Altogether these results indicate that rSurA or rDnaK in adjuvant induce partial protection against B. abortus infection (Delpino et al., 2007).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference687">Immunized mice were challenged by i.p. injection with 1 × 10^4 B. abortus 2308 (Delpino et al., 2007).</challenge_protocol>
			<description refs=""></description>
              <host_gene_response host_gene_response_id="host_gene_response310" gene_id="gene1">
			    <description refs="reference687">Spleen cells from mice were used to determine cytokine levels 1 month after last immunization.  Mice immunized with rSurA and stimulated with SurA had significantly higher levels of IFN-gamma than did mice immunized with PBS and stimulated with SurA (Delpino et al., 2007b).</description>
			  </host_gene_response>
              <host_gene_response host_gene_response_id="host_gene_response311" gene_id="gene1121">
			    <description refs="reference687">Spleen cells from mice were used to determine cytokine levels 1 month after last immunization.  Mice immunized with rSurA and stimulated with SurA had significantly higher levels of IL-2 than did mice immunized with PBS and stimulated with SurA (Delpino et al., 2007b).</description>
			  </host_gene_response>
              <host_gene_response host_gene_response_id="host_gene_response312" gene_id="gene125">
			    <description refs="reference687">Spleen cells from mice were used to determine cytokine levels 1 month after last immunization.  Mice immunized with rSurA and stimulated with SurA had significantly higher levels of IL-4 than did mice immunized with PBS and stimulated with SurA (Delpino et al., 2007b).</description>
			  </host_gene_response>
              <host_gene_response host_gene_response_id="host_gene_response313" gene_id="gene1105">
			    <description refs="reference687">Spleen cells from mice were used to determine cytokine levels 1 month after last immunization.  Mice immunized with rSurA and stimulated with SurA had significantly higher levels of IL-5 than did mice immunized with PBS and stimulated with SurA (Delpino et al., 2007b).</description>
			  </host_gene_response>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine779">
		<vaccine_name>CGV2631</vaccine_name>
		<proper_name>B. melitensis Rev. 1 with bp26 and omp31 deletions</proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0001171</vo_id>
		<type>Live, attenuated vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs="reference195">B. melitensis Rev. 1 with bp26 and omp31 deletions (Jacques et al., 2007).</antigen>
		<host_response host_response_id="host_response540" host_id="host17">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference195">Sheep were conjunctivally or subcutaneously vaccinated at 4 months old (Jacques et al., 2007).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference195">eletion of bp26 and omp31 genes did not significantly affect the well recognised capacity of Rev.1 to protect sheep against B. melitensis challenge. However, the protection conferred by the CGV2631 mutant was significantly lower than that conferred by the CGV26 mutant or the Rev.1 strain (Jacques et al., 2007).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference195">Sheep were challenged with B. melitensis H38 at the middle of the first pregnancy following vaccination (Jacques et al., 2007).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine302">
		<vaccine_name>Divalent DNA B. abortus Vaccine pcDNA3.1-L7/L12-Omp16</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000374</vo_id>
		<type>DNA vaccine</type>
		<status></status>
		<vector>pcDNA3.1(+) [Ref697:Luo et al., 2006b]</vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference697">Full-length open reading frames of the L7/L12 gene and Omp16 gene were amplified with PCR from the genome of B. abortus strain RB51. The gene amplified with L7/L12 primers and/or the gene amplified with Omp16 primers were inserted into pcDNA3.1(+) vector (Invitrogen) (Luo et al., 2006b).</preparation>
		<route refs=""></route>
		<antigen refs="reference697">Brucella abortus L7/L12 protein and Omp16 protein were the antigens used in this vaccine. The vaccine was designated as pcDNA3.1-L7/L12-Omp16 (Luo et al., 2006b).
divalent fusion DNA vaccine encoding both the Brucella abortus L7/L12 protein (ribosomal protein) and Omp16 protein (outer membrane lipoprotein), designated pcDNA3.1-L7/L12-Omp16.</antigen>

		<gene_engineering gene_engineering_id="gene_engineering1501" gene_id="gene1677">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1502" gene_id="gene1678">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response388" host_id="host3">
			<immune_response refs="reference697">The results showed that the total IgG titer of the hyperimmune sera from mice immunized with pcDNA3.1-L7/L12-Omp16, pcDNA3.1-L7/L12, or pcDNA3.1-Omp16 reached 1:1,000, 1:800, or 1:600, respectively. Immunization with rL7/L12 and live RB51 strain elicited much higher humoral immune responses in mice, with IgG titers reaching 1:25,600 and 1:50,000, respectively. The analysis of IgG subtypes showed a significant increase in IgG1 and IgG2a from the DNA vaccine group, fusion protein vaccine group, and live RB51 group compared with the pcDNA3.1 vector control (Luo et al., 2006b).</immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference697">Female BALB/c mice were distributed into two groups: each mouse in one group was inoculated intramuscularly with 100 μg of pcDNA3.1-L7/L12-Omp16, pcDNA3.1-L7/L12, or pcDNA3.1-Omp16 in 100 μl of PBS. A control group was also used in this group, and these mice were infected with PBS or the pcDNA3.1 expression vector alone. Each mouse in the other group was injected with 10 μg of rL7/L12-Omp16 in 100 μl PBS according to the same schedule. Every mouse in this group was injected on weeks 0, 2, and 4. The mice used as positive controls were inoculated intraperitoneally on day 0 with 2× 10^8 CFU of B. abortus strain RB51 in 0.2 ml of PBS (Luo et al., 2006b).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference697">Immunization with any type of DNA vaccine resulted in a significantly higher degree of protection than the controls that received only PBS. Within the three recombinant DNA vaccines, the divalent DNA vaccine provided a higher protection level than either of the univalent DNA vaccines. Immunization with the recombinant fusion protein rL7/L12 also created significant protection. This protective effect was significantly lower than that created by theimmunization with the DNA vaccines (Luo et al., 2006b).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference697">Five mice from each group were challenged intraperitoneally  14 days after initial immunization. These mice were given a higher dose of strain 544, 5 × 10^5 CFU (Luo et al., 2006b).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine298">
		<vaccine_name>E. coli Escheriosome-mediated Cytosolic Delivery of recombinant Brucella rL7/L12 Protein</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000423</vo_id>
		<type>Subunit vaccine</type>
		<status></status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs="reference693">Complete Freund’s Adjuvant (Mallick et al., 2007).</adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference693">The rL7/L12 proteins were purified and introduced into Escherischia coli lipid liposome, allowing for escheriosome-mediated cytosolic delivery of the antigen, recombinant rL7/L12 protein. Combinations containing rL7/L12 protein and different adjuvants were formed for vaccination (Mallick et al., 2007).</preparation>
		<route refs=""></route>
		<antigen refs="reference693">The vaccine antigen is Brucella L7/L12 protein, which was delivered by an E. coli lipid liposome (escheriosome)-mediated cytosolic delivery system (Mallick et al., 2007).</antigen>
		<host_response host_response_id="host_response384" host_id="host3">
			<immune_response refs="reference693">Analysis of the mouse sera revealed non-signiﬁcant antibody titre up to day 14 post-immunization in various groups of immunized mice. Signiﬁcantly higher titre of IgG was detected on day 21 post-immunization in sera of animals which were primed with E-Lip-L7 form of the antigen as compared with the P-Lip-L7. Antibody titre was signiﬁcantly less in the animals immunized with S-19 or IFA-L7 combination. High antibody response was maintained in E-Lip-L7 immunized mice following each booster with maximum antibody level on seventh day after the last immunization as compared with P-Lip-L7 group which was unable to rise to that extent. The antibody response evoked by S-19 or IFA-L7 was signiﬁcantly less as compared to E-Lip-L7 immunized group. It was observed that E-Lip-L7 maintained signiﬁcantly higher titer of IgG1 and IgG2a as compared with P-Lip-L7-immunized group. Both S-19 as well as IFA-L7 combination failed to induce signiﬁcant level of IgG1 and IgG2a titre in the serum after 42 days post-ﬁrst immunization and the trend was maintained even after day 60 post-immunization (Mallick et al., 2007).</immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference693">Four-to-six-week-old female Balb/c mice were randomly distributed into eight experimental groups so that each group consisted of 20 animals. Each group consisted of 20 animals. Various groups of mice were injected separately through subcutaneous route, on days 0,21, and 28 with escheriosome entrapped rL7/L12 (E-Lip-L7), egg PC/Chol liposome entrapped rL7/L12 protein (P-Lip-L7), rL7/L12 protein with Complete Freund’s adjuvant (IFA-L7), rL7/L12 protein alone (free form; F-L7), E. coli lipid sham liposome and sham escheriosome mixed with free rL7/L12 protein, a physical mixture (EL + L7). The positive control in this study were mice vaccinated with about 5 x 10^6 cfu of Brucella S-19. The negative control for this study received only PBS. Each animal was immunized with a priming dose of 50 micrograms of rL7/L12 protein per animal (day 0) and boosted with 30 micrograms per animal (days 21 and 28) (Mallick et al., 2007).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference693">Escherischia coli escheriosome-mediated cytosolic delivery of recombinant rL7/L12 protein can elicit strong immunological responses in the Balb/c mice. However, egg PC/Chol liposome entrapped rL7/L12 was found to impart relatively poor immune response. Escheriosome-entrapped rL7/L12 protein elicited high IgG2a isotype response, suggestive of its relevance in imparting protection against brucellosis in mice(Mallick et al., 2007).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference693">One week after the final immunization, the mice belonging to various groups were challenged with 2 x 10^5 cfu of a virulent culture of B. abortus 544 intraperitoneally in 0.2ml
of saline solution. After 7, 15 and 30 days post-challenge, four mice from each group were euthanatized and their spleens were analyzed (Mallick et al., 2007).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine288">
		<vaccine_name>Live attenuated B. abortus with deletion of znuA</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000386</vo_id>
		<type>Live, attenuated vaccine</type>
		<status></status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs="reference683">The znuA-deleted mutant is very attenuated (Yang et al., 2006).</virulence>
		<preparation refs="reference683">ΔznuA mutant, RB51strains were grown overnight in Brucella broth at 37°C. Cells were pelleted, washed twice in sterile phosphate-buffered saline, and diluted to 1 × 10^8 cells/200 μl in sterile PBS. The actual viable inoculum CFU was confirmed by serial dilution tests on Bacto Potato Infusion Agar. Each vaccine consisted of 0.2 ml of this suspension (Yang et al., 2006).</preparation>
		<route refs=""></route>
		<antigen refs="reference683">The antigen for this vaccine is live, attenuated B. abortus strain 2308 with a znuA knockout mutation (Yang et al., 2006).</antigen>

		<gene_engineering gene_engineering_id="gene_engineering213" gene_id="gene228">
			<type>Gene mutation</type>
			<description refs="reference683">A suicide plasmid and a B. abortus mutant were constructed, then plasmids from transformants were isolated and analyzed by agarose gel electrophoresis after restriction digestion. B. abortus ΔznuA was electroporated with pBznuA to finalize the mutation (Yang et al., 2006).</description>
		</gene_engineering>
		<host_response host_response_id="host_response373" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference683">Experiments were conducted with 7- to 9-week-old age-matched mice. 0.2 ml of  vaccine was administered to mice via intraperitoneal injection (Yang et al., 2006).</vaccination_protocol>
			<persistence refs="reference683">Compared to wild-type strain 2308, splenic CFU in B. abortus ΔznuA-dosed mice were significantly decreased at weeks 1, 4, and 8. Importantly, by week 8, in three of the five B. abortus ΔznuA-dosed mice, splenic CFU could not be detected (Yang et al., 2006).</persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference683">The results showed that the ΔznuA mutant was mostly cleared by 8 weeks postinfection. Splenic CFU detected 4 weeks postchallenge were all wild type, and none were from the ΔznuA mutant. Protection against wild-type B. abortus 2308 challenge was as effective as that obtained with the RB51 or S19 vaccine strain, so this mutant is a potential live vaccine (Yang et al., 2006).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference683">For challenge study, B. abortus 2308 was diluted in sterile PBS, in which 100 μl of bacterial suspension contained 5 × 10^4 CFU bacteria, and immunized and naive mice were subsequently challenged intraperitoneally. The challenge dose was confirmed by plating B. abortus on PIA (Yang et al., 2006).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine297">
		<vaccine_name>Live, Attenuated Rifampin-Resistant Rough Mutants of Brucella melitensis</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004147</vo_id>
		<type>Live, attenuated vaccine</type>
		<status></status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference692">The vaccines were made through suspensions of  B. melitensis mutant strains at a concentration of 5 × 10^8 CFU/ml (Adone et al., 2005).</preparation>
		<route refs=""></route>
		<antigen refs="reference692">This vaccine contains rifampin-resistant rough mutants of Brucella melitensis (Adone et al., 2005).</antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine304">
		<vaccine_name>Microencapsulated B. melitensis vjbR mutant vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000398</vo_id>
		<type>Live, attenuated vaccine</type>
		<status></status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs="reference699">The vaccine was stored at 4°C (Arenas-Gamboa et al., 2008).</storage>
		<virulence refs="">B. melitensis mutant bjvR::Tn5 is an attenuated live strain.</virulence>
		<preparation refs="reference699">6 x 10^6 CFU of the live  B. melitensis mutant bjvR::Tn5 was suspended in 1ml of MOPS buffer (buffer containing MOPS and NaCl) and mixed with 5 ml of alginate solution. Spheres were obtained by extruding the suspension through a 200 micron nozzle into a 100 mM calcium chloride solution and stirred for 15 minutes. After extrusion of the bacteria-alginate mixture into the CaCl2, the capsules were washed twice with MOPS for 5 minutes and further crosslinked with 0.05% poly-L-lysine for 10 minutes.  Following two successive washes, the beads were stirred for five minutes in a solution of 0.03% (w/v) alginate to apply a final outer shell and washed twice with MOPS (Arenas-Gamboa et al., 2008).</preparation>
		<route refs=""></route>
		<antigen refs="reference699">An attenuated mutant of Brucella meletensis called vjbR::Tn5 (BMEII1116) is the antigen used in this vaccine (Arenas-Gamboa et al., 2008).</antigen>

		<gene_engineering gene_engineering_id="gene_engineering215" gene_id="gene233">
			<type>Gene mutation</type>
			<description refs="reference699">Live B. melitensis attenuated mutant vjbR::Tn5 was generated by mutation of the vjbR gene through interruption with a Tn5 (Arenas-Gamboa et al., 2008).</description>
		</gene_engineering>
		<host_response host_response_id="host_response390" host_id="host3">
			<immune_response refs="reference699">Immunization with BM vjbR::Tn5 elicited an IgG response that was clearly detectable after 2 weeks post-vaccination for either encapsulated or nonencapsulated vaccines. In mice vaccinated with the nonencapsulated BM vjbR::Tn5 vaccine, IgG levels peaked at 8 weeks post-immunization, whereas IgG responses in mice immunized with the BM vjbR::Tn5 with VpB in the shell, levels increased steadily and reached a maximum after 18 weeks post immunization. In this case, an induction of  higher and sustained antibody levels correlated with enhanced protection for both BM vjbR::Tn5 in alginate and vjbR::Tn5 in VpB shell formulations. Mice vaccinated with the encapsulated vjbR::Tn5 revealed elevated secretion from spleen cells of INF-γ, IL-12, but no IL-4. These suggested an induction of a T helper 1 (Th1) response reflecting the enhanced immunity associated with microencapsulation (Arenas-Gamboa et al., 2008).</immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference699">Sixty female BALB/c mice were randomly  distributed into groups of 10 for intraperitoneally (IP) vaccination. Each animal was given a single dose of microcapsules containing 1 x 10^5 CFU of  either: encapsulated B. melitensis mutant vjbR::Tn5 in alginate (vjbR::Tn5/alginate), encapsulated vjbR::Tn5 in alginate with VpB inside the capsule (vjbR::Tn5/VpB core), or encapsulated vjbR::Tn5 in alginate with VpB in the shell of the sphere (vjbR::Tn5/VpB shell).  The control groups received 1 x 10^5 CFU of either nonencapsulated vjbR::Tn5, empty capsules (no bacteria entrapped), or two hundred microliters  of MOPS buffer (Arenas-Gamboa et al., 2008).</vaccination_protocol>
			<persistence refs="reference699">There appears to be a brief period between week one and two during which the organism replicates and the numbers of B. melitensis vjbR::Tn5 in the spleen increase, but by three weeks post-inoculation the number of organisms in the spleen exhibits a drastic decline and drops below the level of detection by four weeks post-infection (Arenas-Gamboa et al., 2008).</persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="">A single immunization dose in BALB/c mice with the encapsulated vjbR mutant improved protection against wild-type B. melitensis 16M challenge compared to the nonencapsulated vaccine strain (P&lt;0.05) .</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="">At certian times after vaccination,  mice were challenged IP using 1 x 10^5  CFU/mouse of B.melitensis wild-type 16M.  One week post challenge, mice were euthanizediation and  their spleens were removed .</challenge_protocol>
			<description refs=""></description>
              <host_gene_response host_gene_response_id="host_gene_response108" gene_id="gene1">
			    <description refs="reference699">Cytokine secretion from spleen cells of mice vaccinated with the encapsulated vjbR::Tn5 revealed significantly elevated secretion of gamma interferon compared to non-vaccinated mice 10 and 30 weeks post vaccination (Arenas-Gamboa et al., 2008).</description>
			  </host_gene_response>
              <host_gene_response host_gene_response_id="host_gene_response109" gene_id="gene1127">
			    <description refs="reference699">Cytokine secretion from spleen cells of mice vaccinated with the encapsulated vjbR::Tn5 revealed significantly elevated secretion of interleukin-12 compared to non-vaccinated mice 10 and 30 weeks post vaccination (Arenas-Gamboa et al., 2008).</description>
			  </host_gene_response>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine275">
		<vaccine_name>NPAP Brucella vaccine</vaccine_name>
		<proper_name>Brucella vaccine using nonpathogenic alphaproteobacteria</proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000450</vo_id>
		<type>Inactivated or "killed" vaccine</type>
		<status></status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs="">incomplete Freund's adjuvant</adjuvant>
		<storage refs=""></storage>
		<virulence refs="">Not noted. </virulence>
		<preparation refs="reference666">Bacterial cultures were grown on plates, then centrifuged at 15,000 x g. Bacterial pellets were washed with PBS, then the bacteria were heat-killed. These suspensions were centrifuged at 15,000 x g again, then washed with Tris buffer. The cells were suspended in Tris buffer , then disrupted with a French press. Bacterial cells were broken by two passages and then digested for 1 hour with D. Nase and R. Nase. Unbroken cells were seperated by centrifugation. Particulate matter was pelleted by centrifugation, and the resulting supernatent was stored for vaccine (Delpino et al., 2007a).  
  </preparation>
		<route refs=""></route>
		<antigen refs="reference666">The angtiens for this vaccine were Ochrobactrum anthropi, Sinorhizobium meliloti, Mesorhizobium loti, Agrobacterium tumefaciens, or Brucella melitensis H38. These were used because provious findings indicate that Brucella antigens and those from Nonpathogenic Alphaproteobacteria (NPAP) are cross-recognized by the immune system (Delpino et al., 2007a). </antigen>
		<host_response host_response_id="host_response349" host_id="host3">
			<immune_response refs="reference666">Subcutaneous immunization with with heat-killed bacteria elicited a strong antobody response against CYT antigens. Antibody levels were highest after the second immunization, in most cases. In mice immunized with nonpathogenic species. Anti-Brucella antibody levels were augmented in all groups compared to preimmunization levels (Delpino et al., 2007a).   </immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference666">Mice were immunized with 3 doses (at 2 week intervals) of heat-killed bacteria (1 x 10^9 CFU per dose) mixed with adjuvant and administered subcutaneously in the back or with 3 doses of CYTs administered intraperitoneally. Control groups received PBS. The Brucella group was immunized with B. Melitensis H38 (Delpino et al., 2007a). </vaccination_protocol>
			<persistence refs="">Not noted. </persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference666">Cross-reacting anibodies were detected in serum samples obtained at the moment of challenge in all groups of mice. Spleen counts were significantly lower in immunized mice than in mice injected with PBS. Protection levels for nonpathogenic bacteria were lower than that obtained with Brucella immunization . Counts of CFU in mice immunized with B. melitensis were significantly lower than those of mice immunized with any other bacteria. Anti-brucella antibodies were detected in all groups 30 days postchallenge at levels similar to those found at the moment of challenge (Delpino et al., 2007a). </protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference666">One month after the final immunization, mice were challenged intravenously with 1.3 x 10^4 CFU of live B. abortus 2308. The mice were killed 30 days later and had their spleens analyzed and plated (Delpino et al., 2007)</challenge_protocol>
			<description refs=""></description>
		</host_response>
		<host_response host_response_id="host_response350" host_id="host3">
			<immune_response refs="reference666">Anti-Brucella IgG levels were significatly higher than preinfection levels in all groups of mice infected with NPAP. Mice infected with HKBA exhibited a significant rise in anti-Brucella IgG in serum. No significant increase in IgA was detected at the time of challenge for mice immunized with HKBA or infected with NPAP (Delpino et al., 2007a).      </immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference666">Two separate experiments of oral immunization were performed. Mice were inoculated intragastrically at weekly intervals with three doses of live NPAP(1 x 10^8 CFU) or heat-killed B. abortus (HKBA) strain 2308 (1 x 10^8 CFU)or PBS by an intragastric feeding tube (Delpino et al., 2007a).  </vaccination_protocol>
			<persistence refs="">Not noted. </persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference666">Serum levels of anti-Brucella IgA increased significantly in mice previously infected with O. anthropi and in mice orally infected with HKBA. Fecal levels of anti-Brucella IgA also increased after challenge (Delpino et al., 2007a). </protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference666">Twenty days after the last infecting dose, mice were challenged by the same route with live B. abortus 2308 (Delpino et al., 2007a). </challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine291">
		<vaccine_name>Porin and S-LPS Extracted from Virulent Brucella abortus 2308</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000403</vo_id>
		<type>Subunit vaccine</type>
		<status></status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs="reference686">The porin-S-LPS was given without adjuvant or in several adjuvants: trehalose dimycolate and muramyl dipeptide; the pluronic polymer L-121 and muramyl dipeptide; or complexed with Quil A in immunostimulating complexes (Winter et al., 1988).</adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference686">The S-LPS  was produced from smooth strain 2308 by extraction in hot phenol followed by treatment with guanidinium thiocyanate. Inocula were prepared from a freshly thawed vial which was diluted in sterile phosphate buffered saline to yield an infecting dose of 5 x 10^4 bacteria per 0.1 ml. Each dose was mixed with its appropriate adjuvant (Winter et al., 1988).</preparation>
		<route refs=""></route>
		<antigen refs="reference686">The antigen for this vaccine is  a complex of porin and smooth lipopolysaccharide (S-LPS) extracted from virulent Brucella abortus 2308 (Winter et al., 1988).</antigen>
		<host_response host_response_id="host_response376" host_id="host3">
			<immune_response refs="reference686">Protective vaccines caused the formation of increased concentrations of circulating O-polysaccharide-specific antibodies, although there were individual exceptions to the quantitative associatiQn between O-polysaccharide-specific antibodies and protection. Antibodies specific for porin or R-LPS were found in negligible quantities in vaccinated mice (Winter et al., 1988).</immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference686">Five week-old female mice were used. The mice were vaccinated subcutaneously. Blood samples were taken on one or more occasions during the course of some experiments. Quantitative cultures for viable B. abortus were performed on spleens at 1 and 4 weeks postinfection. Each mouse was vaccinated with 30 micrograms of porin-S-LPS (Winter et al., 1988).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference686">Vaccination with porin-S-LPS conferred significant protection against challenge infections with either B. abortus 2308 or 19 at both 1 and 4 weeks postinfection. The magnitude of protection was not significantly enhanced at either time period by the inclusion of TDM and MDP adjuvant in the vaccine. In contrast, vaccination with the same quantity of porin-R-LPS with or without adjuvant provided no significant protection against either challenge strain (Winter et al., 1988).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference686">B. abortus smooth strain 2308 of known virulence was used for challenge infections. In some experiments, vaccination or challenge was performed with vaccine strain 19. Animals were challenged 4 weeks postinfection with approximnately 5 x 10^4 CFU of live B. abortus cells (Winter et al., 1988).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3293">
		<vaccine_name>Recombinant B. abortus AsnC protein with CFA/IFA adjuvant</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004286</vo_id>
		<type>Subunit vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs="">CFA/IFA</adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs="reference2099">Recombinant B. abortus AsnC protein (Fu et al., 2012)</antigen>

		<gene_engineering gene_engineering_id="gene_engineering852" gene_id="gene1103">
			<type>Recombinant protein preparation</type>
			<description refs=""></description>
		</gene_engineering>
	</vaccine>
	<vaccine vaccine_id="vaccine3292">
		<vaccine_name>Recombinant B. abortus CobB protein with CFA/IFA adjuvant</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004285</vo_id>
		<type>Subunit vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs="">CFA/IFA</adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs="reference2099">Recombinant Brucella abortus CobB (Fu et al., 2012)</antigen>

		<gene_engineering gene_engineering_id="gene_engineering851" gene_id="gene1102">
			<type>Recombinant protein preparation</type>
			<description refs=""></description>
		</gene_engineering>
	</vaccine>
	<vaccine vaccine_id="vaccine11">
		<vaccine_name>Recombinant B. abortus RB51SOD</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000720</vo_id>
		<type>Live attenuated B. abortus strain</type>
		<status></status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference187">RB51SOD is a recombinant strain of B. abortus cattle vaccine strain RB51. RB51SOD overexpresses B. abortus Cu/Zn superoxide dismutase (SOD). Overexpression of this enzyme significantly increases vaccine efficacy against strain 2308 challenge (Vemulapalli et al., 2004).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs="">RB51SOD does not increase virulence compared to RB51.</storage>
		<virulence refs="reference187">RB51SOD is not more virulent than RB51 (Vemulapalli et al., 2004).</virulence>
		<preparation refs="reference14">The gene for B. abortus Cu/Zn SOD (sodC) along with its own promoter was initially obtained from a genomic library of B. abortus strain 2308, and later subcloned into pBBR1MCS, a broad-host-range plasmid. The resulting plasmid pBBSOD was transformed into E. coli DH5a, confirmed, purified, and then electroporated into B. abortus strain RB51. Strain RB51 containing the plasmid pBBSOD was designated RB51SOD (Vemulapalli et al., 2000a).</preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering2" gene_id="gene3">
			<type>Protein overexpression</type>
			<description refs="reference14">B. abortus Cu/Zn SOD is over-expressed in recombinant strain RB51SOD using the broad-range plasmid pBBR1MCS (Vemulapalli et al., 2000a).</description>
		</gene_engineering>
		<host_response host_response_id="host_response12" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">BALB/c mice</host_strain>
			<vaccination_protocol refs="">RB51SOD was used to vaccinate mice with a dose of ~4 x 10^8 cfu per mouse.</vaccination_protocol>
			<persistence refs="reference14">The presence of the Cu/Zn SOD plasmid in strain RB51 does not alter its vaccine efficacy. Overexpression of SOD does not alter the attenuation characteristic of strain RB51 (Vemulapalli et al., 2000a).</persistence>
			<immune_response_type refs="">VO_0003068</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference14">Recombinant strain RB51SOD in mice induces better protection against virulent B. abortus infection compared to B. abortus vaccine strain RB51 (Vemulapalli et al., 2000a). 
</protection_efficacy>
			<side_effects refs="">None observed.</side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs="reference14">Mice vaccinated with RB51SOD, but not RB51, develop antibodies and cell-mediated immune responses to Cu/Zn SOD (Vemulapalli et al., 2000a). 
</description>
              <host_gene_response host_gene_response_id="host_gene_response3" gene_id="gene1">
			    <description refs="reference14">Mice vaccinated with strain RB51SOD developed a Th1 immune response to the CuZn SOD, indicated by specific induction of serum IgG2a antibodies, but not IgG1 antibodies. IFN-gamma , but not IL -4 is secreted by CuZn SOD-stimulated splenocytes (Vemulapalli et al., 2000a). The enhanced protective immunity conferred by strain RB51SOD my be attributed to the specific cell-mediated responses, especially IFN-gamma secretion (Vemulapalli et al., 2000a).</description>
			  </host_gene_response>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine13">
		<vaccine_name>Recombinant B. abortus RB51WboA</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000404</vo_id>
		<type>Live attenuated B. abortus strain</type>
		<status></status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs="reference189">RB51WboA is not more virulent than RB51  (Vemulapalli et al., 2000b).</virulence>
		<preparation refs="reference189">RB51WboA is a recombinant Brucella strain that complements RB51 with a functional wboA gene. Rough Brucella abortus RB51 is a stable, attenuated mutant vaccine generated strain derived from virulent strain 2308. The wboA gene in RB51 is disrupted by an IS711 element. Abrogation of the wboA gene in smooth , virulent B. abortus, B. melitensis , and B. suis results in rough , attenuated mutants which fail to produce O polysaccharide (O antigen) (Vemulapalli et al., 2000).</preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
		<host_response host_response_id="host_response140" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference187">Groups of 13 mice each were vaccinated by intraperitoneal (i.p.) inoculation of viable strains RB51 (3 × 10^8 CFU/mouse), RB51SOD (5 × 10^8 CFU/mouse), RB51WboA (2.5 × 10^8 CFU/mouse) and RB51SOD/WboA (2.8 × 10^8 CFU/mouse)  (Vemulapalli et al., 2004).</vaccination_protocol>
			<persistence refs="reference187">No bacteria were isolated from the strain RB51WboA- and RB51SOD/WboA vaccinated mice at the time of challenge (Vemulapalli et al., 2004).</persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference187">Mice vaccinated with strains RB51 and RB51SOD showed significant protection in comparison to control. Mice vaccinated with strain RB51SOD showed a significantly better protection (mean reduction in CFU/spleen = 2.9 logs) than the mice vaccinated with strain RB51 (mean reduction in CFU/spleen = 1 log) (P = 0.02). No bacteria were isolated from the strain RB51WboA- and RB51SOD/WboA vaccinated mice, indicating that these mice developed a superior immunity that prevented the infection of B. abortus 2308 (Vemulapalli et al., 2004).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference187">Seven weeks after vaccination, five mice from each group were challenged i.p. with 3 × 10^4 CFU/mouse of virulent B. abortus 2308, and the remaining five mice were challenged i.p. with 2.4 × 10^4 CFU/mouse of virulent B. melitensis 16 M. Two weeks after challenge, the mice were euthanized and the number of CFUs in their spleens were determined (Vemulapalli et al., 2004).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine292">
		<vaccine_name>Recombinant Brucella DnaK protein vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000373</vo_id>
		<type>Subunit vaccine</type>
		<status></status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs="reference687">Two different adjuvants were used in these vaccines: Complete Freund's Adjuvant (CFA) and Incomplete Freund's Adjuvant (IFA). CFA was administered on day 0 and IFA was administered on day 15 (Delpino et al., 2007).</adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference687">The open reading frame of DnaK was cloned in the Pet17b vector (Novagen, Madison, WI, USA). The specific primers for B. abortus DnaK contain with XbaI and BamHI restriction sites at the 5′ ends: sense 5′ GCAGTTTCTAGAATGGAGAGAAATA 3′, antisense 5′ TAAAAGGATCCAATTACGACGAC 3′. B. abortus genomic DNA was used as template for PCR with Pfu DNA polymerase (Stratagene). Plasmid Pet17b was digested with BamHI and NheI. After ligation, the mix was used to transform E. coli JM109 competent cells. The plasmid DNA of a clone containing the insert was purified and used to transform E. coli strain BL21 (DE3) competent cells. Upon induction with 1 mM isopropyl-β-d-thiogalactopyranoside (IPTG), recombinant DnaK (rDnaK) was successfully expressed, and purified using a Mono Q column in an AKTA apparatus (Amersham Pharmacia, Uppsala, Sweden). Recombinant proteins were adsorbed with Sepharose-polymyxin B (Sigma, St. Louis, MO) to eliminate lipopolysaccharide contamination (Delpino et al., 2007).</preparation>
		<route refs=""></route>
		<antigen refs="reference687">The antigen for this vaccine is rDnaK protein from B. abortus strain 2308, B. abortus strain S19, and Brucella melitensis strain H38 (Delpino et al., 2007).</antigen>
		<host_response host_response_id="host_response377" host_id="host3">
			<immune_response refs="reference687">Immunization with rSurA elicited a vigorous IgG response that was detectable after the first immunization, increased further after the second Ag injection. PBS-immunized animals challenged with B. abortus 2308 developed antibodies against rSurA at 1 month after infection. Anti-rSurA IgG2a titers were higher than IgG1 titers during the whole immunization. rSurA stimulated significant production of IFN-γ, IL-2, IL-4 and IL-5 in spleen cells from rSurA-immunized animals but not from the PBS control group. All animals immunized with rDnaK alone elicited a humoral immune response that was detectable 15 days after the first immunization and increased further after the second injection to reach an IgG mean titer of 217,000 at day 30 post-vaccination. Immunization with rDnaK plus adjuvant induced similar anti-rDnaK IgG titers than immunization with rDnaK alone. None of the animals inoculated with PBS showed specific anti-rDnaK Abs at the time of challenge but notably, 30 days after infection all of them produced anti-rDnaK. Stimulation with rDnaK induced a significant production of IFN-γ and IL-2 in spleen cells from all mice immunized with rDnaK plus adjuvant Cells from rDnaK alone- or PBS-immunized mice were unable to stimulate the secretion of IFN-γ, IL-2, IL-4, IL-5 or IL-10 in response to rDnaK (Delpino et al., 2007b).</immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference687">Female BALB/c mice of 6 to 8-weeks old were used for the testing of these vaccines. Mice were anaesthetized with methoxyfuorane and immunized by the intraperitoneal route with (i) 30 μg of rSurA, (ii) 30 μg of rDnaK, (iii) rSurA + rDnaK (30 μg + 30 μg) or iv) PBS, which was the negative control. Antigens and PBS were administered mixed with Complete Freund's Adjuvant (CFA) on day 0 and with Incomplete Freund's Adjuvant (IFA) on day 15. A fifth group of mice was immunized i.p with 30 μg rDnaK in PBS without no adjuvant on days 0 and 15. As reference vaccinated controls other groups were immunized once (i) by the subcutaneous route at day 0 with 8 × 10^8 formalin-killed B. melitensis H38S in IFA or (ii) i.p with 1 × 10^4 live B. abortus S19. Two separate assays of immunization were performed. The first experiment included groups immunized with rDnaK plus adjuvant, rDnaK without adjuvant, rSurA, and the negative (PBS) and reference (H38) control groups. The second experiment included groups immunized with rDnaK, rSurA, and rDnaK + rSurA, all with adjuvant, and the negative (PBS) and reference (B. abortus S19) control groups. Sera for antibody detection were obtained by retro-orbital bleeding under anaesthesia at 15, 30, 45 and 75 days after the first immunization (Delpino et al., 2007b).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference687">Mice given rSurA or rDnaK plus adjuvant exhibited a significant degree of protection against B. abortus when compared with controls receiving PBS. Formalin-killed B. melitensis H38S, the control vaccine, induced 2.19 units of protection against B. abortus. Immunization with rDnaK alone induced a low but still significant level of protection. In a second experiment, both evaluated vaccines (rDnaK or rSurA plus adjuvant) induced significant protection against B. abortus infection. There was no additive protection by the simultaneous immunization with both rDnaK and rSurA. All evaluated vaccines induced less protection  than H38 or B. abortus strain 19 control vaccines. Altogether these results indicate that rSurA or rDnaK in adjuvant induce partial protection against B. abortus infection (Delpino et al., 2007b).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference687">Immunized mice were challenged by i.p. injection with 1 × 104 B. abortus 2308 (Delpino et al., 2007b).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine212">
		<vaccine_name>Recombinant chimera vaccine BLSOmp31</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000413</vo_id>
		<type>Subunit vaccine</type>
		<status></status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference485">The chimerical protein BLSOmp31 is synthesized using parts of Brucella Lumazine Synthase (BLS) and an outer membrane protein of 31 kDa (Omp31), which have given limited protection in mouse models  (Cassataro et al., 2007).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs="">None.</virulence>
		<preparation refs="reference486">Recombinant BLS (rBLS), rOmp31 and rBLSOmp31 were expressed in E. coli and purified as previously described (Laplagne et al., 2004).  Purity was assessed by Coomassie blue stain, and recombinant proteins were adsorbed with Sepharose-polymyxin B to eliminate LPS contamination.  The peptide was further purified by HPLC using a C-18 reverse phase column and the molecular weight was confirmed by mass spectroscopy  (Laplagne et al., 2004).</preparation>
		<route refs=""></route>
		<antigen refs="">The antigen used in this vaccine is a chimerical protein containing parts of Brucella Lumazine Synthase (BLS) and an outer membrane protein of 31 kDa (Omp31).</antigen>
		<host_response host_response_id="host_response252" host_id="host3">
			<immune_response refs="reference485">Immunization with recombinant BLSOmp31 elicited a strong specific IgG response that was detectable after the first immunization, increased after the second boost and reached IgG mean titers of 78,400 or 26,000 (anti-rOmp31 and anti-Omp31(48–74) , respectively) at the time of bacterial challenge.  Immunizatio with rBLSOmp31 elicited high levels of anti-Omp31 IgG1 as well as IgG2a antibodies (IgG1 mean titer: 17,600; IgG2a mean titer: 5300). IgG1 titers predominated over IgG2a titers during the whole immunization schedule for both recombinant antigens.  The elicited anti-peptide antibodies recognized the recombinant Omp31 as well as the native membrane protein, as demonstrated by the reactivity of the sera against whole rough B. ovis bacteria. These antibodies also produced complement mediated B. ovis cells lysis  (Cassataro et al., 2007).</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="">Mice (eight/group) were anaesthetized with methoxyfuorane and immunized by the intraperitoneal route with 30 </vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference485">The chimera significantly increases the protection elicited against B. ovis with respect to either BLS or Omp31.   In fact, rBLSOmp31 induced the highest protection level (2.45 log) against B. ovis, which was only comparable with that induced by the control vaccine (2.42 log), but significantly higher (P &lt; 0.01) than the vaccination with rBLS plus Omp31(48–74) (1.08 log)  (Cassataro et al., 2007).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference485">Immunized mice were challenged, by intravenous injection, with 1×10^4 B. melitensis H38S or 1×10^4 B. ovis.  Mice were killed by cervical dislocation 30 days after being challenged and their spleens were removed aseptically. Each spleen was homogenized in a stomacher bag, serially diluted, plated on supplemented TSA yeast extract (TSA-YE) and incubated  (Cassataro et al., 2007).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine113">
		<vaccine_name>Recombinant O. anthropi 49237SOD</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000407</vo_id>
		<type>Recombinant vector vaccine</type>
		<status></status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference196">Ochrobactrum anthropi is very closely related to Brucella, and has been used as a vaccine or vaccine vector for Brucellosis  (He et al., 2002).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs="reference196">O. anthropi strains are rarely pathogenic to humans  (He et al., 2002)</virulence>
		<preparation refs="reference196">Ochrobactrum anthropi strain 47237 was originally isolated from soil. Plasmids pBBSOD and pBBR1MCS were electroporated into electrocompetent O. anthropi strain 49237 using a protocol described previously for Brucella. Colonies of the O. anthropi strain 49237 containing pBBSOD or pBBR1MCS (designated O. anthropi strain 49237SOD or 49237pBB, respectively) were selected from TSA plates containing chloramphenicol at a concentration of 30 μg/ml  (He et al., 2002)</preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
		<host_response host_response_id="host_response145" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference196">Experiment 1 (Exp. 1):
Groups of eight mice were inoculated (i.p.) with either saline (negative control), B. abortus strain RB51 (2×10^8 CFU/mouse; positive control), recombinant B. abortus strain RB51SOD (2×108 CFU/mouse; positive control), O. anthropi 49237 (5×10^8 CFU/mouse), O. anthropi 49237pBB (5 × 108 CFU/mouse), or O. anthropi 49237SOD (5×10^8 CFU/mouse). At 2, 4, and 6 weeks after inoculation, three mice from each group were bled retroorbitally.  The sera obtained were stored at −40°C until use in an enzyme-linked immunosorbent assay (ELISA) or for Western blot analysis.  

In a second experiment (Exp. 2) whether multiple injections were required for protection was asessed . Groups of five mice were immunized i.p. with either saline, B. abortus strain RB51, or O. anthropi 49237SOD at the doses described above.  After two weeks, mice inoculated with O. anthropi 49237SOD were reimmunized with O. anthropi 49237/SOD (5×10^8 CFU/mouse).  To determine whether different doses influenced the results of protection, four groups of five mice each were inoculated with O. anthropi 49237 at four different doses: 5×10^8, 5×10^7, 5×10^6, and 5×10^5 CFU/mouse. A fifth group (five mice) was inoculated i.p. with saline as negative control.  Synthetic CpG-containing oligodeoxynucleotides (CpG-ODN) were administered to group four as an immunostimulatory adjuvant. One group (eight mice) was inoculated i.p. with O. anthropi strain 49237 (5×10^8 CFU/mouse); one group with strain 49237 (5×10^8 CFU/mouse) and CpG adjuvant, one group with strain 49237SOD alone (5×10^8 CFU/mouse), and one group with strain 49237SOD (5×10^8 CFU/mouse) and CpG adjuvant. The CpG adjuvant (10 nmol) was administered i.p. 4 h before inoculation and again at the time of inoculation of the bacterial strains.  Three groups of mice (eight/group) served as controls and  were inoculated with saline alone, CpG-ODN alone, or E. coli DH5α (10^6 CFU/mouse) and CpG-ODN.  The mice were bled at 2, 4, and 6 weeks after inoculation (He et al., 2002).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference196">Six weeks after inoculation, mice (5) from each group were challenged i.p. with 2×10^4 CFU of virulent B. abortus 2308/mouse. The mice were sacrificed after two weeks.  Their spleens were  homogenized, and spleens from the dilutions were plated to determine the numbers of Brucella CFU per spleen. The remaining unchallenged mice (each group) were sacrificed 6 to 8 weeks postinoculation, and spleen cells collected for cell culture in vitro  (He et al., 2002).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<gene gene_id="gene1103">
        <gene_name>AsnC</gene_name>
        <strain>Brucella abortus 2308</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>3788213</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>489054600</ncbi_protein_id>
        <gene_locus_tag>BAB_RS24000</gene_locus_tag>
        <gene_refseq>JMRZ01000003</gene_refseq>
        <protein_refseq>WP_002964767</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>359391</taxonomy_id>
        <chromosome>I</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>1633929</gene_start>
        <gene_end>1634399</gene_end>
        <gene_strand>-</gene_strand>
        <protein_name>ArsR family transcriptional regulator</protein_name>
        <protein_pi>5.32</protein_pi>
        <protein_weight>15857.78</protein_weight>
        <protein_length>156</protein_length>
        <protein_note></protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_007618.1:1633929-1634399 Brucella melitensis biovar Abortus 2308 chromosome I, complete sequence, strain 2308
TCTAACGCCCATCCAGCGGGACGGCTGTGGTGTCCTTGATCTCTTCCATCACGAAAGAGGCCGATACATC
CGATAGCGGTACACAGGCTATGAGGCGCTGGTAGAGCCGGTCATAAGCTCTGACATCGGAAATGCGTGCC
TTCAGCACATAGTCCAGATCGCCGGTCATGCGATAGGCGCCGACGATTTCCGGGAAGCGAGCCACGGCAG
CGCGGAATTTGTTCAGCCATTCGGGATCATGGGCGGAGGTGCGCACCAGAATGAAAACCGAGAGGCCATA
GCCGACCATTTCCGCATCCACCAGCGCCACGCGACCTTTGATGACGCCATCGTCTTCCATGCGCTTTACG
CGCCGCCAGCAGGCATTGCGCGAAAGATTCACCCGTTCGGAAAGGGAATCAACCGACAAAGTGCCGTCGT
TTTGCAACTCAGCCAGGATTTTTCGGTCTATATCGTCCATAGATGCTGTCA

</dna_sequence>
        <protein_sequence>>WP_002964767.1 MULTISPECIES: Lrp/AsnC family transcriptional regulator [Brucella]
MTASMDDIDRKILAELQNDGTLSVDSLSERVNLSRNACWRRVKRMEDDGVIKGRVALVDAEMVGYGLSVF
ILVRTSAHDPEWLNKFRAAVARFPEIVGAYRMTGDLDYVLKARISDVRAYDRLYQRLIACVPLSDVSASF
VMEEIKDTTAVPLDGR

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>Mice given BAB1_1688 (AsnC) plus adjuvant could provide protection against virulent B. abortus infection, similarly with the known protective antigen Cu-Zn SOD and the license vaccine S19 [Ref2099:Fu et al., 2012].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene997">
        <gene_name>asp24</gene_name>
        <strain></strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id>2352999</ncbi_nucleotide_id>
        <ncbi_protein_id>2353000</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq>AAB69346.1</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:151121</xrefs>
        <taxonomy_id>235</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>acid shock protein</protein_name>
        <protein_pi></protein_pi>
        <protein_weight></protein_weight>
        <protein_length>184</protein_length>
        <protein_note>Secreted protein acidic and rich in cysteine Ca binding region; pfam10591</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>gi|2353000|gb|AAB69346.1| acid shock protein [Brucella abortus]
MESRTMKSKTAFIAVIATSLFAIPALAQEKSNANTDKPAAEAAVSSNQDAKNKRGPIDLEKFSRMDQLKA
ADTNGDGVLSRDEIEALALKRVVSRAADRMERRLDVNGDGKVTLDEIQNQRKKEFAALDRNDDGKLDRHE
MRAAKMSHRGHKGHHEMGKHHKSGDHKGGDHKGPMKTKAQKPQE</protein_sequence>
        <phi_function>Virmugen</phi_function>
        <phi_annotation>A asp24 mutation in Brucella abortus is attenuated and provides significant protection in mice [Ref694:Kahl-McDonagh et al., 2007].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene114">
        <gene_name>B. abortus strain 19 L7/L12</gene_name>
        <strain>Strain 19</strain>
        <vo_id>VO_0010928</vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>304271</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq>L19101</gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:234671
CDD:100102</xrefs>
        <taxonomy_id>235</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>ribosomal protein L7/L12</protein_name>
        <protein_pi>4.49</protein_pi>
        <protein_weight>11795.56</protein_weight>
        <protein_length>183</protein_length>
        <protein_note>biovar Abortus</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>gi|304270|gb|L19101.1|BRURPL712X Brucella abortus ribosomal protein L7/L12 gene, complete cds 
CAAGCTCGTTATTCTCGGTGGCGCAATGGGTGCAACGACGCTTAGACCGATGGCGTCAAGTCGCTTCGTT
CGCTCCCGTCGCTCGACGAACTGCGCGCAAAGCTGGTTGGTATGATCCAGACCCCGGCTCAGCGTCTTGC
AGTGCTTACCAGCGCTCCGCGGGCCAGATCGCCCGCGTTATTGCGCGCACGCCCGGAAGAACGAGGCGGC
TTAAGGCCGTTTCTCGCTGTCAACAGTTCAAACCTTAATTATAGGAAATACAAAAATGGCTGATCTCGCA
AAGATCGTTGAAGACCTTTCGGCCCTGACCGTTCTGGAAGCCGCTGAGCTGTCCAAGCTTCTCGAAGAGA
AGTGGGGCGTTTCGGCTGCTGCTCCGGTCGCTGTTGCTGCTGCCGGTGGCGCTGCCCCTGCTGCTGCCGC
AGAAGAAAAGACCGAATTCGACGTCGTTCTCGCTGACGGCGGCGCTAACAAGATCAACGTGATCAAGGAA
GTGCGCGCACTCACCGGTCTCGGCCTCAAGGAAGCCAAGGACCTGGTCGAAGGCGCTCCGAAGGCTGTCA
AGGAAGGCGCCTCGAAGGACGAAGCTGAGAAGATCAAGGCACAGCTCGAAGCTGCTGGCGCCAAGGTTGA
ACTCAAGTAAGTTTGGACTATT</dna_sequence>
        <protein_sequence>>AAA19863.1 ribosomal protein L7/L12 [Brucella abortus]
MADLAKIVEDLSALTVLEAAELSKLLEEKWGVSAAAPVAVAAAGGAAPAAAAEEKTEFDVVLADGGANKI
NVIKEVRALTGLGLKEAKDLVEGAPKAVKEGASKDEAEKIKAQLEAAGAKVELK

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene110">
        <gene_name>B. melitensis M5 P39</gene_name>
        <strain>B. melitensis strain M5</strain>
        <vo_id>VO_0010948</vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>122892474</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq>EF189139</gene_refseq>
        <protein_refseq>ABM67295</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:224567
CDD:304360</xrefs>
        <taxonomy_id>1004957</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>immunogenic 39-kDa protein</protein_name>
        <protein_pi>4.69</protein_pi>
        <protein_weight>40682.69</protein_weight>
        <protein_length>483</protein_length>
        <protein_note>biovar: 1 str. M5</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>gi|122892473|gb|EF189139.1| Brucella melitensis strain M5 immunogenic 39-kDa protein gene, complete cds
ATGGGTACGGCTTCCTGTGGTTTGCTCGCCGGAATGGCGCCTGTTGCCAATGCGCAGGAAAAGCAGAATG
TCGAGGTTCTGCACTGGTGGACGTCCGGCGGCGAAGCGTCCGCGCTTGAAGTTTTGAAAAAAGATCTTGA
AAGCAAGGGCATTAGCTGGACCGATATGCCGGTTGCAGGTGGCGGCGGCACGGAAGCCATGACCGTTTTG
CGCGCGCGCGTTACCGCAGGCAATGCGCCAACCGCGGTGCAGATGCTGGGTTTTGACATTCGCGACTGGG
CGGAGCAGGGCGCACTCGGCAATCTCGATACGGTTGCTTCCAAGGAAGGCTGGGAAAAGGTTATTCCGGC
TCCCTTGCAGGAATTTGCCAAATATGACGGCCACTGGATTGCTGCGCCCGTCAATATTCACTCCACCAAC
TGGATGTGGATCAACAAGGCTGCTCTCGACAAGGCTGGCGGCAAGGAGCCGACCAATTGGGATGAGCTGA
TTGCGCTTCTCGACAATTTCAAGGCGCAGGGCATTACGCCGATCGCGCATGGCGGCCAGCCGTGGCAGGA
TGCAACCATTTTCGATGCGGTTGTTCTTTCATTCGGCCCGGATTTCTACAAGAAGGCCTTCATCGATCTC
GACCCGGAAGCACTGGGCAGCGATACCATGAAGCAGGCCTTCGACCGCATGTCCAAGCTTCGCACCTATG
TTGATGACAACTTCTCCGGCCGTGACTGGAACCTTGCTTCGGCCATGGTTATCGAAGGCAAGGCCGGTGT
CCAGTTCATGGGCGACTGGGCGAAGGGCGAGTTCCTCAAGGCGGGCAAGAAGCCGGGTGAGGATTTCGTC
TGCATGCGTTATCCGGGCACGCAGGGTGCTGTCACTTTCAATTCCGGCATGTTCGCCATGTTCAAGGTTT
CGGAAGACAAGGTTCCCGCACAGCTTGAAATGGCTTCGGCGATTGAAAGCCCTGCCTTCCAGTCTGCCTT
TAATGTGGAGAAGGGGTCGGCCCCGGCACGCACGGATGTGCCCGATACCGCTTTCGATGCCTGTGGCAAG
AAGACCATTGCCGATGTCAAGGAAGCAAACAGCAAGGGCACTCTGCTTGGCTCCATGGCGCATGGCTATG
CCAATCCGGCTGCCGTGAAGAATGCGATCTACGACGTCGTGACCCGCCAGTTCAACGGCCAGCTTTCTTC
GGAAGATGCCGTCAAGGAACTCGTTGTGGCGGTTGAAGCCGCAAAATAAGGCCACGCGGAAACGTCCGGG
GGAACCTCCCGGACGTTTTTCCTGCGTGCTCCAGCAGAAGCGCATAGGCGGTTGGCGCAGCTAACCGGCA
CTTACGACGGAATTGCATGCCGATATGCCCGCCTCACCATCCGAGGCGCGTTTCGTGGGACATAGAGC</dna_sequence>
        <protein_sequence>>ABM67295.1 immunogenic 39-kDa protein [Brucella melitensis bv. 1 str. M5]
MAPVANAQEKQNVEVLHWWTSGGEASALEVLKKDLESKGISWTDMPVAGGGGTEAMTVLRARVTAGNAPT
AVQMLGFDIRDWAEQGALGNLDTVASKEGWEKVIPAPLQEFAKYDGHWIAAPVNIHSTNWMWINKAALDK
AGGKEPTNWDELIALLDNFKAQGITPIAHGGQPWQDATIFDAVVLSFGPDFYKKAFIDLDPEALGSDTMK
QAFDRMSKLRTYVDDNFSGRDWNLASAMVIEGKAGVQFMGDWAKGEFLKAGKKPGEDFVCMRYPGTQGAV
TFNSGMFAMFKVSEDKVPAQLEMASAIESPAFQSAFNVEKGSAPARTDVPDTAFDACGKKTIADVKEANS
KGTLLGSMAHGYANPAAVKNAIYDVVTRQFNGQLSSEDAVKELVVAVEAAK

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>The 39-kDa protein is  immunogenic.</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1644">
        <gene_name>BAB1_0278</gene_name>
        <strain>Brucella melitensis biovar Abortus 2308</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>82615279</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:264424
EnsemblGenomes-Gn:BAB1_0278
EnsemblGenomes-Tr:CAJ10234
InterPro:IPR011681
UniProtKB/TrEMBL:Q2YPC5</xrefs>
        <taxonomy_id>359391</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>conserved hypothetical protein</protein_name>
        <protein_pi>8.51</protein_pi>
        <protein_weight>8787.28</protein_weight>
        <protein_length>148</protein_length>
        <protein_note>GcrA cell cycle regulator; cl11564</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>CAJ10234.1 conserved hypothetical protein [Brucella abortus 2308]
MHWKSRSPLSEALPMFDKLTSPHEGFRLADLSRRQCKWPVNRAQAGELHLFCGEAVQNGHPYCEEHCGKA
YTGKAGSR

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1676">
        <gene_name>BCSP31</gene_name>
        <strain>Brucella abortus</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id>144104</ncbi_nucleotide_id>
        <ncbi_protein_id>144105</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq>AAA22993.1</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:273982</xrefs>
        <taxonomy_id>235</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>cell surface protein</protein_name>
        <protein_pi>7.77</protein_pi>
        <protein_weight>32204.04</protein_weight>
        <protein_length>397</protein_length>
        <protein_note>biovar Abortus</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>gi|144104|gb|M20404.1|BRUBCSP B.abortus BCSP31 gene encoding a 31-KDa cell surface protein, complete cds
GCGCCTATACGCGCGACCTGATCCAGTCTTTTGCATCGCGGTGCCATGTGCGTCTGGTGGGGGCCGACGG
GCTGGCGGCGATTGCCGAAGCGCATATTCGCGGTGAAAGTTTCGATGAGGCGCTGGTCATGGCGCAGATC
GCGCCATGTTTTATCGAAAAGGATGGCAAGCGCACCGATATCGTGGTGCTTGCCTGTACGCATTATCCGT
TTCTCGTCAATGTATTGCGCCGTCTGGCTCCATGGCCGGTGGATTGGCTGGACCCGGCGGAAGCCATTGC
ACGACGCATGAAATCGCTTTTGCCTGCGCGAAGTGACGATGATGAATTTCATTCTCAAGATGACCTAGCA
TTCTTCACATCCAGGAAACCCGACTATGCCATTCGCCGCCTGATGCAGGGTTTTGGGCTGCGTTTTTAAT
CGTTTCAGTCGGCTCTGGCGGCGCTTGTCGGCAAGCGATTGTATTCTTTGGGAAAATCCAGAATAATGGA
ATGCGGTGGTTGACAATCGGCCTCAAGCTTCCTATGGTTTTCGGCATAATCTATGCGGGAAGAGGACTGG
TATTATGAAATTCGGAAGCAAAATCCGTCGCTTGGCTGTTGCGGCGGTGGCGGGCGCGATTGCGTTGGGA
GCGAGCTTTGCGGTTGCACAGGCCCCGACATTTTTCCGTATCGGCACTGGCGGCACAGCCGGAACCTATT
ATCCGATTGGTGGTCTGATCGCGAACGCGATTTCCGGCGCAGGCGAAAAGGGCGTGCCGGGTCTCGTCGC
GACGGCCGTTTCGTCGAATGGCTCGGTTGCCAATATCAATGCGATCAAGTCGGGCGCTCTGGAGTCCGGC
TTTACGCAGTCAGACGTTGCCTATTGGGCCTATAACGGCACCGGCCTTTATGATGGCAAGGGCAAGGTGG
AAGATTTGCGCCTTCTGGCGACGCTTTACCCGGAAACGATCCATATCGTTGCGCGTAAGGATGCAAACAT
CAAATCGGTCGCAGACCTGAAAGGCAAGCGCGTTTCGCTGGATGAGCCGGGTTCTGGCACCATCGTCGAT
GCGCGTATCGTTCTTGAAGCCTACGGCCTCACGGAAGACGATATCAAGGCTGAACACCTGAAGCCGGGAC
CGGCAGGCGAGAGGCTGAAAGATGGTGCGCTGGACGCCTATTTCTTTGTGGGCGGCTATCCGACGGGCGC
AATCTCGGAACTGGCCATCTCGAACGGTATTTCGCTCGTTCCGATCTCCGGGCCGGAAGCGGACAAGATT
CTGGAGAAATATTCCTTCTTCTCGAAGGATGTGGTTCCTGCCGGAGCCTATAAGGACGTGGCGGAAACAC
CGACCCTTGCCGTTGCCGCACAGTGGGTGACGAGCGCCAAGCAGCCGGACGACCTCATCTATAACATCAC
CAAGGTTCTCTGGAACGAGGATACACGCAAGGCACTCGATGCGGGCCATGCGAAGGGCAAGCTCATCAAG
CTCGATAGTGCGACGAGCAGCCTCGGTATTCCGCTGCATCCCGGCGCAGAACGCTTTTACAAGGAAGCGG
GCGTGCTGAAATAATCCCTCAATGATCGGTTCCTGATATCTTATTCCGAATTGAAGGGTGACATTGCGGC
AGCTCGTTATGCGCGCTGCTGCGCTCCCGTTTTCCAGAGCGGTTCCGGTTAGAACGGAATCGTTGGAACC
GCTCTATCTCTTTGTTTTTACGCATTATCCGACGCAAAACCGTTTCACGCTTTTGCTGGAAATGCTCTAG
CCTATTGAAATGCACGACCGGCAAAGTGGAGTTGGCCCGCATGACAGAAGAACAAAATGCAAAGCTT</dna_sequence>
        <protein_sequence>>AAA22993.1 cell surface protein precursor [Brucella abortus]
MKFGSKIRRLAVAAVAGAIALGASFAVAQAPTFFRIGTGGTAGTYYPIGGLIANAISGAGEKGVPGLVAT
AVSSNGSVANINAIKSGALESGFTQSDVAYWAYNGTGLYDGKGKVEDLRLLATLYPETIHIVARKDANIK
SVADLKGKRVSLDEPGSGTIVDARIVLEAYGLTEDDIKAEHLKPGPAGERLKDGALDAYFFVGGYPTGAI
SELAISNGISLVPISGPEADKILEKYSFFSKDVVPAGAYKDVAETPTLAVAAQWVTSAKQPDDLIYNITK
VLWNEDTRKALDAGHAKGKLIKLDSATSSLGIPLHPGAERFYKEAGVLK

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1053">
        <gene_name>bp26</gene_name>
        <strain>Brucella melitensis bv. 1 str. Rev.1</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>265991532</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:194028</xrefs>
        <taxonomy_id>520464</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>outer membrane protein Bp26</protein_name>
        <protein_pi></protein_pi>
        <protein_weight></protein_weight>
        <protein_length>250</protein_length>
        <protein_note>Protein of unknown function (DUF541); cl01077</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>gi|265991532|ref|ZP_06104089.1| outer membrane protein Bp26 [Brucella melitensis bv. 1 str. Rev.1]
MNTRASNFLAASFSTIMLVGAFSLPAFAQENQMTTQPARIAVTGEGMMTASPDMAILNLSVLRQAKTARE
AMTANNEAMTKVLDAMKKAGIEDRDLQTGGINIQPIYVYPDDKNNLKEPTITGYSVSTSLTVRVRELANV
GKILDESVTLGVNQGGDLNLVNDNPSAVINEARKRAVANAIAKAKTLADAAGVGLGRVVEISELSRPPMP
MPIARGQFRTMLAAAPDNSVPIAAGENSYNVSVNVVFEIK</protein_sequence>
        <phi_function>Virmugen</phi_function>
        <phi_annotation>A bp26 mutant in Brucella melitensis was attenuated and provided protection against challenge in mice [Ref1988:Cloeckaert et al., 2004].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1102">
        <gene_name>cobB</gene_name>
        <strain>Brucella abortus 2308</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>3787893</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>489054238</ncbi_protein_id>
        <gene_locus_tag>BAB_RS22225</gene_locus_tag>
        <gene_refseq>JMRZ01000005</gene_refseq>
        <protein_refseq>WP_002964414</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>359391</taxonomy_id>
        <chromosome>I</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>1271743</gene_start>
        <gene_end>1273053</gene_end>
        <gene_strand>-</gene_strand>
        <protein_name>hydrogenobyrinate a,c-diamide synthase</protein_name>
        <protein_pi>6.89</protein_pi>
        <protein_weight>44156.43</protein_weight>
        <protein_length>436</protein_length>
        <protein_note>responsible for the amidation of carboxylic groups at position A and C of cobyrinic acid or hydrogenobrynic acid</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_007618.1:1271743-1273053 Brucella melitensis biovar Abortus 2308 chromosome I, complete sequence, strain 2308
CTCACGCCGCTTCTCCGCTAAAATCAATGACATGCATGAAGGAGCCGGAGACGGAACCAACCCGCAAGCC
CGCTTCGCCAAGGTTCTCGCCCGATGCATCGCGCACCCGGAACAGGCGGTCGGCCTTTTCTTCCCGCACG
ATGCTTGCATAATGGAATTCATGCGCTTTCAAAGGCATGTCCCACGGCAATCCGCCAAGCGGCTCCAGCA
GGCGATAGCCAAGATGCAGTTTCCGCCTGGCAAAGCTCGTTTCCAATGGCAAAAGCCCCAGCATGGGATG
GTGAACGCCTGCCGCATCCTCCAGTGTTTTCCCGAGGACCATATAGCCGCCGCACTCGCCATAGACCGTG
ACGCCACGCGCGGCAGCGTCCCCTATCGCCGTGCGGAAACGGGATGCACCGGCCAATCGTTGCGCATGAA
GTTCTGGATAACCACCGGGAAGATAGATTGCATCCGCATCTGCCTTCGGTGCTTCATCTGCCAGCGGGGA
AAAGAAAGAGATTTCCGCACCCCGCCTGCGCCAGCCTTCAAAAAGATGCATATAGGCAAAAGCAAAGGCA
TCGTCCCGCGCCACGGCAATGCGGTTTCCAAGCGGTTTCAGACGCGCGACATTGGCCATGGCGTCATAGC
GCTTCGGGCGTAGCCAGATGGTCTGAAGCGCATCCATGTCGATATGCGCTTCCATCACATCGGCCGCTTG
TTCGAGAAAGCTTTCAAGACCGGCATGTTCGTCCGCCTGCACCAGCCCCAGATGCCTTTCCGGCAAGGAA
AGTGCCGGATCTCGCGGCAGCGCGCCCAGAACCGGGACGCCAAGGGGTGCCAGAGCGCCCCGCAGCATGG
CTTCATGGCGGGGACTTCCGACACGATTGAGAATGACACCCTCAATCAGCACATCCTTGCGAAACTGGCT
GAAACCCCACACCAGCGCCGCGATGGAGTGGGATTGCCGGGCGCAATCCACCACCAGCACGACTGGCAAA
TCCAGAAGCCGCGCCAGATCGGCAGAAGAGCCCTTACCGTCAATCGCCCCGTCGAAAAGCCCCATCATGC
CTTCGGCGACAAGAACACGCGCGCCGCTTTCCGTCATGCGGGAGGAAAGCGCACTGATGAGTTCCGGTCG
CATGGCCCAGGGGTCGAGATTGAAACAATCCACGCCACTCGCCGCCCTGTGATAGGCGGGGTCGATATAA
TCCGGCCCGGCCTTCACCGGCGCAAGCACCTCGCCCCTGCGTTTCAGGGCGCGCAACAAACCCAAGGTCA
CGGTCGTCTTGCCCGACCCGGAGGCCGGTGCGGCAATCATGAATCCCTTCA

</dna_sequence>
        <protein_sequence>>WP_002964414.1 MULTISPECIES: hydrogenobyrinate a,c-diamide synthase [Brucella]
MKGFMIAAPASGSGKTTVTLGLLRALKRRGEVLAPVKAGPDYIDPAYHRAASGVDCFNLDPWAMRPELIS
ALSSRMTESGARVLVAEGMMGLFDGAIDGKGSSADLARLLDLPVVLVVDCARQSHSIAALVWGFSQFRKD
VLIEGVILNRVGSPRHEAMLRGALAPLGVPVLGALPRDPALSLPERHLGLVQADEHAGLESFLEQAADVM
EAHIDMDALQTIWLRPKRYDAMANVARLKPLGNRIAVARDDAFAFAYMHLFEGWRRRGAEISFFSPLADE
APKADADAIYLPGGYPELHAQRLAGASRFRTAIGDAAARGVTVYGECGGYMVLGKTLEDAAGVHHPMLGL
LPLETSFARRKLHLGYRLLEPLGGLPWDMPLKAHEFHYASIVREEKADRLFRVRDASGENLGEAGLRVGS
VSGSFMHVIDFSGEAA

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>Mice given BAB1_1316 (CobB) plus adjuvant could provide protection against virulent B. abortus infection, similarly with the known protective antigen Cu-Zn SOD and the license vaccine S19 [Ref2099:Fu et al., 2012].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene934">
        <gene_name>exsA</gene_name>
        <strain>Brucella melitensis biovar Abortus 2308</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>3787220</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>82699354</ncbi_protein_id>
        <gene_locus_tag>BAB1_0468</gene_locus_tag>
        <gene_refseq>AM040264</gene_refseq>
        <protein_refseq>YP_413928</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>359391</taxonomy_id>
        <chromosome>I</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>459774</gene_start>
        <gene_end>461660</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>ABC transporter ATPase</protein_name>
        <protein_pi>7.04</protein_pi>
        <protein_weight>65025</protein_weight>
        <protein_length>628</protein_length>
        <protein_note>identified by match to protein family HMM PF00005; match to protein family HMM PF00664</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>gi|82698932:459774-461660 Brucella melitensis biovar Abortus 2308 chromosome chromosome I, complete sequence
GATGAATGCCCCCAAGACGGTTTCTGCCGAATCCGGCGAGACGCTGAAAACATTGCGAAATCTGTGGCCC
TACATGTGGCCGTCCGACAGGCCGGACCTGCGAATGCGCGTGGTCTGGGCCACATTCTATCTGGTTCTGT
CCAAGATTGTGCTGATCCTCGTACCCTATTTCTTCAAATGGGTGACCAATGCGCTGAACGGCCAGCTTCA
TGCGCCGGATTATATTCCGGTCGTTCTGGTCGGCGCGGTCATGCTGGTGCTGGCCTATAATGCGGCGAAA
ATCGTGCAGGCTGGCCTCAACCAGCTTCGTGACGCACTTTTTGCCAGTGTTGGCCAATATGCGGTGCGCC
AGCTTGCCTACAAGACCTTTGTGCATATGCATGAGCTTTCGCTGCGCTTTCATCTGGAGCGGCGCACGGG
CGGCCTGTCGCGCGTCATCGAGCGCGGCACCAAGGGCATTGAAACCATCGTCCGTTTTACCATCCTGAAC
ACGCTGCCTACCATTCTGGAATTTGCGCTGACGGCGGTGATCTTCGCTTTCGCCTATGGCCTGTCCTATC
TCGTGGTCGTGGCGGCGACGGTCTGGCTCTATACGTGGTTCACCATCAGGGCGAGCGATTGGCGCATCAA
TATCCGTCGCGAGATGAACGATTCCGATACCGACGCCAATACCAAGGCCATCGATTCGCTTCTCAACTTC
GAGACGGTCAAATATTTCGGCAATGAAGCGATGGAGGCCAAGCGTTTCGATGGGGCTATGGCGCGATATG
AAAAGGCTGCAACCCAGACCTGGACCTCGCTTGGCTGGCTGAACTTCGGTCAGGCCGTGATTTTCGGCGC
GGGCATGGCCATTGTCATGGTCATGTCGGCCATGGAGGTGCAGAAGGGCACACAGTCGCTGGGCGATTTC
GTCTTCATCAATGCGCTTTTGATGCAGCTTTCCATCCCGCTCAATTTCATCGGCTTTATCTATCGTGAAA
TCCGTCAGGGCCTCACCGATATCGAGCAGATGTTCGACCTTCTGGACGTCAAGCAGGAAGTGAAAGACAA
GCCCGGCGCTCCTGCGCTGAAAGTCGATAGCGGCGCAATCTCCTTCAAGGATGTGCACTTTGCCTATGAT
CCGCAGCGCCCCATCCTGCGCGGCATCAGCTTCGACGTTCCCGCAGGAAAGACGGTGGCGATTGTCGGCC
CTTCGGGGGCTGGTAAATCCACCATATCGCGGCTTCTGTTCCGCTTTTACGATATCCAGTCCGGTTCGAT
CACCATCGATGGGCAGGATGTGCGCGACGTGACCCAGGAAAGCCTGCGCAAGTTTATCGGCATGGTGCCG
CAGGATACGGTCCTGTTCAACGACACCATCGCCTATAATATCCGCTATGGCCGCACCGATGCGAGCGAGG
AGGATGTGGAAAAAGCAGCCGAGCTCGCGCAGATTGCCGGCTTCATCAAGCATCTGCCGGATGGCTACAA
ATCCATGGTTGGCGAGCGCGGCCTGAAGCTTTCCGGCGGCGAAAAGCAGCGTGTGGCGATTGCCCGCACG
ATCCTCAAGGCCCCGCCTATTCTTATTCTGGACGAGGCGACCTCGGCACTCGATACCGCGACCGAGCAGG
ACATCCAGTCGGCGCTTGATATTGTCAGCCGCGGGCGCACCACGCTGGTGATCGCGCATCGCCTTTCCAC
CGTGATCGGTGCGGATGAGATCATCGTCCTGAAAGACGGCCTGATCGCCGAGTGCGGCACGCACCGCCAT
CTCCTTGACCAGAAGGGGCTTTATGCTTCCATGTGGGATCGCCAGCGCGAGGCGAGCGAGGCTGAGGAGC
GCCTGCGCCAGGTGCGTGAAAGCGACGATATGGGCGTGGTTCTGCGCGGGACGCCGGCGGCGGAATA</dna_sequence>
        <protein_sequence>>gi|82699354|ref|YP_413928.1| ABC transporter ATPase [Brucella melitensis biovar Abortus 2308]
MNAPKTVSAESGETLKTLRNLWPYMWPSDRPDLRMRVVWATFYLVLSKIVLILVPYFFKWVTNALNGQLH
APDYIPVVLVGAVMLVLAYNAAKIVQAGLNQLRDALFASVGQYAVRQLAYKTFVHMHELSLRFHLERRTG
GLSRVIERGTKGIETIVRFTILNTLPTILEFALTAVIFAFAYGLSYLVVVAATVWLYTWFTIRASDWRIN
IRREMNDSDTDANTKAIDSLLNFETVKYFGNEAMEAKRFDGAMARYEKAATQTWTSLGWLNFGQAVIFGA
GMAIVMVMSAMEVQKGTQSLGDFVFINALLMQLSIPLNFIGFIYREIRQGLTDIEQMFDLLDVKQEVKDK
PGAPALKVDSGAISFKDVHFAYDPQRPILRGISFDVPAGKTVAIVGPSGAGKSTISRLLFRFYDIQSGSI
TIDGQDVRDVTQESLRKFIGMVPQDTVLFNDTIAYNIRYGRTDASEEDVEKAAELAQIAGFIKHLPDGYK
SMVGERGLKLSGGEKQRVAIARTILKAPPILILDEATSALDTATEQDIQSALDIVSRGRTTLVIAHRLST
VIGADEIIVLKDGLIAECGTHRHLLDQKGLYASMWDRQREASEAEERLRQVRESDDMGVVLRGTPAAE</protein_sequence>
        <phi_function>Virmugen</phi_function>
        <phi_annotation>Brucella DeltaexsA mutant showed decreased survival in mice compared to the survival of parental strain S2308. This demonstrated that ExsA is critical for full bacterial virulence. The B. abortus exsA deletion mutant was used as a live vaccine candidate. Challenge experiments revealed that the exsA mutant strain induced superior protective immunity in BALB/c mice compared to the protective immunity induced by strain S19 or RB51 [Ref1786:Rosinha et al., 2002a].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene254">
        <gene_name>IalB</gene_name>
        <strain>Brucella melitensis bv. 1 str. 16M</strain>
        <vo_id>VO_0010967</vo_id>
        <ncbi_gene_id>1197295</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>17987867</ncbi_protein_id>
        <gene_locus_tag>BMEI1584</gene_locus_tag>
        <gene_refseq>AE008917</gene_refseq>
        <protein_refseq>NP_540501</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>224914</taxonomy_id>
        <chromosome>I</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>1632893</gene_start>
        <gene_end>1633414</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>invasion protein B</protein_name>
        <protein_pi>8.98</protein_pi>
        <protein_weight>17016.04</protein_weight>
        <protein_length>173</protein_length>
        <protein_note></protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_003317.1:1632893-1633414 Brucella melitensis bv. 1 str. 16M chromosome I, complete sequence
TATGAAAAATTATCGTGCAATCGGTCTTGCATTCACGTTCACTGCCCTTTCCAGTCTTTCGGCCTTTGCA
GCCTCCCTGCCCGGCGGAGCAAGCACCTTGCAGGAAACCTATCAGGACTGGACCGTGTCTTGCCAGTCGC
AGAAGGATACAACAGCCTGCGTGATGCGTCAGGAGCAAAGCAGCGCCCAGGCCGGCCAGCGCGTTCTGAC
TGCCGAGCTGCGCAACGTCGCCGGCGGCAAAGTTGACGGTGTGTTGCTGATGCCGTTCGGTCTTGATCTT
GCCAAGGGCGCCTCGCTCAAGATTGATGACACCGCTGGGCCAAACCTCACCTTCTCCACCTGCCTGCCGC
AGGGCTGCCTCGCGCCAGTGAGCTTCGATGCCAAGCAGGTTGCTGCGCTGAAATCCGGCACCAACATCAA
TGTCACCACGACGGCGCTCAGCCCGAGCCAGCCGGTTGCCTTCAAGATTTCCCTGAAAGGCTTCGGTGCC
GCGCTCGACCGCATTCAGGCATTGACCAAGTA

</dna_sequence>
        <protein_sequence>>NP_540501.1 invasion protein B [Brucella melitensis bv. 1 str. 16M]
MKNYRAIGLAFTFTALSSLSAFAASLPGGASTLQETYQDWTVSCQSQKDTTACVMRQEQSSAQAGQRVLT
AELRNVAGGKVDGVLLMPFGLDLAKGASLKIDDTAGPNLTFSTCLPQGCLAPVSFDAKQVAALKSGTNIN
VTTTALSPSQPVAFKISLKGFGAALDRIQALTK

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>Brucella IalB is a protective antigen [Ref863:Commander et al., 2007].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1">
        <gene_name>Ifng (Interferon gamma)</gene_name>
        <strain>Mouse</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>15978</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>33468859</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq>NM_008337</gene_refseq>
        <protein_refseq>NP_032363.1</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>MGI:107656; UniProt:P01580</xrefs>
        <taxonomy_id>10090</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name></protein_name>
        <protein_pi></protein_pi>
        <protein_weight></protein_weight>
        <protein_length></protein_length>
        <protein_note></protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>gi|145966741|ref|NM_008337.3| Mus musculus interferon gamma (Ifng), mRNA
ATAGCTGCCATCGGCTGACCTAGAGAAGACACATCAGCTGATCCTTTGGACCCTCTGACTTGAGACAGAA
GTTCTGGGCTTCTCCTCCTGCGGCCTAGCTCTGAGACAATGAACGCTACACACTGCATCTTGGCTTTGCA
GCTCTTCCTCATGGCTGTTTCTGGCTGTTACTGCCACGGCACAGTCATTGAAAGCCTAGAAAGTCTGAAT
AACTATTTTAACTCAAGTGGCATAGATGTGGAAGAAAAGAGTCTCTTCTTGGATATCTGGAGGAACTGGC
AAAAGGATGGTGACATGAAAATCCTGCAGAGCCAGATTATCTCTTTCTACCTCAGACTCTTTGAAGTCTT
GAAAGACAATCAGGCCATCAGCAACAACATAAGCGTCATTGAATCACACCTGATTACTACCTTCTTCAGC
AACAGCAAGGCGAAAAAGGATGCATTCATGAGTATTGCCAAGTTTGAGGTCAACAACCCACAGGTCCAGC
GCCAAGCATTCAATGAGCTCATCCGAGTGGTCCACCAGCTGTTGCCGGAATCCAGCCTCAGGAAGCGGAA
AAGGAGTCGCTGCTGATTCGGGGTGGGGAAGAGATTGTCCCAATAAGAATAATTCTGCCAGCACTATTTG
AATTTTTAAATCTAAACCTATTTATTAATATTTAAAACTATTTATATGGAGAATCTATTTTAGATGCATC
AACCAAAGAAGTATTTATAGTAACAACTTATATGTGATAAGAGTGAATTCCTATTAATATATGTGTTATT
TATAATTTCTGTCTCCTCAACTATTTCTCTTTGACCAATTAATTATTCTTTCTGACTAATTAGCCAAGAC
TGTGATTGCGGGGTTGTATCTGGGGGTGGGGGACAGCCAAGCGGCTGACTGAACTCAGATTGTAGCTTGT
ACCTTTACTTCACTGACCAATAAGAAACATTCAGAGCTGCAGTGACCCCGGGAGGTGCTGCTGATGGGAG
GAGATGTCTACACTCCGGGCCAGCGCTTTAACAGCAGGCCAGACAGCACTCGAATGTGTCAGGTAGTAAC
AGGCTGTCCCTGAAAGAAAGCAGTGTCTCAAGAGACTTGACACCTGGTGCTTCCCTATACAGCTGAAAAC
TGTGACTACACCCGAATGACAAATAACTCGCTCATTTATAGTTTATCACTGTCTAATTGCATATGAATAA
AGTATACCTTTGCAACC</dna_sequence>
        <protein_sequence>>gi|33468859|ref|NP_032363.1| interferon gamma [Mus musculus]
MNATHCILALQLFLMAVSGCYCHGTVIESLESLNNYFNSSGIDVEEKSLFLDIWRNWQKDGDMKILQSQI
ISFYLRLFEVLKDNQAISNNISVIESHLITTFFSNSKAKKDAFMSIAKFEVNNPQVQRQAFNELIRVVHQ
LLPESSLRKRKRSRC</protein_sequence>
        <phi_function></phi_function>
        <phi_annotation>IFN-gamma plays a critical role in Th1 type immune response. It is important for protection against infections by various viruses and intracellular bacteria.</phi_annotation>
        <phi_function2>Vaximmutor</phi_function2>
        <phi_annotation2>The experimental data demonstrated that three time vaccinations with BCG in BALB/c mice induced strong TB Ag-specific IFN-gamma immune responses in splenocytes  [Ref2101:Wang et al., 2009].</phi_annotation2>
    </gene>
	<gene gene_id="gene1161">
        <gene_name>IgG</gene_name>
        <strain>Mus musculus</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>16059</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id></ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq>AF010213</gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>10090</taxonomy_id>
        <chromosome>12</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>881411</gene_start>
        <gene_end>914690</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>immunoglobulin heavy chain (V7183 family)</protein_name>
        <protein_pi></protein_pi>
        <protein_weight></protein_weight>
        <protein_length></protein_length>
        <protein_note>Also known as IgG; IgH; VI24H; VH7183; B9-scFv; IgVH1(VSG)</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>gi|94393741:881411-914690 Mus musculus strain 129/SvJ chromosome 12 unlocalized genomic contig, MGSCv37 alternate locus group 129/SvJ
CATGGACTTTGGGCTCAGCTGTGTTTTCCTTGTCCTCATTTTAAGAGGTAATTTGTAGAAATAAGATCCT
GCCAGTATTGTGTACAGGAGAAATAGAAAAATTTTTCTTTCCTCTATTTTGTTTTGTTTTGTTAGTGACA
GTTTACAAATAAGCATTCTCTGTTGTGAGGTGCCCAGTGTGAGGTGAAGATGGTGGAGTCTGTGGGAGGC
TTAGTGCAGCCTGTAGGGTCATTGAAACCCTCCTGTGCAGCCTCTGGATTCATTCTCACTGACTACTGAA
TGACCTGGATCCTTCAGGCTTCAAAGAAAAGGATGGAGAGGGTGACAATAAAATTTTTCCCACTCACACC
CACTTGCTGGCCCTGGCGTTCCCCTGTAATGAGGCACATAAAGTTTGCAAAACCAAGGGGCCTCTCTTCT
CAATGATGGCTGACTAGGACATCTTCTGATACATATGCAGCTAGAGACATGAGCTCCCGGGATACTGGTT
ACTTCATATTGTTGTTCCCCCACAACAGTTGCAGACCCTTTTATTTCTGTGGGTACTTTCACTAGCTCCT
CCATTGGGGGCCCTGTGTTCCATCCAATAGCTGACTGTGAGCATCCACTTCTGTAGTTGCTAGGCCCCGG
CATAGCCTCACAAGAGACAGCTATATCAGGGTCCTTTCAGCAAAATCTTGCTGGTGTATGCAATGGTGTC
AGAGTTTGGAGTCTGATTATGGGATGGATCCCCAGGTATGGCAAACTCTAGATGGTCCATCCTTTCCCAA
CAATAATTTTTAATGGTGGAGATAGCACCTACTATCCAGACACAATGAAGGGCCAATTCACTATCTCTAG
AGATGATGCCAAAAACACACTTTACCTGAAAATAAACAGTCTGAGGTCTGAGTACACAGCCATGTATACA
TATATTCCTAAGCTTGAGTAAGTGGACTTAAACTGATTCCATCACAACTTGCATGAGATGGATATTCCCC
AGTGTTAAGACCTGTCACCATCACTGTCAATCAGAAGACAAAGTTTATGCACAACAAAACAAAAAAACCA
AAAGCAGAGGCCTCCAATTACAAGTAATAGACCCAGACCCACAGTCTCTGAAAACTGACTGTACAGTTGG
ATCCAGTCTTTTACTTCTTTTCCCTGGATTTTATATTACTGAGGAAATGAGGAAAGCTCTACAATATCTG
TTCTCCATAGTGCTCAACACCTCCAAGCACAGGTTACCCATATTCATGCCTGCCTTCTGCTACACTTCTT
GTCTTGTAGACTACTTCAACCTATTTTGTACTCCAGTTAATGAAACTCAAGTCTAGCAGCCTGTCACTGT
TTATTCTAAAGTATTATGAACAGGTGACCTCCCATCCTTCCCCAACGCAATAATCATATTTAGGAATTTG
AGGTTTTATGAGATATGATCTCAGGGTAGAGAGAGAAAGCAAACTACATAGAAATATAGACTGACATAAA
TCAAGACTTGCATAAGCTAGTCCCCAAGTTCCATGTCCCTAAGTGGCAAGGACTATCTTCTGAGCCTAAT
GAGATGAGATCCAAATCAAACCTCCTGGGTCTTTTTAGATAAACATGTGAGATCAATAGACTAAATGCTT
TGGCTGGGCTTCCTTGCAATCCAATTCCCAAACAAAAATGGATCTGGCTCCACAGACACCACAAGAATAG
TCTTAAATAGTTCTTTAAGTAGAATGTCTGATCACTACGAGCCCAATTCCATCCTAAATACTCTTCTGGA
TTATACATAAATAAAAATTGAACATAGGGCATGGGGCACTGATCTCCCTGTGCTACATGAATGGGGGCTC
ATTTACTAAATGTTCCCATTTTTCTTTCTAGCGCTGCACAGTGCAAATCCTACAACTTCCTGTTTATCTA
CAATGTGAACTCCAAACAGTACAAGAAAAAACGTTCCTTATGTTCCTCTCCAGGTTCTCCAACAAGCACA
GAGCAACCTTCTGTCACCAGGACGGAAAACTGGAAACCTTGCTCACTGCTTCCTTTTATTCCCTCGGGAA
CCTCCCCCAATGCAAAGCAGCCCTCAGGCAGAGGATAAAAGCTCACACAAAGACGAGAAGCCCCATCCTC
TTCTCATAGAGCATCCATCAGAGCATGGCTGTCCTGGGGCTGCTTCTCTGCCTGGTGACTTTCCCAAGCT
GTAAGTGTTTCAGGGTTTCAGAAGAGGGACTAAGACATGTCAGCTAGAAGATGTGTGACTAATGGTGATG
TTGCTTGTCCCCAGGTGTCCTGTCCCAGGTGCAGCTGAAGGAGTCAGGACCTGGCCTGGTGGCGCCCTCA
CAGAGCCTGTCCATCACATGCACCGTCTCAGGGTTCTCATTAACTAGCTATGGTGTACACTGGGTTCGCC
AGCCTCCAGGAAAGGGTCTGGAGTGGCTGGTAGTGATATGGAGTGATGGAAGCACAACCTATAATTCAGC
TCTCAAATCCAGACTGAGCATCAGCAAGGACAACTCCAAGAGCCAAGTTTTCTTAAAAATGAACAGTCTC
CAAACTGATGACACAGCCATGTACTACTGTGCCAGAAACACAGTGTGGGAAGTCCAATGTGAGCCTGCAC
AAATACTTCTCTGCAGGGATGATCACAACCAGCAGGGGGCGCTGATGACCCAAAGGGACTTCCCAGGATC
TCTTCTGGAATCTAGGGAGTTCTGGCCTGTGTCTATCAGCATGTGTTTCAATGTTAGAGTTGTGAGTTTT
CCTTCCAGCAACAGAGATATTTTAGAGCCCACTTTTCATGGTCATTCTACTAAATTTGTTCACATAGTGG
AAAGATTTGTTAAATGATTCTATAGTCTAATAGGGTCAAACAAAAACAAATAATTGAGTTCATATCTACC
AAAAAAAAAAAAATTCCCTCAAAGTGGACAACTGTGTAGGTGAGGAAAACCAGGGGGATTTGGGAATAGA
TTATTTCTCTCCCGACTGTGGTGTTAGTCACCTTTCAGCCATTTACTGTATTTAATTCATGTTTAAAGTT
AATTGTATTCATCTTCCCTAACATGAAGTTTTCAAACACATGTCCACAATTTAATGATGACACAGTTATC
ATTGTGAATGATAACTCATAAGATCTCTCTCCATATATGAAACACACGATATTCTGTTATTAGCTATAGC
CAACAAAGTTACATATCATTATTATTACTGAAATAATTCTTCCCATCTAACTGAATAGTTTTCTCACTCG
ACACTGCCTATGCTGCGATCAGCCTGCTCTAATTTTACCTTTGCTCAGAGCACTGCTTTCTGTTTCATTT
GATAAGATGGTGCCTGGTTGTCACTGAAAATGTGTCCTCCAGTTTCACAGTGATTAATGTGATTTTCAGT
ACATTGAGAACAGAGCCACAGCAAAAATGAGATGGAATGTCATCATTTTTACGCCAGGTGCTGCAGAAAT
AGCTAGGTGGTTAAGAGAGAATATTGAACTTTGAGGGGTTCAGATTAAATTCCTGATACCCACAATGTGC
ACCTCATAACCACATGTACATATAGAAAACTCAGTATAAATGTGGCCTCCGTGAGCACCACACTACTCCC
ACAAACACATATACACATAATTAAAAGTAAAGATTTTAGAAAAATGGCTAATCTAATGATAGGAAGTAGT
CAAAAAGAGAGTTCTTTTGTCATGTACATATGTGTAGCAGACTTAAATGTTAAACATTCAAGAATACATT
CCTCGATCCACATTAAAATTTTGCAAAGAGTAGCACAGACGGTGGCAATTGCTAAACTTATATCTAGAAA
CACAATTATGTGTGGTGATATTTAATTACACATTTATACCAGGACATATGACAATATGGAAACCAAACAT
GTTGTATCCACATGCTCTAAGGAAAACTAAATGGAGTGTGATAAAACCAAAGAAAATGTGAATATGAAAT
ATTTTTCCAACTCTGCATCTTAAAACGGTTTCTTTCATGTGTCATATCTGCTATGAGGACTTTCTTCTGC
CCATGTCCAACTCCAGAGCATGCCACAGCAGGAAGACCTACAGGTATTACTTCTCTGCACCCAGGAAAAC
CACCTCTGTCCTGACCCTGCAGCTCTCAGAAGAGCCCAGACCTTCATTCTCAGGCCCTCATCCAGTAATC
AGCACTGAATACAGAGCACTCACCATGGACTTTGGGCTCAGCTTGGTTTTCCTTGTCCTTATTTTAAAAG
GTAATTCATAGAGATAAGATTCTATCTGTTTTGTGTACATGAGAAACAGAAAAATTGTATTGTTTCTCTA
TTTTGTTTTGTTTTGTTAGTGACAGTTTCTGACTCAAGATTCTCTGTTTGAAGGTACCCAGTGTGAGGTG
AAGCTGGTGAAGTCTAAGGGGAGGCATAGTGCAGCCTAGAAGGTCCATGATACTCTACTGTGCAGCCTCG
GATTCACTGTAAGTGACGACTGGTTTGTCCGTGTTTGCCAGGCTCCAAAGAAGGGGCTGCAGTGGGGGAT
GGGAATAATTTTTCATGGTTGTGGTAGCCCCTCTTATGCAGACACCTTGAAGAAGTGGGTTGGACGTAAC
ATATTCAGAATCAATATTTAAAGATTCTAATCCTTGAAGATATCACTTTTGACCAAGTATATATGAACCA
TGTTACTGAGGTTTATGGAGGTTTGAGTATGTTAGGTCCATGGATAGGGAAAATATTAGGGGATTTTAGG
AGTAACTGAGGCTTGTTGTAGGAAGGACATCACTGTAGGGGTAGGCTCCGTGTTCCTATCTTCAAGCTCT
ACCCAGTGCAGAATAGAGCCCTCTTCTGCCGGCAAGTGGAAAGAGTTTCTCTTCCTGGCTGCCTTCAATC
CAAGTTGTAGAATATCAAATCTCCTAACACTATGACTGCGAGCATGCTGACATGCGTCCCACCATAAAAA
TAGACTGAACCTCTGAAGCTTTAAGCCAGCCTCTAGTAACTGTATTCTTTAATAAGACTGAACTTGGCTA
TGGTGTCTTTTCACAGTAAAATGGAAACATAGACAAGGTTCTAACTCTCTGTACTAGAGGACCATCTCTA
TGTCCTTGGTGTTGTATGTAAATTATTGAACAAATACTATAGACAAGTTGTATGGCCAAAAGTCCATCCC
CTTCAACAATCTACTATCTGGAACCATATAGATTAGATTCCTTTCCTGCACTCATTTCCCTTACTTGCTG
AGACATTTTGAAGACATGCTCAGAATCCCTGAACTTCCTGCTGAAAAAAAAATACCCCTCCAATTTGAAG
ACAGTTCTCTTCCAAAATTCATCATAAATACTGATCCACATGTCCAGGCATATCATGTAGTTTTAAAAAA
CAAACCAATCAATGCTAAAGTGGGTAAGTGCCTACATCATTGGTTTATGTCTGTTCATAACCTGGTATAT
AGCTAGAGACCAGGACTGCATGTTTCTCCTAGGCCACACCTCTCCCACAAATGCTGGCTCTGCCTCTCCA
GAATTCCAAGATCATGGATCTCTGGGTCCCCAAGGAACAATAAGTGTGCACTCTTGCCAGCCTGTACACT
ACTGCACTAGCTTCTCCCCCTGGAGCTTGGTCATTGCTCAATCTTCCCTTTCCAAAGCCTGGCCAAATTC
CTCCTACCTTTTGTTCTTTCAGTCAGGCCACCTAAGTCATCTTGAATGAAAAACAACACAAAATCTGAAC
TTAAAATCAACAAATAATACAAGTGCTGCGCACAAAATCAATCATTCTAAACTCATCAACTATTTTATGA
TGGAAATCTTCCAACATACAAGCTACCACCAGGTCTAAGAATTACTCATCTACATGTTGCTTCCTCTCAC
TCACAGCCTAACCATAAAAGGGCTGTTTCTTCCTCCCATGTCCCCTCTTTTGCCTTCAGAAGCAGAAGCT
CCACCTCCTCCTCTTTGCCCAGCAATTGGCTTCTTGTCGTCTTTATTATCATATTAATTACTTAGGGGAA
AATCCCGTGTAGTGGCTATTCCTGGTTGTCAACTTGACAATATTTGGAATGAACTACAATCCGGAATTGG
AAGGCTCACCAGTGACCCTTATCTGGAGGCTTGGAGATCCTTATCTGGATCTTGGTTTGAAGATCTTGAG
CCATAGGGGCTATGGATTCCAGAAGATTGAATCTCCGAGTTTAAGGAACACACCTTTAATCTGGGCTACG
CCTTTCATCTGGGATTAAAGGTGTGGCGGAACACACCTTTAATCTGGACTACACCTTCTGCTGGAGACAA
TATAAGGACATTGAAAGAAGGGAGTCTAGCTCTTGCTCTTGCTCCTTCGCCTGCTTGCTGCGTGAGACTG
AGTAACTGCTAGATCCTTGGACTTCCATTCACAGCTGCGACTGAACAATTGTTGGGAATTGGGCTGCCGA
CTCTAAGTCATCAATAAATTCCTTTACTATCTAGAGACTATCCATAGTTCTGTGACTCTAGAGAACCCTG
ACTAATACAGAAGTTGGTACCAGGAGTGGTTCTAGAGTAACAGAAGTACAAGGATGAATCTTTTAAAATA
CTGGAATTGGCTTGTTGATCCACCAGCACTTTCAACTATTGAAACCTCTCCAGATTCTCTCCCTCCTGGG
AGCTCAGAGAATTTTGAAGACCCATGGTTGAAACTATATTCCGAACTTAAAGAAGCAAATGCCCTTGATT
TTCTTAATGAATTAGGTGATTCAGTGCACAAAGCTTTCTACAAGATGGGGAAAAAATTGGAAAATGATTT
TACTGGCTGGCTGCTCTTAGTATCTGTGGAAAAAATGATGAATGAAAGGAAGGAGTTGTGTGATAAAATC
GAAAGGCTCCAGACACAAGTAAACGATCTAAAAGTTGCTAAGTGTGTCCTTGAGGAGAATCTTCTCTCTT
GTAGCAATAGAGCTCAAGTTGCAGAAAATCAAACAGAAACTCTCATTGTAAGGTTGGCTGAACTACAGCG
AAAATTCAAGTCTCAGCCTCAGAGTGTGTCAACAGTTAAAGTAAGGGCTCTAATTGGCAAAGAATGGGAT
CCTACAACATGGGACGGGGATGTGTGGGAAGACCATGTTGAAGCTGAGAATTTTGAATCTTCAGATTCTC
AAGGGTTTGCCCCACCTGAGGAAGTAGTACCCTCAGCCCCACCCCTTGAAATAATGCCTTCCCCACATGA
GGAAATTAATTTTGCAGAGTCTGATAAACCAGCAATGATTTTCACTACTGATGTTTCTCAAGGCCCACCA
ATAGTTTCTTCTAGACCTGTAACCAGACTCAAAGCAAAACAGGCTCCTAGAGGGGAGGTAGAAAGTGTAG
TCCATGAGGAAATTCGCTACACTACTAAGGAGCTTAATGAGTTTGCTAATTCATTCAAGCAGAAACCTGG
TGAATATGTGTGGGAATGGATTTTAAGGGTGTGGGATAAGGGTGGAAGGAACATAAGACTAGAGCAGGCT
GAGTTTATTGACATGGGTCCTCTGAGTAGAGATTCTAGGTTTAATACGGAAGCTCGCATAATTAAAAAAG
GTGTCAAAAGTTTGTTTGAATGGTTGGCTGAGGTGTTTATCAAAAGATGGCCTACTGGAAATGACTTGGA
GATGCCTGATATTCCGTGGCTTAGTGTTGATGAAGGGATTTTAAGACTTAGGGAAATTGCAATGCTAGAG
TGGATATATTGTGTAAAGCATAATTGTCCACAATGGGAAGGTCCAGAAGATATGCCTTTCACTAGCTCTA
TAAGACGCAAATTGGTGAGAGGGGCACCAGCACATTTGAAGGGTTTTGTTCTTTCCCTTTTCCTTGTACC
AGATCTTAGCATTGGAGATGCTTCTGCTCAATTAGATGAATTAAATTCACTGGGTTTAGTTGGATTCCGA
GGTAACAAGGGCCAGGTGGCAGCATTGAATCGCCGGAGACAAGGTGATTCTAGTTATTATAATGGACAGC
GTAGACAAAAGAATGTTTATAATAACATACCCAGCAATGGTCAGCACAGGAGAGGTGAAATTTATAATGG
CATGACTCGGTTGGACCTTTGGTACTGGCTAACCAATCATGGTGTTTCCAGGAATGAAATACATAGGAAG
CCTACTGCATATTTGTTTGATCTGTATAAGCAGAAAAATTCTCAAACAAATGAAAGAAAGGCTACATTAG
ATCATGGTAAACAGCAATCTCGGCCAGTGAATCAATTTCCAGACTTGAGACAGTTTGCAGATCCAGAACC
CCTTGAATGAAGGGGTGGCCAGGTTCCGCTGAGGAAGGATCTTGATAAGACACCCAAAGGTTTTGCTGTT
ACCCTTTCTCCAGTTCTTCCCCAGAGGGACCTAAGGCCTTTTACAAGGGTAACTGTACACTGGGGAAAAG
GAAATAATCAGACTTTTCAGGGTCTGCTGGATACTGGTTCTGAGTTGACACTGATTCCAGGGGATCCCAA
GAAACATTGTGGCCCTCCAGTTAAAGTAGAGGCTTATGGAGGGCAGGTGATTAATGGAGTTTTGACTGAT
GTCCGACTCACAATAGGTCCAGTAGGTCCCCAGACACATCCTGTGGTGATTTCCCCAGTTCCAGAATGTA
TAATTGGGATAGATATACTCAGAAATTGGCAGAATTCTCATATTGGTTCCCTGAACTGTAGAGTGAGGGC
TATTATGGTTGGAAAGGCCAAATGGAAACCTTTAGAGTTGCCTCTGCCAAAGAAAATAGTGAATCAAAAA
CAGTATCGTATTCCTGGAGGCATTGCAGAAATTACTGCCACTATCAAGGACTTGAAAGATGCAGGGGTGG
TGGTTCCCACCACATCTCCGTTTAACTCTCCTATCTGGCCAGTGCAGAAAACAGATGGATCATGGAGAAT
GACAGTTGATTATCGAAAACTAAATCAGGTAGTAACTCCAATTGCAGCTGCTGTACCAGATGTAGTTTCA
TTACTTGAGCAAATTAACACATCTCCTGGCACCTGGTATGCGGCTATTGATCTGGCAAATGCCTTCTTCT
CAGTACCTGTCCATAAGGACCACCAGAAGCAATTTGCTTTCAGTTGGCAAGGCCAACAGTATACTTTCAC
AGTTTTGCCTCAAGGATATATTAACTCTCCTGCCCTGTGTCATAATTTAGTTAGAAGGGATCTTGATCGT
TTGGATCTTCCACAAAATATCACATTGGTGCACTATATTGATGACATTATGCTGATTGGACCAAGTGAGC
AGGAAGTAGCAACCACTTTGGACTCATTGGTAACACATATGCGTATCAGAGGATGGGAAATAAATCCAAC
CAAAATTCAAGGACCATCTACCTCAGTGAAATTCTTAGGAGTCCAGTGGTGTGGAGCATGCAGAGATATT
CCTTCTAAGGTGAAAGATAAGTTATTGCACCTGGCCCCTCCTACAACCAAGAAAGAAGCACAACGTTTAG
TGGGTCTATTTGGATTCTGGAGACAACACATCCCTCACTTGGGTGTGTTACTTAGGCCTATTTACCAAGT
GACTCGGAAAGCTGCTAGCTTTGTGTGGGGCCTGGAACAGGAGAAGGCCCTTCAACAGGTCCAGGCTGCT
GTGCAGGCTGCACTACCACTTGGACCATATGACCCAGCAGACCCGATGGTACTTGAGGTGTCTGTGGCTG
ATAGAGATGCTGTTTGGAGCCTCTGGCAGGCCCCTGTAGGTGAATCACAGAAAAGACCTTTGGGATTTTG
GAGCAAAGCTCTACCATCATCTGCAGACAACTATTCTCCCTTTGAAAAACAGCTCTTGGCCTGCTATTGG
GCCTTAGTGGAAACTGAACGTTTGACAATAGGACACCAAGTTACTATGCGACCTGAACTACCCATCATGA
GCTGGGTACTATCAGACCCTGCAAGTCATAAAGTGGGACGCGCACAGCAGCAGTCTGTTATCAAATGGAA
GTGGTATATACGTGATCGGGCCAGAGCAGGTCCTGAAGGCACAAGCAAGTTACATGAAGAAGTTGCTCAA
ATGCCTATGGTTTCTACTCCTGTTACACTGCCATCTGCTGCCAAACATGTGCCTATAGCCTCATGGGGTG
TTCCCTATGATCGACTGACCGAAGAGGAAAAGACTAGAGCCTGGTTTACTGATGGCTCTGCACGTTATGC
AGGCACCACCCAGAAGTGGACAGACAGCTGCAGCATTACAACCCCTTTCTGGGACAACCCTGAAAGACAC
AGGTGAAGGGAAATCTTCACAGTGGGCAGAACTTCGGGCAGTACACATGGTATTACAGTTTGTTTGCAAG
AAGAAATGGCCAGATGTACGATTATTCACTGACTCATGGGCTGTAGCCAATGGATTGGCTGGATGGTCAG
GGACTTGGAAAGATCACAATTGGAAAATTGGTGAGAAAGACATCTGGGGAAGAAGTATGTGGATAGATCT
CTCCAAATGGGCAAAGGATGTGAAGATATTTGTGTCCCATGTAAATGCTCACCAAAAGGTGACTTCAGCT
GAGGAGGAGTTCAATAATCAAGTGGATAAGATGACCCGTTCTGTGGACAGTCAGCCTCTCTCCCCAGCCA
TCCCTGTCATTGCTCAATGGGCACATGAACAAAGTGGCCATGGTGGTCGAGATGGAGGTTATGCTTGGGC
TCAGCAACACGGGCTTCCACTCACCAAGGCTGACCTGGCTACAGCTGCTGCTGATTGCCAGATCTGCCAA
CAGCAGAAACCAACACTGAGTCCCAGATATGGCACCATTCCTCGAGGTGACCAGCCAGCAACCTGGTGGC
AGGTTGACTACATTGGACCACTTCCTTCGTGGAAAGGACAGCGTTTTGTTCTTACTGGAGTAGATACTTA
TTCTGGTTATGGATTTGCCTTTCCTGTACGTAATGCCTCTGCTAAAACCACCATTAACGGACTGACAGAA
TGCCTTATCTATCGTCATGGTATTCCACACAGTATTGCTTCTGACCAAGGAACTCATTTCACAGCCAGAG
AAGTACGACAGTGGGCCCACGATCATGGAATTCACTGGTCTTACCACATTCCCCATCATCCTGAAGCAGC
TGGTCTGATAGAAAGATGGAATGGCCTTCTGAAGACGCAGTTACAGCGCCAATTAGGTGGTAACAGCTTG
GAAGGCTGGGGTAGAGTTCTTCAGAAGGCAGTATATGCTTTGAATCAGCGCTCGATATATAGTACAGTTT
CACCCATAGCCAGGATTCATGGGTCCAGGAATCAAGGGGTGGAAAAAGGAATAGTTCCACTTACTATCAC
TCCTAGTGACCCTCTAGGAAAATTTTTGCTTCCTGTCCCCATAACTCTAGGTTCTGCTGGCTTAGAAGTT
TTGGCTCCAGAGAGGGGAGTGCTCCTACCAGGAGCTACAACAAACATTCCATTGAACTGGAAGCTCAGAC
TTCCCCCTGGTCATTTTGGGCTTCTAATGCCCTTAAACCAACAGGCTAAAAAAGGAGTAACAGTGTTAGG
AGGGGTGATAGATCCAGATTACCATGGGGAAATTGGATTACCTCTTCACAATGGTGGTAAGCAAGATTAT
GTCTGGAGTGTAGGAGATCCCTTAGGGCGTCTCTTAGTACTACCATGTCCTGTGATTAAAGTCAATGGGA
AACTACAACAGCCTAATCCAAGCAGGATGACAAAGGACACAGACCCATCAGGAATGAAGGTATGGGTCAA
TCCTCCAGGAAAAGAGCCAAGACCTGCTGAGGTGCTGACTGAAGGAGAAGGAAATATAGAATGGGTAGTA
GAGGAAGGTAGTTATAAATACCAATTAAGGCCACGTAACCAGTTGCAGAAACGAGGATTATAAAGTAATA
TGAATGCCCATTGTAAATTTACTAATGCGTTTGCGATTGTACGAGGGATAGTTATATCATGTTAGGCGTA
TTTACAAACTTGTTATTGTTTTATGTGAACATGAGATATTATTTGTGTCAAGTTGACAAGGGGTGGATTG
TAGTGGCTATTCCTGGTTGTCAACTTGACAATATTTGGAATGAACTACAATCCGGAATTGGAAGGCTCAC
CAGTGACCCTTATCTGGAGGCTTGGAGATCCTTATCTGGATCTTGGTTTGAAGATCTTGAGCCATAGTGG
CTATGGATTCCAGAAGATTGAATCTCCGAGTTTAAGGAACACACCTTTAATCTGGGCTACGCCTTTCATC
TGGGATTAAAGGTGTGGCGGAACACACCTTTAATCTGGACTACACCTTCTGCTGGAGACAATATAAGGAC
ATTGAAAGAAGGGAGTCTAGCTCTTGCTCTTGCTCCTTCGCCTGCTTGCTGCGTGAGACTGAGTAACTAC
TAGATCCTTGGACTTCCATTCACAGCTGCGACTGAACAATTGTTGGGAATTGGGCTGCCGACTCTAAGTC
ATCAATAAATTCCTTTACTATCTAGAGACTATCCATAGTTCTGTGACTCTAGAGAACCCTGACTAATACA
TCCCTACATACAGGAAACTTGATGTATAAGTAAAGAAAATAGTAAATCTAAAAATTTCCTTATCAAATAC
ATGCAAGAAATCCAAAATACCATGAAAAGACCTGATCTAAAAATAGTAGGAACTGAAGGTGAAGTGTCCC
AGCTCTGAAAACTAGAAAATGTTTTCAATATTTTTCCTAACAGTGAAGACATGGATCTAATGAGGCCACC
TCTTATAGCCATGCAAGACTGACAGTGGAGGGATAAGGACACCAATCCACCCACAAAACTTTTGACCCTA
AATCAGTTTTATCTAAAAGCAATGCAGGGGCACAAATGGAGCAGAGACTGGAGGAATGGTCAAACAATAA
CCTGTCATATCTGAGACCCACCTAATTGGCATACACCAGTCACTGACATTATTAATAATGTTCCATTATG
CTTACAGGCATTTCTCTAGCATTACTATTCTTGGAGAGACTTCACACAGCATCTTATTGAAACAGATGCA
GACACCCAGAACCAAACATTGGATGGAGATTGGGATCCTTAAAGAAGAGTTGGGAGGATAATTGAGAGAC
CTCAAAGGAATAGCAACCCCATAGAAAGACACGAACAGGGTCAGTAAACCTGGACCCATGGGGTATCTCA
GAGACTGATCACCAACCAAAAATCACAGAGGGCCTGGATTGATTCCCCTGGCACACATGTAGCAGAGGTC
TGCCTTGTCCTTCAGTAGGTGAAGATGAGCCTAAGGCTTCAGAGACTTGATATATCAGCATACAGCAACA
CCCAAGTGTGTCCCACTATCTCAGAGGTGAAGGGGTGGAGATGGGCAGAAGGGTCCTGATAGGGGACAAC
TGCAAAGAGGCAATATTTGGGACAGAAAGAAAGGAAGAGAGAGGAAGATAAAGAGAGAGATGAAGGAAGG
AAACAAACAAACCAAGATGAAGAGAGAGAAAAGGGGGAAAATAGCCTTGAATGGTTCAGGGATTCAAAGG
GACATACCTAAGCATGGTAAAACAATGCACATAATGGCAGCAAGTAGCTAACACTGAATTAAATAGAAAG
ACACATAAAGCAGTTCTACTAAAGTAAGAGACAGAGTTGCCCAATCTCACCCTATTTATTCAATAATAAT
GTACTTGAAGTTCTAGCTAGGGCTGTAAGACAACTCAAGGAGATCGGAGGATACAAATTAGAAAGAAAAA
TTCAAAGAATTGTAATTGGTAGATGATAGGATAATATACATAAATGACCTCAAAATTCTTCCAGAGAACT
CTGAAAGCTGATAAATACCTTCAGCAAAGTGGCTAGAAACAAAATTACTTCATAGAATTCAGGAGCTATC
CTTTATAGAAAAGTTAAAGTGGCTGAGAAAGAAATTAGGAAAATCACATTCTTTGCAATAACCAAAAATA
ATATGAATTAGCTTGGTGTGACTCTAATCTTGCAAGTGAAAGATGTGTGTGACAAGAGCTTCAGGACCCT
GAAGAAAGAAATCAAAGAACTCAAAGATGCAAAGTACTCTAATGCTCATGGATAGGCAGAATTAACATAA
TGAAAATGCCAAATTTAACAATTCAATCTACAGATTCAGTGGAATTCCCATTAAATATCCAACCCAATTT
ATTACATTCTTGAAAAAGCAAATCTCAACTTCATATAGAAAAACAAGAAATTGAGGGTAGCTAACAAAAT
CCTGAACAATGAAAACACTTCAGGAGAATTCACCATCCCCTACCTCAAGCTGTATTTTAGAGCAATAGTT
ATTAAAACTGCATGGTATTTGTATAGAAACAGATATGATGATCAATGTAATTGAATTGAATACACTGACA
TAAAACCACACTGTTATGGACACTTGATTTTTGACAAAGAACCCAATAATCATAATAAAAATCATAATAA
GAATGCATCCCCCAACAAATGGTCCTGATCTAAATGCAAATAGATTCATATCTATCATCCTGCACGAAAT
TCAAATCAAAGTGAATTGCAGACTTCGACCTAATACTGGATTAACTAAATCTAAATGAACAAAAAGTAGA
GAATAGTTTTGAACTCATTGATGCAGGATTCAATTTCCTGAACAGAACCACAATGGCTCAGGCTCTAGGA
TCATAAATTGGTAGATAGGATCTCATGAAACTGAAAAACTTCTGTAAGGCAAAGGCAATAAAACAAAATG
GCAACCTACAGATTGGAAAAAAAATAATCTTCAGTATCCCTAAATCCCATTGAAGGCCAATATGCAAAGT
ATATAAAGAACTCAAGATGTTATCCTCCACAAAACCAAATAAATCAATTAAAAATGAACTACAGAGCTAA
CAAGAGAATTCTCAACAGAGGAATCACCAATGACTGAGAATCACTTAAAGAAACATTCAATATTTGTAGT
CACCAGAGAATTGCAAATCAAAACTACCCTGAGATTCTACTTTATACCAATCATAATGGTCAAGATAAAA
ATTCAAATGACAGCGCATGTTGGTGAGGATGTGTATACTTTTGCATTGCTGGTGAGGAAAACAATCTGGC
AGCTCCTCAGAAAATTGTAAATAATTCTACCTGAAGATCCAGCCATACCACTCCTGTGCATATACATAAA
ATGTGCTCCACCATACCACTAGGAGATATGTGCCACTATGCCCATAGCAGCCTTATTTGTTAATAGCCAA
AAGATGGATACAACCCTGATGTGCCTCAAACAAAGATTGTATATAGAAAATATGGGTTCCCTTACACAAT
GGTATTCTACTCAGCAATTAAAACGTGAGAACATCATAAAGTTTTCAGGCAAACTGATCAAATGAAAAAG
TATAATCTTGAGTGAGGTAACAGAACCAAAATGACCTGCATGGGATGTACTCACTGGTAAGTGAATATTA
GACTAAAAGTATAGAATATCAATGATGAAAGCCACAGACCATAAAGAGTTTAATAAGATGGAAAGCTCAA
GTACGGATTCTTCAATCCAATATAGAAAGAGGGACAAAATAATCAGGGGAGGCAGAGGGAGAGAGAGACA
TTTGGTGGAAATGGGAGAAGAAGGGAGAAAGGCAGAAAGGATCAGGCGTTGGGGAACACTGGAAAGCAGC
CCAGGGGTCCTGGTAAATGGATTAAATATTCAGCTGAATGGAGGTGGGAGGCAGGGGGAAGCTCTGCAAA
GTCCAAGAGACCTGGGATGTGAGAGGCTCCCCAGATGATAATCTTAGCCTTCATGCCTAACAGTTGTAGA
TAAACCCTGAAGAGATCACTTCCAATAGATGCAGAGGGCCCTAAGTGGTTGGATGGAGTCCCCCAACTTA
CCTCAAAATTGTCAATACTCATAGAAATTAGGACAATGAAAATCAAAACACCCTGAGATTGTATCTTATG
TCTGTCACAATGGTTAAGACCAAAACCTCAAGTGATGGCTTGTGCTGGCAAAGATTCAGAATAGTAAAAG
TCTCCCCATGGCTTGTGGGAATGCAAACTCTTACAACCTCTTTGGAAGTATATTTGATTGTTACCTGGTA
TAAAATGGCAAAAAAAAAAAATGGTTGAAGGGGGACTAAAAAAGGAAGAAAGGGGAGAACTATGGGATGC
GAAACAAGAAAGTTTGTTGCAAAAGAAATATGTTTCCACTGCAAACCCTGAGTCTCAGACAGAAGGGGAC
CTGGAATTCTTCAGATACAAAGAATCTCTAAACCCTGAGGACATTCTATCACAAATAAGTAAAATTCAGA
AAATTCTGAGTGCTCCCATCACGGAGATGAATCTGCTATGAACAGCTCATAGGTGTGACCCTCTACAAAA
GCCATATTATTGAAAAGCCACATTGTGCCCAGACTTTGGAAAGACTGAGCTCATATCCTGAAATACAGTT
ATGTGTGGTTCTATTTAATTACACATTTACACTAAGAAAACATGGCAGTATGGGAATGAAGCTTGTTCTG
TACACATTAACAGAGGGAAACTAAACAAAGTATGGTGAATCCCTAACCAAAAGTAAAAAAAAAAAAAGAA
AGAAAAGAAAATAAAAGTGAAACTACAATATGTTTCAAATGCTGTAACTGAAATCTGGTTTTTTGATGCT
TATATCTGGTATCATCAGTGACTTCAGATTTAGTCCAACTCCAGAGCATGGTATAGCAGAAAGACATGCA
AATAAGCCTTCTCTCTGCCCATGAAAAACACCTCGGCCCTGACCCTGCAGCTCTGACAGAGGAGGCCAGT
CCTGGATTCGATTCCCAGTTCCTCACATTCAGTGATCAGCACTGAACACGGACCCCTCACCATGAACTTG
GGGCTCAGCTTGATTTTCCTTGTCCTTGTTTTAAAAGGTAATTTATTGAGAAGAGATGACATCTGTTGTA
TGCTCATGAGACAGAAAAATTGTTTGTTTTGTTAGTGACAGTTTTCCAACCAGTATTCTCTGTTTGCAGG
TGTCCAGTGTGAAGTGAAGCTGGTGGAGTCTGGGGGAGGCTTAGTGCAGCCTGGAGGGTCCCTGAAACTC
TCCTGTGCAACCTCTGGATTCACTTTCAGTGACTATTACATGTATTGGGTTCGCCAGACTCCAGAGAAGA
GGCTGGAGTGGGTCGCATACATTAGTAATGGTGGTGGTAGCACCTATTATCCAGACACTGTAAAGGGCCG
ATTCACCATCTCCAGAGACAATGCCAAGAACACCCTGTACCTGCAAATGAGCCGTCTGAAGTCTGAGGAC
ACAGCCATGTATTACTGTGCAAGACACACAATGAGGAAATGTTACTGTGAGCTCAAACTAAAACCTCCTG
CAGAGCACCCAGGACCAGCAGGGGGCGCAGAGAGCACATGGAGTTCTGATTCACAGAAGAGTTACAGCCT
GTACAATTAGACCCAATCTTCAACAAACCGTCAAAATATTCGATCCAAAATTGTTCCTGTCTAAAAGTAA
TTCAAGGACAAAATGGACCAGAGACTGAAGAAATGGCTGACCTGTGACCCTCCCAACTTTGGATCTATCT
CATAGGCAGGTACCAAACCTTGACATTTGTCACTGACACTGTATTGTGCTTGCAGACAGGAGCATAGCAT
GGCTGACCTCTAAGAGGCTCTGCAAGCACCTGAATGAGACAGATGTAAATAGAGTGTACAACTGGATTAA
GTTTGAAGACTGCAATGGAAGAGTTAGAGGAAGGAATGAAAAATCTGAAGGGGATCACAACCCCAGAAGA
AGACCAACAGTGCCAATTAAACTGGATGCCTGGGAACTCCCAGAGACTAAGCCACAAACCAAGAATCATG
CAGGCTGGTCTGAGAATCCTGGCACCCAAGTCTCAAGGAACTGCCTTTTCTTGGCTCAGATGGGAGAAGA
TGAGCCTAAAGCTTTAGACTTGACGCCCCAGGGATGGGCAATACAAAGTTGAGTTTCTTGGGAAAGTGAA
GAGGATGGTGGGAGGAGGAATAAATCTGGGAAGTGGGACTGGTTGGGGACAACATATTGGTCCTAAATTT
ATGAAATAATTATCTAATTGATAAAAAGAGTCCTTGGGGTAATGGAGGGCTAGACTCCTCTGTGCCTAGT
TTGTAACTCTACAGGGATCCTCTTTAAAAGAATAGGGTGCACATAGAGTATATGTGTGTGACACTAATAC
AGGGGTAAGTGTTTCTGTAAGAACTTTATGAATAAACTTTATTAAAACATCAAAAAGTATAGGTTGTAGC
AACCCTTGACCTGTACGAATGTTTATAAAACTTTCTATTTTCCTTAATTATATCTGTTTTGCATTTGTTT
ATTTATTTATTTACTTACTTACTTATTTATGATTTCACTGTGTCTTTCTGTAGTCCTGTATGTGTTTATT
TGTCTCTTTATTGCTCTGTTTCTGTTTCTTTCTCTCTGTCTAGTATTGTATCTCTCTGTGTCTCTATGTC
GCCGATTGTGTCTGTGTGTATGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGCATATTGAAA
TGAGATCTCTTCTTCTATCAGTGTACATAATGACTTTGAAATAAAGTCCATCACTGGGCTTGGATATCAC
TATCTTGTTAGAATGGTTGCCCAAAGTGTTCCAACCATCACACTGTTTCTACATATAATAGATGGGTTTA
TTGATTTACTACCAAAACTACCCCATCTTAAGTTATGGATATTAAACACAGATCCTCATGGTGTGTTAAG
AACTTGAAGCACAGAGCTATATGTACAGCCCACTAAAAATGACTTAAATATAAGATAAACTCTGGCTTGA
ACAAAACACAGAGCATCACACGAGGCAGAAGTGAATCTCTATGAGGACCAGGATCACATCCCAAAGAACC
AAAGAACACTTGAGACTGTGGAACCCTAGAGTCAGGGCTGACACTCAGTAAGATTTACTTCATAGAGCAT
GATGTGGGATTCAAGAAGAAATCAGGCAGGGCCTGTGACCCATGAACCAGATGACTTCCAGTCTCTCCAT
CATCCTCACACAAACCATAGGCAACAGCTCAGCACTGACTCACCTGTGATGCTGGTGACAAAATGTGTGC
AAAGCCTCAGAACTGAGACGTGAGGCCAATGTTGCTACCGACACTCAGTGAGCTTCAATTTGCTGCAAAC
TGCTCCAAAACAACTCAAAGGGTAACTTCTTCTTTTTCTATTTGTACTTGTGATGCCTTGGTAGATATAG
TTCCCCAATAATTTAATAGGACAAATCATTTTTCCTTTTAACACATTAATCCCCTTTCCTTCCCCCAAGA
TTCTAAAATTTTTCTTTAACACTGATGTCTGAGAGATATGGCATAATAGATGTTTGTCTTATTCTGAGTT
GTTCCTTATCAAAAGAAATCAGCTGTGGCACTTTGAACCTAAATATAACAATATTTCACAAAGGCATTCT
GGGAATATATAGATGGTATTGCTACAAAAGAATAGGAGGATCTATGGCCATACCACCCTTAATGAACCAG
ATACTATCTAAAAGATTAGGACAGCTGGGCATGTTGGCACAGGCCTTTAATCCCAGCACTAAGGAGGCAG
AGGCAGGCAGATTTCTGATTCGAGGCCAGACTGGACTACAAAGTGAGTTCCAAGACAACCAGGGCTATAC
AGAGAAACCCTGTCTCGAAAAAACAAAACAAAACAAAACAAGAGTAGGAGGGTATTAGATGCGAGGTGAT
GATGGCCATTCAATCAAACCAGAATGTGACCTGAGAAAAGGTCTAAGTTTGTCAGCTTGTCCTGGAGATG
TGTTGCCTCTGATAAATGCAGAGCTGGAACTGCAATACATTGGATTCCTGTGAGTTACGGAGAAATAAAA
GGAATAGCCTCTGTTTCCTTTGGTTCATCAAGTTGGCAGTGAGCTAGAAGATGATACTGGGAACCATCAC
ATGTACTTCTACAGAGTTATTCTACATTCTACAAGTCAGTCTTGCTTGCTTTCGTTTCTGTGAGGAGCTA
AATACAGAATGTTTTCAATGTCTCATAATGTTCTGTGCACACCCATGGGTGCCTAGCCAAGGATAGAAAC
TTGTATCTGATAAGGAAAGAGGATGCTGCAGTGGCCACACTCTGAGATCACCTCCTGCCAAATTATACTA
GAGTGTTTTACATAGTCTTGAAAACACTAGGTCAAATATGTTGTCATCCAGATATGAAAACTCTGTGCAA
CAATTCAGAAATACAGTGGTCAGGACAACTGGTATGTAACACTTTAGTTCCAGCCCACATTAATCTCACA
TCTTTTCTGTGGTTTCAATAAAGAGCACACATGTTTGGAACACCATCTCCACTTTGTATGCTTATCCTTA
TGCATCAAACTTTTCCTGTAATTTCCTACCCCGCACAGGTTCCTGTCTTGATCTCTTTTTCTAATGAACA
GCAATACAGAAGTGTTGGCCAAATGAACACTTTCACCCCAAGTTGCTTTGCCATTGTGTTTCATCACAGC
ATTAGTAACTCCCAGTAAGGCTACTGGTTACCCTGCATCTTCTATGTAGATCTTTTGATGAAGTTCCAGG
CTTGGGGTCTTTATCTGACTGTTATCCTGGTTAATTCATGTCCACCAATAGAATATTGTTCTCATTTTCA
ATATCATATGAAGTTACCTGTTTATAGGATCTTCCTAAAGCAGAAAACTATATAAAATGTCTGCTTACTT
TAAGAAAAGTATGTGTCCTTGGAGGTAAATGGAGGAAAGGGTGGAGGATGTTGAGTAATGGAAGACTGGC
TAATACAGGAAGGTCACAGAATTGAATGATTTTAAAAATTTTAACTCCTCATCAATGAGGTACTTCAAGT
TGAGGCAGGAGTCCTTGATGCACAGGTGACCCAAAGGCCCCAGCCTCTGTTTCTTGGTCTGCTCCAGTCT
CCCGGCTCAGCACAGTTCACTGAGTGACAATCTTTAAGATAGTCTTTCAGGATACAGTTATCACAGTTTT
CAAACTCTCTTCATTGAAACAATATAATGAGTCAGAGTCCAGTGTGCCATTAATAGGCCCTATGCAATAG
GATTTTACTTCATCTGTGGAAAGAAACCACCATGGCCTCATCAAGGCCTCATTTGATGATTAGTGTAGAA
AGCGTCCCCAGAGCTTTGCTGGGATGAAAACCCTGGCAAGATGTTTAGGGCACTCTCCATCTGACAGGAC
AATTCTATCAAGGGTTGCTTCCATATAGAGAGAAATCTCCACATCTGCAGTATTTCCCGATTTATCAACA
GTTCTTTACCCCGTGTCATATGCATAAAATCTTTTCTCTGTAGAATTTTCAGTACTAAAAACTAACAAGG
ATGTTGGTCCTGATATCAGACATAATAAATAAATAAACATCAAATTATACCCTAAACATGTGGAGATGGT
TTTCTGTTATGAATTTATTGGCTCTCTAAAAAGTGTTAATTAAGCCAGGCGTGATGGCACATGCCTTTAA
TCCCAGCACTTGTGAGGCAGAGGCAGGCGAATTTCTGAGTTTGAGGCCAAACTGATCTACAGAGTGATTT
CCAGGACAGCCAGGGTTACACAAAAAAACCCTGTCTCCAAAAAGTAACAAAAAGAAAGTGTTAATTAACA
TCTACACTTTAAGATAATTTGGTGGCAAAGGTTAATAGTCTGAAATACTAGATATGAAAGTATGACACCT
AAATTGCATGCAGAGAATAAAGCTGAATTCCAATGAGATTCATGCCTTGTGAATCCATTCCAATCTGATC
TCAATCTTCAAACATGTTTGTGCATAATTTACATCTTAATCAGTTGCTGGAAATTAAAAGGACATAAGCT
AAACTTAAAACTCTTTCTATTTAATGTGTCAGAATAGAATATGTGCACTGAAGTTTTCATGTGCATAGGA
TATCATTGTTACAATGATGGTTCAAATACGCACCAGTAGCACAGGTGATGCTTGACATGAAAAAAACTGT
GACCAGAGCCCAGACGTTGATGTTGGCTGAAAGAGCCTAGTGTCTCACATTTGATCAAGCAAAGTGTTAT
TCAGAGAAGCAGTGCCAGATTTGGGATCCTTCTTAATGGATCAAGAACATGAGGAAGATTTGGAAGCCAG
ATTGATGAGATTACTAGAATCCTGGATCTGAACACACAACACACAATAGTAAGTTGAACTTTTCCACGCA
ATGCTAAAGATAAAGCATCCAGTATCATGTTATACAGGACCAAGGTGAGGATCAGTCTGTGGGTGAAGTA
CAATGAACTGGAAATTGTTTGGATTTTAAATGTTGGTTTTTAAATTATATATAAAATATATATATATATA
TATATATATACATATATATATATATATATATATATATATATATATCGGAACCAACATTTAAAATTTGGAT
TTTAAATGTTGGTTTTTAAATTATATATAAATTATATATATATATATATATATATATATATATATATATA
TATATATATATATATCGGAACCAACATTTAAATTCCTAATTCTTAAGGACTTCACTTTTGACCAAAAATA
TTTGAAATGGGTTATTTAGGTCTGTGGTGGTTTGAATATGCATAGCCTATAGGAAGTGGAAGTATGGCCA
TTTTGTAGTATGTGTAGCCTTGATGGAGGAAGTACATCACTATATGGTGTTGTGAGAGTTGAGATCCTAT
GTTCAAGTTCTGCCAAAAACAGAAGAGAGTCCCCTCCTGGATATTTGAAACAGATGCAGAGGCCCAAAGC
CAAACATTGGGTATATCTCAGGGTTTCTTATGGAAAAGTTGGCTGAAGGATTGAAGGCCTTAAAGGGGAT
AGGAACTTCACAGGAAAACCAACAGATTCATCTAACCTAGACTCTAGGGGTCTTTCAAAGGTTGAGTCAC
CATACAAAAAGGACACAATGGCTAGACCTAGGTCCCTGATACATATGTAGCAAATGTGCAGCTTAGACTC
CATGTGGATTCCCCAACGACTAGAGCAGGTATTGTCCCTGAAGTTATTGCTTGTCTGTAGAATACATTTC
CCAACATAATTGTCTTGTCTGGCCTCAGTAGGAGAGTATGTTCCAATCCTGGAGAGACTTGATATGCCAG
GATTGAGAGATTAAGGGTCTCCCACCATCTCAAAGTTCATGGGTATGACAGGGGAGGGGCAGTGCAGGTT
TTCCCCATCTCTGATTTCCAGCATTTGCACCCCCAATATTGAGGGGGAGGTCTAGCAATTGGAGGGGGGA
CAAACAGTATGAGAAAGCTAACTTTAGTGGTGTTGTCACAGTGTGGGGTATTGTGGGTGGGAGTGGAGAT
GAATCCTCCTCCTCCTCAGGAGGCTGTAGCAGGTGCTTGCCCTCTTTTGGGACAGTAGAGCTGTGGTCAG
TACTGGCCTGTTCCTGACAAATTTATTCTGTGCTGTGACCATTTATTCAAGGGAGGAAGATTTAAGACTT
GCTATGATAACCTGACGAATCTGGACAAACAAGAGACAGGAGGTAACACCTGAGTTACTCTTTTGCTTGC
TAGTACAGAAGAGCACTATAATCCACAAATTGGGGTCCCACATATTCTTGAGTGGGATCCAAGGTGCCAT
AATTTCAGCCACATTCCAAAGTCCCTCAAGGTCTGACAGTTTAGTCTTTAGGCTTCTCCTAACCAAATCA
TATTTGGAGTTCTTTAACATAAAAGGGTAGTTTCCCCATATCACTGCCAGCAAAACAGGTTGAATTTGGA
CAGACAAGCAAAACTATCACAAACAAGACAGACTATGTGTGCGATCCAAATGTCTTGTGATTAGAGGGGA
AGTTCTGCAGCTTATTAGGCTGTGTCCTTATGCCCACAAATGTCTTCAGATAGGAAAGGGCCATTGGGTG
CCAATCCTTAGTTCTTCTGTTTCCTGGGCTGTCAGTTTTTATGTGGAGAAGACATGAACCAAATGCAAAG
TCATGTATCCTACAAGAACTGACATACACAGACAAACAAGGAATAACAATGAGCTCTCTCATTCACCTAA
GGGGGTCTTATAACATAGAACAGAAAGGGGCCAACTTAGCAAGAATTGACCAAAAGGTGGTCACCTAGAC
CACACCACAATGCAGGAAGGATATCAATGAAGGAAGAACAAAGGAAAGGCCAAATCAAGTTTGTTGGCAC
ATGACATAAAACAGTGCTCAAAAAACAATAGATGCGAGCAAAATGAAGCATTGGAATCATATCGGGGTAC
ATAGGGGTCACTCTTACCCCTGTTCAAGTGCCAGATGTTGTTTTAGCCTTAGGCTCCCTGAGTTTGTCTT
TAGGGGAAATGGGTAAGAATACACAAAAATAATGTCACAGAATCTTAGAGGCAGATGAGAAGTCAAAGCA
GACTCATTTATTGCTATAGAAAAGAATGCCTTTATACCTTCTGTCCATAACACCTCTGCCCATATATGCT
CATCTCTGTGAGGCAATGGACTACCTGCAGACAGGCTGGTATCCAGTCAAGCTGAGGTCTGAACCACAAT
GGTCGTAACTCACCTAAAGGACGTGGTAGGCATGACGCGATAGGCGTTCCCTCATGCTCCTGGAACTCCG
GCCCCTGCCTAAGGTACCACCTCCCACAGCCCCCACAAGAGAAGCATGGTCAGTAGTCATGTAAGCAATG
GCCCAAGCTTCTGACCTTCAGCCTAAACTCCTCCCCAGTTACCTAGCAACAGTGAAGACCATAAAATGGG
ATGTTAGGCCCCCACCTCACTCTCTTACTCCTTTGTTCCTTTACCTCTCACTTCTCTCAATTCTCTCTCC
TCTTCCCTTTCTTTGTCTTCTTCTTTCCTTGTCTCTCTGTCTTTCTCTTTCTCTCTAGCCTTCTCTGCCT
CTCTCTCTCTCTCTGTCTCTCTGTCTCTCTCTTCTCTCTTTCCCTTGAATTTCTTTTTTTCTTTTTTCTT
TTTTTGATGAGCACAGTATAAATAGTTTATTGCATTGTTTCTGAATGTGGCTGTATTCTCTATTGTTCTC
TTTCTTATTTTTTTTCTTTTTTTGGTTGTTTTTGTTTTTATAGTCTCGCACAGAATTCTACATCTACCAA
ATCCCCATTGTGTACTTTAGTTTTGTCTTGTATTCAAAGGTTCTTTCAGAAAGAATCTTAAAGATGAAAT
TTGCCTTCCAACTTTTCAAAAATACATATAAAGATAGATGTTACATAGTTCACGGAATAGACACATATAC
GGAGATGCAGCAATATCTCCTTTGTGCCTCTTGTATATTCATGTTATTTCCTCAACTAAAAATACATAGC
CACAAAGACATACAATGAGCACTCCACTTAGGAAAATATGGCCATATTTTTTTACATTTTTATGATTTTA
TGATTAGGTATATTCTTCATTTACATTTCCAATGCTACCCCAAAAGTCCCCCAACCCTTCCCTCACTCCC
CTTCCCCACTCCCACTTGTTGGCCCTGGAGTTCCCCTGTACTGAGGCATATAAAGTTTGCAAGACCAATG
GGCCTCTCTTTCCACTGATGGCCCACAAGGTCATCTTCTGATACATATGCAGCTAGATACATATACATAC
ACGAGCTCCAGGGGGTACTGGTTAGTTCATATTGTTGTTCCACCTATAGGGTTGCAGATCCCTTCAGCTC
CTTGGGTACTTTCTCTAGCTCCTCCATTGAGGGCCCTGTGATCCATCCAATAGCTGACTGTGAGCATCCA
CTTCTGTGTTTGCTAGGCCCCATTATAGCCTTGCAAGACAGCTATATCAGGGTCCTTTCAGCAAAATCTT
GCTAGTGTGTGCAATGGTGTCAGCATTTGGGGGCTGATTATGGCATGGATCCCCGGATATGGCAGTCTCT
AGATGGTCCATCCTTTCATCTCAGCTCCAATCTTTGTCTCTGTAACTCTTTCCATGGGTGTTTTGTTCCC
AATTCTAAGAAGGAGCAAAGTGTCCACACATTTGTATTCATTACTCTTGAGTTTCATGTGTTTCCCTTGC
ATTTCTATAATAAACCATAAGGAGTCTCTGCTCTACCAAGACCCGCTGCACACTCTGGTCAGTGTTGGGA
ACTTTTCCCCTATTCCCTCTCTCCTATAACTCCGGGGCTACAGGGTGTCTCCTTTGGGTCCCGGTTGGGA
GCTGTCTCTTCTCAACCCCCTGACTCATGGGTCAGAGGCCTAAATCTCCACCCAAGGCTGTGTGAAAAGC
ACCGGGTGGTCTCCCCATATCTCCCTGTCCAGAGCACAGGAACTCTGGCCGGACATGGCATATTTTTCCT
CCCCAACTTCTTCCCCGGCCTCCTCAGGGCTGTCCCTTCATTTTGTTCCCCACACATCTCCACATGGCTG
CCACCATCCAATTGGCTGCTGAGGTCACACACTCTGTCTTTGTTCTTCTCTGAGTCTCATGCAGGTTTTG
TGTTAGTAAATGCAAAAGTGCCTGCTGTGCATGCATGAACCATTACAGGCTGCTAGGCAGAACATGCTGA
CTTGCTCCTGGATTATAAATCCATCACTGTGATAGCAGGACATATCCAGAAGACATTATTTAACAACACT
CCTCTTCGTGCTCAACCTCTCATGGTCTTTCTACCTCCTCTTTCTTAGTGTTCTCTGAGCCTACATGAAA
TGTGAACAAACCTGAAAAAAATCTCTGTGTCAAATACATAGTGTGGATTGGGAAGGAAAAACCCTGCACT
TGTGTGTGGGCAGGGAAATGCTGGTGCTTTAACAGGACAAGTGCGGTGTGGCTAGAGAAAGTGATGAGAA
GAAGGGAAGCATGAGAACTGGGTGGGTGGATCCCATGTCTACTGAAAATGCTATGTTGATGTCAAGATAT
TGTGTCTTGTTACAAAAATTCATTGAGTACCTAGGTTATTCTCAGTATATAAAAGGGGAGGAATGAAACT
AGAATTAAACACACACACACACACACACACACACACACACAAACACACACACACGAGTAGAGAAAAGAAA
TAGTCATGAGTTGCCTAGTGAATGAAGAGCGGAAAATGGTGCAGTTAATAGGGATCATAGAAAGAACTGG
GGGATGCACACGAATGGGTTTCCTGTAATTATGTCTTCATAGTAATCTCTGCTCAATAATCAGACAGTGA
CAATGTATGCCTCATTTACAAGCCCTGATGGCCTCTCAGAGGAAAGCATCTCTCTGAAATGAATAAAGTT
CAGAAATGTCCTAAGTGTCCCTGTCACAGGAAAGCAGTGTTGGTAACGTTTCCAGGAAGCTCAGTCTTTG
TCAAATATCCACAACAAGAAGAAGCCATGTCTAGACAGACAACAGACTGGGAAAGACTGAGCTCATGTAT
GGAAACACAACTATGTGTCATGCTTTTATTTTCACATTATACTGAGGGGATATGACATTATAGAAACACA
GTTTGTTCTTTGCATATGCTGAGAGAGGAACTAGATGAAGTGTGCTAATTCTTAGCAATAAAAAGATATA
CAAAGTGGTACTTTACTGTTTCAATTTTTGTAACTGGCATCATTGTCTTTGATATTTTATATCTTCCTTG
AGCACTGCCTTCTCTCAAGTGTCCAACTTCAGAGTATGCTATAGCAGGAAGACTACCAAATAAGATTAAT
TTTTTTGTACCCATGAAAAAATTATGTGCCCTGACCCCTGTTCTCTGAAAGAGGAGCCAAGTTCTGGATT
CCCAGATCCTCATATTCATTGATCAGCAGTGAACACAGATCATTCACCATGGACATGGGGCTCATCTGGA
TTCTCCTTATTGTTTTTAAAAAAGGATTTCATTGGGAAAAGCTGCCTCATATTTCTATGACCAGGAGAGG
AAGATACAGCTAGAGACACAAGCCCCACCATGTAAAATCTGTATGGTACTCTCGTTTTCATTTTACAACA
TTTTGCTTTTGCATTGCAAAGGAGCAATAAGGGTTCAGCAATCAGCACTGTAACTGTACTTTTAAAATTT
CCACCTCTACCCTCTGTGTCCTCTATCTAGTGATAGAAAGTGAAATAAGCACATAAAGCATGGGACAAGA
AGAACACACAGAGGAGCAGAGACTGGCTACAAGTGGCAGCCAGCATGGAGCTGGACAGAATTTAAAAAGA
TAAAGAGAAATGTCATGGCATGAAGCAGTGACTTTTTCTGTTCACAATGCCTGCAAAAACTTTATGGAGC
CTACTACTGCTGAGATATGCAGGTTTGGTTCCAGAGAGGATTTTCTGTTTTATTTAATTTGCTTTTAAAT
TTTTCTTCTTTGTATAGTCTGTATTTTTAAAAAGGGGTTGAATGAATACCTAAGCAGTTGGAAAATTTGT
GAGTAGAAACCGAGGGCCTGAGAAACAAATAAATCAAAATTTTGAAATGGCAAAAGAAAGGGTTCATTCT
ATTTTCTCTTTTCAGAAAAGGTTGCAAAGTTGGATGTGCAAATGGAGATGTTATGGGTGGACTTGGAACA
TCTTGGGAAGGAAGGAACCCAGGAAAAGAAAGAATGAAATGGCTCAGCCTCAATGACTGAGCAAGAGAGT
TAGAGTCACCCACAGGAGAAAAGAAGAAAATAAACAGCACTGGGGTGAATTTGGGTCAGAGAAAACCTTA
AAATGCCAGAGGACAATGTGATGAAAGAGACCATTTGAAAGAAAGGGTTAACCTCATTCCATCAGTCATG
CCAGAGTTAGAGAATGGGCAGTCTGGAGTTACAAGATCACGATTAGCCTTCCCAGTATGTATACAGCATA
TTCCTGATAATGAGATGAAGCAAAGTTTGACAAGGTAAGATTGTATCCTATAGTAATATATAGATCAAAG
GCATGTTGCAGTAAATCTCCAACAGAAATAAGCCCGGGCAATGAAAACACAACTCAATTAATATGAATAC
GTGCTGTGCACCTAGACTGGGCAGATCTACCACTCCACTACCATATGAGAGATCCCTTATAACTTGTGGT
TTCTCCAGGCCAGCTGCTTCTGCTCTACTTTCCTTCCTCCTCCTCCTATGTCATCCTCTCCCTCACTCTT
TCTCTCCCAAAACTTTCAGCTGCACCTTCCCCTCTTCATCCCCCAATCAGTGGCTCTAGCCTTTATTTAT
AAATTAAGGTAGGAAGAAGGTTTATAGGAAATTACCTGAGTGTTGACGTGTTGATAACCCCACACAAGAG
AACAAAATTAATATCAAATATGATTAGCTCCAGGGTTATATGCAACAAAGGCATGATAAAGTGGTCATGA
TTTCATATGAGATGTACTGGACTCATGTGAAAAAACGTTTAAATACATGGGCTTACTCAAAATATAGACT
CATACCCCCAAGATGGGAAGAGACTGGTAACATTTGTACTGGAGGCTGGTCTGCTGTGGCAGCCATTAAC
ACAGTGGAGGGAAGAGCCTCAAAGAGTGAAATAGAGGAAGGGGAACAAATACAGTAAACCACCAGTTACT
ACTTAAAGGGCAGTGTTCTGATGTCCTAGGGAGGGCACTCCAAAATACCAATGGCCTTATCCTTAAATTT
ATTGTTTAATGAGCCTACACTGATCTCAGTGGCCCACTACTAAGGAGAAATGACAGGCACTTGAACAGCT
GATATGAGAACAGCTGGAGGCACAGTATACAGAAGAGTTTACAAGCCTATGGAACTCCCCTGTATTTTTT
TATGATGAGGAAATCTGAAAAATGTAAAATGTTGAAAGATTTAAGAGCAGTTATTAGAGTAGATCAACCA
ATGAGTCTCTTGCAGCCTGGAATTCTTTTATCTTGTTTGTAACAACAATCAGGCTCCATAAATTATAAAC
TATAAAAATTTACTTTATAAATTATAAATATATATATATGTGTGTCTGTAGATAGATAGATAGATAAATA
GATAGATAGATAGATAGATAGATAGATAGATATATGGATTTGATGGTTGCAGCAAATTCTAATTGGTTCC
AACAACCCTACTCACATAATACATTCATACAGGTTTGATAGATGGAGCTAAGTTTTAAATAAATTATTTT
TCTCCCATGGCTTATATATACACCACCAAAATTCTCAAAAATTAAAATGTGATTGTGTTGTATTTTTCTT
TTACTGAATGACTATAAAAAGTTACAACATTCTCCATAAATTTACATGAAAAAATATTATGTAGTGCAGG
TAAAGAAAACAAATTGACCCAAGAATGGTGTATATTCATTACTAAGCAACTTTTTAGATTCACAAAGTGT
GGGTAAACAAGGTAATTTTTTCAATCAGTTTTTTTTAACTGGCAGGCAGCAATTCAGAGTTACAATGAGA
AGATTAATAATTTTATTGTGTATTTTAAAATAAATCTTACAAAAATATTAATAGAATCACAAATTTATAC
CTTTGTATAAAAACAATCAGTCATTTCTACTTTAAGAAACAGAACTCACATCTACTCATCAATCATTTTA
TTAAGTCATATTACAAAGCTGAGTGCTAACATGGGTATAAGAAAACCATAACCTTATTCACCAGCCCAGC
GTCAAAAAGAAAAAAACCAGTCATATCAGCTGCTGCTTCAAGAGTTCTTGTTCCTTGACATTAACAAAAT
CCCTAGCTTAACTATTAAATTTTTTTTCAAAACTTCTAATTGATCCCTTAGATAAATGTTTGTGCTAACC
ATCGGGACACATCCCATGAGTTCTGAAGCAGTGTGTTGTTCTTCATGCATGGCCCTTTTGTAGAGCTGTG
AGTGTAGGGGAAGAGGGGGGAGAGAGAGCCCGTGTCCAGCCAGAGATCCTGTGCTCTGGGCAGGCAGACA
CGGGAGGACAACGGAACACTTTTCACTCGGCCTTTGGTGGGCATCTGGCTGTGTGAAGTTACTGACCCCA
CATGGTGGGGGATGGACAAGGGGCAGCCCCTGGTACCAGGAGCCCCAGGGCTACACTCTCGGCCCCAGAT
ATACAAGAAGAGGGCAGAGGGAGAGAGGCTCCCACACAGGCGAGAGTCCTTAGTCTGGTCTGTGGCTGGA
GCAGGGGAATTCCTTCTGATTGGAGATTAGGCACAGCTGATTAGGGGAAAGCCTACCCCATCATCCAAGC
ACAATGGACTTTGAGGAACAGAGCCAGTCTAAGCTTTTATAGCTTTATGGTAGAAAGGCAGGGAGAAAGG
AGAGAATGTGGAGAGAGACAGAGAGAGACTGGCCATGGCCAAGAGGAGGGAAGGGGGAAGAGAGAGAAAC
AGGAAAAGCTAGAAAGTAAGATAAGAGAAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGCAAAGTG
GGGCCAAGCAGCCCCTTTTCTAGTGAGCTTGTCATCTCACAGTTGCTAGGTAACTGGGGAGGAGTTTAGT
CTGAAGGTCAGAAGCTTGGGACCTTGTGTATGTGACTACTAACCACAGCTTCTCCTGTCGGGACTGTGGG
AGCAGTAACTTTGACAGGAGACAGGGATCCAGGAGACATGAGGGAACACCTTCTGTCCCACATAGGTGGA
ATCGGTTGTACCAGGGTTCAGAACTCAACTCCACTGGAGACCAGCCTATGTGTGCATAGCCCATTGCCCT
ACAGCCTTTGACATTCTACAGAGTTCTGAGACTGGTAGAGATACAAAATAGCTAGGATTACACAGAGAAA
CACTGGCTTGACAATAAAACTTCCAAAACAAATATAAATGAATAAATACACAAATTGGAGCAAGTGAACT
TGCACTAAATCCATCAAAACTTGCACAGGATGGCTGTCTCCATAATGTTCAGATCTACTTCTATTAATGT
CATTAAGAAGACAAAGATTATGCACAAAAAGAAACAAAACAAGAAACCCAAAAGGTAAAGGCTCCAATTG
TAAGTAATAGACCCACAGTCTCTGAGGCCTGACTGTGCAGGTCCTCACCTTTGGTAATCAGCACTGAATG
CAGACCACTCCTCATGGACTTTGGGCTCAGGTTTGTTTTCCTTGTCCTTATTTTAAAAGGTAATTCATAG
AAATGAGATCCTGCCAGTATTGTGTACATGAGAAATAGAAAAATTGGTTTTCTTTGCTCTATTTTGTTTT
GTTTGGTTAATGACAGTTTCCAAATCAGCATTCTTTGCTTTGAGGTGCCCAGTGTGAGGTGAAGCTGGTA
GGGTCAGGGCAGCCTGGAGGGTCCCTGAAACACTCCTGTGCAGCCTCTGTAGTCACTGTGAGTGACTACT
GAATGACCTGGGTCCTTCAGGCTCTAAAGAAGGGGCTGGAGAGGGTGGAAATAATTTTTAATGGTGGAGG
TAGCACCTATTATCCAGACACCATGAAGGGCTGATTCACCATCTACAGAGATGATGCCAGAAACACACTT
TACCTGAAAATAAACAGTCTGAGGTCTGAGTACACAGCCATGTGTGTGTGTGTGTGTGTGTGTGTGTGTG
TGTGTGTGTGTGTGTGTGTGTGTGAGTGTGTATTCATATATATATATATAGTGTGTATGTATATTCATAT
ATATATGTATATTCATAAGGTTGAGTAAATGGACTTAAACTGATTCCATCACAACTTCCATGGGATGGAT
ATTTCCCAGTGTTAAGACCTGTCAACATCACTGTCATTCAGGAGACAATGATTATGCACAACAAAACAAG
AAACCCAAAAGCAGAGGACTCCAATTACAATAGACCCAGACCCACAGTCTCTGAAGATTGACTGTACAGT
TCAACCCAGCCCTGTACTTCTCTTCCCTAGAATTTACATTACTGAGTAACTGAGGAAAGCTCTACAATAT
CTGTTCTCTATAGTGGTCAACACCTCCAAACACAGGTTACCCATATTCATGCCTGCCTTCTGCTACACTT
CTTGCCATAATGTAGACTACTTCAGCCTATTTTGTACTCCAGTTAACGAAACTCAAGACTAGCTGCATGT
TAGTCCTTATTCTGAAATATTATGAACAGGTGACCTCCCATCATTCACCAATGCAATAATCATATTTAGG
AATATGAGGTTTTATGAGATATAAGCACAAGGGAGAGAAAGTAAGAAAACTACATAGATATATAGACTGA
CATAAATCAAGACTTGCATGAGCTAGTGCCCAAGTACCATGTCCCTAAGTGGCAAGGAGTATCTTTTGAG
CCTAGTGAGATGAGGTACAAATCGGACTCTTACATCTTTTTAGATAAACATGTGAGATCAATGGACTAAA
GGCGTGAGCTGGGCTTCCTTGCAATCCATTTTCCATACAAGATAACAATAGATCTGGCTCCACAGACACG
ATGAGAATAGTCTTAATTAGTTCTTTAAGTAGAATGACTGATCACTAAGAGCCCAATTCCATACTAAATA
CTCTTCTGGATTATGCACAGATAAAAATTGCACATAGGGCATGGGGCACTGATCTCCCTGCACTACATGA
ATGGGGGCTCATTTACTAAATGTTCCCATGTTTCTTCCTAGTGCTGCACAGAGCAAATCCTACAACTTCC
TGCTTGTCTACAATGTAAACTCCAGACAGTACCAGAAAATCATTCCTTATGTTCCTCTCCAGGTGCTTCA
ACAAGCACAGTGCAAATTTCTGTCACCCTG</dna_sequence>
        <protein_sequence></protein_sequence>
        <phi_function>Vaximmutor</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2>Vaximmutor</phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1107">
        <gene_name>Ighg1</gene_name>
        <strain>Mus musculus</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>16017</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id></ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq>AC160982</gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id></taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand></gene_strand>
        <protein_name></protein_name>
        <protein_pi></protein_pi>
        <protein_weight></protein_weight>
        <protein_length></protein_length>
        <protein_note></protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence></protein_sequence>
        <phi_function>Vaximmutor</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1106">
        <gene_name>Ighv1-9</gene_name>
        <strain>Mus musculus</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>668478</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id></ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq>AC073561</gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>10090</taxonomy_id>
        <chromosome>12</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>114583568</gene_start>
        <gene_end>114583861</gene_end>
        <gene_strand></gene_strand>
        <protein_name>immunoglobulin heavy variable V1-9</protein_name>
        <protein_pi></protein_pi>
        <protein_weight></protein_weight>
        <protein_length></protein_length>
        <protein_note>Also known as Igg2a; Gm16697</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>gi|372099098:114583568-114583861 Mus musculus strain C57BL/6J chromosome 12, GRCm38 C57BL/6J
GTCTTGCACAGTAATAGATGGCAGAGTCCTCAGTTGTCAGGCTGCTGAGTTGCATGTAGGCTGTGTTGGA
GGATGTATCTGCAGTGAATGTGGCCTTGCCCTTGAACTTCTCATTGTAGTTAGTACTACCACTTCCAGGT
AAAATCTCTCCAATCCACTCAAGGCCATGTCCAGGCCTCTGCTTTACCCACTCTATCCAGTAGCCAGTGA
ATGTGTAGCCAGTAGCCTTGCAGGAAAGCTTCACTGAGGCCCCAGGCTTCATCAGCTCAGCTCCAGACTG
CTGCAGCTGAACCT</dna_sequence>
        <protein_sequence></protein_sequence>
        <phi_function>Vaximmutor</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene126">
        <gene_name>Il10 (interleukin 10)</gene_name>
        <strain>Mus musculus</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>16153</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>6754318</ncbi_protein_id>
        <gene_locus_tag>AL513351.1</gene_locus_tag>
        <gene_refseq>NM_010548</gene_refseq>
        <protein_refseq>NM_010548</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>MGI:96537; Ensembl:ENSMUSG00000016529; </xrefs>
        <taxonomy_id>10090</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name></protein_name>
        <protein_pi></protein_pi>
        <protein_weight></protein_weight>
        <protein_length></protein_length>
        <protein_note></protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>gi|6754317|ref|NM_010548.1| Mus musculus interleukin 10 (Il10), mRNA
GGGGGGGGGGATTTAGAGACTTGCTCTTGCACTACCAAAGCCACAAAGCAGCCTTGCAGAAAAGAGAGCT
CCATCATGCCTGGCTCAGCACTGCTATGCTGCCTGCTCTTACTGACTGGCATGAGGATCAGCAGGGGCCA
GTACAGCCGGGAAGACAATAACTGCACCCACTTCCCAGTCGGCCAGAGCCACATGCTCCTAGAGCTGCGG
ACTGCCTTCAGCCAGGTGAAGACTTTCTTTCAAACAAAGGACCAGCTGGACAACATACTGCTAACCGACT
CCTTAATGCAGGACTTTAAGGGTTACTTGGGTTGCCAAGCCTTATCGGAAATGATCCAGTTTTACCTGGT
AGAAGTGATGCCCCAGGCAGAGAAGCATGGCCCAGAAATCAAGGAGCATTTGAATTCCCTGGGTGAGAAG
CTGAAGACCCTCAGGATGCGGCTGAGGCGCTGTCATCGATTTCTCCCCTGTGAAAATAAGAGCAAGGCAG
TGGAGCAGGTGAAGAGTGATTTTAATAAGCTCCAAGACCAAGGTGTCTACAAGGCCATGAATGAATTTGA
CATCTTCATCAACTGCATAGAAGCATACATGATGATCAAAATGAAAAGCTAAAACACCTGCAGTGTGTAT
TGAGTCTGCTGGACTCCAGGACCTAGACAGAGCTCTCTAAATCTGATCCAGGGATCTTAGCTAACGGAAA
CAACTCCTTGGAAAACCTCGTTTGTACCTCTCTCCGAAATATTTATTACCTCTGATACCTCAGTTCCCAT
TCTATTTATTCACTGAGCTTCTCTGTGAACTATTTAGAAAGAAGCCCAATATTATAATTTTACAGTATTT
ATTATTTTTAACCTGTGTTTAAGCTGTTTCCATTGGGGACACTTTATAGTATTTAAAGGGAGATTATATT
ATATGATGGGAGGGGTTCTTCCTTGGGAAGCAATTGAAGCTTCTATTCTAAGGCTGGCCACACTTGAGAG
CTGCAGGGCCCTTTGCTATGGTGTCCTTTCAATTGCTCTCATCCCTGAGTTCAGAGCTCCTAAGAGAGTT
GTGAAGAAACTCATGGGTCTTGGGAAGAGAAACCAGGGAGATCCTTTGATGATCATTCCTGCAGCAGCTC
AGAGGGTTCCCCTACTGTCATCCCCCAGCCGCTTCATCCCTGAAAACTGTGGCCAGTTTGTTATTTATAA
CCACCTAAAATTAGTTCTAATAGAACTCATTTTTAACTAGAAGTAATGCAATTCCTCTGGGAATGGTGTA
TTGTTTGTCTGCCTTTGTAGCAGCATCTAATTTTGAATAAATGGATCTTATTCG</dna_sequence>
        <protein_sequence>>gi|6754318|ref|NP_034678.1| interleukin 10 [Mus musculus]
MPGSALLCCLLLLTGMRISRGQYSREDNNCTHFPVGQSHMLLELRTAFSQVKTFFQTKDQLDNILLTDSL
MQDFKGYLGCQALSEMIQFYLVEVMPQAEKHGPEIKEHLNSLGEKLKTLRMRLRRCHRFLPCENKSKAVE
QVKSDFNKLQDQGVYKAMNEFDIFINCIEAYMMIKMKS</protein_sequence>
        <phi_function></phi_function>
        <phi_annotation>IL-10 plays an important role in Th2 type immune response.</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1127">
        <gene_name>Il12b</gene_name>
        <strain>Mus musculus</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>16160</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>6680397</ncbi_protein_id>
        <gene_locus_tag>RP23-388G23.1</gene_locus_tag>
        <gene_refseq>AL607030</gene_refseq>
        <protein_refseq>NP_032378</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>10090</taxonomy_id>
        <chromosome>11</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>44400062</gene_start>
        <gene_end>44414016</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>interleukin 12b</protein_name>
        <protein_pi>6.5</protein_pi>
        <protein_weight>35952.67</protein_weight>
        <protein_length>335</protein_length>
        <protein_note>Also known as p40; Il-12b; Il12p40; Il-12p40</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>gi|372099099:44400062-44414016 Mus musculus strain C57BL/6J chromosome 11, GRCm38 C57BL/6J
CAGAAGGAACAGTGGGTGTCCAGGCACATCAGACCAGGCAGCTCGCAGCAAAGCAAGGTAAGTTCTCTCC
TCTTCCCTGTCGCTAACTCCCTGCATCTAGAGGCTGTCCAGATTCAGACTCCAGGGGACAGGCTACCCCT
GAACCAGGCAGCGTGGGAGTGGGGTAAGTGGATTCTGGGAGCATCTCGGATGGCTTTCCCCGCTGGTGGA
AACCAGGGGCTTTGACGACAGGGGCTTCAAATAGTCATTTAAAAAGTCAGCTAATTACAGATGTGATGGC
GCACACCTGTAATCTCCAAATCTGGGAGGCAGGAAACAGAATGCACAGGAGTTTAAGGCCAGATTCAGCT
GTGTAATGAGTTTGAGAGAGTCTCAAAAAATTGAGCTACTAATAATATGTGCCAAGCATTGTGGACAGAT
GTGTATTTGATAGAAAGGTTTGCTTTGTCTATATAGACACATATACTATGTGCATTTTCTTAAGTATTAA
TGCATATGTGTTAAGGAGTGTTGTTAAAATTCTGTTCTTGCCTTAAGAGTGAAACTTAAAAAAAAAAAAA
GCCTTTCATGTACCCCTTCAAGCCTAAGCTCATCACTGAATGTCCTACCTGTGATGGCCTTTAGAATCAG
CTATGATAATCAAAGTGGAGAGCTGGGTTTGGGGGTTCCTTTGGATTTTAACTAACTTTGCCACCTCTTC
AAAACTGGAAAGCCCAAGGCATGTTCCAAACTATTTCCTAAAGGGTTCTAAAATCTGTGAGAAAGGGAAG
GCTAATCTTCATGGGTTGGCTTCCTCTGCTTGCCCAGGTGAAATCATGAGCACCAGATGGGGCAGGGTGA
TGGGGCAGGGTGACATCTTGCTTTCACCCAGGGATCACTGAGCCTCAGCTGGGGGCTCCGTTTGTTCAAG
CAAGGCATTTCAAGATGAAGTTAGGTCACCCCCAAGAATTCATTTTGCTGAGATCTGAAATACTGTGATT
ATTGCACCAACAATCCATGGACTCTCTCTAGGCTAGATTCTGGATATAAGACTAGACAGATATGACCTCT
GTCACACACCTCGGTATGGGAAAGGGGGGACAGACATTAAAGACGTAATCAAATGATTGTCATTTCAGCG
ATGCTGAAGGGGAAGAGTAGCTATTTGGGGTCCTGTTTTCATTTGGGGCTCAAGCTGGCACTTTCTGTGG
ATCATTTCATGAACTCCTAACCTGACAGAGTTATTTTTAATCTAGGAGTACAGGCTTGACAAAGTCAACA
CAACTTGTCAAGGTCACATAACTAACAAGTGGCAGACTGAGGTCTGTTTGGCTGTAGAACCAAGGCCCTT
TGCCCGTGCCCTCCTTGCCATCCCTGACAGCCACGCCATCTGTACTGTGCATTGTTGTTTCTGGGCATTT
TTATTTTTACATATCATTTCTCTTTTAAATTAAAGAATAACAGAATGAAACTTGCAAAAGGGATGTCCAC
TCAGGCACCCGCTGGCAGCAATGTTTGGAAGCATTTGCATGCTCTAGGGAGCTAGAGTATCCAGCCCAGG
GTTCCTGTGCTCTTTGCACAAGACTTTCAGGACTTAAGAAAACTAATGAAAACAAACAAACAAACAAACA
AACAAAAAAGAATTGTTAAAACATAGCATATGGAAGAATTGTGGAGTGAGAGGGAAACAAAGCCCAGCAT
CTGCCAATCAGCCTGAAAGCCAAAGCCTGGCTACATACTGCACACTTTTTTGCTTGTGCAGATTTGATTA
AGAGGCGACCTGCCATCATCTCCACCCTCTGCTGGTCTTCTATGATCTAAGATGTAGGTGATGCCGAAAT
GAAGATTGTTCCTTGGACCATTGCCAGGGCTCCCTTCAGCCTGAAATATGGTTCACGTGTGATGCTCAAG
TGCATCTGAGGCTGACAGAGGAAATGCTTGGCATGTAGCCAAAGGGGAAATCCCTGTGTTGAGAGCATAT
GAAGAGATCACCAGGAGATGCCAGGAATCTCTGCCTTTTTTCCCTGCCCAGAGTCCTACCATCTGGGTTT
CACAGCCGTGTATAATTGCATCACCTTCTCTGGGCATTTCTCTCTACAGCCTGGCAGATTTTTATTTTTC
AACCCAGTGTGCACAAAACAGAAAGAATTTCAATTTTTTTCCTTAGCTTTTTACTAGTGCAAGGTATTAT
ACAATGTCATCTCACTGCATGCCCAATAGCTCTTGAAGATCACATAAGCCTTATGTCTTTTTATATGAAG
GCAGTCGGGCTCAGAGGAACTAAACCAACACCAAACAGCTACTGAGTAGTAGGGCCAGAATCCAAGTCCA
TGTCTGCTTGACTCCAAGCCTATGAATGTAGCAACCAGCACCATTTCAGCTTGTACTTGTCTTGACTATA
TGATAATTTGGACCTAGACATGTCCTGACTCCTAGTCCTGTCTCTGTCATGAAAAAGAAATCATAGCAGG
GCCCTCAAGAGGTTAGCAGTACTTCTGTTCTCTCAAAGGTCGTGATTTCTGACCAAGGCCTGTTTATTTT
TAAGGCATTTGCCTATAACATTTAAGCCTTAATTCATATGGGTTAGACTGTGGTCTCTCAAATCTTGTTC
CTGACGGGCGGTGGCACCCTCCAGGATAGATGAAAAGTATTTCTGAAGGGAATTAGTAATCTACACTGAT
TATCTCAACCACATTTATGAGTGAGGTATAATCTTTACAGTCTAAAGGTTTGTGTTGCCCTGGTGTTAAT
CTAGACTGGGTTACAATACAGGATGGTTACTGACTTATCTATTTCATGATAGGTTAATCAATATGGTACA
GTCTTCTGCCAAAGAACACCTTGAATTTTAGGAGTTCTGGACTCTCAAACCTAGCTAGCACATTTGCCCT
CACAATGTGTTCAATGGATCATAACATCAGCTTTCAGCACCTCCAAGACATGTTAAGTCAGACACTCTGT
TCTGGGCTGAGACCCAACAGTCTCCGTGAACCCAGGTTATACACACACCCAAGCTTAAGAAATGCTGCAT
TTTGTTGTGAGGGAGAGAATTATTTTAGAATTTGGAGTAATCTCTGCCTAGGTTTAAAAAAACCTAATCC
ACTACAGGTCCTTGTCAGAACTTGAAAGTTTACCCTGTGTCACCTTTCCCACACCTAAGCTGGTCCTCTA
GCCTGGGGCATCCCAGTGCCTACTGCACAGCAGGGTGATTCGGATGCCCAGTGACACTGTTCTCGTCCAT
ACTGGCAGCATGGCAGTACTTTCCCATTCTGTTCAAAGCTCTTTGGGTATTATGTTAATATTACAATCAT
AACTAAGGAAATATCTGATGACTGTGGACCTGGGAAGCCACGGTCATCTCTAAGTTTATGTTTCTGAACC
TTAAAAAAAAATAAATAAGATGGGTGTGGTGGCTCTCGCCTTTAATCCCAGCACTCAGGAAGCAGAGGCA
GGTGGATCCCTGTGAGTTTGGGGTCAGCCTTATCTACATAGAGTTCCAGGACAACGAAGGCTGAAAGTCT
GTCTTAAGAAGAGGGAGGGAGGAGATGATTGTGGATATCAGGAAGACAGTTCAGCAGGTCACATTACTTC
TGCACAAGCCTGGTGACCTGGGTTTGAACCCTGAACCCAGAGTGAAAGGAGACAGTCAACTCCCAAAAGT
TGTCCTCTGACCTCCACACATGCACACATACAATAGTCATACATCAATATATTTTTAAAAAACAAAATGG
TATCAGGTAGCTGGGCCCTATGATTATTTAAGCTCCAGGTAGCCTCTAGTTCTTTATTTGGAGATGTTTT
TACCCAAATCTAGAAGAGACCTCCTATAATCCTGGTCCAACAGTGTGAAAAGAAAGGGGAAAGTGAGTAT
TTGGAAGGCAGATAAGCTGTTGATCGGGTTAATTGGATAACAGTTGACATTCTCTCTCCCATTTCCCCGC
CTTTTCCTTCTCCTCTGCTCCCCTTCTTCCTCCCTCCTGCCCCTCCTCCACACAGATGTGTCCTCAGAAG
CTAACCATCTCCTGGTTTGCCATCGTTTTGCTGGTGTCTCCACTCATGGCCATGTGGGAGCTGGAGAAAG
ACGGTAAGCAGCCTTTTCCCTGTTTTCTTTGGAGCGCCAGCACCTAAACTTGATCTCCAGGCAGCCTGCT
GGGAAGGGATAGTGAAGTCTGAAGTAGGCAACCGTGCATGGGATTGTCTCAGGAAAAATCCTCAGGGAAG
ATGGAGGGTTAGCGTCTCTTCCTCCACCTATCTCTCTCCCTTGTTTGGTTTTCATGTTGGATGACAGGAA
AGGAGTTTCAGGTGAACTATGGTGGTGTGTGGGATATGATCTTGGCCTTAGATACCAGAAAATGACTCTT
CTAAACAATTGAAATTCCCTAATAGAGAATTTGTAACGTAGCAAGATTGTCTTCTACCCTCTCTTGTCTT
GCATATTACAACGTGCTCTCAGTGGGCACCATGATGGTTGTCCTCTGGCTATTTTGGGATTGGCATTCAC
ACTGACTTGGTTTCAGGTCATGGCTCTGCCAGGTATTGATACTGAACCTTTGAGGCTGGGTAGTCTTGTG
ACCTCAGTTTTCTTTCCTTTTTTTTTCCCCCAGACAGGGTTTCTCTATATAGCCTTGACTTGTCCTGAAA
CTCACTCTGTAGACCAGGCTGGCCTTAAACTCAGAAATCTGCCTGCCTCTGCCTCCCGAGTGCTGAGATT
AAAGGAATGCACCACCACTGCCTGGCTGACCTCAGTTTTCTTAATTGGGTGTTCAGTATAGCACAGCCCA
CATGGACTATTGAATATGTTAATAAATACAGAAAATAACATATGGTAGAGTGAGCAAGCACTATTATTTA
AAACAAAAAGTCTCTGAACTTTTCATTATCCCAATGGCAATAAGATTATTAGTAGACAAATAATGAAGGC
ATAGAAGGGGGTGCTCTCTGTCCTCTGTCCTTGTGCCATGTCACAGTTAGCAAATGTCCATCAACTCAGT
CCTCAGATGGTCGTCACAGGATCTCAAATGTTTCATGGAATACAAGGTAATCAAGTCAGGAATTTCTGCT
TTTATAGCTACACTTTAGTAATAATTAATATTTATTTAACACTCAATTTCGCAACAACCATGTAAAGTAG
GAGCTATCTGTATTCCATTTTACAGATAGTAAAAACTGAGGTTCAAGAGGCTAAGTAAGTTTCCCACAAG
GTCCAGAATAGAACTTGATCCCAGTTTAGTCTCACTTCAGAGCCTGTGTGCTTAAATGCTAGATTTTACA
AGTAAGGCGTGAAGCAACTATTTCCTGTGGCCATAAAGAGGAAATGGGTGTAAATTATAAATGAAAAGAT
TTCCCAGCTGCTGATTAGAAATAATCTTCTGAGAATCCAGGAAAAAAAAAAAAGGTGAGCCTTTTTTTCA
TTCTGAAGAATTACAAGAGTTTGAACGATATTCGCAGGTAAAGGTGCTTGCCACCAAGTCCGATGACCTA
GACTTCATCACTGCGATCAGCATGATGGAAGGAGAGGATCGAGTTCTCTAAATTGCCCTCTGCTCTCAAG
ACATGAGCTGTGACACCTGTGCACACACACACACACACACACACACATGAAAGAATTAAATGCAACTTTA
AAAAGAGTAATCTCCAGCCTGGCCACCCACGCCAACAGAATTTTGGATGCTTTCCTAAGTAAAGCCTTTG
CCACAGCCAGATGGACAACTTAGGCCCTGGCAGAGTTAACCCCTTAGTTACTTCTGACCTGATAAACCAC
AGAAATTTCAGAAAAGCAACAGGAGAAACACAGAGAGAGCTTGTGTTGGAGTCACAATGGTGGCCCGAAG
CCCAGCAGATATCTAAGCTCTGATTCCAACGTGTCCAAGAAGTTCTTTCCCTGCCCTGGGGCTAAGGTCT
TCTAGGGTTTCTGAGTTCAGGTTCTAAAAGGAAAATAATAGACAGCCTGTTTCATGGCCTAGGGGACAAA
GGGAAACTGGGAGCCAAAGGGTCCTGTGCACTGGAATCAGCTCAGGCTAACGATTTCTGAAGAGCTTGGC
CTCAAGTGATTTGTACCTCTTATCTTTGCTCCCCATTCAGCAGTGACAAATCCCACTGATGTAAAAGTAA
GAGCTTAGCATTTCACAAGGCTTTAAGCTCCAATGCCAATCACAAAGCCACCATTCACAGGGCACTTAAG
GAAACTGTCTTAAGCTTGCATACAAATTAGTTTAGATGTTACCTTCTAAAGAAAGCACTAATATTTTGCT
TTCTTTTTTCTTTTTTTAAAAGAATGACATCAGACTAGGGCATGGCAGTTCATGCCTGCAATCCCTGAAC
TTGATAGATCAAGACAAGAAGAAAGCCCAATTTTGTGGCCAGCCGGGGCTATAAAGTAAAATTCTAAGTA
GCTGGCTGTCTCTTCCCACCCCCGAGGCCATGGCTCTCTGAAAGCCCTTTGCTGGCTCTGCTCCATAGCC
GTGCTATTCCAAAACCCAGGCTCTTCACCACTATGCCTTCCATATTCAATCAGGCATCAGATGACTGGGG
CCATCCTGATCTGACTCAGCAACCAAGAACAAACCTCACTGATGGGTTTTCAGGTGATGCTGATGATGGA
GGTTGAAAGACGACCCTGCTTTACGGGTCACTGCATTAAGCTAGTCTTTCGATTAATAATTGATATGTAG
GTAACCTTTGAAGCTTTGTCACATGAGGCTTTGGTGTGACCCACTCCAGAATACCTTATGGAGATATTCT
GGAGGCTCCTTCAGAAACTAGCATCAGATATCCATTGCACAACACAGGAGACAAAAGATCCGAAAGACAC
CATTTGTTACCCTTCACACTTGATGGGACCTCACTTAGCCCTTGGCCATCAGCAAAAACAGTTCCTTCAA
AAACTGAGACAATCATCTACTGCTTTGTAAGAGTGTAAAATAGCTTTTAAAAACAAGTAGTTAATGGCAA
TCTCCGTCCACAAATTTCATGCAGAAGAGACTTAAAAAAAAAAAAACCTAAATCTTTCTGGATAATTTTA
AGAGTTTTTCAGTGCATTTGCCTGGCTCTTTGGCCTGTGCATGACAGTGATGATGATGATGGTGGTGGTG
GTGGTGATGATGATGATTTTAAAAAGCTAGCACAGGGTTATCCTGCCGTAACCTTAGCTGTGCTAAGGTG
CATGCTTTTTTACCATCTATCCTCACAGCTAATCCTATTAGCATAGACAATATTGTTCTTACCATTTTGT
GAGGACTCTGGGGCTACTGGTGGTTCAGGACCTTGCTCAAAATCTCCTTTGCAATTAGAGAAGATAGGAT
TTCTGCATCTTTCTTTCTCCACACCTATGCTTTAAGCCACTATGTTATTCTGCTCAATACTCTGCCCTGT
GTATTCCCTGTGAATTACAACTGGAAGCTTACTCCCCCTCATCTCCATTCCCAACACACACACACACACA
CACACACACACACACACACACACACACACTAGTGGCTTCTGACAAGGAATCTTGTGCTGTTTGCATCTTT
TCTTGTTTCAAGGTCTTCCCTTCCTAATCAGAGACCGATTATTACTGGCCACCTGCCAGTTAAATGACTC
GGTGGCAGCTATAGAACTGTTTCTCTGTTCTGTCCCCATGCCCTGAGATCTCTCAGCAAGCACTTGCCAA
ACTCCTGTGAGCTATGACGTTCCAAGGGCCATGGGTGTGTCAAGACACTGAGTGAAACCCAGTTCCCGGG
GTTTGTGAGGCTCCTGGTCCAGGTCCTCACTGCTGGTGCTCTCCAGTTTATGTTGTAGAGGTGGACTGGA
CTCCCGATGCCCCTGGAGAAACAGTGAACCTCACCTGTGACACGCCTGAAGAAGATGACATCACCTGGAC
CTCAGACCAGAGACATGGAGTCATAGGCTCTGGAAAGACCCTGACCATCACTGTCAAAGAGTTTCTAGAT
GCTGGCCAGTACACCTGCCACAAAGGAGGCGAGACTCTGAGCCACTCACATCTGCTGCTCCACAAGAAGG
AAAATGGAATTTGGTCCACTGAAATTTTAAAAAGTAATTCCATCCCCCTTGACAGTATCTTTTCTTCTAC
CCCTCCTTAAAAAGTAATAATTGCAAGTGTGTGTGTGTGTGTGTGTGTGTGCGCGTGCGCGTGCGCGTGC
ACTGAGGCTCAGAAATGTTTCTCATTTCCTTTGAAACAGGAACTCTCATTGGCCCATAGCTTACCAATAA
GCTTTCTTGGTTAGCCAATAACATCCAGAGACCTTGTCTCAAAAAAAAAAAAAAAAAAATCTCACCCTTG
TACCATGTAATGGCCAGTGATCCATCCACAGTAAAAAAGAAATAAATAAATAAAATAAAAATAAAAAATA
ACAAAAACAAATTTCTTTATTAAAAGAAAACTCCTAAATATTTAATTTTTCTTTTCTTTTCAAATGCAGA
TTTCAAAAACAAGACTTTCCTGAAGTGTGAAGCACCAAATTACTCCGGACGGTTCACGTGCTCATGGCTG
GTGCAAAGAAACATGGACTTGAAGTTCAACATCAAGAGCAGTAGCAGGTAAGGGAGCTGCCATGATTTCT
CAAGGTTTTGTGTGATCTACTTCATAACAAAAAGAAGTACAAACTGCCCATGGATTATCAGTGACTGGTA
ATGGAACAGCAAAGTCAATTCTGTATTTTTTTTTTCAACTTCCCTCTGCTCGCCTAAGGAAATAGCATGG
AGCTTTAAGCCAGCCCTCTGAGACTAGTTGGCTGGGTAGTTTGAATTCACTCATCCGAATTGCCTGGCCG
TGCTTCATTAAGGCTCACAGCACCATGGGGAGGAATTAAAAAGAAGCCACAGCTACAAATAACTGGCCAG
AGCTCGACCTTGTGTCAAAAGCAGAATTGAGTGCTCCAGGGCCTTGCTGTTGGAAGCCCTGGAACAGATT
CCAGAACCCTCTGAGGCCTTTCGAGATTTTCCTAGAGCCTTTTCAACTTCTTCCCCCCCCCACCCCCACC
CCCCAACCGTTATTCTGAAGTTCAGTTTCCCCAATGCACTTGGGCTTTTCCTAAAAACATCATCTCCCAG
GGCTGCAGAGCGGGTGTGTCAGACTGCTCTACAGCTGACTTTAGTCAGCAACTAAATCCCTGAGCCACAT
GGAGGGCAGGGAGTGAGCGCCCTGGCTCTCCCACTATTTAAATGAATAAACGGGGGACAGGGGGTGTGGG
GGGGACGACTCCCTTTTCCATCTTTATCATGAATTTGCTATGACTTAACTTAGCTAAGGAAAATAATGGT
TCAGGGTGACATCAGAGTCCTTGTTGCTTCTATGAGAATTTTCTGATCTGGTAAAGGTGGCCCCAAAGGA
GACCAGTGTACAATGCAGATGCTTACATATAGAAACATGCCAGACCTCTATGTGCTTTAAAAAATTAGAC
AAGCACGATACATTTTCCTGCTAGAGAAATCTTGCACGTGTTCCTGAAGAAACTAGTACATGGATAAGGG
TCAGTGGAACATTTTGCATAATTAGCAAAAGCATGCTCAAATGGAACATCAATGTGCATCTATTGAAATA
AATAACTCAACTTTCGTGTTCTGTTTAGAGAACTCCCCCACAATACTTTCAGAGAGGAAAAAGACGTTAC
AAACTCATGCATATATATTTTTCATTTGTCTTTAAAGTTGTGCTACTCTTTGGATAAACTACATATGTAC
ATATATGTCTGTGTGCATGTCTATCTTAAATATTCATTTGGAAAAACTCTAGAAGTAACAAACTGTGAAC
AATGTCTATATGTGGGACTCAGATTTGAGTAAAAAGGAGAATTGTGGCGACACGCATGTTTTCTTTATAA
TCATCTTTGTTGTTATAATTCTTTATAATTCAGCAGTTTCTCTTGCATTACGATATTTTCAGGTTCATTT
AGGCAGAGATGCAACTTTCAGTCTCTTACAGCTAAGCTTCCACTCTGCAAAGGGCAAGGGGGTTTTTGTT
TGGTTTTGGTTTTGGTTGTTTTATTCCACTGGAGAAATCCAACCAGCTGGACAGACTGGCCTCGGACTGT
AGACACCAGGCACTCTATCTCTGATCTATAATACAGAACTCATTCTGTCTTTGCCATCAGTTCCCCTGAC
TCTCGGGCAGTGACATGTGGAATGGCGTCTCTGTCTGCAGAGAAGGTCACACTGGACCAAAGGGACTATG
AGAAGTATTCAGTGTCCTGCCAGGAGGATGTCACCTGCCCAACTGCCGAGGAGACCCTGCCCATTGAACT
GGCGTTGGAAGCACGGCAGCAGAATAAATATGAGAACTACAGCACCAGCTTCTTCATCAGGGACATCAGT
GAGTTTTGCCTGGGAGCAGGTGCTAGGGAAGCAAAGACGATGTCTGCCACGTGTCCATGATACCCTGGGG
CATAGGATTGGCCTGCATTCTTTTCCATTCTCCTAAAAAGCATGATACAGACACTACCCTCTTCATCTTA
CAGATGAGGAAATTAAAGGGTTAAGCTAACCTTTTTCCAGATCTCAAATCTCACAGACAGCAGACCAGAC
CCAGACCTGCCCCAATGGTGGCACCTAATGGATTATGGGTTAACTACATGCTTAGTGTAAAGCAGAAACC
AAGCACAGGGAGGGTTCCCTGATTGCTGAGCCCAGATACGAGACTCTATTAAGCAGAATGACTCAACCAG
TAGGGACTTCCGGTCTGTGCAGTGCAGAAAGGGTTCTAAAATGTAGGATATGGCCAATAATGGTGACTTC
CTCGAGTGGAAAGATCACTCTCAGCAGATCCCTCACAGGTGCTGCCCTGATGCTCAGAGAAGTGAAAGAG
CTATTCCAGAGACTAGAAGGTGGAGGGCTCTGTCAGCCAAGCTCAGGAGCCTAAGTCCTAGCTCCAAAGC
CTGGCCAGGATAATAAAGGATGCTTGTCTTCTTCTGCAGTCAAACCAGACCCGCCCAAGAACTTGCAGAT
GAAGCCTTTGAAGAACTCACAGGTGGAGGTCAGCTGGGAGTACCCTGACTCCTGGAGCACTCCCCATTCC
TACTTCTCCCTCAAGTTCTTTGTTCGAATCCAGCGCAAGAAAGAAAAGATGAAGGAGACAGAGGAGGGGT
GTAACCAGGTAGGATTTATGCAGCCCATGTTGGGGCCATTGGAAAGATCCTGACAACCAGGTGCTTGCCT
CAGGACCAGAACTGTGTTAAGGGCTCTCCATGTGAATCACACACAACCTATACAAAGTCCCAAAGGCAGC
CAGTATTGCTGTCACCTCTCCACAGAGGCCAGGAAAGCTCAGAGAGGCTATGTTTTGCCCACGTTCTTCC
AGCTAGAGCAGTGGCAGAACCAGTACCCAGCAATGGTTTGATGGAGAAAGAGATGGTTAGCTCAACCACT
TCAATTCCTCCAGTATAGTCGATTGTCAATCCTCAACCAAAGTTGTTCATGATATAGAAACCTGGGATCC
AGGAGCCTATAATGATTGTTTAAACTGAGTAAATATAGTAAATGCTAAAACATTGATGCTGGGACCCACC
AAATAAGGATAATCTCTACTTCCTTAATATGAGCAATCATTTCACCTTACAAGATGTCCACCTTTACTGG
GCTAATATGGTGACTTTCTACCTTTCGGGTCCTTAGCACAGTGATCTCTTGCTAGGTTTGAGGAACACTT
TTATGAGCATTTAAGTCACAGAGCAAAGGATTCTTCCAACCTAGCATTGAGAATGTGATAGCAATTCAGC
TCAGAGATTCAACCACTTCCTAAAAGCAGGAGCAAAAAATGGGATTATTTTGAAACAGATTTTAACTGCT
ACCTAAGTTTCATCCCTGTGTGTATGTATTTAATATACCAATCTTAAATAGGTAATGTCTAGTGCTTTCT
ACTTGCTAAAAGCTTTCTACGCATTTTTACATAAATGTTGTATTTAGCTGCTGCAATTCTTAGAGGCAGG
CATCCTGGGACCTACTCATGAATAAGGAGAGACACAGAGAACCAGAGATATTTTCCTGAAGCACCACAGC
TGTTTAGTAGCATTGCCAGGATTTGAAGTCACTTTTGTAAGCTGACAGGCATGGTAATTCTTGATGTCAA
GACAGCTAAAGAAAGCTGGTCTCAGTCCCAACATCAGCTTCATATGGGAGTGGTTACCCATGGGACCTTG
GGGTAATGCTGCTACTTCAAGAGGCAGAAGGGGGAGCAAGCCATTTCTGTTGGAGTTTACTAAATAGAAA
AGTGAGAGTGGGGTGGTGGATGAATCATGCTGGAATATGAAGACCTGAATTTTAACCCCCAGAACCTCTG
TAAAACTGAGTAGTAATGCCTGAACCTGGGCTCTGGAAAGAGGTGGGACACATACACACACACACACACA
CACACACACACACACACACACACACACACACACCTCTGATTATAGCTTCTACCAGCAGGTGGTGCAAGGG
GAGCGCCCATGCCAGCCTGCCTTATATTGCCTAAAGCCCTTACTTAAATTTTCCTCTCCTTTGCAGAAAG
GTGCGTTCCTCGTAGAGAAGACATCTACCGAAGTCCAATGCAAAGGCGGGAATGTCTGCGTGCAAGCTCA
GGATCGCTATTACAATTCCTCATGCAGCAAGTGGGCATGTGTTCCCTGCAGGTGTGTGAGCAGGACCGTG
AAGCCCAACCACACCTGCACATTTAGTGGTCCTGGTGGAGGACAACAGGAGGCTTGTGAGGGAGGTGGGG
GTGGAATTCCTGGCATAGGGATTCCAGTCAGAAACACATTTGTTCATCAGCAGATGTTAACTTGATGTGT
ATGTTAGGTCAGGCACTATGCTAGGCCAAGGATATTACAATAAAGAAAACAAGCATGGGTCCTACCCTTG
TACAGGGAAAGGCAAGAAGGACCAGAGGAGGAGGAAATCAGGAGTCAGAGTATGGAGAACTTGGAAGTAG
ACAGAAGTTGGAACCATATCTTAGGGGTTCTGGGGAACCACTGAAGTCTTTTTAATAAGGAAATATCCCA
ATCAAAGCCCTTTTAAGAAAAATCTCTCAAGAGAGTCCCTGGCAAGCATGAGACCAGCTGAAGTCCAAGC
CCTGTAAGGAAGGGTTGGGCTGTCTCGCACAGAAATCCTCAAGACCCAGTGTCTGGGGATAATAATGTGT
GGTGTGAAATAGGAGGGTATTGAGGCTATACCTCTGACCAATATGGACTTACCTACCCACATTCCTTTAC
AGGGTCCGATCCTAGGATGCAACGTTGGAAAGGAAAGAAAAGTGGAAGACATTAAGGAAGAAAAATTTAA
ACTCAGGATGGAAGAGTCCCCCAAAAGCTGTCTTCTGCTTGGTTGGCTTTTTCCAGTTTTCCTAAGTTCA
TCATGACACCTTTGCTGATTTCTACATGTAAATGTTAAATGCCCGCAGAGCCAGGGAGCTAATGTATGCA
TAGATATTCTAGCATTCCACTTGGCCTTATGCTGTTGAAATATTTAAGTAATTTATGTATTTATTAATTT
ATTTCTGCATTTCACATTTGTATACCAAGATGTATTGAATATTTCATGTGCTCGTGGCCTGATCCACTGG
GACCAGGCCCTATTATGCAAATTGTGAGCTTGTTATCTTCTTCAACAGCTCTTCAATCAGGGCTGCGTAG
GTACATTAGCTTTTGTGACAACCAATAAGAACATAATATTCTGACACAAGCAGTGTTACATATTTGTGAC
CAGTAAAGACATAGGTGGTATTTGGAGACATGAAGAAGCTGTAAAGTTGACTCTGAAGAGTTTAGCACTA
GTTTCAACACCAAGAAAGACTTTTTAGAAGTGATATTGATAAGAAACCAGGGCCTTCTTTAGAAGGGTAC
CTAAATTTAAAAGAATTTTGAAAGGCTGGGTATCGGTGGTATATGCTTTTAATTCCAGCACTCAGGAGAC
CAAGGCAGGCAGATCTCTGTGAGTTTGAGGACAGCCTGGTGTACAGAGGGAGTTCCAGCACAGCCAGTGC
CACACAGAAATTCTGTCTCAAAAAC</dna_sequence>
        <protein_sequence>>gi|6680397|ref|NP_032378.1| interleukin-12 subunit beta precursor [Mus musculus]
MCPQKLTISWFAIVLLVSPLMAMWELEKDVYVVEVDWTPDAPGETVNLTCDTPEEDDITWTSDQRHGVIG
SGKTLTITVKEFLDAGQYTCHKGGETLSHSHLLLHKKENGIWSTEILKNFKNKTFLKCEAPNYSGRFTCS
WLVQRNMDLKFNIKSSSSSPDSRAVTCGMASLSAEKVTLDQRDYEKYSVSCQEDVTCPTAEETLPIELAL
EARQQNKYENYSTSFFIRDIIKPDPPKNLQMKPLKNSQVEVSWEYPDSWSTPHSYFSLKFFVRIQRKKEK
MKETEEGCNQKGAFLVEKTSTEVQCKGGNVCVQAQDRYYNSSCSKWACVPCRVRS</protein_sequence>
        <phi_function>Vaximmutor</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1121">
        <gene_name>Il2</gene_name>
        <strain>Mus musculus</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>16183</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>7110653</ncbi_protein_id>
        <gene_locus_tag>DN-144H19.3</gene_locus_tag>
        <gene_refseq>AF195954</gene_refseq>
        <protein_refseq>NP_032392</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>10090</taxonomy_id>
        <chromosome>3</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>37120712</gene_start>
        <gene_end>37125953</gene_end>
        <gene_strand>-</gene_strand>
        <protein_name>interleukin 2</protein_name>
        <protein_pi>4.63</protein_pi>
        <protein_weight>18506.61</protein_weight>
        <protein_length>169</protein_length>
        <protein_note>Also known as Il-2</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>gi|372099107:37120712-37125953 Mus musculus strain C57BL/6J chromosome 3, GRCm38 C57BL/6J
ATTTTTTTTTAGAGGAGAGCTTTATTTCTTGAAAACACTGATTAACATAGAGTTCACAGGAATAACTGAG
AAGTTATTTTAGCGCTTACTTTGTGCTGTCCTAAAAATGACAGACATCTGAGCTTATTTATATTTGAATC
ATCTAAATACTTTTATTAATGAGTCTACCTACACATGATATTTAACAATTCAATATAATAAATAATTTCA
GATAAATAGTTTAAAACATTTTTGAGCCCTTGGGGCTTACAAAAAGAATCTTTAAAGATCCATATTTATC
ATCTGAAGACTAGTAGTTACAAAAGATAGTAAACAATACATCCAAAAATAAATTAAAGTTAAATATTTAA
ATAAATAGAGAGCCTTATGTGTTGTAAGCAGGAGGTACATAGTTATTGAGGGCTTGTTGAGATGATGCTT
TGACAGAAGGCTATCCATCTCCTCAGAAAGTCCACCACAGTTGCTGACTCATCATCGAATTGGCACTCAA
ATGTGTTGTCAGAGCCCTAAAAAAGAATATAAAATTGTAGGCTAAGGTAGCTTACTTTGCATATAATTAT
TCTTCACGGAAGCTTTTAGGCATTTATTTTAACACTGGTTAAATATATTGAACATTCACATTTCTGAAAT
GATCACAATTATTGGGTTATGTTTTATTATGATATCAAATGGTAAAGCATAAAAAATAAAGCTCTCCAGA
GTTGATTACCAACGAGCATTTGATGGGAACACTGAACACTTCTGTAGAATTCAGTTGCTTGACCACTTTT
TCTCTGGTAAGTGTACACAGCTATGCATCAATTTAGGCTTCAGGAATGGAGAAATGATACTTGTTATATG
TTCTTTGCTAAATCTTAAGAGTCTATTATTCAATTCTTTCCCCCCCAAGTCAGAATGGGAACAACCCAGA
GTAGGTTAGGACAAGCATCTATTGGGGGAAATTTGGAGAATTTTGTTATAGATATACCTACCCTGATACC
AGTGTAGATGAATCACAAAGTTTGTACATGTATAAATATTATAAATTTGTTCTGTGGATTAGCTTTTTGA
AAGCTAACCCTCTTTGCTAAAGGAGATATTTTAATTCTGTTTTTAGGTGACAAGCTGAGAAGGAAATATT
TTGACAAATTTATGGGATGGCTTTTCCAAATCTGACTAATTCCTTGTAAGTCAAATGAGGCAGATTATTC
CTTTTAAATAAATACTCCTTTTCAAATAAGCTGCTGTGGTCTTATATACCCTCTTTACATAGCTACTTCA
ATATTCTAATGTCTTGAATTTTTCATTTTTAAAAATATGTGGCCCTTGAAACATTTTTCTAGTTCTCATG
TAGCTCTAAAGTTTGTACCATTCATTAGGGGTGAACTTTCTGATGTTGGCCATAGATTTTAGAGCATCCA
TCTTTGCATACGTAAGTACTCGATTTTAGAGCATCCATCTTAGCATACGTAAGTACTCACACCTTTCAAC
GTCTAGATGATGTGTATTTCAGCCTGCTTTAAAAACCTCAAATGGAAGCTGGGCAGTGGTGGTGCAGGCC
TTTAATCCCAGCACTTGGGAGGCAGAGGCAGGCGGATTTCTGAGTTCGAGGCCAGCCTGGTCTACAGAGT
GAGTTCCAGGACAGCCAGGGCTACACAGAGAAATCCTGTCTCAAAAAAACAAACAAACAAACAAACAAGA
AACAAACAAACAAAAAAAACAAAAACAAACAAAACAAAACCTCAAATGGAAACAGTGCACTGAAATGTGA
CTTTGGTTTGGAAAGGACTAGCCCACACCCTCTTGGAGGCTTGCTGCTACTGTCTCACCAGAGTCCATGA
TTCTTGTGCATTTAAAAACAAAGCTCTGCAGTGGGCTCTCCCCGTCCTGCTCTGTCCATTTTAATGGCTG
CCATTTTTGGAGAGAAATGTCTGTTTTTCTACCAATACCAGCACAACTTCTCTGGAAAAACTTTTCAGAT
AATTTTTTCTGATCTGATGAATGTAACACCAGCAAGAGTTGCTTGTTTCTTGTGGAATTCTACTCCGTGC
TTTCTCTCACATCCAGTTCTATGCTGGTGTGGAGGGAGCAGAGTGTTCATGTTCCCAGTTTCCTTGCAGG
TGATGGTAGGTGGAAATTCTAGCATCATCCTACAGTGGAAGGATTCACTTGCACAGTGACTTTAAACTTT
GGCTGACTAAATGCACAGAACCCATCAAAGACCAGAAATGGCAAGCCACTTAAAAATGCATTTCTTCTCT
ATTTTATTTCCAGATTAGCAAATAAAGCAACACCTTACCTTTAGTTTTACAACAGTTACTCTGATATTGC
TGATGAAATTCTCAGCATCTTCCAATTGAAAGCTTTTGCTTTGAGTCAAATCCAGAACATGCCGCAGAGG
TCCAAGTTCATCTTCTAGGCACTGAAGATCTTTCAATTCTGTGGCCTAGAGGAGTAATAAGCTTAACCAT
CAGCTCAGCTCACCACATACTGAAGAGCCAGAAAGTTAGTCTGCAGTCTCTCTAATCAAGAGAAGGCAGC
ACATAGCTTTTACCACTCCCTGTCCTCTGTAAAGGGGGACTGAGGTAATCGATGCCATAAATCTAGAAGA
GCAAGAGCTCACAACCATAAGGGTCACCTTGACTGTTAGGCCACTCTAGTGAGCTCTTCTGGCTTCATTA
GACTTTGTAAAAAGTCTGTGTTTCTCTACCAATGCATAGCACAAGTTCAGACTATTGTTCCAATCTACAA
AGAAATCTGCAAGGTTCACATTCTAATATCTAATCGCAGAGTTGAGAATCACAGAAGGGTAAGGGACAGG
AATCCTTGGATGCCAACTGTCATAGGCCTAAATCTTACAGATTAGGTTATCATGGCCCTGACTGAGGGGT
GTCAAGATAGCCAGGAAGACACATGTAATATTTTTTAAATTTATACTTCTCTGCAATTACTAAAGATGAG
TTTTTTAAAAACCCATATGTCAAGCTAGGAAGATGGCTTTTAAGGTAAAGGTACCTGCCACCAAACTTGA
TGATTTGAGTTCAATTGCAGTGACCCACCCACATTGTGGAAAGAATGGCCCAACTTTCATATTTCGTCTT
CTGACCTCCACAGTTACACTGTGATACACATGCACCTCCACACATACATACATACATACATACATACATA
CATACATACATACATACATACATACATAAAATGTAAAATCTATTTGTCCCAATGAAAAAAGTCATAACAT
TTTGGCAGAACACTTGGGAGAATTTTTCTGATCCATGTATGAAATAATGTTTAAATACATCATGCATACT
TACATACATATACAGGGAAAAAGGATATTGTCTAGCTCTATAGTACACTATGATTTCCATAAAGTCAGCT
GCTTTAAGTCTACAGTGAACTGTGTTATCTCCATTTTACCAAGTCTCACAATCAGTGTCTTTCCCACAAC
CACATGAACGGGGAGCAAGGGTGGCCCGGTCGGTCGGTCGCTCCTTTCATTAACCACAGCCTTTGAATTA
CATGCTTCTATTGTTTTTAAAATCTTACATACCGAATGCAGGTTAAATGAAAACATCAGCAGAATTTACC
ACATTACTCTTGTTTTCAATAATTATTTTAAAACTTAGATTTCTAGGAATTTCACCACTCTCTAAATTAA
CATGATCTCTGTTGTTTCTCTAACAATCCTTAGAGGAAGAGGTTTGACAAGATAACACGTAGTTCCTGAT
TGGTCTGCTATTGACCTTCCAACTTGTTATGGTGTGTCTTGGGTATTCAGTGTGGAGCTCCTTCCCTCAC
AGAACTCTCCAGTTTGTTACTGTGGGAGCTGAACATTATGTGACTGTAATTAAGCTGGAAGAGCAACTGG
GGCCTTTCTTTTTCATCTCCTGTAGAACAGCTAGAGGCAAAGTTCCCCTGACTCAATAGGAATGGGTCAA
CAGCTGCCTCTTTGTCCCCTTAGATCCCATTTTGCTCTAGGCTTGGATTTACTTGGGACAAGCTCTTTCT
AGGACCAAAGTTATCCATTCTCTTTTGACTTTCGGGACTAGAGCAAATTTCTACCCTTGCTGGAGTTCTA
AGAGCTTGTGTAAGCTGTTTTGTATCACACAACATTCTGCCTCCAAAGGAGACCAAAAAACCTTTCAATA
TTGAGAGATAGTATCATGTAGTAATATTACAGCTCTCTAGTTCCACTAGTTAAAAGAGACTGTATAAATC
CAAAATTGTTTTATACATCTCGGACTTCTTCTCTAGCACTAATAGTGTGTTTATGTGCTGTTGGCCAGAC
ACTGTTCTGAAACCTGACAAGTGATAAGCATAGCAATGATCATTTATGTAAGTGGGTGAATGAGCATAGA
CAACTTCCTGAGGCCATGAGAGCTAGGCCCTAGCAGGGCTGGACTCCACTGCAGATCATTGGCCCTAGAA
TCTTAACATTGGTTATGCTGCTCCTCAAAAATGCAGTCATAGGAATCATTCTTAAAACAGTAAAGTGTGT
GTAAAATGAGACCCTCTCAAGTCAATTTTTACATTTAAGAAGCTGAAATAATGCACCTCTCTCAAATATC
TGTAGGACAAGCATAAAACAGAAATCAACAGTCTTTAAATTATCCCAGCATCAAAATGCAATCATCTTGC
ATTTTCTTCTCATTCCCTTTCCCAACACATAAATACACAGGAAAAATGTAAAGAAAACCATTTAAAAGAA
GTACCATTGTCAAGATTTTTTTACAGAGAGATATCAGAGAAACTTATTTTCTTCAGATGAGGTACTATTC
ATCTGGTCACATGTTATTTACACGTTATACACATGTATGTTACTTTGAATTCATTAGAGCACCAGTTAAA
CACAGAAACTCACTCACCTGCTTGGGCAAGTAAAATTTGAAGGTGAGCATCCTGGGGAGTTTCAGGTTCC
TGTAATTCTGAGAAAGCGTAACACATTATTATTAAAGGTTATTAAACACAGCCTTTGGCAAGAAAGCTAA
AGGTATTGCCTATAGATGGGATGGCTGTGCACTTACCTCCATCCTGCTCAGGAGCTCCTGTAGGTCCATC
AACAGCTGCTCCAGGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGTGCTTCCGCTGTAGAGC
TTGAAGTGGAGCTTGAAGTGGGTGCGCTGTTGACAAGGAGCACAAGTGTCAATGTGACACAGGATGCGAG
CTGCATGCTGTACATGCCTGCAGGACTTGAGGTCACTGTGAGGAGTGATTAGCAAGGGTGAT</dna_sequence>
        <protein_sequence>>gi|7110653|ref|NP_032392.1| interleukin-2 precursor [Mus musculus]
MYSMQLASCVTLTLVLLVNSAPTSSSTSSSTAEAQQQQQQQQQQQQHLEQLLMDLQELLSRMENYRNLKL
PRMLTFKFYLPKQATELKDLQCLEDELGPLRHVLDLTQSKSFQLEDAENFISNIRVTVVKLKGSDNTFEC
QFDDESATVVDFLRRWIAFCQSIISTSPQ</protein_sequence>
        <phi_function>Vaximmutor</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene125">
        <gene_name>Il4 (interleukin 4)</gene_name>
        <strain>Mus musculus</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>16189</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>10946584</ncbi_protein_id>
        <gene_locus_tag>RP23-188H3.4</gene_locus_tag>
        <gene_refseq>NM_021283.1</gene_refseq>
        <protein_refseq>NM_021283.1</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>10090</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>IL-4, Interleukin 4</protein_name>
        <protein_pi></protein_pi>
        <protein_weight></protein_weight>
        <protein_length></protein_length>
        <protein_note></protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>gi|10946583|ref|NM_021283.1| Mus musculus interleukin 4 (Il4), mRNA
GGATCCCCGGGCAGAGCTGGGGGGGGATTTGTTAGCATCTCTTGATAAACTTAATTGTCTCTCGTCACTG
ACGGCACAGAGCTATTGATGGGTCTCAACCCCCAGCTAGTTGTCATCCTGCTCTTCTTTCTCGAATGTAC
CAGGAGCCATATCCACGGATGCGACAAAAATCACTTGAGAGAGATCATCGGCATTTTGAACGAGGTCACA
GGAGAAGGGACGCCATGCACGGAGATGGATGTGCCAAACGTCCTCACAGCAACGAAGAACACCACAGAGA
GTGAGCTCGTCTGTAGGGCTTCCAAGGTGCTTCGCATATTTTATTTAAAACATGGGAAAACTCCATGCTT
GAAGAAGAACTCTAGTGTTCTCATGGAGCTGCAGAGACTCTTTCGGGCTTTTCGATGCCTGGATTCATCG
ATAAGCTGCACCATGAATGAGTCCAAGTCCACATCACTGAAAGACTTCCTGGAAAGCCTAAAGAGCATCA
TGCAAATGGATTACTCGTAGTACTGAGCCACCATGCTTTAACTTATGAATTTTTAATGGTTTTATTTTAA
TATTTATATATTTATAATTCATAAAATAAAATATTTGTATAATGT</dna_sequence>
        <protein_sequence>>gi|10946584|ref|NP_067258.1| interleukin 4 [Mus musculus]
MGLNPQLVVILLFFLECTRSHIHGCDKNHLREIIGILNEVTGEGTPCTEMDVPNVLTATKNTTESELVCR
ASKVLRIFYLKHGKTPCLKKNSSVLMELQRLFRAFRCLDSSISCTMNESKSTSLKDFLESLKSIMQMDYS</protein_sequence>
        <phi_function>Vaximmutor</phi_function>
        <phi_annotation>IL-4 plays an important role in Th2 immune response.</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1105">
        <gene_name>Il5</gene_name>
        <strain>Mus musculus</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>16191</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>6754336</ncbi_protein_id>
        <gene_locus_tag>RP23-239O19.2</gene_locus_tag>
        <gene_refseq>AC084392</gene_refseq>
        <protein_refseq>NP_034688</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>10090</taxonomy_id>
        <chromosome>11</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>53720793</gene_start>
        <gene_end>53725102</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>interleukin 5</protein_name>
        <protein_pi>8.9</protein_pi>
        <protein_weight>14616.09</protein_weight>
        <protein_length>133</protein_length>
        <protein_note>Also known as Il-5</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>gi|372099099:53720793-53725102 Mus musculus strain C57BL/6J chromosome 11, GRCm38 C57BL/6J
GCGCTCTTCCTTTGCTGAAGGCCAGCGCTGAAGACTTCAGAGTCATGAGAAGGATGCTTCTGCACTTGAG
TGTTCTGACTCTCAGCTGTGTCTGGGCCACTGCCATGGAGATTCCCATGAGCACAGTGGTGAAAGAGACC
TTGACACAGCTGTCCGCTCACCGAGCTCTGTTGACAAGCAATGAGGTAAAGTATAACTTATTCCTTCAGC
TTTGTTTTTAAGATCAGGACCTTGCTATACCGCTCTGACTGGCCTCAAACTTGCTATGTAGGGTAGGCTG
TCCTAACCCCTACCAGATCTCCTTACCTATGTCTCCCAAATACTAGGATTACAGACACATTACCTTGCCT
GACGCTATGGTTCTTCAGAATGCATAAATAGCTGCATTTGGCCTTTAATCCCAGAACTTGGGAGGCAGGG
TCAGGTGGATCTCTGTGAGTTCAAGGCCAGACTTGTCTACGTGGCCAGTTACAGGACAGCCAGAGCTAAA
GCAAGACCCTGATTCAAAATAATTTTTTTTCAAAACAAAAAAAAAAAACCCAAACCATTTGTGGCAATTC
ATTTCTAAACATAAAGATCTGCTTTAAATAGTGCAATTATGGCTTGTTCCCTTGCCTTCTTGCTCCCGTT
CTGTCCTCTTGTCCCACTCTCTCCCCATTCCACCCCCACCATGTGCTCATGGCCCGCATCTCTACTTCTC
TACTCTCTTTCTCTCCCTCTCCCCTCCTTCTTCCTTTCCCTCTCTCTCTCCCTCTTCTTCTCCTCCTCTC
TTTCTCTCTCTCTCCCTCTCTCTCTCTCTTTCTCTCTCTCTCTGCTTTTTTCTATCTCTACTACCCTCTC
AACTCCCCTCTCCATGCCCTGAATAAGCTCTATTCTATACTAAAAAAAAAAAGTGCAATTATGAATGTGT
TAGTGTTAATGCACAGGTGATAACCCTATCACCAGCAAGCATTGCATTAAAAAAGGCAACGGACTCTCTT
TAGGATGACCCTATGATGTTCTTTCCTTTGCAGACGATGAGGCTTCCTGTCCCTACTCATAAAAATGTAA
GTTATTCTTTACTGCCGTGCTTGCATGAGTAAGTCAGCTTCGCATACTAAGCTATAAGTCATCTGCATCT
AGCTTTCTGGTGTTGTGTGTGTCTGGGATGGGGACCTCTCTAGGTCTCAAGCTCCTGGGTTCAAGTGATT
CTCTTGCCTTGATAGAGCAGCTGGGACACAGGCCTGTGCCACCACACCCAGCAGAGCTTTTGATTTCAGT
TAAACTGTTTGACTTTCTTGGAAAAGAAAATTTATGTAGGTAGATATGAAAGTTTGTGCTTATAAATAAA
AAGAATATGAGAGTGGCAAATTATGTAATCCCAGTACTTGGGAGCCAAAGGCAGGGGTAGTCTGAGTCTA
GGGCCAGCTTAGATACATTGCCCTGTATGTATCAAAAGTAAATCCTATAAATAAATAAACAAAAACATTA
GAGGGCTGGAGATATAAGCTCTGTTGATAGATGGCCTAATATGCTGGGTTGACTCTTAGCACCCCATAAA
CTAAACATGGAAGTACCTGGCTGTAATCTCATGATGGTGAAATGGAGGCGGGAAGATCATAGGTTCAAGG
TCATCCTCAGCTACATTTTTGAGCTAGAGGCCAGCCTGGGCTATGAGACACGCAAAAACCACCAGCCAAT
TAATATTAGGAATGGCTTTGAGCTAGATCTGTTATGTAAGTGGCCAGCTGGAGCTGTCAGTCATACATCT
CACAGCCTCACAAGATTCTTTGCATGGCGAGAGGTCCTGCTGGGCTCCCTTTGGCTCTGTCCATGGCTCT
CTTCATCCTAGTGCCTCTCTTTGTTTTCCTTGTCTTATTTCTTACTGCTGAGGATCAAGCCCAGGGCCTT
CAGTGTGTGAAGTGAGCACTCTACCACTGAATTCCAGAGCCCGCCCACTCTAATGCCTTTCTGAAAGTAT
TAAGAGTTTAGGGTTATATATTCCTTTTGTTTATTTTATGTGTATGAGCATTTTGCCTGCATATATATAT
ATATATATATATATATATGTGTGTGTGTGTGTGTGTGTGTGTGTATATATATATGTATGTATGTATGTAT
GTATGTATGTATGTATATGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTTCCACGTATGTGTCTATGTG
TCTGGTGTTCCTGAAGGCTAAAAGAAGGGCATCAGATCACCTGGGGCTGGATATGCAGATGGTTGTGAGC
CAACCATCTGGATGCTGGGAACTGCATCAAGTGTTCTTAACCACTGAGCCATCTCTCCCGCTCAGAGGGT
TATATTCTTAGGTAATGATAGAAAGACATAAAAATATCATGAATGCCTTTATTAATAATTTCTAAACAGT
TTAATGAATATGACTATGTAGTGATATTGTATACATTTCAATATTATCTTATTCTAGCGTAAAGTACATT
ATTTAACTTTTTCTAAATAGAAGAAAATTCATCAGCCTAAATTTCAAAAGAAAATATTAATATGGGTGTG
GTACCACTCACCTTTAATCCAGATGGTTGTGAGCCACCACAAGGGTGCTGGTAACTGAACCCAGGTCCTC
TGGAAGAGGACCCAGTGATCTTAACCACTGAGCCATCTCCCCAGCCCCAATCCTAACTTTGGGTTCATTT
TTTTGAAATGATCTCATGTAGCACTAGCTGGCCTCAAACTCTATGTATCAGAGGCTGGCCTTCAACTCCT
GATCCTCTTACCTCAACTTCCTGAATGCTGGCATTACAGATAAGCACCATCACATCTTGTATTGTCTGGG
GTTTTTTATTGATGCATTTAAATTGCATGTATTTATTGCATATGGCATGATATTTCAAAATATGTGTACG
TTGTGGGCAGTCTGATCTATTTGCTTCTTGATAATCTTCTTTCAGCACCAGCTATGCATTGGAGAAATCT
TTCAGGGGCTAGACATACTGAAGAATCAAACTGTCCGTGGGGGTACTGTGGAAATGCTATTCCAAAACCT
GTCATTAATAAAGAAATACATTGACCGCCAAAAAGTAAGTTCCCCAGGGACCCTGTGAATCCGGCTGCAG
CTGGTTCTCCAGGAGCCAACCTGACAGTCTGTTCTTTTCACAGGAGAAGTGTGGCGAGGAGAGACGGAGG
ACGAGGCAGTTCCTGGATTACCTGCAAGAGTTCCTTGGTGTGATGAGTACAGAGTGGGCAATGGAAGGCT
GAGGCTGAGCTGCTCCATGGTGACAGGACTTCACAATTTAAGTTAAATTGTCAACAGATGCAAAAACCCC
ACAAAACTGTGCAAATGCAAGGGATACCATATGCTGTTTCCATTTATATTTATGTCCTGTAGTCAGTTAA
ACCTATCTATGTCCATATATGCAAAGTGTTTAACCTTTTTGTATACGCATAAAAGAAATTCCTGTAGCGC
AGGCTGGCCTCAAACTGGTAATGTAGCCAAGGATAACCTTGAATTTCTGATCCTCCTGCCTCCTCTTCCT
GAAGGCTGAGGTTACAGACATGCACCATTGCCACTAGTTCATGAAGTGCTGGAGATGGAACCCAAGGCTT
TGTGCATGTTACCAACTGAGTTATACTCCCTCCCCCTCATCCTCTTCGTTGCATCAGGGTCTCAAGTATT
CCAGGCTGACTTTGAACTCAGTGTGTAGCCAAGGGTGACCCTGAACTCTTGGTCCAGATGGACGCAGGAG
GATCACATACCCAACCTTAGCATCCTTTCTCCTAGCCCCTTTAGATAGATGATACTTAATGACTCTCTTG
CTGAGGGATGCCACACCGGGGCTTCCTGCTCCTATCTAACTTCAATTTAATACCCACTAGTCAATCTCTC
CTCAACTCCCTGCTACTCTCCCCAAACTCTAGTAAGCCCACTTCTATTTCTTGGGGAGAGAGAAGGTTGA
CTTTTCTTATGTCCTATGTATGAATCAGACTGTGCCATGACTGTGCCTCTGTGCCTGGAGCAGCTGGATT
TTGGAAAAGAAAAGGGACATCTCCTTGCAGTGTGAATGAGAGCCAGCCACATGCTGGGCCTTACTTCTCC
GTGTAACTGAACTTAAGAAGCAAAGTAAATACCACAACCTTACTACCCCATGCCAACAGAAAGCATAAAA
TGGTTGGGATGTTATTCAGGTATCAGGGTCACTGGAGAAGCCTCCCCCAGTTTACTCCAGGAAAAACAGA
TGTATGCTTTTATTTAATTCTGTAAGATGTTCATATTATTTATGATGGATTCAGTAAGTTAATATTTATT
ACAACGTATATAATATTCTAATAAAGCAGAAGGGACAACT</dna_sequence>
        <protein_sequence>>gi|6754336|ref|NP_034688.1| interleukin-5 precursor [Mus musculus]
MRRMLLHLSVLTLSCVWATAMEIPMSTVVKETLTQLSAHRALLTSNETMRLPVPTHKNHQLCIGEIFQGL
DILKNQTVRGGTVEMLFQNLSLIKKYIDRQKEKCGEERRRTRQFLDYLQEFLGVMSTEWAMEG</protein_sequence>
        <phi_function></phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1677">
        <gene_name>L7/L12</gene_name>
        <strain>Brucella abortus RB51-AHVLA</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>479804332</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:100102</xrefs>
        <taxonomy_id>1198700</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>50S ribosomal protein L7/L12</protein_name>
        <protein_pi>4.62</protein_pi>
        <protein_weight>12562.32</protein_weight>
        <protein_length>198</protein_length>
        <protein_note>vaccine strain</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>ENT73302.1 50S ribosomal protein L7/L12 [Brucella abortus RB51-AHVLA]
MADLAKIVEDLSALTVLEAAELSKLLEEKWGVSAAAPVAVAAAGGAAPAAAAEEKTEFDVVLADGGANKI
NVIKEVRALTGLGLKEAKDLVEGAPKAVKEGASKDEAEKIKAQLEAAGAKVELK

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1000">
        <gene_name>manA</gene_name>
        <strain>Brucella melitensis bv. 1 str. 16M</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>260563601</ncbi_protein_id>
        <gene_locus_tag>BAB1_0562</gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:32765
CDD:29324</xrefs>
        <taxonomy_id>224914</taxonomy_id>
        <chromosome>I</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>550431</gene_start>
        <gene_end>551708</gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>ManA family protein</protein_name>
        <protein_pi></protein_pi>
        <protein_weight></protein_weight>
        <protein_length>390</protein_length>
        <protein_note>N-acyl-D-glucosamine 2-epimerase [Carbohydrate transport and metabolism]</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>gi|82698932:550431-551708 Brucella melitensis biovar Abortus 2308 chromosome chromosome I, complete sequence
AATGAATGATGTGATACGTAAACTTCAGGTGGAAGTGGAGCGCTTATCGTCGTGGCTCCACAACGACGCT
TTGCCTCTTTGGTTGTCAGCCGGTGTGGATGCGCCGAATAGCGGTTTCTTTGAACGTATTGGACAGGACG
GCGTCGCAACGGATGCGGATAATCGTCGTTCTCGCGTGCATCCGAGACAGATCTACTGTTTCGCCAAGGC
TGGCGCCATGGGCTGGCAAGGCGAATGGAAGCAGACGGTTGAAGCCGGAATAGAATATTATGATCGCGTC
TATCGGCGAGAAGATGGTTTCTATGGCAGTCTTGCCGGTCAAAGTGGCAAGATGATTGATCACACGTTTG
ATCTCTACAATCAGGCTTTTTCCGTTTTTGCGGCCGCCCAGATCGCGGTTTCCATACCGGATCGGTTTGA
TGAAATGCGTCAGCGAGCGCTTGGTTTGATGAATACGCTCGTGGCAGATTATCACCACCCTCTCGGTGGA
TTTGAGGAAGCCAACCCGCCAAAGCTTCCCTTGTGTTCAAATCCGCACATGCATTTGTTTGAAGCAATGC
TTGCCTGGGAGACTGTCGATCCAGAAACCCAGTTCTGGTCCACATATGCCGATGAGATCGCAAATCTTGC
CTTAACGAAATTCATCGATGGCAAGACCGGTGCGTTGCGTGAATTCTTCGATCACGATTGGAAACCTTAT
CCGGGTGACAAGGGGAGGGTGGTCGAACCAGGACATCAATTCGAATGGTCCTGGCTGATGGGCCAATGGG
CGGACCGACGGCAGAATGGCGATGGCATGATGGCCGCCAAGCGTCTATTCCAGATTGCAGTGGATCGTGG
TGTATGCGAGCAGCGCAAAGTTGCCATCATGAGCTTGTATGATGATTTTTCGGTTCACGACAGTCTGGCC
CGTCTCTGGCCGCAAACTGAATGGATAAAGTCGGCTCTGTTATTTGCTTCTTTGAGCAAGGACGAAGAGC
GAGTTTACTATCTGCAATCCGCATTGCGTGCCATTGACGCCCTACGGCCATTTCTTGAAACGCCAATCAA
AGGCTTATGGTACGACAAGTGGCCGGAAGGTGGTACGCTTATCGATGAGCCCGCGCCGGCATCGACCTTT
TATCATATTCTCTGTGCCTGTTATGAAGCAGAGAAAACAATATCAGAGCTTTATGTTGTGGTGTCGAATT
TTTGGTTGTCGCCGCTGATGATGACGATCAGATGTGCCGATGATGCCGCATCTGTATTGGAGAAACATGC
GAGTTCTTCATTTTTTTA</dna_sequence>
        <protein_sequence>>gi|260563601|ref|ZP_05834087.1| ManA family protein [Brucella melitensis bv. 1 str. 16M]
MNDVIRKLQVEVERLSSWLHNDALPLWLSAGVDAPNSGFFERIGQDGVATDADNRRSRVHPRQIYCFAKA
GAMGWQGEWKQTVEAGIEYYDRVYRREDGFYGSLAGQSGKMIDHTFDLYNQAFSVFAAAQIAVSIPDRFD
EMRQRALGLMNTLVADYHHPLGGFEEANPPKLPLCSNPHMHLFEAMLAWETVDPETQFWSTYADEIANLA
LTKFIDGKTGALREFFDHDWKPYPGDKGRVVEPGHQFEWSWLMGQWADRRQNGDGMMAAKRLFQIAVDRG
VCEQRKVAIMSLYDDFSVHDSLARLWPQTEWIKSALLFASLSKDEERVYYLQSALRAIDALRPFLETPIK
GLWYDKWPEGGTLIDEPAPASTFYHILCACYEAEKTISEL</protein_sequence>
        <phi_function>Virmugen</phi_function>
        <phi_annotation>Unmarked rough B. abortus and B. melitensis deletion mutants of manBA (including manA and manB) were attenuated. These mutants provided protection against virulent Brucella challenge in mice [Ref700:Kahl-McDonagh and Ficht, 2006].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene999">
        <gene_name>manB</gene_name>
        <strain>Brucella melitensis bv. 1 str. 16M</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>1198671</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>17989244</ncbi_protein_id>
        <gene_locus_tag>BMEII0899</gene_locus_tag>
        <gene_refseq>AE008918</gene_refseq>
        <protein_refseq>NP_541877</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>224914</taxonomy_id>
        <chromosome>II</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>940999</gene_start>
        <gene_end>942432</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>phosphomannomutase</protein_name>
        <protein_pi>6.8</protein_pi>
        <protein_weight>47237.87</protein_weight>
        <protein_length>477</protein_length>
        <protein_note>5.4.2.8</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>gi|17988344:940999-942432 Brucella melitensis bv. 1 str. 16M chromosome II, complete sequence
CATGAGCAGCAATTCCCTCAAATTTGGCACGAGCGGCCTTCGCGGGCTGGCGGTAGAACTGAACGGCCTG
CCCGCCTATGCCTATACGATGGCCTTTGTGCAGATGCTTGCTGCAAAAGGGCAGTTGCAGAAGGGCGACA
AGGTGTTTGTCGGCAGGGATTTGCGCCCCTCCAGCCCTGATATTGCAGCCCTTGCCATGGGTGCCATCGA
AGATGCCGGCTTCACACCGGTCAATTGCGGCGTCCTGCCCACGCCTGCGCTGAGCTATTATGCGATGGGC
GCGAAAGCACCCAGCATCATGGTCACGGGAAGCCATATTCCAGATGATCGCAACGGGCTGAAATTCTATC
GCCGCGACGGTGAAATCGACAAGGATGATGAGGCGGCAATCAGTGCAGCCTATCGCAAGCTGCCTGCCAT
TCTCGCTGCCCGCAAACATGTCGGCTCCACCGAAACCGATGCGGCCTTGCAGGCTTATGCCGATCGCTAT
GCAGGTTTTCTTGGGAAAGGGAGCCTGAATGGCCTGCGGGTCGGCGTTTATCAACATTCTTCCGTGGCGC
GCGATCTTCTGATGTACCTGCTCACGACACTCGGCGTGGAACCCGTGGCGCTCGGACGATCCGATATATT
CGTGCCGGTCGATACCGAGGCATTGCGCCCCGAAGACATTGCGCTGCTTGCCCAATGGGGCAAAAGCGAC
AGGCTTGATGCCATCGTCTCCACCGACGGAGACGCGGATCGCCCGCTGATTGCCGATGAGCATGGACAAT
TCGTTCGCGGCGATCTTGCTGGCGCCATCACCGCCACATGGGTGGGGGCGGATACGCTCGTCACGCCAGT
CACCTCCAACACCGCATTGGAAAGCCGCTTTCCCAAGGTTTTGAGAACGCGCGTCGGTTCGCCTTATGTC
ATCGCAAGCATGGCACAGGTATCCACGGGCAATTCCGGCCCGGTCATCGGGTTTGAGGCCAATGGCGGCG
TTCTGCTTGGCAGCACGGTCGAGAGGAATGGACGAAGCCTGACGGCCCTGCCGACGCGCGACGCCTTGTT
GCCCATTCTGGCTTGCCTTGCCACGGTTCACGAAAAGAAAACGCCGCTTTCAACAATCGCCCGGTCCTAT
GGCTTCCGCGTCGCGCTTAGCGACCGGCTGCAAAACATTCCGCAGGAGGCGAGCACCGCCTTCCTCGCGC
TCTTGGAGGATGCGGATAAACGCGCCTCGCTCTTTCCTGCTGGCGACGCAATCGTGCGGGTGGAAACCAT
CGACGGCGTGAAGCTTTTCTTTCAATCAGGCAATGCGGTTCATTATCGGGCATCGGGCAATGCGCCGGAA
CTGCGCTGCTATGTGGAATCTTCGGATGACACACAAGCCGCCAAGCTTCAGGCGCTTGGCTTGGAAATCG
CACGCAAAGCACTAAAGGATGCGACGAGGCCATG</dna_sequence>
        <protein_sequence>>gi|17989244|ref|NP_541877.1| phosphomannomutase [Brucella melitensis bv. 1 str. 16M]
MSSNSLKFGTSGLRGLAVELNGLPAYAYTMAFVQMLAAKGQLQKGDKVFVGRDLRPSSPDIAALAMGAIE
DAGFTPVNCGVLPTPALSYYAMGAKAPSIMVTGSHIPDDRNGLKFYRRDGEIDKDDEAAISAAYRKLPAI
LAARKHVGSTETDAALQAYADRYAGFLGKGSLNGLRVGVYQHSSVARDLLMYLLTTLGVEPVALGRSDIF
VPVDTEALRPEDIALLAQWGKSDRLDAIVSTDGDADRPLIADEHGQFVRGDLAGAITATWVGADTLVTPV
TSNTALESRFPKVLRTRVGSPYVIASMAQVSTGNSGPVIGFEANGGVLLGSTVERNGRSLTALPTRDALL
PILACLATVHEKKTPLSTIARSYGFRVALSDRLQNIPQEASTAFLALLEDADKRASLFPAGDAIVRVETI
DGVKLFFQSGNAVHYRASGNAPELRCYVESSDDTQAAKLQALGLEIARKALKDATRP</protein_sequence>
        <phi_function>Virmugen</phi_function>
        <phi_annotation>Mutants manB and manA were attenuated in Brucella melitensis and provided protection against challenge in mice's livers [Ref694:Kahl-McDonagh et al., 2007].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1084">
        <gene_name>mucR</gene_name>
        <strain>Brucella melitensis bv. 1 str. 16M</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>1197075</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>17987647</ncbi_protein_id>
        <gene_locus_tag>BMEI1364</gene_locus_tag>
        <gene_refseq>AE008917</gene_refseq>
        <protein_refseq>NP_540281</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>224914</taxonomy_id>
        <chromosome>I</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>1417768</gene_start>
        <gene_end>1418253</gene_end>
        <gene_strand>-</gene_strand>
        <protein_name>transcriptional regulatory protein MUCR</protein_name>
        <protein_pi>9.56</protein_pi>
        <protein_weight>16771.01</protein_weight>
        <protein_length>161</protein_length>
        <protein_note></protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>gi|17986284:1417768-1418253 Brucella melitensis bv. 1 str. 16M chromosome chromosome I, complete sequence
ATCAGGCGTCCTTCGGCTTGCGGCCGAGGCCCATCTTCTTGGCAAGGCGCGAGCGCGCTGCAGCATAGTT
CGGAGCAACCATAGGATAGTTCGGATCGAGATCCCACTTTTCGCGGTACTGCTCAGGCGTCATGTTGTAA
TGGGTCACCAGGTGACGCTTCAGCGACTTGAACTTCTTGCCGTCTTCAAGGCAGACAATATAGTCGTCAT
GAACAGACTTCTTCGGGTTCACCGCTGGCTTCGGCTTTTCAACAACGACCGGGGCCTCTTCGCGTTCGAC
GTGGCGCTTGAAAGCAGCATGAACTTCAGCAATCAGAACCGGGAGTTCGCCTGCACGAATGGAATTATTG
CCGACATAGGCTGCAACGACATCGGCGGTCAAACTCAAAAGCAGCTCGGTGCTTTCGTCGTTCGTTTCCA
GATTTTCCATAAGTTTTCCTTTTTTAATTTTTTGTTGTCCGCGCAGCGGCTGACAATGGCAACCCA</dna_sequence>
        <protein_sequence>>gi|17987647|ref|NP_540281.1| transcriptional regulatory protein MUCR [Brucella melitensis bv. 1 str. 16M]
MGCHCQPLRGQQKIKKGKLMENLETNDESTELLLSLTADVVAAYVGNNSIRAGELPVLIAEVHAAFKRHV
EREEAPVVVEKPKPAVNPKKSVHDDYIVCLEDGKKFKSLKRHLVTHYNMTPEQYREKWDLDPNYPMVAPN
YAAARSRLAKKMGLGRKPKDA</protein_sequence>
        <phi_function>Virmugen</phi_function>
        <phi_annotation>A mucR mutant has a significantly reduced degree of colonization in mice and protects against wild type B. melitensis 16M [Ref2071:Arenas-Gamboa et al., 2011].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene260">
        <gene_name>Omp16</gene_name>
        <strain>Brucella abortus 2308</strain>
        <vo_id>VO_0010973</vo_id>
        <ncbi_gene_id>3788229</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>489056820</ncbi_protein_id>
        <gene_locus_tag>BAB_RS24085</gene_locus_tag>
        <gene_refseq>AM040264</gene_refseq>
        <protein_refseq>WP_002966947</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>359391</taxonomy_id>
        <chromosome>I</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>1654432</gene_start>
        <gene_end>1654938</gene_end>
        <gene_strand>-</gene_strand>
        <protein_name>hypothetical protein</protein_name>
        <protein_pi>10.24</protein_pi>
        <protein_weight>17438.15</protein_weight>
        <protein_length>168</protein_length>
        <protein_note></protein_note>
        <protein_annotation>Synonyms: Omp16, MotY</protein_annotation>
        <dna_sequence>>NC_007618.1:1654432-1654938 Brucella melitensis biovar Abortus 2308 chromosome I, complete sequence, strain 2308
TTTACCGTCCGGCCCCGTTGAGAACGGTGACGGCGCGACGGTTCTGCGACCAGCATGTGTCGGCATCGCA
GACGGCAACCGGGCGCTCATTACCGTAGGAAATGGTGCGCATGCGGTTGGTCGGCACACCGCGCGAAGCG
AGGAAGTCGCGGGTGGCGGCAGCACGGCGCTGGCCAAGGGCGAGGTTGTACTCACGCGTGCCGCGCTCGT
CGGCATGGCCTTCGATCGTGATCGAATACTGCGGATAACGCTGCAACCACTGGGCCTGCTTGGAAAGCGT
CTGCTGCGCATCGGCGCGGATCAGCGACGAATCGAGATCGAAGAAGATGCGGTCGCCGACATTAACGGTG
AAGTCCTGCGAGGAGCCCGGCGTTGCAGCGCCTGCACCGAGACCCAGATCACCGGCATTATTCGGAAGGT
TCTTCTTTGACGCACAGCCGGCAACGGCGAGCGACATGAAAAGCGCAATAGCGATCGGGCTACGTGCAAT
CGACTGGATACGGCGCA

</dna_sequence>
        <protein_sequence>>WP_002966947.1 MULTISPECIES: hypothetical protein [Brucella]
MRRIQSIARSPIAIALFMSLAVAGCASKKNLPNNAGDLGLGAGAATPGSSQDFTVNVGDRIFFDLDSSLI
RADAQQTLSKQAQWLQRYPQYSITIEGHADERGTREYNLALGQRRAAATRDFLASRGVPTNRMRTISYGN
ERPVAVCDADTCWSQNRRAVTVLNGAGR

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>Brucella Omp16 is a protective antigen [Ref864:Pasquevich et al., 2009].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1678">
        <gene_name>omp16</gene_name>
        <strain>Brucella abortus RB51-AHVLA</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>479804733</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:225439
CDD:143586</xrefs>
        <taxonomy_id>1198700</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>outer membrane lipoprotein omp16</protein_name>
        <protein_pi>10.24</protein_pi>
        <protein_weight>18331.05</protein_weight>
        <protein_length>247</protein_length>
        <protein_note>vaccine strain</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>ENT73703.1 outer membrane lipoprotein omp16 [Brucella abortus RB51-AHVLA]
MRRIQSIARSPIAIALFMSLAVAGCASKKNLPNNAGDLGLGAGAATPGSSQDFTVNVGDRIFFDLDSSLI
RADAQQTLSKQAQWLQRYPQYSITIEGHADERGTREYNLALGQRRAAATRDFLASRGVPTNRMRTISYGN
ERPVAVCDADTCWSQNRRAVTVLNGAGR

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene253">
        <gene_name>Omp25</gene_name>
        <strain>Brucella melitensis bv. 1 str. 16M</strain>
        <vo_id>VO_0010966</vo_id>
        <ncbi_gene_id>1196960</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>17987532</ncbi_protein_id>
        <gene_locus_tag>BMEI1249</gene_locus_tag>
        <gene_refseq>AE008917</gene_refseq>
        <protein_refseq>NP_540166</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>224914</taxonomy_id>
        <chromosome>I</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>1297524</gene_start>
        <gene_end>1298165</gene_end>
        <gene_strand>-</gene_strand>
        <protein_name>hypothetical protein</protein_name>
        <protein_pi>9.03</protein_pi>
        <protein_weight>21696.72</protein_weight>
        <protein_length>213</protein_length>
        <protein_note></protein_note>
        <protein_annotation>Reference: http://www.ncbi.nlm.nih.gov/pubmed/17049676</protein_annotation>
        <dna_sequence>>NC_003317.1:1297524-1298165 Brucella melitensis bv. 1 str. 16M chromosome I, complete sequence
ATTAGAACTTGTAGCCGATGCCGACGCGGAAATCCTGCGTGTCCAGCTTGTTGCGAACAGTCGTACCGGC
CAGATCATAGTTCTTGTTGCCGTACTGGGTGTAACGGTACTCAACGCGGCCGAGGATGTTGTCCGTCAGC
TTGGCTTCGAGACCGGCACCAGCCGTCCAACCCACGCGGAACTTGCTTTCGTCGTCCAAGCCGTTGTTAA
GCTTGATCTGCGAACCGGCAATACCAGCCGTGAGGTACGGCATAACCGGGTTCAGGTCGTAGCCAACGCG
GGCACGCAGCGAGCCTTCAAAGCCCTGCTTGACTTCCAGGCCGTCCTTGGACTTCTTGGCCCAGGAATAA
CCTGCATCACCTTCAACACCGTATACGATCTGGTCCTGCTGGAAGTTCCAGCCAGCAAAGGCGCCAGCCT
TCCAATCGTCAGGCTTGATGCTGCCAACGGTGCTGGTCTTGGCCTTGTTCCAGCCGTAGCCAAGGTAAAG
ACCGGTATAGCCACCAGCCCAGCTATACTGGGGAGCTACTTCAACCGGAGCCGGAACCGGAGGCTGTTCC
TGGATGGCGTCGGCAGCAAAAGCGGTCGCAGAGAACGGCAGCAACGCAGCCGAGACGATTACGAGAGACT
TAAGAGTGCGCA

</dna_sequence>
        <protein_sequence>>NP_540166.1 hypothetical protein BMEI1249 [Brucella melitensis bv. 1 str. 16M]
MRTLKSLVIVSAALLPFSATAFAADAIQEQPPVPAPVEVAPQYSWAGGYTGLYLGYGWNKAKTSTVGSIK
PDDWKAGAFAGWNFQQDQIVYGVEGDAGYSWAKKSKDGLEVKQGFEGSLRARVGYDLNPVMPYLTAGIAG
SQIKLNNGLDDESKFRVGWTAGAGLEAKLTDNILGRVEYRYTQYGNKNYDLAGTTVRNKLDTQDFRVGIG
YKF

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>Brucella Omp25 is a protective antigen [Ref863:Commander et al., 2007].</phi_annotation>
        <phi_function2>Virmugen</phi_function2>
        <phi_annotation2>A omp25 mutant is attenuated and provides protection against challenge in mice [Ref1946:Edmonds et al., 2002].</phi_annotation2>
    </gene>
	<gene gene_id="gene231">
        <gene_name>Omp31</gene_name>
        <strain>Brucella abortus 2308</strain>
        <vo_id>VO_0010939</vo_id>
        <ncbi_gene_id>3788834</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>489054549</ncbi_protein_id>
        <gene_locus_tag>BAB_RS23735</gene_locus_tag>
        <gene_refseq>AM040264</gene_refseq>
        <protein_refseq>WP_002964719</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>359391</taxonomy_id>
        <chromosome>I</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>1583642</gene_start>
        <gene_end>1584427</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>membrane protein</protein_name>
        <protein_pi>4.74</protein_pi>
        <protein_weight>25591.47</protein_weight>
        <protein_length>261</protein_length>
        <protein_note></protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_007618.1:1583642-1584427 Brucella melitensis biovar Abortus 2308 chromosome I, complete sequence, strain 2308
CATGTTTAGCTTAAAAGGGACTGTTATGAAAACCGCACTTCTTGCATCCGTCGCAATGTTGTTCACAAGC
TCGGCTATGGCTGCCGACATCATCGTTGCTGAACCGGCACCCGTTGCAGTCGACACGTTCTCTTGGACTG
GCGGCTATATTGGTATCAATGCTGGTTACGCTGGCGGCAAGTTCAAGCATCCGTTCTCAGGCATCGAGCA
GGATGGGGCCCAAGATTTTTCAGGTTCGCTCGACGTCACGGCCAGCGGCTTTGTTGGCGGCGTTCAGGCC
GGTTATAACTGGCAGCTTGCCAACGGCCTCGTGCTTGGTGGCGAAGCTGACTTCCAGGGCTCGACGGTTA
AGAGCAAGCTTGTTGACAACGGTGACCTCTCCGATATCGGCGTTGCAGGCAACCTCAGCGGCGACGAAAG
CTTCGTCCTCGAGACCAAGGTTCAGTGGTTTGGAACGGTGCGTGCGCGCCTCGGCTTCACCCCGACTGAA
CGCCTGATGGTCTATGGTACCGGTGGTTTGGCCTATGGTAAGGTCAAGACGTCGCTTAGCGCCTATGACG
ATGGTGAATCGTTCAGCGCCGGAAACTCTAAGACCAAGGCTGGCTGGACGCTTGGTGCAGGTGTAGAATA
CGCCGTCACCAACAATTGGACCCTGAAGTCGGAATACCTCTACACCGACCTCGGCAAGCGTTCCTTCAAT
TACATTGATGAAGAAAACGTCAATATTAACATGGAAAACAAGGTGAACTTCCACACCGTCCGCCTCGGTC
TGAACTACAAGTTCTA

</dna_sequence>
        <protein_sequence>>WP_002964719.1 MULTISPECIES: porin family protein [Brucella]
MFSLKGTVMKTALLASVAMLFTSSAMAADIIVAEPAPVAVDTFSWTGGYIGINAGYAGGKFKHPFSGIEQ
DGAQDFSGSLDVTASGFVGGVQAGYNWQLANGLVLGGEADFQGSTVKSKLVDNGDLSDIGVAGNLSGDES
FVLETKVQWFGTVRARLGFTPTERLMVYGTGGLAYGKVKTSLSAYDDGESFSAGNSKTKAGWTLGAGVEY
AVTNNWTLKSEYLYTDLGKRSFNYIDEENVNINMENKVNFHTVRLGLNYKF

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1054">
        <gene_name>omp31</gene_name>
        <strain>Brucella melitensis ATCC 23457</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>7676420</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>225853091</ncbi_protein_id>
        <gene_locus_tag>BMEA_A1674</gene_locus_tag>
        <gene_refseq>CP001488</gene_refseq>
        <protein_refseq>YP_002733324</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>546272</taxonomy_id>
        <chromosome>I</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>1588634</gene_start>
        <gene_end>1589242</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>outer membrane protein Omp31</protein_name>
        <protein_pi>4.8</protein_pi>
        <protein_weight>20497.92</protein_weight>
        <protein_length>202</protein_length>
        <protein_note></protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>gi|225851546:1588634-1589242 Brucella melitensis ATCC 23457 chromosome chromosome I, complete sequence
TGTGTTGCAATATAGTGACAGACATTGGAGCCCATATTGGGCCCAAGATTTTTCAGGTTCGCTCGACGTC
ACGGCCAGCGGCTTTGTTGGCGGCGTTCAGGCCGGTTATAACTGGCAGCTTGCCAACGGCCTCGTGCTTG
GTGGCGAAGCTGACTTCCAGGGCTCGACGGTTAAGAGCAAGCTTGTTGACAACGGTGACCTCTCCGATAT
CGGCGTTGCAGGCAACCTCAGCGGCGACGAAAGCTTCGGCCTCGAGACCAAGGTTCAGTGGTTTGGAACG
GTGCGTGCGCGCCTCGGCTTCACCCCGACTGAACGCCTGATGGTCTATGGTACCGGTGGTTTGGCCTATG
GTAAGGTCAAGACGTCGCTTAGCGCCTATGACGATGGTGAATCGTTCAGCGCCGGAAACTCTAAGACCAA
GGCTGGCTGGACGCTTGGTGCAGGTGTAGAATACGCCGTCACCAACAATTGGACCCTGAAGTCGGAATAC
CTCTACACCGACCTCGGCAAGCGTTCCTTCAATTACATTGATGAAGAAAACGTCAATATTAACATGGAAA
ACAAGGTGAACTTCCACACCGTCCGCCTCGGTCTGAACTACAAGTTCTA</dna_sequence>
        <protein_sequence>>gi|225853091|ref|YP_002733324.1| outer membrane protein Omp31 [Brucella melitensis ATCC 23457]
MLQYSDRHWSPYWAQDFSGSLDVTASGFVGGVQAGYNWQLANGLVLGGEADFQGSTVKSKLVDNGDLSDI
GVAGNLSGDESFGLETKVQWFGTVRARLGFTPTERLMVYGTGGLAYGKVKTSLSAYDDGESFSAGNSKTK
AGWTLGAGVEYAVTNNWTLKSEYLYTDLGKRSFNYIDEENVNINMENKVNFHTVRLGLNYKF</protein_sequence>
        <phi_function>Virmugen</phi_function>
        <phi_annotation>A omp31 mutant in Brucella melitensis was attenuated and provided protection against challenge in mice [Ref1988:Cloeckaert et al., 2004].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1609">
        <gene_name>omp31</gene_name>
        <strain>Brucella melitensis bv. 1 str. 16M</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>61229373</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:226163</xrefs>
        <taxonomy_id>224914</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>31 kDa outer-membrane immunogenic protein</protein_name>
        <protein_pi>5.06</protein_pi>
        <protein_weight>24732.46</protein_weight>
        <protein_length>343</protein_length>
        <protein_note>biovar: 1 str. 16M</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>sp|P0A3U4.1|OM31_BRUME RecName: Full=31 kDa outer-membrane immunogenic protein; Flags: Precursor
MKSVILASIAAMFATSAMAADVVVSEPSAPTAAPVDTFSWTGGYIGINAGYAGGKFKHPFSSFDKEDNEQ
VSGSLDVTAGGFVGGVQAGYNWQLDNGVVLGAETDFQGSSVTGSISAGASGLEGKAETKVEWFGTVRARL
GYTATERLMVYGTGGLAYGKVKSAFNLGDDASALHTWSDKTKAGWTLGAGAEYAINNNWTLKSEYLYTDL
GKRNLVDVDNSFLESKVNFHTVRVGLNYKF

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene113">
        <gene_name>ORF</gene_name>
        <strain></strain>
        <vo_id>VO_0010927</vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id>599653</ncbi_nucleotide_id>
        <ncbi_protein_id>599654</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq>CAA86936.1</protein_refseq>
        <pdb_id>1DI0</pdb_id>
        <xrefs>CDD:237096
CDD:187741
GOA:P61711
InterPro:IPR002180
PDB:1DI0
PDB:1T13
PDB:1XN1
UniProtKB/Swiss-Prot:P61711</xrefs>
        <taxonomy_id>235</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name></protein_name>
        <protein_pi>7.41</protein_pi>
        <protein_weight>16119.15</protein_weight>
        <protein_length>197</protein_length>
        <protein_note>riboflavin synthase subunit beta; Provisional</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>gi|599653|emb|Z46864.1| B.abortus gene for open reading frame
GAATTCCGATCAGTGCATAGTTTCCGCGTGCTCGCGCAATGGTGCGCGGGCTTGTTCTCGGGGCGGGGTG
AAACTCCCCACCGGCGGTATGAAAAGCAATTTTCAAGCCCGCGAGCGCCTGAAATGGAAGCCGATTCGCA
TGCCATTTCAGGGTCAGCAGATCCGGTGAGATGCCGGAGCCGACGGTTAAAGTCCGGATGGAAGAGAGCG
AATGAGCGTCACGATTGCGCCTTCCGGCGTCGTTCTTGCGTTCTTTTGTGCGCCCTGATTCTAGTTTCGT
GAGGAACCTATGAACCAAAGCTGTCCGAACAAGACATCCTTTAAAATCGCATTCATTCAGGCCCGCTGGC
ACGCCGACATCGTTGACGAAGCGCGCAAAAGCTTTGTCGCCGAACTGGCCGCAAAGACGGGTGGCAGCGT
CGAGGTAGAGATATTCGACGTGCCGGGTGCATATGAAATTCCCCTTCACGCCAAGACATTGGCCAGAACC
GGGCGCTATGCAGCCATCGTCGGTGCGGCCTTCGTGATCGACGGCGGCATCTATCGTCATGATTTCGTGG
CGACGGCCGTTATCAACGGCATGATGCAGGTGCAGCTTGAAACGGAAGTGCCGGTGCTGAGCGTCGTGCT
GACGCCGCACCATTTCCATGAAAGCAAGGAGCATCACGACTTCTTCCATGCTCATTTCAAGGTGAAGGGC
GTGGAAGCGGCCCATGCCGCCTTGCAGATCGTGAGCGAGCGCAGCCGCATCGCCGCGCTTGTCTGACTAA
CCCTCTATAATACGCCCGCAATGGGTATAAATGTCGAATTC</dna_sequence>
        <protein_sequence>>CAA86936.1 ORF [Brucella abortus]
MNQSCPNKTSFKIAFIQARWHADIVDEARKSFVAELAAKTGGSVEVEIFDVPGAYEIPLHAKTLARTGRY
AAIVGAAFVIDGGIYRHDFVATAVINGMMQVQLETEVPVLSVVLTPHHFHESKEHHDFFHAHFKVKGVEA
AHAALQIVSERSRIAALV

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>This  gene was originally isolated from a lambda gt11 expression library probed with sera from Brucella-infected sheep. Sequence analysis of the cloned gene revealed the presence of an open reading frame of 158 amino acids encoding a protein of 17.3 kDa [Ref417:Hemmen et al., 1995]. It was later identified as a cytoplasmic protein lumazine synthase [Ref418:Goldbaum et al., 1999]. This gene can be used for diagnosis [Ref417:Hemmen et al., 1995] [Ref418:Goldbaum et al., 1999] and vaccine development [Ref416:Velikovsky et al., 2002].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1358">
        <gene_name>P39 from Brucella abortus</gene_name>
        <strain>Brucella abortus bv. 1 str. 9-941</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>68067499</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:224567</xrefs>
        <taxonomy_id>262698</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>Probable sugar-binding periplasmic protein</protein_name>
        <protein_pi>5.06</protein_pi>
        <protein_weight>44330.68</protein_weight>
        <protein_length>589</protein_length>
        <protein_note>biovar: 1 str. 9-941</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>sp|O06875.3|SP39_BRUAB RecName: Full=Probable sugar-binding periplasmic protein; AltName: Full=Immunogenic 39 kDa protein; AltName: Full=P39; Flags: Precursor
MHKLLKLAAMGTAACALLAGMAPVANAQEKQNVEVLHWWTSGGEASALEVLKKDLESKGISWTDMPVAGG
GGTEAMTVLRARVTAGNAPTAVQMLGFDIRDWAEQGALGNLDTVASKEGWEKVIPAPLQEFAKYDGHWIA
APVNIHSTNWMWINKAALDKAGGKEPTNWDELIALLDNFKAQGITPIAHGGQPWQDATIFDAVVLSFGPD
FYKKAFIDLDPEALGSDTMKQAFDRMSKLRTYVDDNFSGRDWNLASAMVIEGKAGVQFMGDWAKGEFLKA
GKKPGEDFVCMRYPGTQGAVTFNSDMFAMFKVSEDKVPAQLEMASAIESPAFQSAFNVVKGSAPARTDVP
DTAFDACGKKAIADVKEANSKGTLLGSMAHGYANPAAVKNAIYDVVTRQFNGQLSSEDAVKELVAAVEAA
K

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene955">
        <gene_name>pgk</gene_name>
        <strain>Brucella melitensis biovar Abortus 2308</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>3788256</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>82700518</ncbi_protein_id>
        <gene_locus_tag>BAB1_1742</gene_locus_tag>
        <gene_refseq>AM040264</gene_refseq>
        <protein_refseq>YP_415092</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>359391</taxonomy_id>
        <chromosome>I</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>1682955</gene_start>
        <gene_end>1684142</gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>phosphoglycerate kinase</protein_name>
        <protein_pi>5.91</protein_pi>
        <protein_weight>37696.73</protein_weight>
        <protein_length>395</protein_length>
        <protein_note>Converts 3-phospho-D-glycerate to 3-phospho-D-glyceroyl phosphate during the glycolysis pathway</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>gi|82698932:1682955-1684142 Brucella melitensis biovar Abortus 2308 chromosome chromosome I, complete sequence
GATGTTCCGCACCCTTGACGATGCCAATGTCCAATCCAAGCGCGTGCTGGTCCGTGTTGACCTCAACGTG
CCGATGGCAAACGGCGAAGTCACCGACCTTACCCGCATCGAACGCATCGTTCCGACCATCGCGGAACTGT
CAAGGAAGGGCGCGAAGGTCATCCTGCTCGCCCATTTCGGTCGCCCGAAGGGGGTTGCCTCGGATGAAAA
TTCGCTGAAGCATGTCGTGAAGCCGCTCTCCAAGGTTCTGGATCACAGTGTTCATTTTGCCGAAGACTGC
ATCGGCGACAAGGCGAAAGCGGCCGTCGATGCGCTGAAGGACGGCGACGTCCTGCTTCTGGAAAATACCC
GTTTCCACAAGGGCGAGGAAAAGAACGATCCTGAATTCGTGCAGGCGCTGGCCGCCAATGGCGATCTCTA
TGTGAACGATGCCTTTTCCGCCGCTCACCGCGCCCATGCCTCGACTGAAGGTCTGGCCCATGTCCTGCCT
GCCTTCGCGGGCCGCGCCATGCAGGCTGAGCTTGAAGCACTTGAAAAGGGCCTCGGCAATCCGGCCCGCC
CGGTGGTCGCCATCGTCGGCGGTGCAAAGGTTTCGACCAAGCTCGACCTCCTGTCCAACCTGATCGAAAA
GGTCGATGCGCTTGTCATCGGCGGCGGCATGGCCAACACGTTCCTTGCAGCCAAGGGTCTTGATGTCGGC
AAATCGCTCTGCGAGCATGAGCTGGCCTCGACCGCACGCGAAATCATGGCCAAGGCCGAAACCACCAAAT
GCGCCATCATCCTGCCGGTGGACGCGGTCGTGGGCTGGCACTTCGCCGCCGATACGCCACACCAGACCTA
TGGCGTGGATTCGGTTCCGGGCGACGCCATGATCCTTGACGCAGGCGAGCTTTCGACCGACCTCATTGCT
TCGGCCATCGATGATGCCGCAACATTGGTCTGGAACGGCCCGCTTGGGGCTTTCGAGTTGCGCCCCTTTG
ACACAGCAACGGTGAAGGTCGCAAGGCATGTCGCAAAGCGCACAAAGGAAGGCAAGCTTGTTTCGGTCGG
CGGCGGCGGCGATACGGTGGCAGCCCTCAACCATGCGGGCGTGGCCGACGACTTCACCTATATCTCAACC
GCTGGCGGCGCTTTCCTCGAATGGATGGAAGGCAAACCGCTTCCGGGCGTCGATGTATTGAAGAAGTG</dna_sequence>
        <protein_sequence>>gi|82700518|ref|YP_415092.1| phosphoglycerate kinase [Brucella melitensis biovar Abortus 2308]
MFRTLDDANVQSKRVLVRVDLNVPMANGEVTDLTRIERIVPTIAELSRKGAKVILLAHFGRPKGVASDEN
SLKHVVKPLSKVLDHSVHFAEDCIGDKAKAAVDALKDGDVLLLENTRFHKGEEKNDPEFVQALAANGDLY
VNDAFSAAHRAHASTEGLAHVLPAFAGRAMQAELEALEKGLGNPARPVVAIVGGAKVSTKLDLLSNLIEK
VDALVIGGGMANTFLAAKGLDVGKSLCEHELASTAREIMAKAETTKCAIILPVDAVVGWHFAADTPHQTY
GVDSVPGDAMILDAGELSTDLIASAIDDAATLVWNGPLGAFELRPFDTATVKVARHVAKRTKEGKLVSVG
GGGDTVAALNHAGVADDFTYISTAGGAFLEWMEGKPLPGVDVLKK</protein_sequence>
        <phi_function>Virmugen</phi_function>
        <phi_annotation>A pgk mutant is attenuated in mice and induces significant protection from challenge with wild type B. abortus [Ref1811:Trant et al., 2010].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene978">
        <gene_name>pgm</gene_name>
        <strain>Brucella melitensis biovar Abortus 2308</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>3788847</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>82698981</ncbi_protein_id>
        <gene_locus_tag>BAB1_0055</gene_locus_tag>
        <gene_refseq>AM040264</gene_refseq>
        <protein_refseq>YP_413555</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>359391</taxonomy_id>
        <chromosome>I</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>60852</gene_start>
        <gene_end>62483</gene_end>
        <gene_strand>-</gene_strand>
        <protein_name>phosphoglucomutase</protein_name>
        <protein_pi>6.52</protein_pi>
        <protein_weight>55523.82</protein_weight>
        <protein_length>543</protein_length>
        <protein_note>catalyzes the interconversion of alpha-D-glucose 1-phosphate to alpha-D-glucose 6-phosphate</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>gi|82698932:60852-62483 Brucella melitensis biovar Abortus 2308 chromosome chromosome I, complete sequence
CTCAAGTAACCACCGACGGCTCTGTCCGCCCGCTGCGTTTTTTTACTTCGGCGATCTGTTCAGCCGCGTC
GATCAGTGGGGCCAGCGTTGCCTGCGTGTCGAGATTATGTTTTGCAGGATCGGCTTCATAGCGTTCGATA
TAGATGCGGATGGTCGCGCCTGACGTCCCGGTACCGGACAGGCGAAGCACGATGCGCGCACCTCCTTCAA
AATAGATGCGGATGCCCTGATGTTCGCTGGTCGAGCCATCAACGGGATCATGATAGGCGAAGTCGTCGGC
CTTTTCGATCCTGAGGCCATTGACGCTCGTGCCGGGCAGGCCGGCAAGCTTGCCGCGCAGGTCAGCCACC
AGCTTCGTCGCAATATCGGAATCGACGGCTTCATAGTCGTGGCGAGTGTAATAATTGCGCCCGAAACGTG
CCCAATGGTCGTCCGCGATTGCCTTCACACTTTCCTTGCGCACCGCCAGAATGTTGAGCCAGAGCAGAAC
GGCCCACAAACCATCTTTTTCGCGCACATGGTCGGAGCCGGTGCCGGAGCTTTCCTCGCCGCAGATCGTC
ACCTTGCCGCTGTCGAGAAGATTGCCGAAGAATTTCCAGCCGGTCGGGGTTTCATACATGCCGATACCGA
GTTTTTCCGCCACGCGGTCGGCGGCGGCGCTCGTCGGCATGGAACGGGCAATGCCCTTGATACCGCCTTT
ATAGCCCGGCGCCAGATGGGCATTTGCGGCCAGCATGGCAAGCGAATCTGACGGCGTGATGAAGATACCG
CGCCCGAGAATGAGGTTGCGATCGCCATCGCCGTCGGAGGCGGCGCCAAAATCCGGCGCATGGCTGGACA
TCAGAAGATCGTAGAGATCCTTGGCATAGACGAGGTTTGGATCCGGGTGATGGCCACCGAAATCCGGCAG
GGGCACGAAATTGACGACGCTGCCTTCGGGCGCACCGAGGCGGCGCTCGAAGATTTCCTTGGCATAAGGC
CCGGTCACCGCATGCATGGCGTCGAACTTCATCTGGAAGCCGCCTTTTATCATGGCGCGGATGGCGGCGA
AATCGAACAGGCTTTCCATCAATTCAGCATAATCGGCCACCGGATCGAAGATGACCACCTCGGTATCGCC
GATCTTGCTTGTGCCGATCTTGTCGATATCGATATCGGCTGCATCTGCAATTTTATACTGGTCGATCACC
TTTGAGCGGGCGAAGATCGCTTCGGTGATCTTTTCGGGTGCCGGTCCACCATTGCCGATATTGTACTTGA
TGCCGAAATCCTGCGTAGGCCCGCCCGGATTGTGGCTGGCCGAAAGGATCATGCCACCGAAGGCTTTGTA
CTTGCGGATCATGTTGGAGGCGGCTGGCGTGGAAAGAATGCCGCCCTGTCCCACCATGATACGGCCAAAA
CCGTTGGCGGCTGCGATCTTGATAAGCTTCTGGATCACCTCGCGGTTATAAAAGCGTCCGTCGCCGCCAA
CCACGAGCGTCTTGCCCTTGAACCCCTCCAGCACGTCGAAGATCGACTGGATGAAATTTTCTGCATAATT
GGGCTGCTGGAAAACCGGAACCTTCTTGCGCAAGCCCGAAGTGCCCGGCTGTTGATCCTGGTATGGCGTG
GTCGCAATGGTCTTGACGGTCA</dna_sequence>
        <protein_sequence>>gi|82698981|ref|YP_413555.1| phosphoglucomutase [Brucella melitensis biovar Abortus 2308]
MTVKTIATTPYQDQQPGTSGLRKKVPVFQQPNYAENFIQSIFDVLEGFKGKTLVVGGDGRFYNREVIQKL
IKIAAANGFGRIMVGQGGILSTPAASNMIRKYKAFGGMILSASHNPGGPTQDFGIKYNIGNGGPAPEKIT
EAIFARSKVIDQYKIADAADIDIDKIGTSKIGDTEVVIFDPVADYAELMESLFDFAAIRAMIKGGFQMKF
DAMHAVTGPYAKEIFERRLGAPEGSVVNFVPLPDFGGHHPDPNLVYAKDLYDLLMSSHAPDFGAASDGDG
DRNLILGRGIFITPSDSLAMLAANAHLAPGYKGGIKGIARSMPTSAAADRVAEKLGIGMYETPTGWKFFG
NLLDSGKVTICGEESSGTGSDHVREKDGLWAVLLWLNILAVRKESVKAIADDHWARFGRNYYTRHDYEAV
DSDIATKLVADLRGKLAGLPGTSVNGLRIEKADDFAYHDPVDGSTSEHQGIRIYFEGGARIVLRLSGTGT
SGATIRIYIERYEADPAKHNLDTQATLAPLIDAAEQIAEVKKRSGRTEPSVVT</protein_sequence>
        <phi_function>Virmugen</phi_function>
        <phi_annotation>A pgm mutant is attenuated in mice and induces significant protection from challenge with wild type B. abortus [Ref1909:Ugalde et al., 2003].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene939">
        <gene_name>purE</gene_name>
        <strain>Brucella melitensis bv. 1 str. 16M</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>600729</ncbi_protein_id>
        <gene_locus_tag>BMEI0295</gene_locus_tag>
        <gene_refseq>NZ_GG703781</gene_refseq>
        <protein_refseq>NP_539212</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:200634</xrefs>
        <taxonomy_id>29459</taxonomy_id>
        <chromosome>I</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>308233</gene_start>
        <gene_end>309321</gene_end>
        <gene_strand>-</gene_strand>
        <protein_name>5'-phosphoribosyl-5-amino-4-imidazole carboxylase</protein_name>
        <protein_pi>5.29</protein_pi>
        <protein_weight>36300.44</protein_weight>
        <protein_length>161</protein_length>
        <protein_note>AIR carboxylase; cl00310</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>gi|17986284:308233-309321 Brucella melitensis bv. 1 str. 16M chromosome chromosome I, complete sequence
CTTAAATTGTGCGGGGCTTTATGCGGGTCACATGGCCTATTTTCCGGCCCGCGCGAGCTTCCTTTTTACC
GTAAAGATGCAGCACGGCGTTCTTCTCGCAGAGAATCGCCGGAACCTTTTCGATATCGTCGCCAATCAGG
TTTTCCATCACACAGTCGCTATGGCGATCCGTATTGCCGAGCGGCAGTCCCGCCACAGCGCGGATATGCT
GCTCAAATTGGGAAATGGCGCAGGCTGCTTCCGTCCAGTGGCCCGAATTATGCACACGCGGGGCAAATTC
ATTGGCGAGCAGCGTGCCGTCCTTCAGCACGAAGAATTCAAGCCCCAGCACACCGACATAGTCCAGCGCG
TGCAACAGTTTTTCGGCGGCTGTGCGCGCGGCTTCTGCCGTCTGTACGCTGATCGCGGCAGGCACTGTGG
ACGTGGCGAGAATGCCATCCTTGTGGACGTTTTCCGCAAGATCGAAGATGGCGACATTGCCGCTGCGATC
GCGCGCGGCGATGACGGAGACTTCGCGCTCGAATTCCACGAAGCCTTCGAGAATCGCAGGCGCCTTGTTG
ATGGCTGCAAAAGCGTTGCAGGCCTGGGTTTCATCGAGGGAGGCAAGGCGCACCTGCCCCTTGCCGTCAT
AACCCAGACGCCGTATCTTGAGGATGCCACGCCCGCCCAGTGCGCCGAGCGCGGCGATGAGCGTTTCCTC
GTCATCCACGAGCCGCCAGGGCGCGGTTTCAATGCCGCTTTCGTTGAGAAACTGCTTTTCTGTGAAGCGG
TCCTGAGAGATTTCCAGTGCGGCGGGCGGGGGCAGAACAAGCGCCGTTTCAGCCAGCTTGTCGGCGGCGC
TGACTGGCACATTTTCAAATTCATAGGTGATGACGTCGGAAGCGGCGGCAAGTTCGGCCAGCGCCTTCGG
GTCATCATAGGCGGCGACAATCTGGCGATTGGCAACCTGTGCTGCCGGGCAACCGGCCTGCGGCTCAAGG
ATTATGGTTTCATAACCGAAGCGCGCCGCTGCCATGGCGAGCATACGGCCAAGCTGGCCCCCGCCGATAA
TGCCGATGGTGGAGCCGGGCTTGAGAGATGTCTTGTCCA</dna_sequence>
        <protein_sequence>>gi|600729|gb|AAA57002.1| 5'-phosphoribosyl-5-amino-4-imidazole carboxylase [Brucella melitensis]
MSVDVAIIMGSQSDWETMHHAADTLEALGISFDARIVSAHRTPDRLVAFAKGAKREGFKVIIAGAGRAHL
PGMAAAMTPLPVFGVPVQSKALSGQDSLLSIVQMPAGIPVGTLAIGRAGAVNAALLAAAVLALYDEALAA
RLDEWRKAQTESVAERPSNEA</protein_sequence>
        <phi_function>Virmugen</phi_function>
        <phi_annotation>Mice were infected with delta purE201 or wild type parent strain 16M. The number of bacteria in the spleen and spleen weight peaked for both strains between 1 and 2 weeks postinfection (p.i.), though the number of delta purE201 cells was significantly less than the number of 16M cells recovered from the spleens of infected mice [Ref1799:Crawford et al., 1996].  Later, a purE/purK mutant demonstrated protection from challenge with wild type B. melitensis [Ref704:Hoover et al., 1999].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene239">
        <gene_name>purK</gene_name>
        <strain>Brucella melitensis bv. 1 str. 16M</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>20141763</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:180352
CDD:200773
CDD:194530</xrefs>
        <taxonomy_id>224914</taxonomy_id>
        <chromosome>I</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>N5-carboxyaminoimidazole ribonucleotide synthase</protein_name>
        <protein_pi></protein_pi>
        <protein_weight></protein_weight>
        <protein_length>362</protein_length>
        <protein_note>biovar: 1 str. 16M</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>gi|3788877|gb|AQ262397.1|AQ262397 CITBI-E1-2502P3.TF CITBI-E1 Homo sapiens genomic clone 2502P3, DNA sequence
CACCACCCCCCAGCCTGAGACCAAAGTCACAGTTTAACTCTGTCATGGGTCATGTGCAGAGGGAAGGGAC
TGCCCCAGAATTAGCAGTTGGCTGAACACCCTGCTTAAAAACTTTTTCTTTTCCTTTTTTTGTGAGTACC
GTCCGCTTGGACTAAAGAAGTTTTGGTTCGTTGTTTTCTTAATTTTGGGCTACAGAGTCTCTACCTACAT
TTGTGTTTTGTGTTTTGGTAACCACATGTAACAGCCGGTGGAATCTTTTTTCTCTTTGCTTTCTCTGAAC
TTTTCAAAGAGTAGGCCCCTATCTTTCGGGGGATTAACTCCTTGTGGCCCCTGTGTCGTTGGTGCT</dna_sequence>
        <protein_sequence>>gi|20141763|sp|P52559.2|PURK_BRUME RecName: Full=N5-carboxyaminoimidazole ribonucleotide synthase; Short=N5-CAIR synthase; AltName: Full=5-(carboxyamino)imidazole ribonucleotide synthetase
MDKTSLKPGSTIGIIGGGQLGRMLAMAAARFGYETIILEPQAGCPAAQVANRQIVAAYDDPKALAELAAA
SDVITYEFENVPVSAADKLAETALVLPPPAALEISQDRFTEKQFLNESGIETAPWRLVDDEETLIAALGA
LGGRGILKIRRLGYDGKGQVRLASLDETQACNAFAAINKAPAILEGFVEFEREVSVIAARDRSGNVAIFD
LAENVHKDGILATSTVPAAISVQTAEAARTAAEKLLHALDYVGVLGLEFFVLKDGTLLANEFAPRVHNSG
HWTEAACAISQFEQHIRAVAGLPLGNTDRHSDCVMENLIGDDIEKVPAILCEKNAVLHLYGKKEARAGRK
IGHVTRIKPRTI</protein_sequence>
        <phi_function>Virmugen</phi_function>
        <phi_annotation>A purE/purK mutant of B. melitensis 16M was attenuated in mice when given intraperitoneally.  Nine weeks after immunization, mice were protected from challenge with wild type B. melitensis [Ref706:Drazek et al., 1995].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene237">
        <gene_name>RL3382</gene_name>
        <strain>Rhizobium leguminosarum bv. viciae 3841</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>4399754</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>116253124</ncbi_protein_id>
        <gene_locus_tag>RL3382</gene_locus_tag>
        <gene_refseq>NC_008380</gene_refseq>
        <protein_refseq>YP_768962</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>216596</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>3553339</gene_start>
        <gene_end>3554079</gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>putative outer membrane protein related to bp26 antigen of Brucella</protein_name>
        <protein_pi>4.91</protein_pi>
        <protein_weight>23778</protein_weight>
        <protein_length>246</protein_length>
        <protein_note>similarity:fasta; with=UniProt:Q5W9U9_9RHIZ (EMBL:AB126349); Brucella sp. JM13/00.; bp26; Outer membrane protein Bp26.; length=250; id 51.515; 231 aa overlap; query 20-245; subject 21-250~similarity:fasta; with=UniProt:Q92NA6_RHIME (EMBL:SME591790); Rhizobium meliloti (Sinorhizobium meliloti).; Hypothetical protein SMc01556.; length=262; id 58.594; 256 aa overlap; query 7-246; subject 8-262</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>gi|4399754|gb|AI501903.1|AI501903 UI-R-C2p-sd-g-11-0-UI.s1 UI-R-C2p Rattus norvegicus cDNA clone UI-R-C2p-sd-g-11-0-UI 3', mRNA sequence
TTTTTTTTTTTTTTATTCGGTTTTATTTATTTATTTTTGGTGCAGACAAGAAACATAACAGTAACATGTC
TTTCCTTCGAGCACAAAGAAGACAGAGGACTAAGATCCTCATGTAGTTGCTAAGCAGTTCTAGTCCTCAC
ACTGGTTAAGAACAAAATGTCAAGTATTACTACAGCAAGAAATATCAGTAAGACAAGTTACATTTGTCTT
TTTGAAACCACTTTTATAAGACATAGCCACAGTTCTCAAAAGTTCTTCAGACTTCAGAGATCACATTGTA
CGGATTGTACTTCTAAGGATACAGCTATACGTGAACAGACACCAGAACAAGTTAATCTAGTAATGAATAT
TCACAGGAGTCTTCATACTGCAAATGACAGAAATTCCAACGTTTGCACTGTTCTCAGCG</dna_sequence>
        <protein_sequence>>gi|116253124|ref|YP_768962.1| putative outer membrane protein related to bp26 antigen of Brucella [Rhizobium leguminosarum bv. viciae 3841]
MAPIYTKTVLMTALLALSLAAAAPAFAQEAKPREPVISVTGDGESSVAPDMAIVNLAVVKQAKTAREALD
ENNKAMNDVLAALKSGGIAERDLQTSGFSIQPQYNYPQPVDGQQQQPQLIGYQTINSVTVRLRDLAKLGA
VIDQSVTLGINQGGEIQFTNDKPDAAIEAARKAAVADAVKRAKTLSEAAGVKLGRILEINENVPRAMPQP
VYRATMMKEASDAAVPVQGGENNYNVSVTVTFAIEQ</protein_sequence>
        <phi_function></phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene682">
        <gene_name>RplL</gene_name>
        <strain>Brucella abortus 2308</strain>
        <vo_id>VO_0010908</vo_id>
        <ncbi_gene_id>3788918</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>489054195</ncbi_protein_id>
        <gene_locus_tag>BAB_RS21965</gene_locus_tag>
        <gene_refseq>AM040264</gene_refseq>
        <protein_refseq>WP_002964371</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>359391</taxonomy_id>
        <chromosome>I</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>1229918</gene_start>
        <gene_end>1230292</gene_end>
        <gene_strand>-</gene_strand>
        <protein_name>50S ribosomal protein L7/L12</protein_name>
        <protein_pi>4.49</protein_pi>
        <protein_weight>11356.05</protein_weight>
        <protein_length>124</protein_length>
        <protein_note>present in two forms; L12 is normal, while L7 is aminoacylated at the N-terminal serine; the only multicopy ribosomal protein; 4:1 ratio of L7/L12 per ribosome; two L12 dimers bind L10; critically important for translation efficiency and fidelity; stimulates GTPase activity of translation factors</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_007618.1:1229918-1230292 Brucella melitensis biovar Abortus 2308 chromosome I, complete sequence, strain 2308
CTTACTTGAGTTCAACCTTGGCGCCAGCAGCTTCGAGCTGTGCCTTGATCTTCTCAGCTTCGTCCTTCGA
GGCGCCTTCCTTGACAGCCTTCGGAGCGCCTTCGACCAGGTCCTTGGCTTCCTTGAGGCCGAGACCGGTG
AGTGCGCGCACTTCCTTGATCACGTTGATCTTGTTAGCGCCGCCGTCAGCGAGAACGACGTCGAATTCGG
TCTTTTCTTCTGCGGCAGCAGCAGGGGCAGCGCCACCGGCAGCAGCAACAGCGACCGGAGCAGCAGCCGA
AACGCCCCACTTCTCTTCGAGAAGCTTGGACAGCTCAGCGGCTTCCAGAACGGTCAGGGCCGAAAGGTCT
TCAACGATCTTTGCGAGATCAGCCA

</dna_sequence>
        <protein_sequence>>WP_002964371.1 MULTISPECIES: 50S ribosomal protein L7/L12 [Brucella]
MADLAKIVEDLSALTVLEAAELSKLLEEKWGVSAAAPVAVAAAGGAAPAAAAEEKTEFDVVLADGGANKI
NVIKEVRALTGLGLKEAKDLVEGAPKAVKEGASKDEAEKIKAQLEAAGAKVELK

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>Study was designed to evaluate the immunogenicity and the protective efficacy of a divalent fusion DNA vaccine encoding both the Brucella abortus L7/L12 protein (ribosomal protein, rplL) and Omp16 protein (outer membrane lipoprotein). This divalent DNA vaccine induced a significant level of protection against challenge with the virulent B. abortus in BALB/c mice [Ref697:Luo et al., 2006b].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene236">
        <gene_name>RpsL</gene_name>
        <strain>Brucella melitensis bv. 1 str. 16M</strain>
        <vo_id>VO_0010963</vo_id>
        <ncbi_gene_id>1196463</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>161511151</ncbi_protein_id>
        <gene_locus_tag>BMEI0752</gene_locus_tag>
        <gene_refseq>NZ_GG703780</gene_refseq>
        <protein_refseq>NP_539669</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>224914</taxonomy_id>
        <chromosome>I</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>782951</gene_start>
        <gene_end>783322</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>30S ribosomal protein S12</protein_name>
        <protein_pi>12.15</protein_pi>
        <protein_weight>12482.71</protein_weight>
        <protein_length>123</protein_length>
        <protein_note>interacts with and stabilizes bases of the 16S rRNA that are involved in tRNA selection in the A site and with the mRNA backbone; located at the interface of the 30S and 50S subunits, it traverses the body of the 30S subunit contacting proteins on the other side; mutations in the S12 gene confer streptomycin resistance</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>gi|17986284:782951-783322 Brucella melitensis 16M chromosome I, complete sequence
AATGCCTACCGTAAACCAGCTTATCCGCAAGCCGCGCACTGCGCCGGTGAAGCGCAATAAGGTTCCTGCA
CTGCAGGCAAACCCTCAGAAGCGCGGCGTTTGCACCCGCGTTTACACGACGACCCCGAAGAAGCCGAACT
CGGCTCTGCGTAAGGTTGCCAAGGTTCGTCTGACGAACGGCTTTGAAGTCATTGGTTATATCCCTGGTGA
AGGGCATAACCTGCAGGAGCACTCCGTCGTGATGATCCGTGGCGGTCGTGTGAAGGACTTGCCGGGTGTG
CGTTACCACATCATCCGTGGCGTTCTCGATACCCAGGGTGTCAAGAACCGCAAGCAGCGCCGTTCCAAGT
ACGGTGCAAAGCGTCCGAAGTA</dna_sequence>
        <protein_sequence>>gi|161511151|ref|NP_539669.2| 30S ribosomal protein S12 [Brucella melitensis 16M]
MPTVNQLIRKPRTAPVKRNKVPALQANPQKRGVCTRVYTTTPKKPNSALRKVAKVRLTNGFEVIGYIPGE
GHNLQEHSVVMIRGGRVKDLPGVRYHIIRGVLDTQGVKNRKQRRSKYGAKRPK</protein_sequence>
        <phi_function>Other</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene3">
        <gene_name>SodC from B. abortus strain 2308</gene_name>
        <strain>Brucella abortus 2308</strain>
        <vo_id>VO_0010856</vo_id>
        <ncbi_gene_id>3827840</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>489062065</ncbi_protein_id>
        <gene_locus_tag>BAB_RS28905</gene_locus_tag>
        <gene_refseq>AM040265</gene_refseq>
        <protein_refseq>WP_002972093</protein_refseq>
        <pdb_id>2AQM</pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>359391</taxonomy_id>
        <chromosome>II</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>534068</gene_start>
        <gene_end>534589</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>superoxide dismutase [Cu-Zn]</protein_name>
        <protein_pi>6.74</protein_pi>
        <protein_weight>16741.77</protein_weight>
        <protein_length>173</protein_length>
        <protein_note></protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_007624.1:534068-534589 Brucella melitensis biovar Abortus 2308 chromosome II, complete sequence, strain 2308
GATGAAGTCCTTATTTATTGCATCGACAATGGTGCTTATGGCTTTTCCGGCTTTCGCAGAAAGCACGACG
GTAAAAATGTATGAGGCGCTGCCGACCGGACCGGGTAAAGAAGTTGGCACCGTGGTCATTTCCGAAGCCC
CGGGCGGGCTGCACTTCAAGGTGAATATGGAAAAGCTGACGCCGGGCTATCATGGCTTTCATGTTCACGA
AAATCCAAGCTGCGCTCCGGGAGAAAAAGACGGCAAGATCGTACCGGCTCTTGCTGCCGGCGGGCATTAT
GATCCGGGTAATACCCATCACCATTTAGGACCTGAAGGTGATGGACATATGGGCGATTTGCCACGCCTGA
GCGCCAATGCTGACGGCAAGGTGAGTGAAACCGTTGTCGCTCCACATCTCAAGAAATTGGCGGAAATCAA
GCAGCGTTCTTTGATGGTCCATGTCGGAGGGGATAATTATTCCGATAAGCCTGAGCCGCTTGGTGGCGGT
GGTGCCCGTTTTGCCTGCGGCGTGATCGAATA

</dna_sequence>
        <protein_sequence>>WP_002972093.1 MULTISPECIES: superoxide dismutase [Cu-Zn] [Brucella]
MKSLFIASTMVLMAFPAFAESTTVKMYEALPTGPGKEVGTVVISEAPGGLHFKVNMEKLTPGYHGFHVHE
NPSCAPGEKDGKIVPALAAGGHYDPGNTHHHLGPEGDGHMGDLPRLSANADGKVSETVVAPHLKKLAEIK
QRSLMVHVGGDNYSDKPEPLGGGGARFACGVIE

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>IMMUNOGENICITY: Induces antigen-specific Th1 immune response, as indicated by the specific induction of serum IgG2a, but not IgG1, antibodies and by the secretion of IFN-γ, but not IL-4, by the Cu/Zn SOD-stimulated splenocytes. Has been used for vaccine development [Ref578:Vemulapalli et al., 2000][Ref579:He et al., 2002][Ref580:Onate et al., 2003].    

MUTATION: An isogenic sodC mutant constructed from B abortus 2308 by gene replacement exhibited much greater susceptibility to killing by exogenous O(2)(-) than the parental 2308 strain, supporting a role for SodC in protecting this bacterium from O(2)(-) stress. The B abortus sodC mutant was much more sensitive to killing by cultured resident peritoneal macrophages from C57BL6J mice than 2308, and its attenuation in cultured murine macrophages was enhanced when these phagocytes were treated with gamma interferon. The attenuation of the B abortus sodC mutant in both resting and IFN-gamma-activated macrophages was alleviated in the presence of the NADPH oxidase inhibitor apocynin. Consistently, the B abortus sodC mutant also displayed significant attenuation in infected C57BL6J mice compared to the parental strain. These findings suggest that SodC protects B abortus 2308 from the respiratory burst of host macrophages [Ref581:Gee et al., 2005].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene258">
        <gene_name>SurA</gene_name>
        <strain>Brucella abortus 2308</strain>
        <vo_id>VO_0010971</vo_id>
        <ncbi_gene_id>3787419</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>489056605</ncbi_protein_id>
        <gene_locus_tag>BAB_RS19295</gene_locus_tag>
        <gene_refseq>JMRZ01000012</gene_refseq>
        <protein_refseq>WP_002966738</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>359391</taxonomy_id>
        <chromosome>I</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>688353</gene_start>
        <gene_end>689309</gene_end>
        <gene_strand>-</gene_strand>
        <protein_name>molecular chaperone SurA</protein_name>
        <protein_pi>10.47</protein_pi>
        <protein_weight>32511.89</protein_weight>
        <protein_length>318</protein_length>
        <protein_note></protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_007618.1:688353-689309 Brucella melitensis biovar Abortus 2308 chromosome I, complete sequence, strain 2308
GTCAACGATTGACGATGGTGGCCTTTTCGCGCAGTTCCTGCACGTATTTCTTGCTGAGTTCCTCAGCCTT
CTTTTCCTGCCCCGCAGGGGAATCCGCGCCTTCCATGGAGAAGACAAGCTGTGCAACGCGGTCATCCGAC
ACCTGACGGGTGGAGCATACGGCCAGGAATTCAACACCCTTTTCCGTATCGTGCGGCTTGGTCGTCCGGT
TGACGCCAGCGGCCTTCACATCCTTGGACCATTCGCCGGGCAATTGCGGCTCGATGATACGGCCAAGATC
GCGGACGGTCACATCGAGAATGCCCTTGGCTTGCTGGCGCGTGCTGTCACAATTCTGGAAGCGCGCGCGC
AACGCATTGGCTTCCTGACGGCGTTTTGCCAGAAGAGCGGGCGAACGCTTGGAGGCGGGGACCACGAAAA
TCACCTGCTGGAGATGATATTCAGTTGCAACGGGCTTCTTTCCGCCGTTCTTCAGCATACGCTGCACGGC
TTCCTGCTCACTGACCATGCCGGTCGCGCGGAAGCGGGCGCTGACAAGGCGGCCCCAGCCCATCTGGACC
ATGATATATTTCTTGAAATGTTCCGGCGTGACGCCCGACTGGTTCATAACCTGATTGAGCTGCGCCAGCG
TCATCTTGTTGCGGCTTGCAAACCCGGCATAGGCGTCATCCACTTCCTTATCGGAAATATTGATGCCACG
CGATTTCATCTCGATGCGCTTGAGCATTTCTTCGGTAAGCTCGTTGCGCGCAAGCTGGTTGAGATTGCCG
CTTTTACGCTGAAGCTTGAGGAAGGCCATACGGTGCTTGATGTCGCTATTGGTAATAGCATTGCCGGACA
CGATGACTTTGACCTCGGATTCTCCTGCGGCGAAAGCTGGAGCCGCAACCGTTCCAAGCGCCGTCAAGCA
AACGGCAGCGCCTAGCATGGAGGCGATAAGAGGTCTTGCAAACATCA

</dna_sequence>
        <protein_sequence>>WP_002966738.1 MULTISPECIES: peptidylprolyl isomerase [Brucella]
MMFARPLIASMLGAAVCLTALGTVAAPAFAAGESEVKVIVSGNAITNSDIKHRMAFLKLQRKSGNLNQLA
RNELTEEMLKRIEMKSRGINISDKEVDDAYAGFASRNKMTLAQLNQVMNQSGVTPEHFKKYIMVQMGWGR
LVSARFRATGMVSEQEAVQRMLKNGGKKPVATEYHLQQVIFVVPASKRSPALLAKRRQEANALRARFQNC
DSTRQQAKGILDVTVRDLGRIIEPQLPGEWSKDVKAAGVNRTTKPHDTEKGVEFLAVCSTRQVSDDRVAQ
LVFSMEGADSPAGQEKKAEELSKKYVQELREKATIVNR

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>Brucella SurA is a protective antigen [Ref687:Delpino et al., 2007b].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene256">
        <gene_name>Tig</gene_name>
        <strain>Brucella melitensis bv. 1 str. 16M</strain>
        <vo_id>VO_0010969</vo_id>
        <ncbi_gene_id>1196780</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>17987352</ncbi_protein_id>
        <gene_locus_tag>BMEI1069</gene_locus_tag>
        <gene_refseq>AE008917</gene_refseq>
        <protein_refseq>NP_539986</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>224914</taxonomy_id>
        <chromosome>I</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>1112655</gene_start>
        <gene_end>1114112</gene_end>
        <gene_strand>-</gene_strand>
        <protein_name>trigger factor</protein_name>
        <protein_pi>4.64</protein_pi>
        <protein_weight>50680.09</protein_weight>
        <protein_length>485</protein_length>
        <protein_note>Tig; RopA; peptidyl-prolyl cis/trans isomerase; promotes folding of newly synthesized proteins; binds ribosomal 50S subunit; forms a homodimer</protein_note>
        <protein_annotation>Also called Tf: Trigger Factor.</protein_annotation>
        <dna_sequence>>NC_003317.1:1112655-1114112 Brucella melitensis bv. 1 str. 16M chromosome I, complete sequence
ATCAAGCCTCTTCGGACTTGCCTTCTTCGGCCTTCTTCTTCGGCGCAGCCTTCTTCTTCGCAGCCGCCTT
CTTGGCAGGCTTTGCTTCCGAAGCTGCATCTTCGTCTTCAGCCGTCAGCTCTTCCTTCGAGACCTTCTTG
TCGGTCACATTGATGTTGGCCAGCAGATGATCGACGACCTTTTCTTCAAAGATCGGCGCGCGCAGATTGG
CGACGGCATCCGGCGTACGGCGCAGGAAGTCGTAGATTTCCTTTTCCTGACCCGGATAGCGGCGAACCTG
ATCGTAAACAGCGCGCTGCAGTTCTTCTTCGGTCACTTCCACGCCTGCCTTCTCGCCGATTTCGGAGAGA
ACGAGGCCAAGACGAACGCGGCGTTCTGCAAGCTTGCGATATTCTTCGCGAGCAGCTTCTTCCGTCGTTT
CCTCGTCTTCAAAGGTGCGGCCAGCCTGCTGCAGGTCGAAGTTGATCTGCTGCCAGATGTTGTTGAACTC
GGCGTCAACCAGCTTCTGCGGGGTTTCAAACTGATAATCACCATCAAGGGCGTCGAGAATCTGACGCTTC
ACTTTCTGGCGGGTGATCTGGCCGTACTGGCTTTCGATCTGTTCGCGCACAACCTGACGCAGACGCTCAA
GCGACTCAATGCCGAGCTTCTTTGCGGTTTCGTCATCGAGAACGAGTTCGTTCGGCTTGGCAACTTCCTT
CACCTTGATGTCGAAGGTTGCTTCCTTGCCAGCCAGATGCGCAGCGCCGTATTCAGCCGGGAACGTTACG
GTGATGACCTTCTCGTCGCCAGCCTTCAAGCCAATGAGCTGTTCTTCAAAGCCCGGAATGAACTGGCCGG
AACCGAGAACGAGCTGTGCGTCATTGTCTGCACCGCCTTCAAACGGCTCGCCGTCGAGCTTGCCCAGATA
GTCGATCGTGACGCGATCTTCGTTTTCGGCCTTGCCCTTCTTGGTTTCAAAGGTGCGGGTCGACGACGCA
ATGCGCTTGACCTGTTCATCGACTTCCTCATCGGAAATGTCGACGACTTCACGGGTCACGGCGATCTTGG
AGAAGTCCTTGACCTCGATTGCCGGCAGCACTTCATAGTTCAGCGAGAAAACGAAATCGGCCTTGCCGTC
GAGAACCTTCTCGGCTTCTTTTTCGTCTTCCGACATGATGACTTCAGGCTGGGTCGCCGACTTTTCGTTG
CGTTCGGCAAGGATGGAACGCGACGAATCGTTGAGGATTTCGTTGACGATCTCGGCCATGAAGGACTTGC
CGTACATCTTGCGCAGGTGAGCCGTCGGCACCTTGCCCGGACGGAAGCCGTTGATGCGGGCGCGGCCGCG
CGCGGTTTCGAGCCGCTCAGCGAGCTTGGCTTCAAGATCCCCGGCCGGAACCACGACTTTGATCTCGCGC
TTCAGCCCTTCATTGAGCGTTTCGGTAACCTGCATGTTCAAACCTTCACTTCTTGTCA

</dna_sequence>
        <protein_sequence>>NP_539986.1 trigger factor [Brucella melitensis bv. 1 str. 16M]
MTRSEGLNMQVTETLNEGLKREIKVVVPAGDLEAKLAERLETARGRARINGFRPGKVPTAHLRKMYGKSF
MAEIVNEILNDSSRSILAERNEKSATQPEVIMSEDEKEAEKVLDGKADFVFSLNYEVLPAIEVKDFSKIA
VTREVVDISDEEVDEQVKRIASSTRTFETKKGKAENEDRVTIDYLGKLDGEPFEGGADNDAQLVLGSGQF
IPGFEEQLIGLKAGDEKVITVTFPAEYGAAHLAGKEATFDIKVKEVAKPNELVLDDETAKKLGIESLERL
RQVVREQIESQYGQITRQKVKRQILDALDGDYQFETPQKLVDAEFNNIWQQINFDLQQAGRTFEDEETTE
EAAREEYRKLAERRVRLGLVLSEIGEKAGVEVTEEELQRAVYDQVRRYPGQEKEIYDFLRRTPDAVANLR
APIFEEKVVDHLLANINVTDKKVSKEELTAEDEDAASEAKPAKKAAAKKKAAPKKKAEEGKSEEA

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>protective antigen [Ref695:Yang et al., 2007]</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene998">
        <gene_name>virB2</gene_name>
        <strain>Brucella melitensis biovar Abortus 2308</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>3827981</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>83269021</ncbi_protein_id>
        <gene_locus_tag>BAB2_0067</gene_locus_tag>
        <gene_refseq>AM040265</gene_refseq>
        <protein_refseq>YP_418312</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>359391</taxonomy_id>
        <chromosome>II</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>65610</gene_start>
        <gene_end>65927</gene_end>
        <gene_strand>-</gene_strand>
        <protein_name>type IV secretion system protein VirB2</protein_name>
        <protein_pi>10.63</protein_pi>
        <protein_weight>10115.27</protein_weight>
        <protein_length>105</protein_length>
        <protein_note></protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>gi|83268957:65610-65927 Brucella melitensis biovar Abortus 2308 chromosome chromosome II, complete sequence
TTTACCTAAGCAGGTAAGAGGCAATTTCGGCGGCAGCGCCAACCACCAGGGCGCCGCCCAGCACCGGCAC
TACATCCATGAAGCGGGCGTGCCGGAATGCCATCTTGTAACCGGACCAGATGATGGCTATGGTAACGATG
GTGATCGATACGCCGCTTAGCAAGTCCAGCACTTTTTGCATGCTTGTATTTACCTTATCGAGGCCACCGT
TGGCGTGCGCCAGGTTAGGCTCGATTGCAGCGATGGAGACAATGAGGGCCAGCAGTAGGTGAGGTAGAAT
CCGCGACAGCGACTTCTTGCTGGGGGAAGCGGTTTTCA</dna_sequence>
        <protein_sequence>>gi|83269021|ref|YP_418312.1| type IV secretion system protein VirB2 [Brucella melitensis biovar Abortus 2308]
MKTASPSKKSLSRILPHLLLALIVSIAAIEPNLAHANGGLDKVNTSMQKVLDLLSGVSITIVTIAIIWSG
YKMAFRHARFMDVVPVLGGALVVGAAAEIASYLLR</protein_sequence>
        <phi_function>Virmugen</phi_function>
        <phi_annotation>A virB2 mutant is attenuated in Brucella abortus and provides protection in mice [Ref694:Kahl-McDonagh et al., 2007].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene233">
        <gene_name>VjbR</gene_name>
        <strain>Brucella melitensis 16M</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>1198888</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>17989461</ncbi_protein_id>
        <gene_locus_tag>BMEII1116</gene_locus_tag>
        <gene_refseq>NC_003318</gene_refseq>
        <protein_refseq>NP_542094</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>224914</taxonomy_id>
        <chromosome>II</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>1150819</gene_start>
        <gene_end>1151526</gene_end>
        <gene_strand>-</gene_strand>
        <protein_name>TRANSCRIPTIONAL ACTIVATOR, LUXR FAMILY</protein_name>
        <protein_pi>6.65</protein_pi>
        <protein_weight>23978.21</protein_weight>
        <protein_length>235</protein_length>
        <protein_note></protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>gi|1198888|gb|N56040.1|N56040 J6249F Human fetal heart, Lambda ZAP Express Homo sapiens cDNA clone J6249 5', mRNA sequence
GTGAACATTTTAGACACCTTTTCTTTGGGTAGGCTCTTGCCCAGGCGCCGGCTCTTCTCCCAAAAAAAAA
AAAAACCTTATCCTTTCCCTAACCTGATAACCTCCAGATCCAGGGTTTCTAACTAAGTGAGTCTTTGAAG
TATTAAGGGACATGAATAGCT</dna_sequence>
        <protein_sequence>>gi|17989461|ref|NP_542094.1| TRANSCRIPTIONAL ACTIVATOR, LUXR FAMILY [Brucella melitensis 16M]
MALLTRIRDEIGCRYVTHTYRGRVGDCTKVNSADLTVLMTLPATWVARYSSKNYFAIDPVFQEDAPYYRN
DTSAIARDLKEDADICPAVAELLHDAEKHGLGNLFIAVSARNPKGVAGCTVFTFEVEDEDRTQFLARMRP
RLLSLAGIIHGTVCGCKDANSVASLLTPREVDCLRWAANGKTDGEIAEILSIARWTVVTYLQNAKIKLNC
SNRTSAVATALSLGIIDMPEVQHLV</protein_sequence>
        <phi_function>Virmugen</phi_function>
        <phi_annotation>The deletion of vjbR gene in Brucella melitensis strain 16M made a live attenuated vaccine and provided significance protection against mice [Ref1910:Wang et al., 2011].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1208">
        <gene_name>vjbR</gene_name>
        <strain>Brucella abortus S19</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>6326704</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>189022339</ncbi_protein_id>
        <gene_locus_tag>BAbS19_II01090</gene_locus_tag>
        <gene_refseq>CP000888</gene_refseq>
        <protein_refseq>YP_001932080</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>430066</taxonomy_id>
        <chromosome>2</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>117845</gene_start>
        <gene_end>118624</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>LuxR family regulatory protein; VjbR</protein_name>
        <protein_pi>6.76</protein_pi>
        <protein_weight>26640</protein_weight>
        <protein_length>259</protein_length>
        <protein_note></protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>gi|189022234:117845-118624 Brucella abortus S19 chromosome 2, complete sequence
AATGAGTCTTGATCTCGTTCATTTTCCGAATTACAAAAAAACCTTTTTTGGTTCTTCCTTTCAAAGCGAT
ACTTTGGCGCTTCTAACCCGCATCCGGGATGAAATAGGATGCCGCTACGTAACGCATACCTATCGTGGTC
GCGTAGGCGACTGCACGAAGGTGAATTCAGCCGATCTGACTGTTCTTATGACGCTGCCTGCTACCTGGGT
CGCGCGCTATTCCTCGAAAAACTACTTTGCCATTGACCCGGTTTTTCAGGAAGACGCTCCGTATTACCGC
AATGATACGAGCGCCATTGCCCGCGACCTGAAAGAAGATGCGGATATTTGCCCGGCCGTTGCCGAACTGT
TGCATGATGCTGAAAAGCACGGCCTGGGAAATCTTTTCATCGCCGTATCCGCGCGCAATCCCAAGGGCGT
TGCGGGTTGTACGGTTTTCACTTTCGAGGTGGAGGACGAAGACCGTACGCAATTCCTTGCCAGGATGCGC
CCGCGCCTTCTAAGCCTTGCCGGCATCATTCATGGAACTGTCTGCGGCTGCAAGGATGCAAATTCAGTTG
CAAGCCTTCTCACCCCGCGCGAGGTCGATTGCCTGCGCTGGGCTGCCAATGGCAAGACTGATGGCGAAAT
CGCCGAAATCCTCAGCATCGCCCGCTGGACGGTGGTGACTTATCTACAGAATGCCAAAATCAAGCTGAAC
TGTTCCAATCGAACGTCGGCAGTGGCGACGGCGCTTTCCCTCGGCATTATCGATATGCCCGAGGTACAGC
ATCTCGTCTG</dna_sequence>
        <protein_sequence>>gi|189022339|ref|YP_001932080.1| LuxR family regulatory protein [Brucella abortus S19]
MSLDLVHFPNYKKTFFGSSFQSDTLALLTRIRDEIGCRYVTHTYRGRVGDCTKVNSADLTVLMTLPATWV
ARYSSKNYFAIDPVFQEDAPYYRNDTSAIARDLKEDADICPAVAELLHDAEKHGLGNLFIAVSARNPKGV
AGCTVFTFEVEDEDRTQFLARMRPRLLSLAGIIHGTVCGCKDANSVASLLTPREVDCLRWAANGKTDGEI
AEILSIARWTVVTYLQNAKIKLNCSNRTSAVATALSLGIIDMPEVQHLV</protein_sequence>
        <phi_function>Virmugen</phi_function>
        <phi_annotation>A vjbR mutant is attenuated in BALB/c mice and induces significant protection against wild type challenge [Ref2096:Arenas-Gamboa et al., 2009].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene228">
        <gene_name>znuA</gene_name>
        <strain>Brucella melitensis biovar Abortus 2308</strain>
        <vo_id>VO_0012365</vo_id>
        <ncbi_gene_id>3827700</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>83269918</ncbi_protein_id>
        <gene_locus_tag>BAB2_1079</gene_locus_tag>
        <gene_refseq>AM040265</gene_refseq>
        <protein_refseq>YP_419209</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>359391</taxonomy_id>
        <chromosome>II</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>1063213</gene_start>
        <gene_end>1064217</gene_end>
        <gene_strand>-</gene_strand>
        <protein_name>periplasmic solute binding protein</protein_name>
        <protein_pi>6.31</protein_pi>
        <protein_weight>33961.81</protein_weight>
        <protein_length>334</protein_length>
        <protein_note>similar to BRA1122, zinc ABC transporter, periplasmic zinc-bnding protein</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>gi|83268957:1063213-1064217 Brucella melitensis biovar Abortus 2308 chromosome chromosome II, complete sequence
TTTATTTCGGCAGGCAGTCTTTCAGCGAATTGGCCAGATTGCGGATGAGTTGCGGATAAAGATCAGGGCC
GTCCTTCAGTTCTGCGCCAAGAGGATCAAGAACACCTGTCCGGGCTTTCGTTCCGTCAACCACCGTCTTC
ACCAGTTTCGGCTCAAATTGCGGCTCTGAGAAAACGCAGGTTGCACCGAGTGACTTTATCTTGTCGTGAA
TTTGCTGGATACGCGCCGCACCCGGCGCTTTTTCCGGGCTGACCGTGATGGAGCCGGCTGCTTTCATGCC
GAAGCGATTCTCGAAATATTGATAGGCATCATGAAAGACGATGAAGGGCTTGTCCTTGACCGGCTTCAGT
TCAGCAGCCACTTCCCTGGTCAAGGCATCGAGTTTTTCTCCATAGGCCTTGGCATTCTTTTCATATTGCG
CGGCGTGTTCCGGGTCGCTCTCGCCAAGCGTTTTGGCGATATCGGCAGCCAGAATCTTGCCATTTTGCGG
GTCAAGCCAGAAATGCAGATCATATTCGCCGTGATGGTGGTGTTCATGGCCTTCTTCTGCGACTTCGGCC
GCATGGTCGTGATCGCCTGAACCATGTGCGTCATGCTCTTCCTCATGGCTCCCCCCATGGCCATGATCGT
GCGCCTCGAACGGCCCACCCTCGCGGAATTTTAGTTTCGTCAACCCTTTCGCATCGCCAAGAGCCACCAC
TTTCGCGCCCTCGCCCAGCGTATCAATGGGCTTGTCGAGAAAGGTTTCCATGGATGGCCCGGCCCAGAAA
ATCACCTTGGCGTGCTCGATAGCCTCGGCATCGGAGGGTTTCAGACTATAAACATGCTCGGACCCAGCCC
CCTGAACGATCAGCTTCGGCTTACCCACGCCCTGCATGACGGCGGAAACAATCGAGTGAAGCGGCTTGAT
CGAAACAACCACGCCCTCACGTTCGCCTGCAAGGGAAGAACCGCAAAAGCCAGCCAGAAAGGCAGAAGCA
AGAAACAAGGAATGCAGATTTTTCA</dna_sequence>
        <protein_sequence>>gi|83269918|ref|YP_419209.1| periplasmic solute binding protein [Brucella melitensis biovar Abortus 2308]
MKNLHSLFLASAFLAGFCGSSLAGEREGVVVSIKPLHSIVSAVMQGVGKPKLIVQGAGSEHVYSLKPSDA
EAIEHAKVIFWAGPSMETFLDKPIDTLGEGAKVVALGDAKGLTKLKFREGGPFEAHDHGHGGSHEEEHDA
HGSGDHDHAAEVAEEGHEHHHHGEYDLHFWLDPQNGKILAADIAKTLGESDPEHAAQYEKNAKAYGEKLD
ALTREVAAELKPVKDKPFIVFHDAYQYFENRFGMKAAGSITVSPEKAPGAARIQQIHDKIKSLGATCVFS
EPQFEPKLVKTVVDGTKARTGVLDPLGAELKDGPDLYPQLIRNLANSLKDCLPK</protein_sequence>
        <phi_function>Virmugen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2>Virmugen</phi_function2>
        <phi_annotation2>Deletion of gene znuA attenuates Brucella abortus and this live attenuated vaccine was challenged in mice. These mice showed significantly fewer spenic CFU [Ref683:Yang et al., 2006].</phi_annotation2>
    </gene>
	<reference reference_id="reference2102">
		<reference_name>Abtahi et al., 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Abtahi H, Salmanian AH, Rafati S, Nejad GB, Saffari M, Ghazavi A, Mosayebi G</authors>
		<title>The profile of cytokines and IgG subclasses in BALB/c mice after immunization with Brucella ribosomal gene</title>
		<year>2008</year>
		<volume>11</volume>
		<issue>21</issue>
		<pages>2472-2477</pages>
		<journal_book_name>Pakistan journal of biological sciences: PJBS</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference692">
		<reference_name>Adone et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Adone R, Ciuchini F, Marianelli C, Tarantino M, Pistoia C, Marcon G, Petrucci P, Francia M, Riccardi G, Pasquali P</authors>
		<title>Protective properties of rifampin-resistant rough mutants of Brucella melitensis</title>
		<year>2005</year>
		<volume>73</volume>
		<issue>7</issue>
		<pages>4198-4204</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference407">
		<reference_name>Al-Mariri et al., 2001</reference_name>
		<reference_type>journal</reference_type>
		<authors>Al-Mariri A, Tibor A, Mertens P, De Bolle X, Michel P, Godefroid J, Walravens K, Letesson JJ</authors>
		<title>Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant</title>
		<year>2001 Aug</year>
		<volume>69</volume>
		<issue>8</issue>
		<pages>4816-22</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2291">
		<reference_name>Al-Mariri et al., 2001</reference_name>
		<reference_type>journal</reference_type>
		<authors>Al-Mariri A, Tibor A, Mertens P, De Bolle X, Michel P, Godfroid J, Walravens K, Letesson JJ</authors>
		<title>Induction of immune response in BALB/c mice with a DNA vaccine encoding bacterioferritin or P39 of Brucella spp</title>
		<year>2001</year>
		<volume>69</volume>
		<issue>10</issue>
		<pages>6264-6270</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1270">
		<reference_name>Al-Mariri et al., 2002</reference_name>
		<reference_type>journal</reference_type>
		<authors>Al-Mariri A, Tibor A, Lestrate P, Mertens P, De Bolle X, Letesson JJ</authors>
		<title>Yersinia enterocolitica as a vehicle for a naked DNA vaccine encoding Brucella abortus bacterioferritin or P39 antigen</title>
		<year>2002</year>
		<volume>70</volume>
		<issue>4</issue>
		<pages>1915-1923</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference699">
		<reference_name>Arenas-Gamboa et al., 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Arenas-Gamboa AM, Ficht TA, Kahl-McDonagh MM, Rice-Ficht AC</authors>
		<title>Immunization with a Single Dose of a Microencapsulated Brucella melitensis Mutant Enhances Protection Against Wild-type Challenge</title>
		<year>2008</year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference882">
		<reference_name>Arenas-Gamboa et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Arenas-Gamboa AM, Ficht TA, Davis DS, Elzer PH, Wong-Gonzalez A, Rice-Ficht AC</authors>
		<title>Enhanced immune response of red deer (Cervus elaphus) to live rb51 vaccine strain using composite microspheres</title>
		<year>2009</year>
		<volume>45</volume>
		<issue>1</issue>
		<pages>165-173</pages>
		<journal_book_name>Journal of wildlife diseases</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2096">
		<reference_name>Arenas-Gamboa et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Arenas-Gamboa AM, Ficht TA, Kahl-McDonagh MM, Gomez G, Rice-Ficht AC</authors>
		<title>The Brucella abortus S19 DeltavjbR live vaccine candidate is safer than S19 and confers protection against wild-type challenge in BALB/c mice when delivered in a sustained-release vehicle</title>
		<year>2009</year>
		<volume>77</volume>
		<issue>2</issue>
		<pages>877-884</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2071">
		<reference_name>Arenas-Gamboa et al., 2011</reference_name>
		<reference_type>journal</reference_type>
		<authors>Arenas-Gamboa AM, Rice-Ficht AC, Kahl-McDonagh MM, Ficht TA</authors>
		<title>The protective efficacy and safety of 16M{Delta}mucR against intraperitoneal and aerosol challenge in BALB/c mice</title>
		<year>2011</year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference193">
		<reference_name>Banai, 2002</reference_name>
		<reference_type>journal</reference_type>
		<authors>Banai M</authors>
		<title>Control of small ruminant brucellosis by use of Brucella melitensis Rev.1 vaccine: laboratory aspects and field observations</title>
		<year>2002 Dec 20</year>
		<volume>90</volume>
		<issue>1-4</issue>
		<pages>497-519</pages>
		<journal_book_name>Veterinary microbiology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference703">
		<reference_name>Bhattacharjee et al., 2002</reference_name>
		<reference_type>journal</reference_type>
		<authors>Bhattacharjee AK, Van de Verg L, Izadjoo MJ, Yuan L, Hadfield TL, Zollinger WD, Hoover DL</authors>
		<title>Protection of mice against brucellosis by intranasal immunization with Brucella melitensis lipopolysaccharide as a noncovalent complex with Neisseria meningitidis group B outer membrane protein</title>
		<year>2002</year>
		<volume>70</volume>
		<issue>7</issue>
		<pages>3324-3329</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference219">
		<reference_name>Bhattacharjee et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Bhattacharjee AK, Izadjoo MJ, Zollinger WD, Nikolich MP, Hoover DL</authors>
		<title>Comparison of protective efficacy of subcutaneous versus intranasal immunization of mice with a Brucella melitensis lipopolysaccharide subunit vaccine</title>
		<year>2006 Oct</year>
		<volume>74</volume>
		<issue>10</issue>
		<pages>5820-5</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference210">
		<reference_name>Blasco et al., 1993</reference_name>
		<reference_type>journal</reference_type>
		<authors>Blasco JM, Gamazo C, Winter AJ, Jimenez de Bagues MP, Marin C, Barberan M, Moriyon I, Alonso-Urmeneta B, Diaz R</authors>
		<title>Evaluation of whole cell and subcellular vaccines against Brucella ovis in rams</title>
		<year>1993 Aug</year>
		<volume>37</volume>
		<issue>3-4</issue>
		<pages>257-70</pages>
		<journal_book_name>Veterinary immunology and immunopathology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference428">
		<reference_name>Bosseray, 1991</reference_name>
		<reference_type>journal</reference_type>
		<authors>Bosseray N</authors>
		<title>Brucella melitensis Rev. 1 living attenuated vaccine: stability of markers, residual virulence and immunogenicity in mice</title>
		<year>1991 Oct</year>
		<volume>19</volume>
		<issue>4</issue>
		<pages>355-63</pages>
		<journal_book_name>Biologicals : journal of the International Association of Biological Standardization</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2293">
		<reference_name>Cassataro et al., 2002</reference_name>
		<reference_type>journal</reference_type>
		<authors>Cassataro J, Velikovsky CA, Giambartolomei GH, Estein S, Bruno L, Cloeckaert A, Bowden RA, Spitz M, Fossati CA</authors>
		<title>Immunogenicity of the Brucella melitensis recombinant ribosome recycling factor-homologous protein and its cDNA</title>
		<year>2002</year>
		<volume>20</volume>
		<issue>11-12</issue>
		<pages>1660-1669</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference488">
		<reference_name>Cassataro et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Cassataro J, Pasquevich K, Bruno L, Wallach JC, Fossati CA, Baldi PC</authors>
		<title>Antibody reactivity to Omp31 from Brucella melitensis in human and animal infections by smooth and rough Brucellae</title>
		<year>2004 Jan</year>
		<volume>11</volume>
		<issue>1</issue>
		<pages>111-4</pages>
		<journal_book_name>Clinical and diagnostic laboratory immunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference489">
		<reference_name>Cassataro et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Cassataro J, Velikovsky CA, de la Barrera S, Estein SM, Bruno L, Bowden R, Pasquevich KA, Fossati CA, Giambartolomei GH</authors>
		<title>A DNA vaccine coding for the Brucella outer membrane protein 31 confers protection against B. melitensis and B. ovis infection by eliciting a specific cytotoxic response</title>
		<year>2005 Oct</year>
		<volume>73</volume>
		<issue>10</issue>
		<pages>6537-46</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference222">
		<reference_name>Cassataro et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Cassataro J, Pasquevich KA, Estein SM, Laplagne DA, Zwerdling A, de la Barrera S, Bowden R, Fossati CA, Giambartolomei GH, Goldbaum FA</authors>
		<title>A DNA vaccine coding for the quimera BLSOmp31 induced a better degree of protection against B. ovis and a similar degree of protection against B. melitensis than Rev.1 vaccination</title>
		<year>2007 Jun 12</year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference485">
		<reference_name>Cassataro et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Cassataro J, Pasquevich KA, Estein SM, Laplagne DA, Velikovsky CA, de la Barrera S, Bowden R, Fossati CA, Giambartolomei GH, Goldbaum FA</authors>
		<title>A recombinant subunit vaccine based on the insertion of 27 amino acids from Omp31 to the N-terminus of BLS induced a similar degree of protection against B. ovis than Rev.1 vaccination</title>
		<year>2007 May 30</year>
		<volume>25</volume>
		<issue>22</issue>
		<pages>4437-46</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference855">
		<reference_name>Cassataro et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Cassataro J, Velikovsky CA, Bruno L, Estein SM, de la Barrera S, Bowden R, Fossati CA, Giambartolomei GH</authors>
		<title>Improved immunogenicity of a vaccination regimen combining a DNA vaccine encoding Brucella melitensis outer membrane protein 31 (Omp31) and recombinant Omp31 boosting</title>
		<year>2007</year>
		<volume>14</volume>
		<issue>7</issue>
		<pages>869-874</pages>
		<journal_book_name>Clinical and vaccine immunology : CVI</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference188">
		<reference_name>Cheville, 2000</reference_name>
		<reference_type>journal</reference_type>
		<authors>Cheville NF</authors>
		<title>Development, testing and commercialization of a new brucellosis vaccine for cattle</title>
		<year>2000</year>
		<volume>916</volume>
		<issue></issue>
		<pages>147-53</pages>
		<journal_book_name>Annals of the New York Academy of Sciences</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference192">
		<reference_name>Cloeckaert et al., 2002</reference_name>
		<reference_type>journal</reference_type>
		<authors>Cloeckaert A, Grayon M, Grepinet O</authors>
		<title>Identification of Brucella melitensis vaccine strain Rev.1 by PCR-RFLP based on a mutation in the rpsL gene</title>
		<year>2002 Jun 7</year>
		<volume>20</volume>
		<issue>19-20</issue>
		<pages>2546-50</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1988">
		<reference_name>Cloeckaert et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Cloeckaert A, Jacques I, Grilló MJ, Marín CM, Grayon M, Blasco JM, Verger JM</authors>
		<title>Development and evaluation as vaccines in mice of Brucella melitensis Rev.1 single and double deletion mutants of the bp26 and omp31 genes coding for antigens of diagnostic significance in ovine brucellosis</title>
		<year>2004</year>
		<volume>22</volume>
		<issue>21-22</issue>
		<pages>2827-2835</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference893">
		<reference_name>Colby et al., 2002</reference_name>
		<reference_type>journal</reference_type>
		<authors>Colby LA, Schurig GG, Elzer PH</authors>
		<title>An indirect ELISA to detect the serologic response of elk (Cervus elaphus nelsoni) inoculated with Brucella abortus strain RB51</title>
		<year>2002</year>
		<volume>38</volume>
		<issue>4</issue>
		<pages>752-759</pages>
		<journal_book_name>Journal of wildlife diseases</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference863">
		<reference_name>Commander et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Commander NJ, Spencer SA, Wren BW, MacMillan AP</authors>
		<title>The identification of two protective DNA vaccines from a panel of five plasmid constructs encoding Brucella melitensis 16M genes</title>
		<year>2007</year>
		<volume>25</volume>
		<issue>1</issue>
		<pages>43-54</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference898">
		<reference_name>Cook et al., 2001</reference_name>
		<reference_type>journal</reference_type>
		<authors>Cook WE, Williams ES, Thorne ET, Taylor SK, Anderson S</authors>
		<title>Safety of Brucella abortus strain RB51 in deer mice</title>
		<year>2001</year>
		<volume>37</volume>
		<issue>3</issue>
		<pages>621-625</pages>
		<journal_book_name>Journal of wildlife diseases</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference410">
		<reference_name>Corbel, 1997</reference_name>
		<reference_type>journal</reference_type>
		<authors>Corbel MJ</authors>
		<title>Recent advances in brucellosis</title>
		<year>1997 Feb</year>
		<volume>46</volume>
		<issue>2</issue>
		<pages>101-3</pages>
		<journal_book_name>Journal of medical microbiology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1799">
		<reference_name>Crawford et al., 1996</reference_name>
		<reference_type>journal</reference_type>
		<authors>Crawford RM, Van De Verg L, Yuan L, Hadfield TL, Warren RL, Drazek ES, Houng HH, Hammack C, Sasala K, Polsinelli T, Thompson J, Hoover DL</authors>
		<title>Deletion of purE attenuates Brucella melitensis infection in mice</title>
		<year>1996</year>
		<volume>64</volume>
		<issue>6</issue>
		<pages>2188-2192</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference666">
		<reference_name>Delpino et al., 2007a</reference_name>
		<reference_type>journal</reference_type>
		<authors>Delpino MV, Estein SM, Fossati CA, Baldi PC</authors>
		<title>Partial protection against Brucella infection in mice by immunization with nonpathogenic alphaproteobacteria</title>
		<year>2007</year>
		<volume>14</volume>
		<issue>10</issue>
		<pages>1296-1301</pages>
		<journal_book_name>Clinical and vaccine immunology : CVI</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference687">
		<reference_name>Delpino et al., 2007b</reference_name>
		<reference_type>journal</reference_type>
		<authors>Delpino MV, Estein SM, Fossati CA, Baldi PC, Cassataro J</authors>
		<title>Vaccination with Brucella recombinant DnaK and SurA proteins induces protection against Brucella abortus infection in BALB/c mice</title>
		<year>2007</year>
		<volume>25</volume>
		<issue>37-38</issue>
		<pages>6721-6729</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference706">
		<reference_name>Drazek et al., 1995</reference_name>
		<reference_type>journal</reference_type>
		<authors>Drazek ES, Houng HS, Crawford RM, Hadfield TL, Hoover DL, Warren RL</authors>
		<title>Deletion of purE attenuates Brucella melitensis 16M for growth in human monocyte-derived macrophages</title>
		<year>1995</year>
		<volume>63</volume>
		<issue>9</issue>
		<pages>3297-3301</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1946">
		<reference_name>Edmonds et al., 2002</reference_name>
		<reference_type>journal</reference_type>
		<authors>Edmonds MD, Cloeckaert A, Elzer PH</authors>
		<title>Brucella species lacking the major outer membrane protein Omp25 are attenuated in mice and protect against Brucella melitensis and Brucella ovis</title>
		<year>2002</year>
		<volume>88</volume>
		<issue>3</issue>
		<pages>205-221</pages>
		<journal_book_name>Veterinary microbiology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference685">
		<reference_name>ELBERG and FAUNCE, 1957</reference_name>
		<reference_type>journal</reference_type>
		<authors>ELBERG SS, FAUNCE K Jr</authors>
		<title>Immunization against Brucella infection.  VI.  Immunity conferred on goats by a nondependent mutant from a streptomycin-dependent mutant strain of Brucella melitensis</title>
		<year>1957</year>
		<volume>73</volume>
		<issue>2</issue>
		<pages>211-217</pages>
		<journal_book_name>Journal of bacteriology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference487">
		<reference_name>Estein et al., 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Estein SM, Cassataro J, Vizcaino N, Zygmunt MS, Cloeckaert A, Bowden RA</authors>
		<title>The recombinant Omp31 from Brucella melitensis alone or associated with rough lipopolysaccharide induces protection against Brucella ovis infection in BALB/c mice</title>
		<year>2003 Feb</year>
		<volume>5</volume>
		<issue>2</issue>
		<pages>85-93</pages>
		<journal_book_name>Microbes and infection / Institut Pasteur</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference691">
		<reference_name>Estevan et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Estevan M, Gamazo C, Grilló MJ, Del Barrio GG, Blasco JM, Irache JM</authors>
		<title>Experiments on a sub-unit vaccine encapsulated in microparticles and its efficacy against Brucella melitensis in mice</title>
		<year>2006</year>
		<volume>24</volume>
		<issue>19</issue>
		<pages>4179-4187</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference413">
		<reference_name>Fernandes et al., 1996</reference_name>
		<reference_type>journal</reference_type>
		<authors>Fernandes DM, Jiang X, Jung JH, Baldwin CL</authors>
		<title>Comparison of T cell cytokines in resistant and susceptible mice infected with virulent Brucella abortus strain 2308</title>
		<year>1996 Dec 31</year>
		<volume>16</volume>
		<issue>3-4</issue>
		<pages>193-203</pages>
		<journal_book_name>FEMS immunology and medical microbiology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2099">
		<reference_name>Fu et al., 2012</reference_name>
		<reference_type>journal</reference_type>
		<authors>Fu S, Xu J, Li X, Xie Y, Qiu Y, Du X, Yu S, Bai Y, Chen Y, Wang T, Wang Z, Yu Y, Peng G, Huang K, Huang L, Wang Y, Chen Z</authors>
		<title>Immunization of Mice with Recombinant Protein CobB or AsnC Confers Protection against Brucella abortus Infection</title>
		<year>2012</year>
		<volume>7</volume>
		<issue>2</issue>
		<pages>e29552</pages>
		<journal_book_name>PloS one</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2108">
		<reference_name>Galindo et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Galindo RC, Muñoz PM, de Miguel MJ, Marin CM, Blasco JM, Gortazar C, Kocan KM, de la Fuente J</authors>
		<title>Characterization of possible correlates of protective response against Brucella ovis infection in rams immunized with the B. melitensis Rev 1 vaccine</title>
		<year>2009</year>
		<volume>27</volume>
		<issue>23</issue>
		<pages>3039-3044</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference565">
		<reference_name>Gee et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Gee JM, Valderas MW, Kovach ME, Grippe VK, Robertson GT, Ng WL, Richardson JM, Winkler ME, Roop RM 2nd</authors>
		<title>The Brucella abortus Cu,Zn superoxide dismutase is required for optimal resistance to oxidative killing by murine macrophages and wild-type virulence in experimentally infected mice</title>
		<year>2005 May</year>
		<volume>73</volume>
		<issue>5</issue>
		<pages>2873-80</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference190">
		<reference_name>Geong et al., 2000</reference_name>
		<reference_type>journal</reference_type>
		<authors>Geong M, Robertson ID</authors>
		<title>Response of Bali cattle (Bos javanicus) to vaccination with Brucella abortus strain 19 in West Timor</title>
		<year>2000 Nov 16</year>
		<volume>47</volume>
		<issue>3</issue>
		<pages>177-86</pages>
		<journal_book_name>Preventive veterinary medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference418">
		<reference_name>Goldbaum et al., 1999</reference_name>
		<reference_type>journal</reference_type>
		<authors>Goldbaum FA, Velikovsky CA, Baldi PC, Mortl S, Bacher A, Fossati CA</authors>
		<title>The 18-kDa cytoplasmic protein of Brucella species --an antigen useful for diagnosis--is a lumazine synthase</title>
		<year>1999 Sep</year>
		<volume>48</volume>
		<issue>9</issue>
		<pages>833-9</pages>
		<journal_book_name>Journal of medical microbiology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference690">
		<reference_name>Guilloteau et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Guilloteau LA, Laroucau K, Olivier M, Grillo MJ, Marin CM, Verger JM, Blasco JM</authors>
		<title>Residual virulence and immunogenicity of CGV26 and CGV2631 B. melitensis Rev. 1 deletion mutant strains in sheep after subcutaneous or conjunctival vaccination</title>
		<year>2006</year>
		<volume>24</volume>
		<issue>17</issue>
		<pages>3461-3468</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference688">
		<reference_name>Gupta et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Gupta VK, Rout PK, Vihan VS</authors>
		<title>Induction of immune response in mice with a DNA vaccine encoding outer membrane protein (omp31) of Brucella melitensis 16M</title>
		<year>2007</year>
		<volume>82</volume>
		<issue>3</issue>
		<pages>305-313</pages>
		<journal_book_name>Research in veterinary science</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference895">
		<reference_name>Hamdy et al., 2002</reference_name>
		<reference_type>journal</reference_type>
		<authors>Hamdy ME, El-Gibaly SM, Montasser AM</authors>
		<title>Comparison between immune responses and resistance induced in BALB/c mice vaccinated with RB51 and Rev. 1 vaccines and challenged with Brucella melitensis bv. 3</title>
		<year>2002</year>
		<volume>88</volume>
		<issue>1</issue>
		<pages>85-94</pages>
		<journal_book_name>Veterinary microbiology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference13">
		<reference_name>He et al., 2001</reference_name>
		<reference_type>journal</reference_type>
		<authors>He Y, Vemulapalli R, Zeytun A, Schurig GG</authors>
		<title>Induction of specific cytotoxic lymphocytes in mice vaccinated with Brucella abortus RB51</title>
		<year>2001 Sep</year>
		<volume>69</volume>
		<issue>9</issue>
		<pages>5502-8</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference196">
		<reference_name>He et al., 2002</reference_name>
		<reference_type>journal</reference_type>
		<authors>He Y, Vemulapalli R, Schurig GG</authors>
		<title>Recombinant Ochrobactrum anthropi expressing Brucella abortus Cu,Zn superoxide dismutase protects mice against B. abortus infection only after switching of immune responses to Th1 type</title>
		<year>2002 May</year>
		<volume>70</volume>
		<issue>5</issue>
		<pages>2535-43</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference417">
		<reference_name>Hemmen et al., 1995</reference_name>
		<reference_type>journal</reference_type>
		<authors>Hemmen F, Weynants V, Scarcez T, Letesson JJ, Saman E</authors>
		<title>Cloning and sequence analysis of a newly identified Brucella abortus gene and serological evaluation of the 17-kilodalton antigen that it encodes</title>
		<year>1995 May</year>
		<volume>2</volume>
		<issue>3</issue>
		<pages>263-7</pages>
		<journal_book_name>Clinical and diagnostic laboratory immunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference886">
		<reference_name>High et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>High KP, Prasad R, Marion CR, Schurig GG, Boyle SM, Sriranganathan N</authors>
		<title>Outcome and immune responses after Brucella abortus infection in young adult and aged mice</title>
		<year>2007</year>
		<volume>8</volume>
		<issue>5</issue>
		<pages>583-593</pages>
		<journal_book_name>Biogerontology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference704">
		<reference_name>Hoover et al., 1999</reference_name>
		<reference_type>journal</reference_type>
		<authors>Hoover DL, Crawford RM, Van De Verg LL, Izadjoo MJ, Bhattacharjee AK, Paranavitana CM, Warren RL, Nikolich MP, Hadfield TL</authors>
		<title>Protection of mice against brucellosis by vaccination with Brucella melitensis WR201(16MDeltapurEK)</title>
		<year>1999</year>
		<volume>67</volume>
		<issue>11</issue>
		<pages>5877-5884</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2289">
		<reference_name>Hu et al., 2010</reference_name>
		<reference_type>journal</reference_type>
		<authors>Hu XD, Chen ST, Li JY, Yu DH, Yi-Zhang, Cai H</authors>
		<title>An IL-15 adjuvant enhances the efficacy of a combined DNA vaccine against Brucella by increasing the CD8+ cytotoxic T cell response</title>
		<year>2010</year>
		<volume>28</volume>
		<issue>12</issue>
		<pages>2408-2415</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference702">
		<reference_name>Izadjoo et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Izadjoo MJ, Bhattacharjee AK, Paranavitana CM, Hadfield TL, Hoover DL</authors>
		<title>Oral vaccination with Brucella melitensis WR201 protects mice against intranasal challenge with virulent Brucella melitensis 16M</title>
		<year>2004</year>
		<volume>72</volume>
		<issue>7</issue>
		<pages>4031-4039</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference195">
		<reference_name>Jacques et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Jacques I, Verger JM, Laroucau K, Grayon M, Vizcaino N, Peix A, Cortade F, Carreras F, Guilloteau LA</authors>
		<title>Immunological responses and protective efficacy against Brucella melitensis induced by bp26 and omp31 B. melitensis Rev.1 deletion mutants in sheep</title>
		<year>2007 Jan 15</year>
		<volume>25</volume>
		<issue>5</issue>
		<pages>794-805</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference889">
		<reference_name>Januszewski et al., 2001</reference_name>
		<reference_type>journal</reference_type>
		<authors>Januszewski MC, Olsen SC, McLean RG, Clark L, Rhyan JC</authors>
		<title>Experimental infection of nontarget species of rodents and birds with Brucella abortus strain RB51 vaccine</title>
		<year>2001</year>
		<volume>37</volume>
		<issue>3</issue>
		<pages>532-537</pages>
		<journal_book_name>Journal of wildlife diseases</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference884">
		<reference_name>Jensen and Halling, 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Jensen AE, Halling SM</authors>
		<title>Effect of polymyxin B and environmental conditions on isolation of Brucella species and the vaccine strain RB51</title>
		<year>2008</year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name>Comparative immunology, microbiology and infectious diseases</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference904">
		<reference_name>Jiménez et al., 1994</reference_name>
		<reference_type>journal</reference_type>
		<authors>Jiménez de Bagüés MP, Elzer PH, Jones SM, Blasco JM, Enright FM, Schurig GG, Winter AJ</authors>
		<title>Vaccination with Brucella abortus rough mutant RB51 protects BALB/c mice against virulent strains of Brucella abortus, Brucella melitensis, and Brucella ovis</title>
		<year>1994</year>
		<volume>62</volume>
		<issue>11</issue>
		<pages>4990-4996</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference700">
		<reference_name>Kahl-McDonagh and Ficht, 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kahl-McDonagh MM, Ficht TA</authors>
		<title>Evaluation of protection afforded by Brucella abortus and Brucella melitensis unmarked deletion mutants exhibiting different rates of clearance in BALB/c mice</title>
		<year>2006</year>
		<volume>74</volume>
		<issue>7</issue>
		<pages>4048-4057</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference694">
		<reference_name>Kahl-McDonagh et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kahl-McDonagh MM, Arenas-Gamboa AM, Ficht TA</authors>
		<title>Aerosol infection of BALB/c mice with Brucella melitensis and Brucella abortus and protective efficacy against aerosol challenge</title>
		<year>2007</year>
		<volume>75</volume>
		<issue>10</issue>
		<pages>4923-4932</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference894">
		<reference_name>Ko et al., 2002</reference_name>
		<reference_type>journal</reference_type>
		<authors>Ko J, Gendron-Fitzpatrick A, Ficht TA, Splitter GA</authors>
		<title>Virulence criteria for Brucella abortus strains as determined by interferon regulatory factor 1-deficient mice</title>
		<year>2002</year>
		<volume>70</volume>
		<issue>12</issue>
		<pages>7004-7012</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference412">
		<reference_name>Kohler et al., 2002</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kohler S, Foulongne V, Ouahrani-Bettache S, Bourg G, Teyssier J, Ramuz M, Liautard JP</authors>
		<title>The analysis of the intramacrophagic virulome of Brucella suis deciphers the environment encountered by the pathogen inside the macrophage host cell</title>
		<year>2002 Nov 26</year>
		<volume>99</volume>
		<issue>24</issue>
		<pages>15711-6</pages>
		<journal_book_name>Proceedings of the National Academy of Sciences of the United States of America</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2290">
		<reference_name>Kurar and Splitter, 1997</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kurar E, Splitter GA</authors>
		<title>Nucleic acid vaccination of Brucella abortus ribosomal L7/L12 gene elicits immune response</title>
		<year>1997</year>
		<volume>15</volume>
		<issue>17-18</issue>
		<pages>1851-1857</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference486">
		<reference_name>Laplagne et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Laplagne DA, Zylberman V, Ainciart N, Steward MW, Sciutto E, Fossati CA, Goldbaum FA</authors>
		<title>Engineering of a polymeric bacterial protein as a scaffold for the multiple display of peptides</title>
		<year>2004 Dec 1</year>
		<volume>57</volume>
		<issue>4</issue>
		<pages>820-8</pages>
		<journal_book_name>Proteins</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2292">
		<reference_name>Leclerq et al., 2002</reference_name>
		<reference_type>journal</reference_type>
		<authors>Leclerq S, Harms JS, Rosinha GM, Azevedo V, Oliveira SC</authors>
		<title>Induction of a th1-type of immune response but not protective immunity by intramuscular DNA immunisation with Brucella abortus GroEL heat-shock gene</title>
		<year>2002</year>
		<volume>51</volume>
		<issue>1</issue>
		<pages>20-26</pages>
		<journal_book_name>Journal of medical microbiology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference899">
		<reference_name>Lee et al., 1999</reference_name>
		<reference_type>journal</reference_type>
		<authors>Lee IK, Olsen SC, Kehrli M, Bolin CA</authors>
		<title>The adjuvant effect of a single dose of interleukin-12 on murine immune responses to live or killed Brucella abortus strain RB51</title>
		<year>1999</year>
		<volume>63</volume>
		<issue>4</issue>
		<pages>284-287</pages>
		<journal_book_name>Canadian journal of veterinary research = Revue canadienne de recherche veterinaire</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference896">
		<reference_name>Lee et al., 2001</reference_name>
		<reference_type>journal</reference_type>
		<authors>Lee IK, Olsen SC, Bolin CA</authors>
		<title>Effects of exogenous recombinant interleukin-12 on immune responses and protection against Brucella abortus in a murine model</title>
		<year>2001</year>
		<volume>65</volume>
		<issue>4</issue>
		<pages>223-228</pages>
		<journal_book_name>Canadian journal of veterinary research = Revue canadienne de recherche veterinaire</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference408">
		<reference_name>Letesson et al., 1997</reference_name>
		<reference_type>journal</reference_type>
		<authors>Letesson JJ, Tibor A, van Eynde G, Wansard V, Weynants V, Denoel P, Saman E</authors>
		<title>Humoral immune responses of Brucella-infected cattle, sheep, and goats to eight purified recombinant Brucella proteins in an indirect enzyme-linked immunosorbent assay</title>
		<year>1997 Sep</year>
		<volume>4</volume>
		<issue>5</issue>
		<pages>556-64</pages>
		<journal_book_name>Clinical and diagnostic laboratory immunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference415">
		<reference_name>Li, 1991</reference_name>
		<reference_type>journal</reference_type>
		<authors>Li HZ</authors>
		<title>[A pathohistological study on experimental brucellosis in inbred mice]</title>
		<year>1991 Jun</year>
		<volume>20</volume>
		<issue>2</issue>
		<pages>134-6</pages>
		<journal_book_name>Zhonghua bing li xue za zhi Chinese journal of pathology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference880">
		<reference_name>Longo et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Longo M, Mallardo K, Montagnaro S, De Martino L, Gallo S, Fusco G, Galiero G, Guarino A, Pagnini U, Iovane G</authors>
		<title>Shedding of Brucella abortus rough mutant strain RB51 in milk of water buffalo (Bubalus bubalis)</title>
		<year>2009</year>
		<volume>90</volume>
		<issue>1-2</issue>
		<pages>113-118</pages>
		<journal_book_name>Preventive veterinary medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference491">
		<reference_name>Luo et al., 2006a</reference_name>
		<reference_type>journal</reference_type>
		<authors>Luo DY, Li P, Xing L, Zhao GY, Shi W, Zhang SL, Wang XL</authors>
		<title>DNA vaccine encoding L7/L12-P39 of Brucella abortus induces protective immunity in BALB/c mice</title>
		<year>2006 Feb 20</year>
		<volume>119</volume>
		<issue>4</issue>
		<pages>331-4</pages>
		<journal_book_name>Chinese medical journal</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference697">
		<reference_name>Luo et al., 2006b</reference_name>
		<reference_type>journal</reference_type>
		<authors>Luo D, Ni B, Li P, Shi W, Zhang S, Han Y, Mao L, He Y, Wu Y, Wang X</authors>
		<title>Protective immunity elicited by a divalent DNA vaccine encoding both the L7/L12 and Omp16 genes of Brucella abortus in BALB/c mice</title>
		<year>2006</year>
		<volume>74</volume>
		<issue>5</issue>
		<pages>2734-2741</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference590">
		<reference_name>Makar et al., 1975</reference_name>
		<reference_type>journal</reference_type>
		<authors>Makar AB, McMartin KE, Palese M, Tephly TR</authors>
		<title>Formate assay in body fluids: application in methanol poisoning</title>
		<year>1975</year>
		<volume>13</volume>
		<issue>2</issue>
		<pages>117-126</pages>
		<journal_book_name>Biochemical medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference693">
		<reference_name>Mallick et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Mallick AI, Singha H, Khan S, Anwar T, Ansari MA, Khalid R, Chaudhuri P, Owais M</authors>
		<title>Escheriosome-mediated delivery of recombinant ribosomal L7/L12 protein confers protection against murine brucellosis</title>
		<year>2007</year>
		<volume>25</volume>
		<issue>46</issue>
		<pages>7873-7884</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference879">
		<reference_name>Martins et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Martins H, Garin-Bastuji B, Lima F, Flor L, Pina Fonseca A, Boinas F</authors>
		<title>Eradication of bovine brucellosis in the Azores, Portugal-Outcome of a 5-year programme (2002-2007) based on test-and-slaughter and RB51 vaccination</title>
		<year>2009</year>
		<volume>90</volume>
		<issue>1-2</issue>
		<pages>80-89</pages>
		<journal_book_name>Preventive veterinary medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference414">
		<reference_name>Montaraz et al., 1986</reference_name>
		<reference_type>journal</reference_type>
		<authors>Montaraz JA, Winter AJ</authors>
		<title>Comparison of living and nonliving vaccines for Brucella abortus in BALB/c mice</title>
		<year>1986 Aug</year>
		<volume>53</volume>
		<issue>2</issue>
		<pages>245-51</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference209">
		<reference_name>Moriyon et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Moriyon I, Grillo MJ, Monreal D, Gonzalez D, Marin C, Lopez-Goni I, Mainar-Jaime RC, Moreno E, Blasco JM</authors>
		<title>Rough vaccines in animal brucellosis: structural and genetic basis and present status</title>
		<year>2004 Jan-Feb</year>
		<volume>35</volume>
		<issue>1</issue>
		<pages>1-38</pages>
		<journal_book_name>Veterinary research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference220">
		<reference_name>Munoz-Montesino et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Munoz-Montesino C, Andrews E, Rivers R, Gonzalez-Smith A, Moraga-Cid G, Folch H, Cespedes S, Onate AA</authors>
		<title>Intraspleen delivery of a DNA vaccine coding for superoxide dismutase (SOD) of Brucella abortus induces SOD-specific CD4+ and CD8+ T cells</title>
		<year>2004 Apr</year>
		<volume>72</volume>
		<issue>4</issue>
		<pages>2081-7</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference881">
		<reference_name>Nol et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Nol P, Olsen SC, Rhyan JC</authors>
		<title>Experimental infection of Richardson's ground squirrels (Spermophilus richardsonii) with attenuated and virulent strains of Brucella abortus</title>
		<year>2009</year>
		<volume>45</volume>
		<issue>1</issue>
		<pages>189-195</pages>
		<journal_book_name>Journal of wildlife diseases</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference420">
		<reference_name>Oliveira et al., 1994</reference_name>
		<reference_type>journal</reference_type>
		<authors>Oliveira SC, Zhu Y, Splitter G</authors>
		<title>Sequences of the rplJL operon containing the L10 and L7/L12 genes from Brucella abortus</title>
		<year>1994 Mar 11</year>
		<volume>140</volume>
		<issue>1</issue>
		<pages>137-8</pages>
		<journal_book_name>Gene</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference419">
		<reference_name>Oliveira et al., 1996</reference_name>
		<reference_type>journal</reference_type>
		<authors>Oliveira SC, Splitter GA</authors>
		<title>Immunization of mice with recombinant L7/L12 ribosomal protein confers protection against Brucella abortus infection</title>
		<year>1996 Jul</year>
		<volume>14</volume>
		<issue>10</issue>
		<pages>959-62</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference888">
		<reference_name>Olsen et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Olsen SC, Rhyan J, Gidlewski T, Goff J, Stoffregen WC</authors>
		<title>Safety of Brucella abortus strain RB51 in black bears</title>
		<year>2004</year>
		<volume>40</volume>
		<issue>3</issue>
		<pages>429-433</pages>
		<journal_book_name>Journal of wildlife diseases</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference891">
		<reference_name>Olsen et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Olsen SC, Waters WR, Stoffregen WS</authors>
		<title>An aerosolized Brucella spp. challenge model for laboratory animals</title>
		<year>2007</year>
		<volume>54</volume>
		<issue>8</issue>
		<pages>281-285</pages>
		<journal_book_name>Zoonoses and public health</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference890">
		<reference_name>Olsen et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Olsen SC, Boyle SM, Schurig GG, Sriranganathan NN</authors>
		<title>Immune responses and protection against experimental challenge after vaccination of bison with Brucella abortus strain RB51 or RB51 overexpressing superoxide dismutase and glycosyltransferase genes</title>
		<year>2009</year>
		<volume>16</volume>
		<issue>4</issue>
		<pages>535-540</pages>
		<journal_book_name>Clinical and vaccine immunology : CVI</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference564">
		<reference_name>Onate et al., 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Onate AA, Cespedes S, Cabrera A, Rivers R, Gonzalez A, Munoz C, Folch H, Andrews E</authors>
		<title>A DNA vaccine encoding Cu,Zn superoxide dismutase of Brucella abortus induces protective immunity in BALB/c mice</title>
		<year>2003 Sep</year>
		<volume>71</volume>
		<issue>9</issue>
		<pages>4857-61</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference901">
		<reference_name>Palmer et al., 1996</reference_name>
		<reference_type>journal</reference_type>
		<authors>Palmer MV, Cheville NF, Tatum FM</authors>
		<title>Morphometric and histopathologic analysis of lymphoid depletion in murine spleens following infection with Brucella abortus strains 2308 or RB51 or an htrA deletion mutant</title>
		<year>1996</year>
		<volume>33</volume>
		<issue>3</issue>
		<pages>282-289</pages>
		<journal_book_name>Veterinary pathology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2109">
		<reference_name>Paranavitana et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Paranavitana C, Zelazowska E, Izadjoo M, Hoover D</authors>
		<title>Interferon-gamma associated cytokines and chemokines produced by spleen cells from Brucella-immune mice</title>
		<year>2005</year>
		<volume>30</volume>
		<issue>2</issue>
		<pages>86-92</pages>
		<journal_book_name>Cytokine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference696">
		<reference_name>Parent et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Parent MA, Goenka R, Murphy E, Levier K, Carreiro N, Golding B, Ferguson G, Roop RM 2nd, Walker GC, Baldwin CL</authors>
		<title>Brucella abortus bacA mutant induces greater pro-inflammatory cytokines than the wild-type parent strain</title>
		<year>2007</year>
		<volume>9</volume>
		<issue>1</issue>
		<pages>55-62</pages>
		<journal_book_name>Microbes and infection / Institut Pasteur</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference897">
		<reference_name>Pasquali et al., 2001</reference_name>
		<reference_type>journal</reference_type>
		<authors>Pasquali P, Adone R, Gasbarre LC, Pistoia C, Ciuchini F</authors>
		<title>Mouse cytokine profiles associated with Brucella abortus RB51 vaccination or B. abortus 2308 infection</title>
		<year>2001</year>
		<volume>69</volume>
		<issue>10</issue>
		<pages>6541-6544</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference892">
		<reference_name>Pasquali et al., 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Pasquali P, Rosanna A, Pistoia C, Petrucci P, Ciuchini F</authors>
		<title>Brucella abortus RB51 induces protection in mice orally infected with the virulent strain B. abortus 2308</title>
		<year>2003</year>
		<volume>71</volume>
		<issue>5</issue>
		<pages>2326-2330</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference864">
		<reference_name>Pasquevich et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Pasquevich KA, Estein SM, García Samartino C, Zwerdling A, Coria LM, Barrionuevo P, Fossati CA, Giambartolomei GH, Cassataro J</authors>
		<title>Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection</title>
		<year>2009</year>
		<volume>77</volume>
		<issue>1</issue>
		<pages>436-445</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference689">
		<reference_name>Poester et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Poester FP, Gonçalves VS, Paixão TA, Santos RL, Olsen SC, Schurig GG, Lage AP</authors>
		<title>Efficacy of strain RB51 vaccine in heifers against experimental brucellosis</title>
		<year>2006</year>
		<volume>24</volume>
		<issue>25</issue>
		<pages>5327-5334</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference883">
		<reference_name>Rajasekaran et al., 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Rajasekaran P, Seleem MN, Contreras A, Purwantini E, Schurig GG, Sriranganathan N, Boyle SM</authors>
		<title>Brucella abortus strain RB51 leucine auxotroph as an environmentally safe vaccine for plasmid maintenance and antigen overexpression</title>
		<year>2008</year>
		<volume>74</volume>
		<issue>22</issue>
		<pages>7051-7055</pages>
		<journal_book_name>Applied and environmental microbiology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference885">
		<reference_name>Ramamoorthy et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Ramamoorthy S, Sanakkayala N, Vemulapalli R, Duncan RB, Lindsay DS, Schurig GS, Boyle SM, Kasimanickam R, Sriranganathan N</authors>
		<title>Prevention of lethal experimental infection of C57BL/6 mice by vaccination with Brucella abortus strain RB51 expressing Neospora caninum antigens</title>
		<year>2007</year>
		<volume>37</volume>
		<issue>13</issue>
		<pages>1521-1529</pages>
		<journal_book_name>International journal for parasitology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference411">
		<reference_name>Roop et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Roop RM 2nd, Bellaire BH, Valderas MW, Cardelli JA</authors>
		<title>Adaptation of the Brucellae to their intracellular niche</title>
		<year>2004 May</year>
		<volume>52</volume>
		<issue>3</issue>
		<pages>621-30</pages>
		<journal_book_name>Molecular microbiology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1786">
		<reference_name>Rosinha et al., 2002a</reference_name>
		<reference_type>journal</reference_type>
		<authors>Rosinha GM, Freitas DA, Miyoshi A, Azevedo V, Campos E, Cravero SL, Rossetti O, Splitter G, Oliveira SC</authors>
		<title>Identification and characterization of a Brucella abortus ATP-binding cassette transporter homolog to Rhizobium meliloti ExsA and its role in virulence and protection in mice</title>
		<year>2002</year>
		<volume>70</volume>
		<issue>9</issue>
		<pages>5036-5044</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1484">
		<reference_name>Rosinha et al., 2002b</reference_name>
		<reference_type>journal</reference_type>
		<authors>Rosinha GM, Myioshi A, Azevedo V, Splitter GA, Oliveira SC</authors>
		<title>Molecular and immunological characterisation of recombinant Brucella abortus glyceraldehyde-3-phosphate-dehydrogenase, a T- and B-cell reactive protein that induces partial protection when co-administered with an interleukin-12-expressing plasmid in a DNA vaccine formulation</title>
		<year>2002</year>
		<volume>51</volume>
		<issue>8</issue>
		<pages>661-671</pages>
		<journal_book_name>Journal of medical microbiology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference12">
		<reference_name>Schurig et al., 1991</reference_name>
		<reference_type>journal</reference_type>
		<authors>Schurig GG, Roop RM 2nd, Bagchi T, Boyle S, Buhrman D, Sriranganathan N</authors>
		<title>Biological properties of RB51; a stable rough strain of Brucella abortus</title>
		<year>1991 Jul</year>
		<volume>28</volume>
		<issue>2</issue>
		<pages>171-88</pages>
		<journal_book_name>Veterinary microbiology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference11">
		<reference_name>Schurig et al., 2002</reference_name>
		<reference_type>journal</reference_type>
		<authors>Schurig GG, Sriranganathan N, Corbel MJ</authors>
		<title>Brucellosis vaccines: past, present and future</title>
		<year>2002 Dec 20</year>
		<volume>90</volume>
		<issue>1-4</issue>
		<pages>479-96</pages>
		<journal_book_name>Veterinary microbiology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2664">
		<reference_name>Sislema-Egas et al., 2012</reference_name>
		<reference_type>journal</reference_type>
		<authors>Sislema-Egas F, CÃ©spedes S, FernÃ¡ndez P, Retamal-DÃ­az A, SÃ¡ez D, OÃ±ate A</authors>
		<title>Evaluation of protective effect of DNA vaccines encoding the BAB1_0263 and BAB1_0278 open reading frames of Brucella abortus in BALB/c mice</title>
		<year>2012</year>
		<volume>30</volume>
		<issue>50</issue>
		<pages>7286-7291</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference903">
		<reference_name>Stevens et al., 1994a</reference_name>
		<reference_type>journal</reference_type>
		<authors>Stevens MG, Olsen SC, Pugh GW Jr</authors>
		<title>Lymphocyte proliferation in response to Brucella abortus 2308 or RB51 antigens in mice infected with strain 2308, RB51, or 19</title>
		<year>1994</year>
		<volume>62</volume>
		<issue>10</issue>
		<pages>4659-4663</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference191">
		<reference_name>Stevens et al., 1994b</reference_name>
		<reference_type>journal</reference_type>
		<authors>Stevens MG, Olsen SC, Pugh GW Jr, Palmer MV</authors>
		<title>Immune and pathologic responses in mice infected with Brucella abortus 19, RB51, or 2308</title>
		<year>1994 Aug</year>
		<volume>62</volume>
		<issue>8</issue>
		<pages>3206-12</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference902">
		<reference_name>Stevens et al., 1995a</reference_name>
		<reference_type>journal</reference_type>
		<authors>Stevens MG, Olsen SC, Pugh GW Jr</authors>
		<title>Comparison of spleen cell proliferation in response to Brucella abortus 2308 lipopolysaccharide or proteins in mice vaccinated with strain 19 or RB51</title>
		<year>1995</year>
		<volume>63</volume>
		<issue>8</issue>
		<pages>3199-3205</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference905">
		<reference_name>Stevens et al., 1995b</reference_name>
		<reference_type>journal</reference_type>
		<authors>Stevens MG, Olsen SC, Pugh GW Jr, Brees D</authors>
		<title>Comparison of immune responses and resistance to brucellosis in mice vaccinated with Brucella abortus 19 or RB51</title>
		<year>1995</year>
		<volume>63</volume>
		<issue>1</issue>
		<pages>264-270</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference900">
		<reference_name>Stevens et al., 1996</reference_name>
		<reference_type>journal</reference_type>
		<authors>Stevens MG, Olsen SC, Palmer MV, Pugh GW Jr</authors>
		<title>Immune responses and resistance to brucellosis in mice vaccinated orally with Brucella abortus RB51</title>
		<year>1996</year>
		<volume>64</volume>
		<issue>11</issue>
		<pages>4534-4541</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference887">
		<reference_name>Stoffregen et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Stoffregen WC, Olsen SC, Bricker BJ</authors>
		<title>Parenteral vaccination of domestic pigs with Brucella abortus strain RB51</title>
		<year>2006</year>
		<volume>67</volume>
		<issue>10</issue>
		<pages>1802-1808</pages>
		<journal_book_name>American journal of veterinary research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4785">
		<reference_name>Suryanarayana et al., 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>Suryanarayana N, Verma M, Thavachelvam K, Saxena N, Mankere B, Tuteja U, Hmuaka V</authors>
		<title>Generation of a novel chimeric PALFn antigen of Bacillus anthracis and its immunological characterization in mouse model</title>
		<year>2016</year>
		<volume>100</volume>
		<issue>19</issue>
		<pages>8439-8451</pages>
		<journal_book_name>Applied microbiology and biotechnology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference877">
		<reference_name>Tibor et al., 1998</reference_name>
		<reference_type>journal</reference_type>
		<authors>Tibor A, Jacques I, Guilloteau L, Verger JM, Grayon M, Wansard V, Letesson JJ</authors>
		<title>Effect of P39 gene deletion in live Brucella vaccine strains on residual virulence and protective activity in mice</title>
		<year>1998</year>
		<volume>66</volume>
		<issue>11</issue>
		<pages>5561-5564</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference906">
		<reference_name>Tobias et al., 1992</reference_name>
		<reference_type>journal</reference_type>
		<authors>Tobias L, Schurig GG, Cordes DO</authors>
		<title>Comparative behaviour of Brucella abortus strains 19 and RB51 in the pregnant mouse</title>
		<year>1992</year>
		<volume>53</volume>
		<issue>2</issue>
		<pages>179-183</pages>
		<journal_book_name>Research in veterinary science</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1811">
		<reference_name>Trant et al., 2010</reference_name>
		<reference_type>journal</reference_type>
		<authors>Trant CG, Lacerda TL, Carvalho NB, Azevedo V, Rosinha GM, Salcedo SP, Gorvel JP, Oliveira SC</authors>
		<title>The Brucella abortus phosphoglycerate kinase mutant is highly attenuated and induces protection superior to that of vaccine strain 19 in immunocompromised and immunocompetent mice</title>
		<year>2010</year>
		<volume>78</volume>
		<issue>5</issue>
		<pages>2283-2291</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1909">
		<reference_name>Ugalde et al., 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Ugalde JE, Comerci DJ, Leguizamón MS, Ugalde RA</authors>
		<title>Evaluation of Brucella abortus phosphoglucomutase (pgm) mutant as a new live rough-phenotype vaccine</title>
		<year>2003</year>
		<volume>71</volume>
		<issue>11</issue>
		<pages>6264-6269</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference416">
		<reference_name>Velikovsky et al., 2002</reference_name>
		<reference_type>journal</reference_type>
		<authors>Velikovsky CA, Cassataro J, Giambartolomei GH, Goldbaum FA, Estein S, Bowden RA, Bruno L, Fossati CA, Spitz M</authors>
		<title>A DNA vaccine encoding lumazine synthase from Brucella abortus induces protective immunity in BALB/c mice</title>
		<year>2002 May</year>
		<volume>70</volume>
		<issue>5</issue>
		<pages>2507-11</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference14">
		<reference_name>Vemulapalli et al., 2000a</reference_name>
		<reference_type>journal</reference_type>
		<authors>Vemulapalli R, He Y, Cravero S, Sriranganathan N, Boyle SM, Schurig GG</authors>
		<title>Overexpression of protective antigen as a novel approach to enhance vaccine efficacy of Brucella abortus strain RB51</title>
		<year>2000 Jun</year>
		<volume>68</volume>
		<issue>6</issue>
		<pages>3286-9</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference189">
		<reference_name>Vemulapalli et al., 2000b</reference_name>
		<reference_type>journal</reference_type>
		<authors>Vemulapalli R, He Y, Buccolo LS, Boyle SM, Sriranganathan N, Schurig GG</authors>
		<title>Complementation of Brucella abortus RB51 with a functional wboA gene results in O-antigen synthesis and enhanced vaccine efficacy but no change in rough phenotype and attenuation</title>
		<year>2000 Jul</year>
		<volume>68</volume>
		<issue>7</issue>
		<pages>3927-32</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference187">
		<reference_name>Vemulapalli et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Vemulapalli R, Contreras A, Sanakkayala N, Sriranganathan N, Boyle SM, Schurig GG</authors>
		<title>Enhanced efficacy of recombinant Brucella abortus RB51 vaccines against B. melitensis infection in mice</title>
		<year>2004 Sep 8</year>
		<volume>102</volume>
		<issue>3-4</issue>
		<pages>237-45</pages>
		<journal_book_name>Veterinary microbiology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1910">
		<reference_name>Wang et al., 2011</reference_name>
		<reference_type>journal</reference_type>
		<authors>Wang Y, Bai Y, Qu Q, Xu J, Chen Y, Zhong Z, Qiu Y, Wang T, Du X, Wang Z, Yu S, Fu S, Yuan J, Zhen Q, Yu Y, Chen Z, Huang L</authors>
		<title>The 16MΔvjbR as an ideal live attenuated vaccine candidate for differentiation between Brucella vaccination and infection</title>
		<year>2011</year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name>Veterinary microbiology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference686">
		<reference_name>Winter et al., 1988</reference_name>
		<reference_type>journal</reference_type>
		<authors>Winter AJ, Rowe GE, Duncan JR, Eis MJ, Widom J, Ganem B, Morein B</authors>
		<title>Effectiveness of natural and synthetic complexes of porin and O polysaccharide as vaccines against Brucella abortus in mice</title>
		<year>1988</year>
		<volume>56</volume>
		<issue>11</issue>
		<pages>2808-2817</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference216">
		<reference_name>Winter et al., 1996</reference_name>
		<reference_type>journal</reference_type>
		<authors>Winter AJ, Schurig GG, Boyle SM, Sriranganathan N, Bevins JS, Enright FM, Elzer PH, Kopec JD</authors>
		<title>Protection of BALB/c mice against homologous and heterologous species of Brucella by rough strain vaccines derived from Brucella melitensis and Brucella suis biovar 4</title>
		<year>1996 May</year>
		<volume>57</volume>
		<issue>5</issue>
		<pages>677-83</pages>
		<journal_book_name>American journal of veterinary research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference876">
		<reference_name>Xin, 1986</reference_name>
		<reference_type>journal</reference_type>
		<authors>Xin X</authors>
		<title>Orally administrable brucellosis vaccine: Brucella suis strain 2 vaccine</title>
		<year>1986</year>
		<volume>4</volume>
		<issue>4</issue>
		<pages>212-216</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference683">
		<reference_name>Yang et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Yang X, Becker T, Walters N, Pascual DW</authors>
		<title>Deletion of znuA virulence factor attenuates Brucella abortus and confers protection against wild-type challenge</title>
		<year>2006</year>
		<volume>74</volume>
		<issue>7</issue>
		<pages>3874-3879</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference695">
		<reference_name>Yang et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Yang X, Walters N, Robison A, Trunkle T, Pascual DW</authors>
		<title>Nasal immunization with recombinant Brucella melitensis bp26 and trigger factor with cholera toxin reduces B. melitensis colonization</title>
		<year>2007</year>
		<volume>25</volume>
		<issue>12</issue>
		<pages>2261-2268</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference480">
		<reference_name>Yu et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Yu DH, Hu XD, Cai H</authors>
		<title>A combined DNA vaccine encoding BCSP31, SOD, and L7/L12 confers high protection against Brucella abortus 2308 by inducing specific CTL responses</title>
		<year>2007 Jun</year>
		<volume>26</volume>
		<issue>6</issue>
		<pages>435-43</pages>
		<journal_book_name>DNA and cell biology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2294">
		<reference_name>Yu et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Yu DH, Li M, Hu XD, Cai H</authors>
		<title>A combined DNA vaccine enhances protective immunity against Mycobacterium tuberculosis and Brucella abortus in the presence of an IL-12 expression vector</title>
		<year>2007</year>
		<volume>25</volume>
		<issue>37-38</issue>
		<pages>6744-6754</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
</VIOLIN>


